

AWARD NUMBER: W81XWH-10-1-0341

TITLE: Genetic Modifiers of Ovarian Cancer

PRINCIPAL INVESTIGATOR: Fergus J. Couch, Ph.D.

CONTRACTING ORGANIZATION: Mayo Clinic
Rochester, MN 55905

REPORT DATE: AUGUST 2014

TYPE OF REPORT: FINAL

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE AUG 2014		2. REPORT TYPE Final		3. DATES COVERED 15MAY2010 - 14MAY2014	
4. TITLE AND SUBTITLE Genetic Modifiers of Ovarian Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-10-1-0341	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Fergus J. Couch, Ph.D. E-Mail: couch.fergus@mayo.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Mayo Clinic 200 First Street SW Rochester, MN 55905				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Individuals with germline mutations in <i>BRCA1</i> have an elevated but incomplete risk of developing ovarian cancer suggesting the presence of genetic modifiers of ovarian cancer in this population. A genome wide association study (GWAS) for ovarian cancer in BRCA1 mutation carriers has identified several novel modifiers of ovarian cancer risk for BRCA1 mutation carriers that can be used for individualized ovarian cancer risk assessment.					
15. SUBJECT TERMS BRCA1, ovarian cancer, genome-wide association study, association study					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
b. Unclassified	Unclassified	Unclassified	Unclassified	150	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	4
2. Key Words.....	4
3. Overall Project Summary.....	4
4. Key Research Accomplishments.....	13
5. Conclusion.....	13
6. Publications, Abstracts, and Presentations.....	13
7. Inventions, Patents, and Licenses.....	47
8. Reportable Outcomes.....	48
9. Other Achievements.....	48
10. References.....	48
11. Appendices.....	53

1. Introduction:

Inactivating mutations in the *BRCA1* tumor suppressor gene have been detected in approximately 10% of all ovarian cancers. Individuals with germline mutations in *BRCA1* have a substantially increased risk of developing ovarian cancer as compared to the general population, with an estimated cumulative risk of ovarian cancer by age 70 of 39% [1]. These findings indicate that although *BRCA1* mutation carriers are at high risk for developing ovarian cancer, a sizeable proportion of women who carry a deleterious mutation will not develop this disease. In addition, the findings show that there is considerable variation in the age of onset of ovarian cancer in this population. This variable penetrance and age of onset of ovarian cancer suggest that there are additional genetic and environmental factors that modify the age specific risk of ovarian cancer for *BRCA1* mutation carriers [2]. Common genetic variants that are associated with the risk of ovarian cancer have recently been identified through candidate gene and genome wide association studies in the general population [3,4]. This suggested that common genetic variants may also modify ovarian cancer risk in carriers of *BRCA1* mutations. Identification of these genetic risk factors may prove useful for identifying those *BRCA1* carriers at elevated or lowered risk of ovarian cancer compared to the average *BRCA1* carrier. Women at increased risk may subsequently benefit from enhanced screening or certain prevention measures such as prophylactic oophorectomy, whereas women at lowered risk may be able to avoid these types of intervention. Thus, we proposed a study aimed at identifying genetic risk factors for ovarian cancer in *BRCA1* mutation carriers through a genome wide association study in *BRCA1* mutation carriers. The overall intent was to complete a genome wide association study of *BRCA1* carriers, validate candidate risk modifiers, assess the contribution of these modifiers to sporadic ovarian cancer, and develop risk prediction models for *BRCA1* mutation carriers that incorporate the common genetic modifiers identified in the GWAS.

2. Key Words:

BRCA1, ovarian cancer, genome-wide association study, risk factors

3. Overall Project Summary:

Aim 1: To conduct a genome-wide association scan in 1,000 *BRCA1* carriers with ovarian cancer and 1,000 age-matched unaffected *BRCA1* carriers.

Task 1. Aliquot DNA samples for genotyping.

All samples used for the GWAS were contributed by collaborators in the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA) [5]. We collected DNA samples in the Couch laboratory in two phases. The first phase included DNA from 361 *BRCA1* mutation carriers diagnosed with ovarian cancer and 1250 unaffected *BRCA1* carriers. The second phase resulted in collection of DNA from an additional 434 *BRCA1* mutation carriers diagnosed with ovarian cancer [3].

Task 2. Genotype DNA samples on Human 660W-Quad arrays.

We genotyped all of these DNA samples on Human 660W-Quad arrays in the Medical

Genome Facility at the Mayo Clinic. In addition we acquired GWAS genotype data for 120 additional *BRCA1* mutation carriers affected with ovarian cancer from CIMBA collaborators, resulting in GWAS genotype data from 915 *BRCA1* ovarian cancer cases [3].

Task 3. Genotype quality control analysis.

Genotyping calls were obtained using the standard Illumina calling algorithm incorporated in the BeadStudio software. As expected gender checks using PLINK software failed to identify male *BRCA1* carriers. Duplicates were identified by identify-by-descent analyses and were removed. Quality control thresholds of >95% variant call rates and >95% sample call rates were applied. Variant with minor allele frequency <0.05 were excluded. In addition single nucleotide polymorphisms (SNPs) displayed divergence from Hardy Weinberg equilibrium $p < 1 \times 10^{-7}$ were removed. Final analyses included 897 *BRCA1* mutation carriers with ovarian cancer and approximately 540,000 SNPs. Genetic relatedness among samples from different countries and ethnicities can introduce heterogeneity into association studies and cause important SNPs to be overlooked. While this study was restricted to Caucasian *BRCA1* carriers the study did include DNA samples from many countries. To account for population stratification, the genotyping data in combination with HapMap data (CEU, Yoruban, Han Chinese populations) on 40,000 SNPs with known phase were analyzed by Eigenstrat. A total of 17 individuals were excluded because of non-caucasian admixture of between 15% and 25% [3].

Task 4. Data analysis.

Final analyses of genotyping data included 897 *BRCA1* mutation carriers with ovarian cancer and approximately 540,000 single nucleotide polymorphisms (SNPs). In collaboration with Drs. Douglas Easton and Antonis Antoniou at the University of Cambridge, we evaluated associations with both breast and ovarian cancer using a retrospective likelihood model. This accounts for the age extremes of affected and unaffected and also applies age related penetrance estimates for *BRCA1* carriers. Carriers were censored at age of onset of disease for those affected with breast or ovarian cancer and age of last follow up or age at prophylactic mastectomy/oophorectomy for those with no cancer diagnosis. Analyses were adjusted for Country of origin because samples from 26 different centers in 18 countries were included in the study.

For ovarian cancer, no SNPs showed genome wide significance ($p < 1 \times 10^{-7}$). However, 10 SNPs exhibited associations of $p < 1 \times 10^{-5}$ and 37 had associations of $p < 1 \times 10^{-4}$. Interestingly, rs1339552 on chromosome 9 in *BCN2* and rs7651446 from *TIPARP* on chromosome 3 that exhibited genome wide associations with ovarian cancer in the general population also showed highly significant associations ($p = 1.9 \times 10^{-5}$ and $p = 1.7 \times 10^{-4}$, respectively) with ovarian cancer in *BRCA1* mutation carriers [3]. These loci can be considered genetic risk factors for ovarian cancer in *BRCA1* mutation carriers.

Aim 2: To further evaluate observed associations between ovarian cancer risk and SNPs implicated in Aim 1 by genotyping 1,500 *BRCA1* ovarian cancer cases and 1,500 unaffected *BRCA1* carriers.

Task 5. Design and order 384 arrays.

Phase 1: Validation of Chromosome 19p13.1 associations

An interim validation study of the 89 SNPs most significantly associated with breast cancer in the *BRCA1* GWAS was undertaken. SNPs were selected based on p-values identified in Task 4, and a multiplex Illumina bead array was designed.

Phase 2: GWAS validation studies

We planned to evaluate the 384 most significantly associated SNPs from the *BRCA1* ovarian cancer GWAS in 3,000 additional *BRCA1* mutation carriers including 1,500 with ovarian cancer. Instead in 2010 we designed a SNP array (iCOGS) containing 211,000 candidate SNPs from GWAS of various tumor types. A total of 35,000 candidate SNPs were selected from the *BRCA1* GWAS including 6,000 from the *BRCA1* Ovarian Cancer GWAS.

Task 6. Aliquot DNA samples for replication study.

Phase 1: Validation of Chromosome 19p13.1 associations

An additional 12,599 *BRCA1* and 7,132 *BRCA2* mutation carriers, which included 1,465 *BRCA1* mutation carriers and 453 *BRCA2* mutation carriers with ovarian cancer were collected from CIMBA members. Each of these samples was evaluated for DNA quality by conducting picogreen and E-gel (Invitrogen) analysis. Samples with low levels of DNA (<250ng available) or with degraded DNA, identified as smearing on Egel analysis, were excluded. Samples were manually aliquoted into 96-well plates in preparation for genotyping.

Phase 2: GWAS validation studies

We proposed to genotype 14,000 DNA samples from *BRCA1* mutation carriers on these arrays in contrast to the 3,000 originally planned for Stage 2 of the ovarian cancer GWAS. Investigators in 52 CIMBA groups from around the world provided non-amplified genomic DNA samples from approximately 15,000 from female *BRCA1* mutation carriers including 1,400 with ovarian cancer. Each of these samples was evaluated for DNA quality by conducting picogreen and E-gel (Invitrogen) analysis. Samples with low levels of DNA (<250ng available) or with degraded DNA, identified as smearing on Egel analysis, were excluded (n=1,200). A total of 12,700 Caucasian, 150 Malaysian and 204 Hong Kong DNA samples were identified as useful for further validation studies. Overall, high quality DNA samples from 8,054 unaffected and 1,264 *BRCA1* carriers affected with ovarian cancer were available for genotyping. Samples were manually aliquoted into 96-well plates in preparation for genotyping.

Task 7. Genotype 3,000 DNA samples using the 384 SNP array.

Phase 1: Validation of Chromosome 19p13.1 associations

An additional 12,599 *BRCA1* and 7,132 *BRCA2* mutation carriers including 1,465 *BRCA1* mutation carriers and 453 *BRCA2* mutation carriers with ovarian cancer were genotyped for 89 candidate SNPs on an Illumina custom bead array in the Medical Genome Facility at the Mayo Clinic.

Phase 2: GWAS validation studies

Genotyping of 8,054 unaffected and 1,264 *BRCA1* carriers affected with ovarian cancer using the

iCOGS array was performed in the Medical Genome Facility at the Mayo Clinic.

Task 8. Genotype quality control analysis.

Phase 1: Validation of Chromosome 19p13.1 associations

Quality control was performed as described for Task 3. Seven SNPs displayed SNP call rates of <95% and were excluded.

Phase 2: GWAS validation studies

Quality control was performed as described for Task 3. Testing of the iCOGS array showed that 204,000 of the SNPs yielded good quality genotyping. The other 7,000 SNPs were excluded from further consideration.

Task 9. Data analysis.

Phase 1: Validation of Chromosome 19p13.1 associations

Association studies for breast cancer among *BRCA1* mutation carriers identified genome wide significant associations for five SNPs from a single locus on chromosome 19p13.1 ($P = 2.3 \times 10^{-9}$ to 3.9×10^{-7}). To assess the influence of these SNPs on ovarian cancer risk in *BRCA1* and *BRCA2* mutation carriers we used a competing risk analysis that accounted for the effects on breast and ovarian cancer in parallel. In this competing risk analysis rs67397200 at 19p13.1 was strongly associated with ovarian cancer risk in *BRCA1* (HR=1.16; 95%CI 1.05-1.29; $p=3.8 \times 10^{-4}$) and *BRCA2* (HR=1.30; 95%CI 1.10-1.52; $p=1.8 \times 10^{-3}$) mutation carriers. Similar results were obtained for rs8170 at 19p13.1. These results suggested that variants in this locus were modifiers of ovarian cancer risk among *BRCA1* and *BRCA2* mutation carriers [6]. This was the first study to identify common variants that influenced both breast and ovarian cancer risk in either *BRCA1* or *BRCA2* mutation carriers [6].

Phase 2: GWAS validation studies

Analyses of associations with ovarian cancer risk for 8,054 unaffected and 1,264 affected *BRCA1* carriers (Stage 2) revealed no evidence of inflation in the association test-statistic ($\lambda=1.039$, adjusted to 1000/1000 cases/controls $\lambda=1.018$). When combining the iCOGS and original GWAS, genotype data from 9866 unaffected *BRCA1* mutation carriers and 1839 affected with ovarian cancer were available for analysis. A total of 62 SNPs in 17 regions were associated with ovarian cancer risk for *BRCA1* carriers at $P < 10^{-4}$. Associations ($P < 0.01$) with ovarian cancer risk were observed for SNPs in all known ovarian cancer susceptibility loci from the general population (3q25, 8q24, 9p22, 17q21, 19p13) except 2q31. After excluding SNPs from known ovarian cancer susceptibility regions, there were 48 SNPs in 15 regions with $P = 5 \times 10^{-7}$ to 10^{-4} . Genotype data for 5 SNPs from four of these loci were available from 2,204 *BRCA1* unaffected carriers and 442 *BRCA1* carriers (stage 3). In the combined stage 1-3 analyses, SNPs rs17631303 and rs183211 ($r^2=0.68$) on chromosome 17q21.31 had genome wide significant associations for ovarian cancer, of 2.8×10^{-10} and 2.0×10^{-9} , respectively. The SNP rs4691139 at 4q32.3 also had a genome wide significant association ($p=3.4 \times 10^{-8}$). None of these SNPs were associated with breast cancer in *BRCA1* mutation carriers [7].

Imputation using data from the 1000 Genomes Project, identified several SNPs in 17q21.31 with stronger associations than the most significant genotyped SNP in the combined *BRCA1/2* analysis (rs169201, $P=6.24 \times 10^{-11}$) [7]. This large region of strong linkage disequilibrium has previously been identified as a 17q21.31 inversion (~900kb long) consisting of two haplotypes (termed H1 and H2). The most significant SNP (rs140338099 (17-44034340), $P=3 \times 10^{-12}$) located in *MAPT*, was highly correlated ($r^2=0.78$) with the most significantly associated genotyped SNP (rs169201) in *NSF*. This locus appears to be distinct from a previously identified sporadic ovarian cancer susceptibility locus located >1Mb distal on 17q21 (spanning 43.3-44.3Mb, build 36.3) [4]. None of the SNPs in the novel region were strongly correlated with any of the SNPs in the 43.3-44.3Mb region (maximum $r^2=0.07$). The most significantly associated SNP from the *BRCA1* GWAS from the 43.3-44.3Mb locus was rs11651753 ($p=4.6 \times 10^{-4}$) ($r^2<0.023$ with the seven most significant SNPs in the novel 17q21.31 region). An analysis of the joint associations of rs11651753 and rs17631303 from the two 17q21 loci with ovarian cancer risk for *BRCA1* carriers (Stage 1 and 2 samples) revealed that both SNPs remained significant in the model (P -for inclusion=0.001 for rs11651753, 1.2×10^{-6} for rs17631303), further suggesting that the two regions are independently associated with ovarian cancer for *BRCA1* carriers.

The minor allele of rs4691139 at the novel 4q32.3 region was also associated with an increased ovarian cancer risk for *BRCA1* carriers (per-allele HR=1.20, 95%CI:1.17-1.38), but was not associated with breast cancer risk [7]. Analysis of associations with variants identified through 1000 Genomes Project based imputation of the Stage 1 and 2 samples, also revealed 19 SNPs with stronger evidence of association ($P=5.4 \times 10^{-7}$ to 1.1×10^{-6}) than rs4691139 on 4q32.3. All were highly correlated (pairwise $r^2>0.89$) and the most significant (rs4588418) had $r^2=0.97$ with rs4691139 [7]. No association was found between rs4691139 and ovarian cancer risk in the general population based on data by the Ovarian Cancer Association Consortium (OCAC) in 18,174 cases and 26,134 controls (Odds Ratio=1.00, 95%CI:0.97-1.04, $P=0.76$). Thus, the 4q32.3 is an ovarian cancer risk factor specific to *BRCA1* mutation carriers.

Table 2. Associations with breast and ovarian cancer risk for SNPs found to be associated with risk at all 3 stages of the experiment. [7]

SNP, Chr, Position, Allele1/Allele2	Stage	Number		Hazard ratio (95%CI)	P-trend
		Unaffected	Affected		
rs17631303, 17q21, 40872185, A/G	Stage 1	1797	574	1.46 (1.22–1.74)	1.3×10^{-5}
	Stage 2	7996	1257	1.20 (1.07–1.35)	1.5×10^{-3}
	Stages1+2	9793	1831	1.27 (1.16–1.40)	3.0×10^{-7}
	Stage 3	2204	442	1.27 (1.07–1.51)	0.014
	Combined	11997	2273	1.27 (1.17–1.38)	1.4×10^{-8}
rs183211, 17q21, 42143493, G/A	Stage 1	1812	575	1.45 (1.23–1.71)	2.5×10^{-5}
	Stage 2	8054	1264	1.20 (1.07–1.33)	1.1×10^{-3}
	Stages1+2	9866	1839	1.25 (1.15–1.37)	5.7×10^{-7}
	Stage 3	2204	442	1.25 (1.06–1.48)	0.018
	Combined	12070	2281	1.25 (1.16–1.35)	3.1×10^{-8}
rs4691139, 4q32.3, 166128171, A/G	Stage 1	1812	575	1.24 (1.08–1.42)	3.6×10^{-3}
	Stage 2	8054	1264	1.18 (1.08–1.29)	1.3×10^{-4}
	Stages1+2	9866	1839	1.20 (1.11–1.29)	1.1×10^{-6}
	Stage 3	2204	441	1.20 (1.04–1.39)	9×10^{-3}
	Combined	12070	2280	1.20 (1.17–1.38)	3.4×10^{-8}

In summary, SNPs in 3q25, 4q32.3, 8q24, 9p22, 17q21.31, and 19p13 were associated with ovarian cancer in *BRCA1* mutation carriers.

Note: There are many publications resulting from this grant beyond those referenced in this report (see Publications, Abstracts, and Presentations). Funding from the grant was used to design the iCOGS and Oncoarray custom genotyping arrays, and was used to cover the cost of genotyping BRCA1 carrier DNA samples for the GWAS, iCOGS, and Oncoarray projects. Any manuscript using these arrays or using data derived from genotyping studies of BRCA1 carriers using these arrays was required to acknowledge the grant.

Aim 3: To evaluate risk modifiers from the *BRCA1* breast cancer GWAS and risk factors from sporadic ovarian cancer GWAS as modifiers of ovarian cancer in *BRCA1* carriers.

Task 10. Compare data with *BRCA1* breast GWAS and sporadic ovarian GWAS.

Meta-analysis for ovarian cancer risk in *BRCA1* carriers and the general population

To improve statistical power to identify ovarian cancer risk loci for *BRCA1* mutation carriers, a meta-analysis of association test results from the *BRCA1* iCOGS study (12,790 unaffected; 2,462 affected) and Ovarian Cancer Association Consortium iCOGS study of ovarian cancer in the general population (18,174 EOC cases; 26,134 controls) was conducted. Six new genome wide significant loci were identified through this process including: rs3820282 in *WNT4* ($p=2.0 \times 10^{-8}$); rs12039431 *RSPO1* ($p=1.44 \times 10^{-11}$); rs17329882 in *SYNPO2* ($p=1.95 \times 10^{-8}$); rs115344852 in *GPX5* ($p=3.15 \times 10^{-8}$); 136138765 in *ABO* ($p=1.95 \times 10^{-8}$); rs8044477 in *GOT2* ($p=1.0 \times 10^{-8}$). All were novel associations that also showed significance ($p<0.05$) in *BRCA1* carriers alone. This effort increased the number of risk loci for ovarian cancer in *BRCA1* mutation carriers to 18 [8]. All of these ovarian cancer risk loci combined explain 3.9% of the excess familial relative risk of epithelial ovarian cancer in the general population and account for approximately 5.2% of the polygenic modifying variance for epithelial ovarian cancer in *BRCA1* mutation carriers and 9.3% of the variance in *BRCA2* mutation carriers.

Ovarian cancer risk models

All variants associated with ovarian cancer risk in *BRCA1* carriers were used to develop risk models for improved age specific ovarian cancer risk assessments for *BRCA1* mutation carriers. Based on the distribution of the established *BRCA1* ovarian cancer risk modifiers, the 5% of *BRCA1* mutation carriers at lowest risk will have a lifetime risk of developing ovarian cancer of 28% or lower whereas the 5% at highest risk will have a lifetime risk of 63% or higher. Such differences in lifetime or age-specific risks may have practical implications for cancer screening, timing of interventions and family planning for *BRCA1* mutation carriers [7,8].

Position Dependent Risks associated with *BRCA1* and *BRCA2* mutations

An observational study of women with disease-associated *BRCA1* or *BRCA2* mutations who were ascertained between 1937 and 2011 (median, 1999) was conducted. The international sample comprised 19,581 carriers of *BRCA1* mutations and 11,900 carriers of *BRCA2* mutations from 55 centers in 33 countries on 6 continents. Among *BRCA1* mutation carriers, 9052 women (46%) were diagnosed with breast cancer, 2317 (12%) with ovarian cancer, 1041 (5%) with breast and ovarian cancer, and 7171 (37%) without cancer. Among *BRCA2* mutation carriers, 6180 women (52%) were diagnosed with breast cancer, 682 (6%) with ovarian cancer, 272 (2%) with breast and ovarian cancer, and 4766 (40%) without cancer. Hazard ratios for breast and

ovarian cancer were estimated based on mutation type, function, and nucleotide position. The ratio of breast vs ovarian cancer hazard ratios (RHR) was also estimated.

In *BRCA1*, an ovarian cancer cluster region (OCCR) from c.1380 to c.4062 (approximately exon 11) ($P = 9 \times 10^{-17}$) was identified. In *BRCA2*, two OCCRs were identified. The first (OCCR1) spanned c.3249 to c.5681 ($P = 6 \times 10^{-17}$). The second OCCR spanned c.6645 to c.7471 ($P = 0.001$) [9]. In summary, breast and ovarian cancer risks varied by type and location of *BRCA1/2* mutations. With appropriate validation, these data may have implications for risk assessment and cancer prevention decision making for carriers of *BRCA1* and *BRCA2* mutations [9].

19p13.1 fine mapping

We previously reported that variants from the 19p13.1 locus were associated with ovarian cancer risk with the rs67397200 SNP at 19p13.1 associated with ovarian cancer risk in *BRCA1* (HR=1.16; 95%CI 1.05-1.29; $p=3.8 \times 10^{-4}$) and *BRCA2* (HR=1.30; 95%CI 1.10-1.52; $p=1.8 \times 10^{-3}$) mutation carriers. This SNP and others in this locus were also associated with breast cancer risk in *BRCA1* mutation carriers. To fine map the 19p13.1 locus in an effort to identify the causative variants in this region a meta-analysis of results from the OCAC and *BRCA1* ovarian cancer studies and the BCAC and *BRCA1* breast cancer studies using 1000 Genomes imputed SNP was conducted. Genotyping data from the iCOGS genotyping array for 438 SNPs in this region in 46,451 breast and 15,438 ovarian cancer cases, 15,252 *BRCA1* mutation carriers and 73,444 controls were used. A region containing 13 highly correlated SNPs spanning the *BABAM1*, *ANKLE1* and *ABHD8* genes was associated with serous ovarian cancer (top hit rs4808075, $P=9.2 \times 10^{-20}$), ER-negative breast cancer (rs67397200, $P=1.1 \times 10^{-13}$) and breast cancer in *BRCA1* mutation carriers (rs61494113, $P=7.7 \times 10^{-16}$). This region was also associated specifically with triple negative breast cancer in the general population ($P\text{-diff}=2 \times 10^{-5}$). Functional characterization of this locus was performed in breast and ovarian tissues and cell lines. Genotype-gene expression associations were identified for *ANKLE1* in normal ovarian epithelial cells ($P=0.002$) and for *ABHD8* in breast and ovarian tumors ($P = 3.0 \times 10^{-5}$) and normal breast tissues ($P=2 \times 10^{-3}$); *ABHD8* overexpression induced a significant reduction in invasion and migration; chromosome conformation capture (3C) identified an interaction between four risk SNPs and the *ABHD8* promoter; CRISPR/Cas9 targeted deletion of a risk SNP (rs56069439) overlapping a putative enhancer induced *ANKLE1* downregulation; and mRNA stability and enhancer assays indicated functional effects for six candidate causal SNPs. Taken together, these data suggest that multiple risk SNPs in this region regulate *ABHD8* and *ANKLE1* expression, and indicate there are common underlying mechanisms in both breast and ovarian cancer.

Task 11. Design genotyping assays for candidate SNPs.

We designed a custom Illumina array named the ‘OncoArray’, in order to replicate previous GWAS findings and identify new cancer susceptibility loci. The OncoArray includes ~533,000 variants (of which 260,660 formed a GWAS backbone) and has been used to genotype over 500,000 samples, including ovarian cancer case-control studies of the Ovarian Cancer Association Consortium (OCAC) and *BRCA1* and *BRCA2* mutation carriers of the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA).

Task 12. Genotype *BRCA1* carrier DNAs for candidate SNPs.

A total of 15,694 *BRCA1* mutation-carriers including 2,372 with ovarian cancer and 10,988 *BRCA2* mutation carriers including 849 with ovarian cancer were genotyped on the Oncoarray in the Mayo Clinic, NCI-supported Center for Inherited Disease Research, Genome Quebec, and the University of Cambridge. Oncoarray sample quality control was essentially as described for Task 3. Samples with genotyping call rate < 95%, excessively low or high heterozygosity, not female, ambiguous sex, or duplicates (cryptic or intended) were excluded. SNPs with a call rate <95%, SNPs deviating from Hardy-Weinberg equilibrium ($P < 10^{-7}$ in controls or unrelated samples in CIMBA and $P < 10^{-12}$ in cases) and SNPs with concordance <98% among 5,280 duplicate pairs were excluded. For the imputation, SNPs with a MAF <1%, call rate <98%, or not linked to the 1000 genomes reference were excluded. Of the 533,631 SNPs manufactured on the array, 494,813 SNPs passed the initial quality control and 470,825 SNPs were used for imputation.

Task 13. Data analysis.

At the conclusion of the grant the research described below had not yet been completed. We include a brief description of the data analysis and outcome from the Oncoarray project that has been completed since then in order to demonstrate that all Tasks in the SOW were completed. Much of this material is unpublished.

To identify SNPs associated with ovarian cancer data from OCAC and CIMBA from iCOGS and Oncoarray studies were combined in a meta-analysis. We obtained genotype data on 3,342 (584 affected) *BRCA1* and 1,424 (105 affected) *BRCA2* non-overlapping samples from iCOGS array. When combined with the oncoarray study, genotype data from 19,036 *BRCA1* carriers including 2,933 with ovarian cancer and 12,412 *BRCA2* mutation carriers including 954 with ovarian cancer were available for analysis. The OCAC OncoArray data set comprised 63 genotyping project/case-controls sets including 66,450 samples from seven genotyping projects: 40,941 controls, 22,406 invasive cases and 3,103 borderline cases. For the logarithm of the per-allele hazard ratio estimate for the association with ovarian cancer risk in *BRCA1* and *BRCA2* mutation carriers and the logarithm of the per-allele odds ratio estimate for the association with ovarian cancer in OCAC. Association analyses for OCAC revealed 12 novel loci associated with ovarian cancer at genome-wide significance ($p < 5 \times 10^{-8}$) in the general population (unpublished data). The meta-analysis of OCAC and CIMBA revealed three additional ovarian cancer loci. Eighteen of the 22 previously published ovarian cancer loci were associated with the same histotype at genome-wide significance. Of these, 11 showed an association with serous ovarian cancer risk for *BRCA1* mutation carriers and eight showed an association with risk for *BRCA2* carriers ($P < 0.05$) (unpublished data). In total there are 34 loci associated with various subtypes of ovarian cancer for women of European ancestry, of which 27 are associated with all invasive serous ovarian cancer ($P < 0.01$) and 27 are associated with ovarian cancer in *BRCA1* mutation carriers. These 27 loci account for approximately 6.4% of the polygenic risk in the population (unpublished data). Incorporating common susceptibility variants into risk assessment tools will improve risk prediction and may be particularly useful for refining risk estimates in *BRCA1* and *BRCA2* mutation carriers.

Personnel Receiving Pay from this Grant at Any Point in the Project:

	Year 1	Year 2	Year 3	NCE
Fergus J. Couch, Ph.D.	7.33%	8.17%	7.50%	6.58%

Gaofeng Cui, Ph.D.	20.83%	
Susan Slager, Ph.D.	2.83%	
Xianshu Wang, Ph.D.		12.5%

NOTE: Informatics and statistics personnel are not itemized here because they were billed as Internal Services at a departmental charge-out rate rather than receiving individual salary support.

4. Key Research Accomplishments:

- Genome wide associations studies have identified 27 modifiers of ovarian cancer risk among *BRCA1* carriers.
- A modifier locus on chromosome 4q32 is unique to *BRCA1* carriers.
- Altered expression of *ABHD8* and *ANKLE1* account for the increased ovarian cancer risk associated with common variants on chromosome 19p13.1.
- Personalized ovarian cancer risk prediction models for *BRCA1* carriers identified women with lifetime risks ranging from 28% to 63%.
- Risks of ovarian cancer associated with *BRCA1* mutations are modified by the position of the mutation in the *BRCA1* gene.

5. Conclusion:

In summary, we have completed multiple phases of GWAS aimed at identifying ovarian cancer risk modifiers among *BRCA1* mutation carriers. We showed that variants from 25 loci that have been associated with risk of ovarian cancer in the general population are risk modifiers of ovarian cancer for *BRCA1* mutation carriers. In addition, two novel loci at 4q32 and 17q21 have been associated with ovarian cancer risk in *BRCA1* carriers but not in the general population. Of these the 4q32 locus was not associated with ovarian cancer in *BRCA2* mutation carriers. Thus, specific modifiers of ovarian cancer risk exist for this population. The 27 risk modifiers of ovarian cancer risk are useful for predicting differences in individual ovarian cancer risk among *BRCA1* mutation carriers. Estimation of personalized risks of ovarian cancer for *BRCA1* mutation carriers will be made available in the Boadicea risk prediction program.

6. Publications, Abstracts, and Presentations:

1. Lay Press: Nothing to Report
2. Peer Reviewed Scientific Journals

Note: There are many publications resulting from this grant beyond those referenced in this report (see Publications, Abstracts, and Presentations). Funding from the grant was used to design the iCOGS and Oncoarray custom genotyping arrays, and was used to cover the cost of genotyping *BRCA1* carrier DNA samples for the GWAS, iCOGS, and Oncoarray projects. Any manuscript using these arrays or using data derived from genotyping studies of *BRCA1* carriers using these arrays was required to acknowledge the grant.

1. Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, Lee A, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Barile M, Pensotti V, Pasini B, Dolcetti R, Giannini G, Laura Putignano A, Varesco L, Radice P, Mai PL, Greene MH, Andrulis IL, Glendon G, Ozcelik H, Thomassen M, Gerdes AM, Kruse TA, Birk Jensen U, Crüger DG, Caligo MA, Laitman Y, Milgrom R, Kaufman B, Paluch-Shimon S, Friedman E, Loman N, Harbst K, Lindblom A, Arver B, Ehrencrona H, Melin B, SWE-BRCA, Nathanson KL, Domchek SM, Rebbeck T, Jakubowska A, Lubinski J, Gronwald J, Huzarski T, Byrski T, Cybulski C, Gorski B, Osorio A, Ramón Y Cajal T, Fostira F, Andrés R, Benitez J, Hamann U, Hogervorst FB, Rookus MA, Hooning MJ, Nelen MR, van der Luijt RB, van Os TA, van Asperen CJ, Devilee P, Meijers-Heijboer

HE, Gómez García EB; HEBON, Peock S, Cook M, Frost D, Platte R, Leyland J, Gareth Evans D, Lalloo F, Eeles R, Izatt L, Adlard J, Davidson R, Eccles D, Ong KR, Cook J, Douglas F, Paterson J, John Kennedy M, Miedzybrodzka Z; EMBRACE, Godwin A, Stoppa-Lyonnet D, Buecher B, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Lasset C, Leroux D, Faivre L, Bronner M, Prieur F, Nogues C, Rouleau E, Pujol P, Coupier I, Frénay M; CEMO Study Collaborators, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D; Breast Cancer Family Registry, Singer CF, Tea MK, Pfeiler G, Catharina Dressler A, Hansen TV, Jønson L, Ejlersen B, Bjork Barkardottir R, Kirchhoff T, Offit K, Piedmonte M, Rodriguez G, Small L, Boggess J, Blank S, Basil J, Azodi M, Ewart Toland A, Montagna M, Tognazzo S, Agata S, Imyanitov E, Janavicius R, Lazaro C, Blanco I, Pharoah PD, Sucheston L, Karlan BY, Walsh CS, Olah E, Bozsik A, Teo SH, Seldon JL, Beattie MS, van Rensburg EJ, Sluiter MD, Diez O, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ruehl I, Varon-Mateeva R, Kast K, Deissler H, Niederacher D, Arnold N, Gadzicki D, Schönbuchner I, Caldes T, de la Hoya M, Nevanlinna H, Aittomäki K, Dumont M, Chiquette J, Tischkowitz M, Chen X, Beesley J, Spurdle AB; kConFab investigators, Neuhausen SL, Chun Ding Y, Fredericksen Z, Wang X, Pankratz VS, Couch F, Simard J, Easton DF, Chenevix-Trench G; on behalf of CIMBA. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Hum Mol Genet.* 20(16):3304-3321, 2011. PMC3652640.

2. Cox DG, Simard J, Sinnett D, Hamdi Y, Soucy P, Ouimet M, Barjhoux L, Verny-Pierre C, McGuffog L, Healey S, Szabo C, Greene MH, Mai PL, Andrulis IL; Ontario Cancer Genetics Network, Thomassen M, Gerdes AM, Caligo MA, Friedman E, Laitman Y, Kaufman B, Paluch SS, Borg A, Karlsson P, Stenmark Askmalm M, Barbany Bustinza G; SWE-BRCA Collaborators, Nathanson KL, Domchek SM, Rebbeck TR, Benítez J, Hamann U, Rookus MA, van den Ouweland AM, Ausems MG, Aalfs CM, van Asperen CJ, Devilee P, Gille HJ; HEBON; EMBRACE, Peock S, Frost D, Evans DG, Eeles R, Izatt L, Adlard J, Paterson J, Eason J, Godwin AK, Remon MA, Moncoutier V, Gauthier-Villars M, Lasset C, Giraud S, Hardouin A, Berthet P, Sobol H, Eisinger F, Bressac de Paillerets B, Caron O, Delnatte C; GEMO Study Collaborators, Goldgar D, Miron A, Ozelik H, Buys S, Southey MC, Terry MB; The Breast Cancer Family Registry, Singer CF, Dressler AC, Tea MK, Hansen TV, Johannsson O, Piedmonte M, Rodriguez GC, Basil JB, Blank S, Toland AE, Montagna M, Isaacs C, Blanco I, Gayther SA, Moysich KB, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Niederacher D, Sutter C, Gadzicki D, Fiebig B, Caldes T, Laframboise R, Nevanlinna H, Chen X, Beesley J, Spurdle AB, Neuhausen SL, Ding YC, Couch FJ, Wang X, Peterlongo P, Manoukian S, Bernard L, Radice P, Easton DF, Chenevix-Trench G, Antoniou AC, Stoppa-Lyonnet D, Mazoyer S, Sinilnikova OM; on behalf of the Consortium of Investigators of Modifiers of BRCA1/2. Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. *Hum Mol Genet.* 20(23):4732-4747, 2011. PMC3733139.
3. Ramus SJ, Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Sinilnikova OM, Healey S, Barrowdale D, Lee A, Thomassen M, Gerdes AM, Kruse TA, Jensen UB, Skytte AB, Caligo MA, Liljegren A, Lindblom A, Olsson H, Kristoffersson

U, Stenmark-Askmal M, Melin B; SWE-BRCA, Domchek SM, Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J, Jaworska K, Durda K, Złowocka E, Gronwald J, Huzarski T, Byrski T, Cybulski C, Toloczko-Grabarek A, Osorio A, Benitez J, Duran M, Tejada MI, Hamann U, Rookus M, van Leeuwen FE, Aalfs CM, Meijers-Heijboer HE, van Asperen CJ, van Roozendaal KE, Hoogerbrugge N, Margriet Collée J, Kriege M, van der Luijt RB; HEBON; EMBRACE, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Jacobs C, Eeles R, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Paterson J, Douglas F, Brewer C, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Pathak H, Godwin AK, Stoppa-Lyonnet D, Caux-Moncoutier V, de Pauw A, Gauthier-Villars M, Mazoyer S, Léoné M, Calender A, Lasset C, Bonadona V, Hardouin A, Berthet P, Bignon YJ, Uhrhammer N, Faivre L, Loustalot C; GEMO, Buys S, Daly M, Miron A, Beth Terry M, Chung W, John EM, Southey M, Goldgar D, Singer CF, Tea Maria MK, Pfeiler G, Fink-Retter A, Hansen TV, Ejlersen B, Johannsson OT, Offit K, Kirchhoff T, Gaudet MM, Vijai J, Robson M, Piedmonte M, Phillips KA, Van Le L, Hoffman JS, Toland AE, Montagna M, Tognazzo S, Imyanitov E, Isaacs C, Janavicius R, Lazaro C, Blanco I, Tornero E, Navarro M, Moysich KB, Karlan BY, Gross J, Olah E, Vaszko T, Teo SH, Ganz PA, Beattie MS, Dorfing CM, van Rensburg EJ, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Schäfer D, Caldes T, de la Hoya M, Nevanlinna H, Aittomäki K, Plante M, Spurdle AB; kConFab, Neuhausen SL, Ding YC, Wang X, Lindor N, Fredericksen Z, Pankratz VS, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Bonanni B, Bernard L, Dolcetti R, Papi L, Ottini L, Radice P, Greene MH, Mai PL, Andrulis IL, Glendon G, Ozcelik H; OCGN, Pharoah PD, Gayther SA, Simard J, Easton DF, Couch FJ, Chenevix-Trench G. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Hum Mutat.* 33(4):690-702, 2012. PMC3458423.

4. Stevens KN, Kelemen LE, Wang X, Fridley BL, Vierkant RA, Fredericksen Z, Armasu SM, Tsai YY, Berchuck A, Association Consortium OC, Narod SA, Phelan CM, Sutphen R, Birrer MJ, Schildkraut JM, Sellers TA, Goode EL, Couch FJ. Common variation in Nemo-like kinase (NLK) is associated with risk of ovarian cancer. *Cancer Epidemiol Biomarkers* 21(3):523-8, 2012. PMC3297683.
5. Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Lee A, Barrowdale D, Healey S, Sinilnikova OM, Caligo MA, Loman N, Harbst K, Lindblom A, Arver B, Rosenquist R, Karlsson P, Nathanson K, Domchek S, Rebbeck T, Jakubowska A, Lubinski J, Jaworska K, Durda K, Złowocka-Perłowska E, Osorio A, Duran M, Andres R, Benitez J, Hamann U, Hogervorst FB, A van O T, Verhoef S, Meijers-Heijboer HE, Wijnen J, Gomez Garcia EB, Ligtenberg MJ, Kriege M, Collee JM, Ausems MG, Oosterwijk JC, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Jacobs C, Eeles R, Adlard J, Davidson R, Cole T, Cook J, Paterson J, Douglas F, Brewer C, Hodgson S, Morrison PJ, Walker L, Rogers MT, Donaldson A, Dorkins H, Godwin AK, Bove B, Stoppa-Lyonnet D, Houdayer C, Buecher B, de Pauw A, Mazoyer S, Calender A, Leone M, Bressac-de Paillerets B, Caron O, Sobol H, Frenay M, Prieur F, Fert Ferrer S, Mortemousque I, Buys S, Daly M, Miron A, Terry MB, Hopper JL, John

EM, Southey M, Goldgar D, Singer CF, Fink-Retter A, Tea MK, Geschwantler Kaulich D, Hansen TV, Nielsen FC, Barkardottir RB, Gaudet M, Kirchhoff T, Joseph V, Dutra-Clarke A, Offit K, Piedmonte M, Kirk J, Cohn D, Hurteau J, Byron J, Fiorica J, Toland AE, Montagna M, Olini C, Imyanitov E, Isaacs C, Tihomirova L, Blanco I, Lazaro C, Teule A, Del Valle J, Gayther SA, Odunsi K, Gross J, Karlan BY, Olah E, Teo SH, Ganz PA, Beattie MS, Dorfling CM, Jansen van Rensburg E, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Schafer D, Caldes T, de la Hoya M, Nevanlinna H, Muranen TA, Lesperance B, Spurdle AB, Neuhausen SL, Ding YC, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Bonanni B, Bernard L, Dolcetti R, Papi L, Ottini L, Radice P, Greene MH, Loud JT, Andrulis IL, Ozcelik H, Mulligan AM, Glendon G, Thomassen M, Gerdes AM, Jensen UB, Skytte AB, Kruse TA, Chenevix-Trench G, Couch FJ, Simard J, Easton DF, Swedish Breast Cancer Study, HEBON, EMBRACE, GEMO Collaborators, kConFab Investigators. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. *Breast Cancer Res.* 14(1):R33, 2012. PMC3496151.

6. Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, Wang X, Kirchhoff T, McGuffog L, Barrowdale D, Lee A, Healey S, Sinilnikova OM, Andrulis IL; for OCGN, Ozcelik H, Mulligan AM, Thomassen M, Gerdes AM, Jensen UB, Skytte AB, Kruse TA, Caligo MA, von Wachenfeldt A, Barbany-Bustinza G, Loman N, Soller M, Ehrencrona H, Karlsson P; for SWE-BRCA, Nathanson KL, Rebbeck TR, Domchek SM, Jakubowska A, Lubinski J, Jaworska K, Durda K, Zlowocka E, Huzarski T, Byrski T, Gronwald J, Cybulski C, Górski B, Osorio A, Durán M, Tejada MI, Benitez J, Hamann U, Hogervorst FB; for HEBON, van Os TA, van Leeuwen FE, Meijers-Heijboer HE, Wijnen J, Blok MJ, Kets M, Hooning MJ, Oldenburg RA, Ausems MG, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Jacobs C, Eeles RA, Adlard J, Davidson R, Eccles DM, Cole T, Cook J, Paterson J, Brewer C, Douglas F, Hodgson SV, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Side LE; for EMBRACE, Bove B, Godwin AK, Stoppa-Lyonnet D; for GEMO Study Collaborators, Fassy-Colcombet M, Castera L, Cornelis F, Mazoyer S, Léoné M, Boutry-Kryza N, Bressac-de Paillerets B, Caron O, Pujol P, Coupier I, Delnatte C, Akloul L, Lynch HT, Snyder CL, Buys SS, Daly MB, Terry M, Chung WK, John EM, Miron A, Southey MC, Hopper JL, Goldgar DE, Singer CF, Rappaport C, Tea MK, Fink-Retter A, Hansen TV, Nielsen FC, Arason A, Vijai J, Shah S, Sarrel K, Robson ME, Piedmonte M, Phillips K, Basil J, Rubinstein WS, Boggess J, Wakeley K, Ewart-Toland A, Montagna M, Agata S, Imyanitov EN, Isaacs C, Janavicius R, Lazaro C, Blanco I, Feliubadalo L, Brunet J, Gayther SA, Pharoah PP, Odunsi KO, Karlan BY, Walsh CS, Olah E, Teo SH, Ganz PA, Beattie MS, van Rensburg EJ, Dorfling CM, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Heinritz W, Caldes T, de la Hoya M, Muranen TA, Nevanlinna H, Tischkowitz MD, Spurdle AB, Neuhausen SL, Ding YC, Lindor NM, Fredericksen Z, Pankratz VS, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Barile

M, Bernard L, Viel A, Giannini G, Varesco L, Radice P, Greene MH, Mai PL, Easton DF, Chenevix-Trench G; for kConFab investigators, Offit K, Simard J; on behalf of the Consortium of Investigators of Modifiers of BRCA1/2. Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *Cancer Epidemiol Biomarkers Prev.* 21(4):645-657, 2012. PMC3319317.

7. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE, Hillman KM, Mai PL, Lawrenson K, Stutz MD, Lu Y, Karevan R, Woods N, Johnston RL, French JD, Chen X, Weischer M, Nielsen SF, Maranian MJ, Ghoussaini M, Ahmed S, Baynes C, Bolla MK, Wang Q, Dennis J, McGuffog L, Barrowdale D, Lee A, Healey S, Lush M, Tessier DC, Vincent D, Bacot F; Australian Cancer Study; Australian Ovarian Cancer Study; Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer (kConFab); Gene Environment Interaction and Breast Cancer (GENICA); Swedish Breast Cancer Study (SWE-BRCA); Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON); Epidemiological study of BRCA1 & BRCA2 Mutation Carriers (EMBRACE); Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO), Vergote I, Lambrechts S, Despiere E, Risch HA, González-Neira A, Rossing MA, Pita G, Doherty JA, Alvarez N, Larson MC, Fridley BL, Schoof N, Chang-Claude J, Cicek MS, Peto J, Kalli KR, Brooks A, Armasu SM, Schmidt MK, Braaf LM, Winterhoff B, Nevanlinna H, Konecny GE, Lambrechts D, Rogmann L, Guénel P, Teoman A, Milne RL, Garcia JJ, Cox A, Shridhar V, Burwinkel B, Marme F, Hein R, Sawyer EJ, Haiman CA, Wang-Gohrke S, Andrulis IL, Moysich KB, Hopper JL, Odunsi K, Lindblom A, Giles GG, Brenner H, Simard J, Lurie G, Fasching PA, Carney ME, Radice P, Wilkens LR, Swerdlow A, Goodman MT, Brauch H, Garcia-Closas M, Hillemanns P, Winqvist R, Dürst M, Devilee P, Runnebaum I, Jakubowska A, Lubinski J, Mannermaa A, Butzow R, Bogdanova NV, Dörk T, Pelttari LM, Zheng W, Leminen A, Anton-Culver H, Bunker CH, Kristensen V, Ness RB, Muir K, Edwards R, Meindl A, Heitz F, Matsuo K, du Bois A, Wu AH, Harter P, Teo SH, Schwaab I, Shu XO, Blot W, Hosono S, Kang D, Nakanishi T, Hartman M, Yatabe Y, Hamann U, Karlan BY, Sangrajrang S, Kjaer SK, Gaborieau V, Jensen A, Eccles D, Høgdall E, Shen CY, Brown J, Woo YL, Shah M, Azmi MA, Luben R, Omar SZ, Czene K, Vierkant RA, Nordestgaard BG, Flyger H, Vachon C, Olson JE, Wang X, Levine DA, Rudolph A, Weber RP, Flesch-Janys D, Iversen E, Nickels S, Schildkraut JM, Silva Idos S, Cramer DW, Gibson L, Terry KL, Fletcher O, Vitonis AF, van der Schoot CE, Poole EM, Hogervorst FB, Tworoger SS, Liu J, Bandera EV, Li J, Olson SH, Humphreys K, Orlov I, Blomqvist C, Rodriguez-Rodriguez L, Aittomäki K, Salvesen HB, Muranen TA, Wik E, Brouwers B, Krakstad C, Wauters E, Halle MK, Wildiers H, Kiemeny LA, Mulot C, Aben KK, Laurent-Puig P, Altena AM, Truong T, Massuger LF, Benitez J, Pejovic T, Perez JI, Hoatlin M, Zamora MP, Cook LS, Balasubramanian SP, Kelemen LE, Schneeweiss A, Le ND, Sohn C, Brooks-Wilson A, Tomlinson I, Kerin MJ, Miller N, Cybulski C, Henderson BE, Menkiszak J, Schumacher F, Wentzensen N, Le Marchand L, Yang HP, Mulligan AM, Glendon G, Engelholm SA, Knight JA, Høgdall CK, Apicella C, Gore M, Tsimiklis H, Song H, Southey MC, Jager A, den Ouweland AM, Brown R, Martens JW, Flanagan JM, Kriege M, Paul J, Margolin S, Siddiqui N, Severi G, Whittemore AS, Baglietto L,

McGuire V, Stegmaier C, Sieh W, Müller H, Arndt V, Labrèche F, Gao YT, Goldberg MS, Yang G, Dumont M, McLaughlin JR, Hartmann A, Ekici AB, Beckmann MW, Phelan CM, Lux MP, Permuth-Wey J, Peissel B, Sellers TA, Ficarazzi F, Barile M, Ziogas A, Ashworth A, Gentry-Maharaj A, Jones M, Ramus SJ, Orr N, Menon U, Pearce CL, Brüning T, Pike MC, Ko YD, Lissowska J, Figueroa J, Kupryjanczyk J, Chanock SJ, Dansonka-Mieszkowska A, Jukkola-Vuorinen A, Rzepecka IK, Pylkäs K, Bidzinski M, Kauppila S, Hollestelle A, Seynaeve C, Tollenaar RA, Durda K, Jaworska K, Hartikainen JM, Kosma VM, Kataja V, Antonenkova NN, Long J, Shrubsole M, Deming-Halverson S, Lophatananon A, Siriwanarangsarn P, Stewart-Brown S, Ditsch N, Lichtner P, Schmutzler RK, Ito H, Iwata H, Tajima K, Tseng CC, Stram DO, van den Berg D, Yip CH, Ikram MK, Teh YC, Cai H, Lu W, Signorello LB, Cai Q, Noh DY, Yoo KY, Miao H, Iau PT, Teo YY, McKay J, Shapiro C, Ademuyiwa F, Fountzilas G, Hsiung CN, Yu JC, Hou MF, Healey CS, Luccarini C, Peock S, Stoppa-Lyonnet D, Peterlongo P, Rebbeck TR, Piedmonte M, Singer CF, Friedman E, Thomassen M, Offit K, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Garber J, Narod SA, Weitzel JN, Montagna M, Olah E, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Imyanitov EN, Tihomirova L, Arun BK, Campbell I, Mensenkamp AR, van Asperen CJ, van Roozendaal KE, Meijers-Heijboer H, Collée JM, Oosterwijk JC, Hooning MJ, Rookus MA, van der Luijt RB, Os TA, Evans DG, Frost D, Fineberg E, Barwell J, Walker L, Kennedy MJ, Platte R, Davidson R, Ellis SD, Cole T, Bressac-de Paillerets B, Buecher B, Damiola F, Faivre L, Frenay M, Sinilnikova OM, Caron O, Giraud S, Mazoyer S, Bonadona V, Caux-Moncoutier V, Toloczko-Grabarek A, Gronwald J, Byrski T, Spurdle AB, Bonanni B, Zaffaroni D, Giannini G, Bernard L, Dolcetti R, Manoukian S, Arnold N, Engel C, Deissler H, Rhiem K, Niederacher D, Plendl H, Sutter C, Wappenschmidt B, Borg A, Melin B, Rantala J, Soller M, Nathanson KL, Domchek SM, Rodriguez GC, Salani R, Kaulich DG, Tea MK, Paluch SS, Laitman Y, Skytte AB, Kruse TA, Jensen UB, Robson M, Gerdes AM, Ejlersen B, Foretova L, Savage SA, Lester J, Soucy P, Kuchenbaecker KB, Olswold C, Cunningham JM, Slager S, Pankratz VS, Dicks E, Lakhani SR, Couch FJ, Hall P, Monteiro AN, Gayther SA, Pharoah PD, Reddel RR, Goode EL, Greene MH, Easton DF, Berchuck A, Antoniou AC, Chenevix-Trench G, Dunning AM. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nat Genet.* 45(4):371-84, 2013. PMC3670748.

8. Gaudet MM, Kuchenbaecker KB, Vijai J, Klein RJ, Kirchhoff T, McGuffog L, Barrowdale D, Dunning AM, Lee A, Dennis J, Healey S, Dicks E, Soucy P, Sinilnikova OM, Pankratz VS, Wang X, Eldridge RC, Tessier DC, Vincent D, Bacot F, Hogervorst FB, Peock S, Stoppa-Lyonnet D; KConFab Investigators, Peterlongo P, Schmutzler RK, Nathanson KL, Piedmonte M, Singer CF, Thomassen M; Ontario Cancer Genetics Network, Hansen TV, Neuhausen SL, Blanco I, Greene MH, Garber J, Weitzel JN, Andrulis IL, Goldgar DE, D'Andrea E, Caldes T, Nevanlinna H, Osorio A, van Rensburg EJ, Arason A, Rennert G, van den Ouweland AM, van der Hout AH, Kets CM, Aalfs CM, Wijnen JT, Ausems MG; HEBON; EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Jacobs C, Adlard J, Tischkowitz M, Porteous ME, Damiola F; GEMO Study Collaborators, Golmard L, Barjhoux L, Longy M, Belotti M, Ferrer SF, Mazoyer S, Spurdle AB, Manoukian S, Barile M, Genuardi M, Arnold N, Meindl A, Sutter C, Wappenschmidt B, Domchek SM, Pfeiler G, Friedman E, Jensen UB, Robson M, Shah

S, Lazaro C, Mai PL, Benitez J, Southey MC, Schmidt MK, Fasching PA, Peto J, Humphreys MK, Wang Q, Michailidou K, Sawyer EJ, Burwinkel B, Guénel P, Bojesen SE, Milne RL, Brenner H, Lochmann M; GENICA Network, Aittomäki K, Dörk T, Margolin S, Mannermaa A, Lambrechts D, Chang-Claude J, Radice P, Giles GG, Haiman CA, Winqvist R, Devillee P, García-Closas M, Schoof N, Hooning MJ, Cox A, Pharoah PD, Jakubowska A, Orr N, González-Neira A, Pita G, Alonso MR, Hall P, Couch FJ, Simard J, Altshuler D, Easton DF, Chenevix-Trench G, Antoniou AC, Offit K. Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. *PLoS Genet.* 9(3):e1003173, 2013. PMC3609647.

9. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, Lee A, Bacot F, Vincent D, Hogervorst FB, Peock S, Stoppa-Lyonnet D, Jakubowska A, Investigators K, Radice P, Schmutzler RK; SWE-BRCA, Domchek SM, Piedmonte M, Singer CF, Friedman E, Thomassen M; Ontario Cancer Genetics Network, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Greene MH, Karlan BY, Garber J, Phelan CM, Weitzel JN, Montagna M, Olah E, Andrulis IL, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Nevanlinna H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, Hamann U, Ramus SJ, Ewart Toland A, Caligo MA, Olopade OI, Tung N, Claes K, Beattie MS, Southey MC, Imyanitov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez O, Balmaña J, Barkardottir RB, Arun BK, Rennert G, Teo SH, Ganz PA, Campbell I, van der Hout AH, van Deurzen CH, Seynaeve C, Gómez Garcia EB, van Leeuwen FE, Meijers-Heijboer HE, Gille JJ, Ausems MG, Blok MJ, Ligtenberg MJ, Rookus MA, Devillee P, Verhoef S, van Os TA, Wijnen JT; HEBON; EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Izatt L, Eeles RA, Adlard J, Eccles DM, Cook J, Brewer C, Douglas F, Hodgson S, Morrison PJ, Side LE, Donaldson A, Houghton C, Rogers MT, Dorkins H, Eason J, Gregory H, McCann E, Murray A, Calender A, Hardouin A, Berthet P, Delnatte C, Nogues C, Lasset C, Houdayer C, Leroux D, Rouleau E, Prieur F, Damiola F, Sobol H, Coupier I, Venat-Bouvet L, Castera L, Gauthier-Villars M, Léoné M, Pujol P, Mazoyer S, Bignon YJ; GEMO Study Collaborators, Złowocka-Perłowska E, Gronwald J, Lubinski J, Durda K, Jaworska K, Huzarski T, Spurdle AB, Viel A, Peissel B, Bonanni B, Melloni G, Ottini L, Papi L, Varesco L, Tibiletti MG, Peterlongo P, Volorio S, Manoukian S, Pensotti V, Arnold N, Engel C, Deissler H, Gadzicki D, Gehrig A, Kast K, Rhiem K, Meindl A, Niederacher D, Ditsch N, Plendl H, Preisler-Adams S, Engert S, Sutter C, Varon-Mateeva R, Wappenschmidt B, Weber BH, Arver B, Stenmark-Askmal M, Loman N, Rosenquist R, Einbeigi Z, Nathanson KL, Rebbeck TR, Blank SV, Cohn DE, Rodriguez GC, Small L, Friedlander M, Bae-Jump VL, Fink-Retter A, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, Lindor NM, Kaufman B, Shimon Paluch S, Laitman Y, Skytte AB, Gerdes AM, Pedersen IS, Moeller ST, Kruse TA, Jensen UB, Vijai J, Sarrel K, Robson M, Kauff N, Mulligan AM, Glendon G, Ozelik H, Ejlertsen B, Nielsen FC, Jønson L, Andersen MK, Ding YC, Steele L, Foretova L, Teulé A, Lazaro C, Brunet J, Pujana MA, Mai PL, Loud JT, Walsh C, Lester J, Orsulic S, Narod SA, Herzog J, Sand SR, Tognazzo S, Agata S, Vaszko T, Weaver J, Stavropoulou AV, Buys SS, Romero A, de la Hoya M, Aittomäki K, Muranen TA, Duran M, Chung WK, Lasa A, Dorfling CM, Miron A; BCFR, Benitez J, Senter L, Huo D, Chan SB, Sokolenko AP, Chiquette J, Tihomirova L,

Friebel TM, Agnarsson BA, Lu KH, Lejbkowitz F, James PA, Hall P, Dunning AM, Tessier D, Cunningham J, Slager SL, Wang C, Hart S, Stevens K, Simard J, Pastinen T, Pankratz VS, Offit K, Easton DF, Chenevix-Trench G, Antoniou AC; CIMBA. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. *PLoS Genet.* 9(3):e1003212, 2013. PMC3609646.

10. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Chen YA, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Antonenkova N, Antoniou AC, Armasu SM; Australian Cancer Study; Australian Ovarian Cancer Study, Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ, Cicek MS, Coetzee GA; Consortium of Investigators of Modifiers of BRCA1/2, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Despiere E, Doherty JA, Dörk T, du Bois A, Dürst M, Easton DF, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher DA, Flanagan JM, Garcia-Closas M, Gentry-Maharaj A, Giles GG, Glasspool RM, Gonzalez-Bosquet J, Goodman MT, Gore M, Górski B, Gronwald J, Hall P, Halle MK, Harter P, Heitz F, Hillemanns P, Hoatlin M, Høgdall CK, Høgdall E, Hosono S, Jakubowska A, Jensen A, Jim H, Kalli KR, Karlan BY, Kaye SB, Kelemen LE, Kiemeny LA, Kikkawa F, Konecny GE, Krakstad C, Kjaer SK, Kupryjanczyk J, Lambrechts D, Lambrechts S, Lancaster JM, Le ND, Leminen A, Levine DA, Liang D, Lim BK, Lin J, Lissowska J, Lu KH, Lubiński J, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson SH, Orlov I, Paul J, Pearce CL, Pejovic T, Pelttari LM, Pike MC, Poole EM, Raska P, Renner SP, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shridhar V, Shu XO, Shvetsov YB, Sieh W, Song H, Southey MC, Spiewankiewicz B, Stram D, Sutphen R, Teo SH, Terry KL, Tessier DC, Thompson PJ, Tworoger SS, van Altena AM, Vergote I, Vierkant RA, Vincent D, Vitonis AF, Wang-Gohrke S, Palmieri Weber R, Wentzensen N, Whittemore AS, Wik E, Wilkens LR, Winterhoff B, Woo YL, Wu AH, Xiang YB, Yang HP, Zheng W, Ziogas A, Zulkifli F, Phelan CM, Iversen E, Schildkraut JM, Berchuck A, Fridley BL, Goode EL, Pharoah PD, Monteiro AN, Sellers TA, Gayther SA. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nat Commun.* 4: 1627, 2013. PMC3709460.
11. Rudolph A, Hein R, Lindström S, Beckmann L, Behrens S, Liu J, Aschard H, Bolla MK, Wang J, Truong T, Cordina-Duverger E, Menegaux F, Brüning T, Harth V; GENICA Network, Severi G, Baglietto L, Southey M, Chanock SJ, Lissowska J, Figueroa JD, Eriksson M, Humpreys K, Darabi H, Olson JE, Stevens KN, Vachon CM, Knight JA, Glendon G, Mulligan AM, Ashworth A, Orr N, Schoemaker M, Webb PM; kConFab Investigators; AOCs Management Group, Guénel P, Brauch H, Giles G, García-Closas M, Czene K, Chenevix-Trench G, Couch FJ, Andrulis IL, Swerdlow A, Hunter DJ, Flesch-Janys D, Easton DF, Hall P, Nevanlinna H, Kraft P, Chang-Claude J; Breast Cancer Association Consortium. Genetic modifiers of menopausal hormone replacement

therapy and breast cancer risk: a genome-wide interaction study. *Endocr Relat Cancer*. 20(6):875-87, 2013. PMC3863710.

12. Johnatty SE, Beesley J, Gao B, Chen X, Lu Y, Law MH, Henderson MJ, Russell AJ, Hedditch EL, Emmanuel C, Fereday S, Webb PM; Australian Ovarian Cancer Study Group, Goode EL, Vierkant RA, Fridley BL, Cunningham JM, Fasching PA, Beckmann MW, Ekici AB, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Brown R, Paul J, Lambrechts S, Despiere E, Vergote I, Lester J, Karlan BY, Heitz F, du Bois A, Harter P, Schwaab I, Bean Y, Pejovic T, Levine DA, Goodman MT, Cane ME, Thompson PJ, Lurie G, Schildkraut J, Berchuck A, Terry KL, Cramer DW, Norris MD, Haber M, MacGregor S, deFazio A, Chenevix-Trench G. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. *Gynecol Oncol*. 131(1):8-14, 2013. PMC3795832.

13. Pooley KA, Bojesen SE, Weischer M, Nielsen SF, Thompson D, Amin Al Olama A, Michailidou K, Tyrer JP, Benlloch S, Brown J, Audley T, Luben R, Khaw KT, Neal DE, Hamdy FC, Donovan JL, Kote-Jarai Z, Baynes C, Shah M, Bolla MK, Wang Q, Dennis J, Dicks E, Yang R, Rudolph A, Schildkraut J, Chang-Claude J, Burwinkel B, Chenevix-Trench G, Pharoah PD, Berchuck A, Eeles RA, Easton DF, Dunning AM, Nordestgaard BG. A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk. *Hum Mol Genet*. 22(24):5056-64, 2013. PMC3836481.

14. Meyer KB, O'Reilly M, Michailidou K, Carlebur S, Edwards SL, French JD, Prathalingham R, Dennis J, Bolla MK, Wang Q, de Santiago I, Hopper JL, Tsimiklis H, Apicella C, Southey MC, Schmidt MK, Brooks A, Van 't Veer LJ, Hogervorst FB, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsana P, Fasching PA, Lux MP, Ekici AB, Beckmann MW, Peto J, Dos Santos Silva I, Fletcher O, Johnson N, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Guénel P, Truong T, Laurent-Puig P, Menegaux F, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Milne RL, Zamora MP, Arias JI, Benitez J, Neuhausen S, Anton-Culver H, Ziogas A, Dur CC, Brenner H, Müller H, Arndt V, Stegmaier C, Meindl A, Schmutzler RK, Engel C, Ditsch N, Brauch H, Brüning T, Ko YD; GENICA Network, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Matsuo K, Ito H, Iwata H, Yatabe Y, Dörk T, Helbig S, Bogdanova NV, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Chenevix-Trench G; kConFab Investigators; Australian Ovarian Cancer Study Group, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Lambrechts D, Thienpont B, Christiaens MR, Smeets A, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Radice P, Peterlongo P, Bonanni B, Bernard L, Couch FJ, Olson JE, Wang X, Purrington K, Giles GG, Severi G, Baglietto L, McLean C, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Simard J, Goldberg MS, Labrèche F, Dumont M, Teo SH, Yip CH, Phuah SY, Kristensen V, Grenaker Alnæs G, Børresen-Dale AL, Zheng W, Deming-Halverson S, Shrubsole M, Long J, Winqvist R, Pylkäs K,

Jukkola-Vuorinen A, Kauppila S, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Devilee P, Tollenaar RA, Seynaeve CM, García-Closas M, Figueroa J, Chanock SJ, Lissowska J, Czene K, Darabi H, Eriksson K, Hooning MJ, Martens JW, van den Ouweland AM, van Deurzen CH, Hall P, Li J, Liu J, Humphreys K, Shu XO, Lu W, Gao YT, Cai H, Cox A, Reed MW, Blot W, Signorello LB, Cai Q, Pharoah PD, Ghoussaini M, Harrington P, Tyrer J, Kang D, Choi JY, Park SK, Noh DY, Hartman M, Hui M, Lim WY, Buhari SA, Hamann U, Försti A, Rüdiger T, Ulmer HU, Jakubowska A, Lubinski J, Jaworska K, Durda K, Sangrairang S, Gaborieau V, Brennan P, McKay J, Vachon C, Slager S, Fostira F, Pilarski R, Shen CY, Hsiung CN, Wu PE, Hou MF, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, Ponder BA, Dunning AM, Easton DF. Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. *Am J Hum Genet.* 93(6):1046-60, 2013. PMC3852923.

15. Charbonneau B, Moysich KB, Kalli KR, Oberg AL, Vierkant RA, Fogarty ZC, Block MS, Maurer MJ, Goergen KM, Fridley BL, Cunningham JM, Rider DN, Preston C, Hartmann LC, Lawrenson K, Wang C, Tyrer J, Song H, deFazio A, Johnatty SE, Doherty JA, Phelan CM, Sellers TA, Ramirez SM, Vitonis AF, Terry KL, Van Den Berg D, Pike MC, Wu AH, Berchuck A, Gentry-Maharaj A, Ramus SJ, Diergaarde B, Shen H, Jensen A, Menkiszak J, Cybulski C, Lubinski J, Ziogas A, Rothstein JH, McGuire V, Sieh W, Lester J, Walsh C, Vergote I, Lambrechts S, Despierre E, Garcia-Closas M, Yang H, Brinton LA, Spiewankiewicz B, Rzepecka IK, Dansonka-Mieszkowska A, Seibold P, Rudolph A, Paddock LE, Orlov I, Lundvall L, Olson SH, Hogdall CK, Schwaab I, du Bois A, Harter P, Flanagan JM, Brown R, Paul J, Ekici AB, Beckmann MW, Hein A, Eccles D, Lurie G, Hays LE, Bean YT, Pejovic T, Goodman MT, Campbell I, Fasching PA, Konecny G, Kaye SB, Heitz F, Hogdall E, Bandera EV, Chang-Claude J, Kupryjanczyk J, Wentzensen N, Lambrechts D, Karlan BY, Whittemore AS, Culver HA, Gronwald J, Levine DA, Kjaer SK, Menon U, Schildkraut JM, Pearce CL, Cramer DW, Rossing MA, Chenevix-Trench G; AOCS group; ACS, Pharoah PD, Gayther SA, Ness RB, Odunsi K, Sucheston LE, Knutson KL, Goode EL. Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. *Cancer Immunol Res.* 2(4):332-40, 2014. PMC4000890.
16. Block MS, Charbonneau B, Vierkant RA, Fogarty Z, Bamlet WR, Pharoah PD; Georgia Chenevix-Trench; for AOCS; /ACS Group, Rossing MA, Cramer D, Pearce CL, Schildkraut J, Menon U, Kjaer SK, Levine DA, Gronwald J, Culver HA, Whittemore AS, Karlan BY, Lambrechts D, Wentzensen N, Kupryjanczyk J, Chang-Claude J, Bandera EV, Hogdall E, Heitz F, Kaye SB, Fasching PA, Campbell I, Goodman MT, Pejovic T, Bean YT, Hays LE, Lurie G, Eccles D, Hein A, Beckmann MW, Ekici AB, Paul J, Brown R, Flanagan JM, Harter P, du Bois A, Schwaab I, Hogdall CK, Lundvall L, Olson SH, Orlov I, Paddock LE, Rudolph A, Eilber U, Dansonka-Mieszkowska A, Rzepecka IK, Ziolkowska-Seta I, Brinton LA, Yang H, Garcia-Closas M, Despierre E, Lambrechts S, Vergote I, Walsh CS, Lester J, Sieh W, McGuire V, Rothstein JH, Ziogas A, Lubinski J, Cybulski C, Menkiszak J, Jensen A, Gayther SA, Ramus SJ, Gentry-Maharaj A, Berchuck A, Wu AH, Pike MC, Van Den Berg D, Terry KL, Vitonis AF, Ramirez SM,

Rider DN, Knutson KL, Sellers TA, Phelan CM, Doherty JA, Johnatty SE, deFazio A, Song H, Tyrer J, Kalli KR, Fridley BL, Cunningham JM, Goode EL. Variation in NF- κ B signaling pathways and survival in invasive epithelial ovarian cancer. *Cancer Epidemiol Biomarkers Prev.* 23(7):1421-7, 2014. PMC4082406.

17. Li J, Lindström LS, Foo JN, Rafiq S, Schmidt MK, Pharoah PD, Michailidou K, Dennis J, Bolla MK, Wang Q, Van 't Veer LJ, Cornelissen S, Rutgers E, Southey MC, Apicella C, Dite GS, Hopper JL, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Blomqvist C, Muranen TA, Aittomäki K, Lindblom A, Margolin S, Mannermaa A, Kosma VM, Hartikainen JM, Kataja V, Chenevix-Trench G; kConFab Investigators, Phillips KA, McLachlan SA, Lambrechts D, Thienpont B, Smeets A, Wildiers H, Chang-Claude J, Flesch-Janys D, Seibold P, Rudolph A, Giles GG, Baglietto L, Severi G, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Kristensen V, Alnæs GI, Borresen-Dale AL, Nord S, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Devilee P, Tollenaar R, Seynaeve C, Hooning M, Kriege M, Hollestelle A, van den Ouweland A, Li Y, Hamann U, Torres D, Ulmer HU, Rüdiger T, Shen CY, Hsiung CN, Wu PE, Chen ST, Teo SH, Taib NA, Har Yip C, Fuang Ho G, Matsuo K, Ito H, Iwata H, Tajima K, Kang D, Choi JY, Park SK, Yoo KY, Maishman T, Tapper WJ, Dunning A, Shah M, Luben R, Brown J, Khor CC, Eccles DM, Nevanlinna H, Easton D, Humphreys K, Liu J, Hall P, Czene K. 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. *Nat Commun.* 5:4051, 2014. PMC4082638.
18. Perry JR, Hsu YH, Chasman DI, Johnson AD, Elks C, Albrecht E, Andrulis IL, Beesley J, Berenson GS, Bergmann S, Bojesen SE, Bolla MK, Brown J, Buring JE, Campbell H, Chang-Claude J, Chenevix-Trench G, Corre T, Couch FJ, Cox A, Czene K, D'adamo AP, Davies G, Deary IJ, Dennis J, Easton DF, Engelhardt EG, Eriksson JG, Esko T, Fasching PA, Figueroa JD, Flyger H, Fraser A, Garcia-Closas M, Gasparini P, Gieger C, Giles G, Guenel P, Hägg S, Hall P, Hayward C, Hopper J, Ingelsson E; kConFab investigators, Kardia SL, Kasiman K, Knight JA, Lahti J, Lawlor DA, Magnusson PK, Margolin S, Marsh JA, Metspalu A, Olson JE, Pennell CE, Polasek O, Rahman I, Ridker PM, Robino A, Rudan I, Rudolph A, Salumets A, Schmidt MK, Schoemaker MJ, Smith EN, Smith JA, Southey M, Stöckl D, Swerdlow AJ, Thompson DJ, Truong T, Ulivi S, Waldenberger M, Wang Q, Wild S, Wilson JF, Wright AF, Zgaga L, Consortium R, Ong KK, Murabito JM, Karasik D, Murray A. DNA mismatch repair gene MSH6 implicated in determining age at natural menopause. *Hum Mol Genet.* 23(9):2490-7, 2014. PMC3976329.
19. Osorio A, Milne RL, Kuchenbaecker K, Vaclová T, Pita G, Alonso R, Peterlongo P, Blanco I, de la Hoya M, Duran M, Díez O, Ramón Y Cajal T, Konstantopoulou I, Martínez-Bouzas C, Andrés Conejero R, Soucy P, McGuffog L, Barrowdale D, Lee A, Swe-Brca, Arver B, Rantala J, Loman N, Ehrencrona H, Olopade OI, Beattie MS, Domchek SM, Nathanson K, Rebbeck TR, Arun BK, Karlan BY, Walsh C, Lester J, John EM, Whittemore AS, Daly MB, Southey M, Hopper J, Terry MB, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Hansen TV, Jønson L, Ejlersen B, Gerdes AM, Infante M, Herráez B, Moreno LT, Weitzel JN, Herzog J, Weeman K, Manoukian S, Peissel B, Zaffaroni D, Scutera G, Bonanni B, Mariette F,

Volorio S, Viel A, Varesco L, Papi L, Ottini L, Tibiletti MG, Radice P, Yannoukakos D, Garber J, Ellis S, Frost D, Platte R, Fineberg E, Evans G, Laloo F, Izatt L, Eeles R, Adlard J, Davidson R, Cole T, Eccles D, Cook J, Hodgson S, Brewer C, Tischkowitz M, Douglas F, Porteous M, Side L, Walker L, Morrison P, Donaldson A, Kennedy J, Foo C, Godwin AK, Schmutzler RK, Wappenschmidt B, Rhiem K, Engel C, Meindl A, Ditsch N, Arnold N, Plendl HJ, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Gehrig A, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Damiola F, Poppe B, Claes K, Piedmonte M, Tucker K, Backes F, Rodríguez G, Brewster W, Wakeley K, Rutherford T, Caldés T, Nevanlinna H, Aittomäki K, Rookus MA, van Os TA, van der Kolk L, de Lange JL, Meijers-Heijboer HE, van der Hout AH, van Asperen CJ, Gómez García EB, Hoogerbrugge N, Collée JM, van Deurzen CH, van der Luijt RB, Devilee P, Hebon, Olah E, Lázaro C, Teulé A, Menéndez M, Jakubowska A, Cybulski C, Gronwald J, Lubinski J, Durda K, Jaworska-Bieniek K, Johannsson OT, Maugard C, Montagna M, Tognazzo S, Teixeira MR, Healey S, Investigators K, Olswold C, Guidugli L, Lindor N, Slager S, Szabo CI, Vijai J, Robson M, Kauff N, Zhang L, Rau-Murthy R, Fink-Retter A, Singer CF, Rappaport C, Geschwantler Kaulich D, Pfeiler G, Tea MK, Berger A, Phelan CM, Greene MH, Mai PL, Lejbkowitz F, Andrulis I, Mulligan AM, Glendon G, Toland AE, Bojesen A, Pedersen IS, Sunde L, Thomassen M, Kruse TA, Jensen UB, Friedman E, Laitman Y, Shimon SP, Simard J, Easton DF, Offit K, Couch FJ, Chenevix-Trench G, Antoniou AC, Benitez J. DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS Genet.* 10(4):e1004256, 2014. PMC3974638.

20. Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. *Science.* 343(6178):1466-70, 2014. PMC4074902.
21. Purrington KS, Slettedahl S, Bolla MK, Michailidou K, Czene K, Nevanlinna H, Bojesen SE, Andrulis IL, Cox A, Hall P, Carpenter J, Yannoukakos D, Haiman CA, Fasching PA, Mannermaa A, Winqvist R, Brenner H, Lindblom A, Chenevix-Trench G, Benitez J, Swerdlow A, Kristensen V, Guénel P, Meindl A, Darabi H, Eriksson M, Fagerholm R, Aittomäki K, Blomqvist C, Nordestgaard BG, Nielsen SF, Flyger H, Wang X, Olswold C, Olson JE, Mulligan AM, Knight JA, Tchatchou S, Reed MW, Cross SS, Liu J, Li J, Humphreys K, Clarke C, Scott R; ABCTB Investigators, Fostira F, Fountzilas G, Konstantopoulou I, Henderson BE, Schumacher F, Le Marchand L, Ekici AB, Hartmann A, Beckmann MW, Hartikainen JM, Kosma VM, Kataja V, Jukkola-Vuorinen A, Pylkäs K, Kauppila S, Dieffenbach AK, Stegmaier C, Arndt V, Margolin S; Australian Ovarian Cancer Study Group; kConFab Investigators, Balleine R, Arias Perez JJ, Pilar Zamora M, Menéndez P, Ashworth A, Jones M, Orr N, Arveux P, Kerbrat P, Truong T, Bugert P, Toland AE, Ambrosone CB, Labrèche F, Goldberg MS, Dumont M, Ziogas A, Lee E, Dite GS, Apicella C, Southey MC, Long J, Shrubsole M, Deming-Halverson S, Ficarazzi F, Barile M, Peterlongo P, Durda K, Jaworska-Bieniek K, Tollenaar RA, Seynaeve C; The GENICA Network, Brüning T, Ko YD, Van Deurzen CH, Martens JW, Kriege M, Figueroa JD, Chanock SJ, Lissowska J, Tomlinson I, Kerin MJ, Miller N, Schneeweiss A, Tapper WJ, Gerty SM, Durcan L, Mclean C, Milne RL, Baglietto L, Dos Santos Silva

- I, Fletcher O, Johnson N, Van'T Veer LJ, Cornelissen S, Försti A, Torres D, Rüdiger T, Rudolph A, Flesch-Janys D, Nickels S, Weltens C, Floris G, Moisse M, Dennis J, Wang Q, Dunning AM, Shah M, Brown J, Simard J, Anton-Culver H, Neuhausen SL, Hopper JL, Bogdanova N, Dörk T, Zheng W, Radice P, Jakubowska A, Lubinski J, Devilee P, Brauch H, Hooning M, García-Closas M, Sawyer E, Burwinkel B, Marmee F, Eccles DM, Giles GG, Peto J, Schmidt M, Broeks A, Hamann U, Chang-Claude J, Lambrechts D, Pharoah PD, Easton D, Pankratz VS, Slager S, Vachon CM, Couch FJ. Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. *Hum Mol Genet.* 23(22):6034-46, 2014. PMC4204763.
22. Milne RL, Burwinkel B, Michailidou K, Arias-Perez JI, Zamora MP, Menéndez-Rodríguez P, Hardisson D, Mendiola M, González-Neira A, Pita G, Alonso MR, Dennis J, Wang Q, Bolla MK, Swerdlow A, Ashworth A, Orr N, Schoemaker M, Ko YD, Brauch H, Hamann U; The GENICA Network, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Investigators K; Australian Ovarian Cancer Study Group, Matsuo K, Ito H, Iwata H, Tajima K, Li J, Brand JS, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Lambrechts D, Peuteman G, Christiaens MR, Smeets A, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Hartman M, Hui M, Lim WY, Chan CW, Marme F, Yang R, Bugert P, Lindblom A, Margolin S, García-Closas M, Chanock SJ, Lissowska J, Figueroa JD, Bojesen SE, Nordestgaard BG, Flyger H, Hooning MJ, Kriege M, van den Ouweland AM, Koppert LB, Fletcher O, Johnson N, Dos-Santos-Silva I, Peto J, Zheng W, Deming-Halverson S, Shrubsole MJ, Long J, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Cox A, Cross SS, Reed MW, Schmidt MK, Broeks A, Cornelissen S, Braaf L, Kang D, Choi JY, Park SK, Noh DY, Simard J, Dumont M, Goldberg MS, Labrèche F, Fasching PA, Hein A, Ekici AB, Beckmann MW, Radice P, Peterlongo P, Azzollini J, Barile M, Sawyer E, Tomlinson I, Kerin M, Miller N, Hopper JL, Schmidt DF, Makalic E, Southey MC, Teo SH, Yip CH, Sivanandan K, Tay WT, Shen CY, Hsiung CN, Yu JC, Hou MF, Guénel P, Truong T, Sanchez M, Mulot C, Blot W, Cai Q, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Bogdanova N, Dörk T, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsang P, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Shu XO, Lu W, Gao YT, Zhang B, Couch FJ, Toland AE; TNBCC, Yannoukakos D, Sangrajrang S, McKay J, Wang X, Olson JE, Vachon C, Purrington K, Severi G, Baglietto L, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Devilee P, Tollenaar RA, Seynaeve C, Czene K, Eriksson M, Humphreys K, Darabi H, Ahmed S, Shah M, Pharoah PD, Hall P, Giles GG, Benítez J, Dunning AM, Chenevix-Trench G, Easton DF. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. *Hum Mol Genet.* 23(22):6096-111, 2014. PMC4204770.
23. Lindström S, Thompson DJ, Paterson AD, Li J, Gierach GL, Scott C, Stone J, Douglas JA, Dos-Santos-Silva I, Fernandez-Navarro P, Verghese J, Smith P, Brown J, Luben R, Wareham NJ, Loos RJ, Heit JA, Shane Pankratz V, Norman A, Goode EL, Cunningham JM, deAndrade M, Vierkant RA, Czene K, Fasching PA, Baglietto L, Southey MC, Giles GG, Shah KP, Chan HP, Helvie MA, Beck AH, Knoblauch NW, Hazra A, Hunter DJ, Kraft P, Pollan M, Figueroa JD, Couch FJ, Hopper JL, Hall P, Easton DF, Boyd NF,

Vachon CM, Tamimi RM. Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. *Nat Commun.* 5:5303, 2014. PMC4320806.

24. Kuchenbaecker KB, Neuhausen SL, Robson M, Barrowdale D, McGuffog L, Mulligan AM, Andrulis IL, Spurdle AB, Schmidt MK, Schmutzler RK, Engel C, Wappenschmidt B, Nevanlinna H, Thomassen M, Southey M, Radice P, Ramus SJ, Domchek SM, Nathanson KL, Lee A, Healey S, Nussbaum RL, Rebbeck TR, Arun BK, James P, Karlan BY, Lester J, Cass I; Breast Cancer Family Registry, Terry MB, Daly MB, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, v O Hansen T, Ejlersen B, Gerdes AM, Nielsen FC, Dennis J, Cunningham J, Hart S, Slager S, Osorio A, Benitez J, Duran M, Weitzel JN, Tafur I, Hander M, Peterlongo P, Manoukian S, Peissel B, Roversi G, Scuvera G, Bonanni B, Mariani P, Volorio S, Dolcetti R, Varesco L, Papi L, Tibiletti MG, Giannini G, Fostira F, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brewer C, Foo C, Evans DG, Frost D, Eccles D; EMBRACE Study, Douglas F, Brady A, Cook J, Tischkowitz M, Adlard J, Barwell J, Ong KR, Walker L, Izatt L, Side LE, Kennedy MJ, Rogers MT, Porteous ME, Morrison PJ, Platte R, Eeles R, Davidson R, Hodgson S, Ellis S, Godwin AK, Rhiem K, Meindl A, Ditsch N, Arnold N, Plendl H, Niederacher D, Sutter C, Steinemann D, Bogdanova-Markov N, Kast K, Varon-Mateeva R, Wang-Gohrke S, Gehrig A, Markiefka B, Buecher B, Lefol C, Stoppa-Lyonnet D, Rouleau E, Prieur F, Damiola F; GEMO Study Collaborators, Barjhoux L, Faivre L, Longy M, Sevenet N, Sinilnikova OM, Mazoyer S, Bonadona V, Caux-Moncoutier V, Isaacs C, Van Maerken T, Claes K, Piedmonte M, Andrews L, Hays J, Rodriguez GC, Caldes T, de la Hoya M, Khan S, Hogervorst FB, Aalfs CM, de Lange JL, Meijers-Heijboer HE, van der Hout AH, Wijnen JT, van Roozendaal KE, Mensenkamp AR, van den Ouweland AM, van Deurzen CH, van der Looij RB; HEBON, Olah E, Diez O, Lazaro C, Blanco I, Teulé A, Menendez M, Jakubowska A, Lubinski J, Cybulski C, Gronwald J, Jaworska-Bieniek K, Durda K, Arason A, Maugard C, Soucy P, Montagna M, Agata S, Teixeira MR; KConFab Investigators, Olswold C, Lindor N, Pankratz VS, Hallberg E, Wang X, Szabo CI, Vijai J, Jacobs L, Corines M, Lincoln A, Berger A, Fink-Retter A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Phelan CM, Mai PL, Greene MH, Rennert G, Imyanitov EN, Glendon G, Toland AE, Bojesen A, Pedersen IS, Jensen UB, Caligo MA, Friedman E, Berger R, Laitman Y, Rantala J, Arver B, Loman N, Borg A, Ehrencrona H, Olopade OI, Simard J, Easton DF, Chenevix-Trench G, Offit K, Couch FJ, Antoniou AC; CIMBA. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res.* 16(6):3416, 2014. PMC4406179.
25. Agarwal D, Pineda S, Michailidou K, Herranz J, Pita G, Moreno LT, Alonso MR, Dennis J, Wang Q, Bolla MK, Meyer KB, Menéndez-Rodríguez P, Hardisson D, Mendiola M, González-Neira A, Lindblom A, Margolin S, Swerdlow A, Ashworth A, Orr N, Jones M, Matsuo K, Ito H, Iwata H, Kondo N; kConFab Investigators; Australian Ovarian Cancer Study Group, Hartman M, Hui M, Lim WY, Iau PT, Sawyer E, Tomlinson I, Kerin M, Miller N, Kang D, Choi J-, Park SK, Noh D-, Hopper JL, Schmidt DF, Makalic E, Southey MC, Teo SH, Yip CH, Sivanandan K, Tay W-, Brauch H, Brüning T, Hamann

U; GENICA Network, Dunning AM, Shah M, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Schmidt MK, Broeks A, Rosenberg EH, van't Veer LJ, Fasching PA, Renner SP, Ekici AB, Beckmann MW, Shen C-, Hsiung C-, Yu J-, Hou M-, Blot W, Cai Q, Wu AH, Tseng C-, Van Den Berg D, Stram DO, Cox A, Brock IW, Reed MW, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsarn P, Zheng W, Deming-Halverson S, Shrubsole MJ, Long J, Shu X-, Lu W, Gao Y-, Zhang B, Radice P, Peterlongo P, Manoukian S, Mariette F, Sangrajrang S, McKay J, Couch FJ, Toland AE; TNBCC, Yannoukakos D, Fletcher O, Johnson N, dos Santos Silva I, Peto J, Marme F, Burwinkel B, Guénel P, Truong T, Sanchez M, Mulot C, Bojesen SE, Nordestgaard BG, Flyer H, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Mannermaa A, Kataja V, Kosma V-, Hartikainen JM, Lambrechts D, Yesilyurt BT, Floris G, Leunen K, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Wang X, Olson JE, Vachon C, Purrington K, Giles GG, Severi G, Baglietto L, Haiman CA, Henderson BE, Schumacher F, Marchand LL, Simard J, Dumont M, Goldberg MS, Labréche F, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Devilee P, Tollenaar RA, Seynaeve C, García-Closas M, Chanock SJ, Lissowska J, Figueroa JD, Czene K, Eriksson M, Humphreys K, Darabi H, Hooning MJ, Kriege M, Collée JM, Tilanus-Linthorst M, Li J, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Bogdanova N, Dörk T, Hall P, Chenevix-Trench G, Easton DF, Pharoah PD, Arias-Perez JI, Zamora P, Benítez J, Milne RL. FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. *Br J Cancer*. 110(4):1088-100, 2014. PMC3929867.

26. Spurdle AB, Couch FJ, Parsons MT, McGuffog L, Barrowdale D, Bolla MK, Wang Q, Healey S, Schmutzler R, Wappenschmidt B, Rhiem K, Hahnen E, Engel C, Meindl A, Ditsch N, Arnold N, Plendl H, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Ellis S, Frost D, Platte R, Perkins J, Evans DG, Izatt L, Eeles R, Adlard J, Davidson R, Cole T, Scuvera G, Manoukian S, Bonanni B, Mariette F, Fortuzzi S, Viel A, Pasini B, Papi L, Varesco L, Balleine R, Nathanson KL, Domchek SM, Offitt K, Jakubowska A, Lindor N, Thomassen M, Jensen UB, Rantala J, Borg Å, Andrulis IL, Miron A, Hansen TV, Caldes T, Neuhausen SL, Toland AE, Nevanlinna H, Montagna M, Garber J, Godwin AK, Osorio A, Factor RE, Terry MB, Rebbeck TR, Karlan BY, Southey M, Rashid MU, Tung N, Pharoah PD, Blows FM, Dunning AM, Provenzano E, Hall P, Czene K, Schmidt MK, Broeks A, Cornelissen S, Verhoef S, Fasching PA, Beckmann MW, Ekici AB, Slamon DJ, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyer H, Chang-Claude J, Flesch-Janys D, Rudolph A, Seibold P, Aittomäki K, Muranen TA, Heikkilä P, Blomqvist C, Figueroa J, Chanock SJ, Brinton L, Lissowska J, Olson JE, Pankratz VS, John EM, Whittemore AS, West DW, Hamann U, Torres D, Ulmer HU, Rüdiger T, Devilee P, Tollenaar RA, Seynaeve C, Van Asperen CJ, Eccles DM, Tapper WJ, Durcan L, Jones L, Peto J, dos-Santos-Silva I, Fletcher O, Johnson N, Dwek M, Swann R, Bane AL, Glendon G, Mulligan AM, Giles GG, Milne RL, Baglietto L, McLean C, Carpenter J, Clarke C, Scott R, Brauch H, Brüning T, Ko YD, Cox A, Cross SS, Reed MW, Lubinski J, Jaworska-Bieniek K, Durda K, Gronwald J, Dörk T, Bogdanova N, Park-Simon TW, Hillemanns P, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Burwinkel B, Marme F, Surovy H, Yang R, Anton-Culver H, Ziogas A, Hooning MJ, Collée JM, Martens JW, Tilanus-Linthorst

MM, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Lindblom A, Margolin S, Joseph V, Robson M, Rau-Murthy R, González-Neira A, Arias JI, Zamora P, Benítez J, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Peterlongo P, Zaffaroni D, Barile M, Capra F, Radice P, Teo SH, Easton DF, Antoniou AC, Chenevix-Trench G, Goldgar DE; ABCTB Investigators; EMBRACE Group; GENICA Network; HEBON Group; kConFab Investigators. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. *Breast Cancer Res.* 16(6):3419, 2014. PMC4352262.

27. Schoeps A, Rudolph A, Seibold P, Dunning AM, Milne RL, Bojesen SE, Swerdlow A, Andrulis I, Brenner H, Behrens S, Orr N, Jones M, Ashworth A, Li J, Cramp H, Connley D, Czene K, Darabi H, Chanock SJ, Lissowska J, Figueroa JD, Knight J, Glendon G, Mulligan AM, Dumont M, Severi G, Baglietto L, Olson J, Vachon C, Purrington K, Moisse M, Neven P, Wildiers H, Spurdle A, Kosma VM, Kataja V, Hartikainen JM, Hamann U, Ko YD, Dieffenbach AK, Arndt V, Stegmaier C, Malats N, Arias Perez JI, Benítez J, Flyger H, Nordestgaard BG, Truong T, Cordina-Duverger E, Menegaux F, dos Santos Silva I, Fletcher O, Johnson N, Häberle L, Beckmann MW, Ekici AB, Braaf L, Atsma F, van den Broek AJ, Makalic E, Schmidt DF, Southey MC, Cox A, Simard J, Giles GG, Lambrechts D, Mannermaa A, Brauch H, Guénel P, Peto J, Fasching PA, Hopper J, Flesch-Janys D, Couch F, Chenevix-Trench G, Pharoah PD, Garcia-Closas M, Schmidt MK, Hall P, Easton DF, Chang-Claude J. Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions. *Genet Epidemiol.* 38(1):84-93, 2014. PMC3995140.
28. Charbonneau B, Block MS, Bamlet WR, Vierkant RA, Kalli KR, Fogarty Z, Rider DN, Sellers TA, Tworoger SS, Poole E, Risch HA, Salvesen HB, Kiemeny LA, Baglietto L, Giles GG, Severi G, Trabert B, Wentzensen N, Chenevix-Trench G; for AOCS/ACS group, Whittemore AS, Sieh W, Chang-Claude J, Bandera EV, Orlov I, Terry K, Goodman MT, Thompson PJ, Cook LS, Rossing MA, Ness RB, Narod SA, Kupryjanczyk J, Lu K, Butzow R, Dörk T, Pejovic T, Campbell I, Le ND, Bunker CH, Bogdanova N, Runnebaum IB, Eccles D, Paul J, Wu AH, Gayther SA, Hogdall E, Heitz F, Kaye SB, Karlan BY, Anton-Culver H, Gronwald J, Hogdall CK, Lambrechts D, Fasching PA, Menon U, Schildkraut J, Pearce CL, Levine DA, Kjaer SK, Cramer D, Flanagan JM, Phelan CM, Brown R, Massuger LF, Song H, Doherty JA, Krakstad C, Liang D, Odunsi K, Berchuck A, Jensen A, Lubinski J, Nevanlinna H, Bean YT, Lurie G, Ziogas A, Walsh C, Despiere E, Brinton L, Hein A, Rudolph A, Dansonka-Mieszkowska A, Olson SH, Harter P, Tyrer J, Vitonis AF, Brooks-Wilson A, Aben KK, Pike MC, Ramus SJ, Wik E, Cybulski C, Lin J, Sucheston L, Edwards R, McGuire V, Lester J, du Bois A, Lundvall L, Wang-Gohrke S, Szafron LM, Lambrechts S, Yang H, Beckmann MW, Pelttari LM, Van Altena AM, van den Berg D, Halle MK, Gentry-Maharaj A, Schwaab I, Chandran U, Menkiszak J, Ekici AB, Wilkens LR, Leminen A, Modugno F, Friel G, Rothstein JH, Vergote I, Garcia-Closas M, Hildebrandt MA, Sobiczewski P, Kelemen LE, Pharoah PD, Moysich K, Knutson KL, Cunningham JM, Fridley BL, Goode EL. Risk of ovarian cancer and the NF- κ B pathway: genetic association with IL1A and TNFSF10. *Cancer Res.* 74(3):852-61, 2014. PMC3946482.

29. Milne RL, Herranz J, Michailidou K, Dennis J, Tyrer JP, Zamora MP, Arias-Perez JI, González-Neira A, Pita G, Alonso MR, Wang Q, Bolla MK, Czene K, Eriksson M, Humphreys K, Darabi H, Li J, Anton-Culver H, Neuhausen SL, Ziogas A, Clarke CA, Hopper JL, Dite GS, Apicella C, Southey MC, Chenevix-Trench G; kConFab Investigators; Australian Ovarian Cancer Study Group, Swerdlow A, Ashworth A, Orr N, Schoemaker M, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Bojesen SE, Nordestgaard BG, Flyger H, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Wang X, Olson JE, Vachon C, Purrington K, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Dunning AM, Shah M, Guénel P, Truong T, Sanchez M, Mulot C, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Lindblom A, Margolin S, Hooning MJ, Hollestelle A, Collée JM, Jager A, Cox A, Brock IW, Reed MW, Devilee P, Tollenaar RA, Seynaeve C, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Simard J, Dumont M, Soucy P, Dörk T, Bogdanova NV, Hamann U, Försti A, Rüdiger T, Ulmer HU, Fasching PA, Häberle L, Ekici AB, Beckmann MW, Fletcher O, Johnson N, dos Santos Silva I, Peto J, Radice P, Peterlongo P, Peissel B, Mariani P, Giles GG, Severi G, Baglietto L, Sawyer E, Tomlinson I, Kerin M, Miller N, Marme F, Burwinkel B, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Lambrechts D, Yesilyurt BT, Floris G, Leunen K, Alnæs GG, Kristensen V, Børresen-Dale AL, García-Closas M, Chanock SJ, Lissowska J, Figueroa JD, Schmidt MK, Broeks A, Verhoef S, Rutgers EJ, Brauch H, Brüning T, Ko YD; GENICA Network, Couch FJ, Toland AE; TNBCC, Yannoukakos D, Pharoah PD, Hall P, Benítez J, Malats N, Easton DF. A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. *Hum Mol Genet.* 23(7):1934-46, 2014. PMC3943524.
30. Lin WY, Camp NJ, Ghoussaini M, Beesley J, Michailidou K, Hopper JL, Apicella C, Southey MC, Stone J, Schmidt MK, Broeks A, Van't Veer LJ, Rutgers EJ, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsana P, Fasching PA, Häberle L, Ekici AB, Beckmann MW, Peto J, Dos-Santos-Silva I, Fletcher O, Johnson N, Bolla MK, Wang Q, Dennis J, Sawyer EJ, Cheng T, Tomlinson I, Kerin MJ, Miller N, Marmé F, Surowy HM, Burwinkel B, Guénel P, Truong T, Menegaux F, Mulot C, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Benitez J, Zamora MP, Arias Perez JI, Menéndez P, González-Neira A, Pita G, Alonso MR, Alvarez N, Herrero D, Anton-Culver H, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Meindl A, Lichtner P, Schmutzler RK, Müller-Miyhsok B, Brauch H, Brüning T, Ko YD; The GENICA Network, Tessier DC, Vincent D, Bacot F, Nevanlinna H, Aittomäki K, Blomqvist C, Khan S, Matsuo K, Ito H, Iwata H, Horio A, Bogdanova NV, Antonenkova NN, Dörk T, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Investigators K; Australian Ovarian Cancer Study Group, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Neven P, Wauters E, Wildiers H, Lambrechts D, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Radice P, Peterlongo P, Manoukian S, Bonanni B, Couch FJ, Wang X, Vachon C, Purrington K, Giles GG, Milne R, McLean C, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Simard J, Goldberg MS, Labrèche F, Dumont M, Teo SH, Yip CH, Hassan N, Vithana EN, Kristensen V, Zheng W, Deming-

Halverson S, Shrubsole M, Long J, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Devilee P, Tollenaar RA, Seynaeve C, Van Asperen CJ, García-Closas M, Figueroa J, Lissowska J, Brinton L, Czene K, Darabi H, Eriksson M, Brand JS, Hoening MJ, Hollestelle A, van den Ouweland AM, Jager A, Li J, Liu J, Humphreys K, Shu XO, Lu W, Gao YT, Cai H, Cross SS, Reed MW, Blot W, Signorello LB, Cai Q, Pharoah PD, Perkins B, Shah M, Blows FM, Kang D, Yoo KY, Noh DY, Hartman M, Miao H, Chia KS, Putti TC, Hamann U, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Slager S, Toland AE, Yannoukakos D, Shen CY, Hsiung CN, Wu PE, Ding SL, Ashworth A, Jones M, Orr N, Swerdlow AJ, Tsimiklis H, Makalic E, Schmidt DF, Bui QM, Chanock SJ, Hunter DJ, Hein R, Dahmen N, Beckmann L, Aaltonen K, Muranen TA, Heikkinen T, Irwanto A, Rahman N, Turnbull C; The Breast and Ovarian Cancer Susceptibility Study, Waisfisz Q, Meijers-Heijboer HE, Adank MA, van der Luijt RB, Hall P, Chenevix-Trench G, Dunning A, Easton DF, Cox A. Identification and characterisation of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. *Hum Mol Genet.* 24(1):285-98, 2015. PMC4334820.

31. Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, Simard J, Soucy P, Eeles RA, Easton DF, Hamann U, Wilkening S, Chen B, Rookus MA, Schmidt MK, van der Baan FH, Spurdle AB, Walker LC, Lose F, Maia AT, Montagna M, Matricardi L, Lubinski J, Jakubowska A, Gomez-Garcia EB, Olopade OI, Nussbaum RL, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK, Karlan BY, Orsulic S, Lester J, Chung WK, Miron A, Southey MC, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Ding YC, Neuhausen SL, Hansen TV, Gerdes AM, Ejlersen B, Jønson L, Osorio A, Martinez-Bouzas C, Benitez J, Conway EE, Blazer KR, Weitzel JN, Manoukian S, Peissel B, Zaffaroni D, Scutera G, Barile M, Ficarazzi F, Mariette F, Fortuzzi S, Viel A, Giannini G, Papi L, Martayan A, Tibiletti MG, Radice P, Vratimos A, Fostira F, Garber JE, Donaldson A, Brewer C, Foo C, Evans DG, Frost D, Eccles D, Brady A, Cook J, Tischkowitz M, Adlard J, Barwell J, Walker L, Izatt L, Side LE, Kennedy MJ, Rogers MT, Porteous ME, Morrison PJ, Platte R, Davidson R, Hodgson SV, Ellis S, Cole T, Godwin AK, Claes K, Van Maerken T, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Plendl H, Kast K, Rhiem K, Ditsch N, Arnold N, Varon-Mateeva R, Wappenschmidt B, Wang-Gohrke S, Bressac-de Paillerets B, Buecher B, Delnatte C, Houdayer C, Stoppa-Lyonnet D, Damiola F, Coupier I, Barjhoux L, Venat-Bouvet L, Golmard L, Boutry-Kryza N, Sinilnikova OM, Caron O, Pujol P, Mazoyer S, Belotti M, Piedmonte M, Friedlander ML, Rodriguez GC, Copeland LJ, de la Hoya M, Perez Segura P, Nevanlinna H, Aittomäki K, van Os TA, Meijers-Heijboer HE, Van der Hout AH, Vreeswijk MP, Hoogerbrugge N, Ausems MG, Van Doorn HC, Collée JM, Olah E, Díez O, Blanco I, Lazaro C, Brunet J, Feliubadaló L, Cybulski C, Gronwald J, Durda K, Jaworska-Bieniek K, Sukiennicki G, Arason A, Chiquette J, Teixeira MR, Olswold C, Couch FJ, Lindor NM, Wang X, Szabo CI, Offit K, Corines M, Jacobs L, Robson M, Zhang L, Joseph V, Berger A, Singer CF, Rappaport C, Geschwantler Kaulich D, Pfeiler G, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Glendon G, Tchatchou S, Andrulis IL, Toland AE, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Laitman Y, Rantala J, von Wachenfeldt A,

Ehrencrona H, Stenmark Askmalm M, Borg A, Kuchenbaecker KB, McGuffog L, Barrowdale D, Healey S, Lee A, Pharoah PD, Chenevix-Trench G On Behalf Of Aocs Mamagement Group, Antoniou AC, Friedman E. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiol Biomarkers Prev.* 24(1):308-316, 2015. PMC4294951.

32. Painter JN, O'Mara TA, Batra J, Cheng T, Lose FA, Dennis J, Michailidou K, Tyrer JP, Ahmed S, Ferguson K, Healey CS, Kaufmann S, Hillman KM, Walpole C, Moya L, Pollock P, Jones A, Howarth K, Martin L, Gorman M, Hodgson S; National Study of Endometrial Cancer Genetics Group (NSECG); CHIBCHA Consortium, De Polanco MM, Sans M, Carracedo A, Castellvi-Bel S, Rojas-Martinez A, Santos E, Teixeira MR, Carvajal-Carmona L, Shu XO, Long J, Zheng W, Xiang YB; The Australian National Endometrial Cancer Study Group (ANECs), Montgomery GW, Webb PM, Scott RJ, McEvoy M, Attia J, Holliday E, Martin NG, Nyholt DR, Henders AK, Fasching PA, Hein A, Beckmann MW, Renner SP, Dörk T, Hillemanns P, Dürst M, Runnebaum I, Lambrechts D, Coenegrachts L, Schrauwen S, Amant F, Winterhoff B, Dowdy SC, Goode EL, Teoman A, Salvesen HB, Trovik J, Njolstad TS, Werner HM, Ashton K, Proietto T, Otton G, Tzortzatos G, Mints M, Tham E; RENDOCAS, Hall P, Czene K, Liu J, Li J, Hopper JL, Southey MC; Australian Ovarian Cancer Study (AOCS), Ekici AB, Ruebner M, Johnson N, Peto J, Burwinkel B, Marme F, Brenner H, Dieffenbach AK, Meindl A, Brauch H; The GENICA Network, Lindblom A, Depreeuw J, Moisse M, Chang-Claude J, Rudolph A, Couch FJ, Olson JE, Giles GG, Bruinsma F, Cunningham JM, Fridley BL, Børresen-Dale AL, Kristensen VN, Cox A, Swerdlow AJ, Orr N, Bolla MK, Wang Q, Weber RP, Chen Z, Shah M, French JD, Pharoah PD, Dunning AM, Tomlinson I, Easton DF, Edwards SL, Thompson DJ, Spurdle AB. Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. *Hum Mol Genet.* 24(5):1478-1492, 2015. PMC4321445.
33. Carvajal-Carmona LG, O'Mara TA, Painter JN, Lose FA, Dennis J, Michailidou K, Tyrer JP, Ahmed S, Ferguson K, Healey CS, Pooley K, Beesley J, Cheng T, Jones A, Howarth K, Martin L, Gorman M, Hodgson S; National Study of Endometrial Cancer Genetics Group (NSECG); The Australian National Endometrial Cancer Study Group (ANECs), Wentzensen N, Fasching PA, Hein A, Beckmann MW, Renner SP, Dörk T, Hillemanns P, Dürst M, Runnebaum I, Lambrechts D, Coenegrachts L, Schrauwen S, Amant F, Winterhoff B, Dowdy SC, Goode EL, Teoman A, Salvesen HB, Trovik J, Njolstad TS, Werner HM, Scott RJ, Ashton K, Proietto T, Otton G, Wersäll O, Mints M, Tham E; RENDOCAS, Hall P, Czene K, Liu J, Li J, Hopper JL, Southey MC; Australian Ovarian Cancer Study (AOCS), Ekici AB, Ruebner M, Johnson N, Peto J, Burwinkel B, Marme F, Brenner H, Dieffenbach AK, Meindl A, Brauch H; The GENICA Network, Lindblom A, Depreeuw J, Moisse M, Chang-Claude J, Rudolph A, Couch FJ, Olson JE, Giles GG, Bruinsma F, Cunningham JM, Fridley BL, Børresen-Dale AL, Kristensen VN, Cox A, Swerdlow AJ, Orr N, Bolla MK, Wang Q, Weber RP, Chen Z, Shah M, Pharoah PD, Dunning AM, Tomlinson I, Easton DF, Spurdle AB, Thompson DJ. Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. *Hum Genet.* 134:231-345, 2015. PMC4291520.

34. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, Coetzee S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Hansen TV, Jønson L, Gerdes AM, Ejlertsen B, Barrowdale D, Dennis J, Benitez J, Osorio A, Garcia MJ, Komenaka I, Weitzel JN, Ganschow P, Peterlongo P, Bernard L, Viel A, Bonanni B, Peissel B, Manoukian S, Radice P, Papi L, Ottini L, Fostira F, Konstantopoulou I, Garber J, Frost D, Perkins J, Platte R, Ellis S; EMBRACE, Godwin AK, Schmutzler RK, Meindl A, Engel C, Sutter C, Sinilnikova OM; GEMO Study Collaborators, Damiola F, Mazoyer S, Stoppa-Lyonnet D, Claes K, De Leeneer K, Kirk J, Rodriguez GC, Piedmonte M, O'Malley DM, de la Hoya M, Caldes T, Aittomäki K, Nevanlinna H, Collée JM, Rookus MA, Oosterwijk JC; Breast Cancer Family Registry, Tihomirova L, Tung N, Hamann U, Isacacs C, Tischkowitz M, Imyanitov EN, Caligo MA, Campbell IG, Hogervorst FB; HEBON, Olah E, Diez O, Blanco I, Brunet J, Lazaro C, Pujana MA, Jakubowska A, Gronwald J, Lubinski J, Sukiennicki G, Barkardottir RB, Plante M, Simard J, Soucy P, Montagna M, Tognazzo S, Teixeira MR; KConFab Investigators, Pankratz VS, Wang X, Lindor N, Szabo CI, Kauff N, Vijai J, Aghajanian CA, Pfeiler G, Berger A, Singer CF, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Tchatchou S, Andrulis IL, Glendon G, Toland AE, Jensen UB, Kruse TA, Thomassen M, Bojesen A, Zidan J, Friedman E, Laitman Y, Soller M, Liljegren A, Arver B, Einbeigi Z, Stenmark-Askmal M, Olopade OI, Nussbaum RL, Rebbeck TR, Nathanson KL, Domchek SM, Lu KH, Karlan BY, Walsh C, Lester J; Australian Cancer Study (Ovarian Cancer Investigators); Australian Ovarian Cancer Study Group, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambrechts S, Dicks E, Doherty JA, Wicklund KG, Rossing MA, Rudolph A, Chang-Claude J, Wang-Gohrke S, Eilber U, Moysich KB, Odunsi K, Sucheston L, Lele S, Wilkens LR, Goodman MT, Thompson PJ, Shvetsov YB, Runnebaum IB, Dürst M, Hillemanns P, Dörk T, Antonenkova N, Bogdanova N, Leminen A, Pelttari LM, Butzow R, Modugno F, Kelley JL, Edwards RP, Ness RB, du Bois A, Heitz F, Schwaab I, Harter P, Matsuo K, Hosono S, Orsulic S, Jensen A, Kjaer SK, Hogdall E, Hasmad HN, Azmi MA, Teo SH, Woo YL, Fridley BL, Goode EL, Cunningham JM, Vierkant RA, Bruinsma F, Giles GG, Liang D, Hildebrandt MA, Wu X, Levine DA, Bisogna M, Berchuck A, Iversen ES, Schildkraut JM, Concannon P, Weber RP, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Orlov I, Olson SH, Krakstad C, Salvesen HB, Tangen IL, Bjorge L, van Altena AM, Aben KK, Kiemeny LA, Massuger LF, Kellar M, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Cybulski C, Yang H, Lissowska J, Brinton LA, Wentzensen N, Hogdall C, Lundvall L, Nedergaard L, Baker H, Song H, Eccles D, McNeish I, Paul J, Carty K, Siddiqui N, Glasspool R, Whittemore AS, Rothstein JH, McGuire V, Sieh W, Ji BT, Zheng W, Shu XO, Gao YT, Rosen B, Risch HA, McLaughlin JR, Narod SA, Monteiro AN, Chen A, Lin HY, Permuth-Wey J, Sellers TA, Tsai YY, Chen Z, Ziogas A, Anton-Culver H, Gentry-Maharaj A, Menon U, Harrington P, Lee AW, Wu AH, Pearce CL, Coetzee G, Pike MC, Dansonka-Mieszkowska A, Timorek A, Rzepecka IK, Kupryjanczyk J, Freedman M, Noushmehr H, Easton DF, Offit K, Couch FJ, Gayther S, Pharoah PP, Antoniou AC, Chenevix-Trench G; Consortium of Investigators of Modifiers of BRCA1 and BRCA2. Identification of six new

susceptibility loci for invasive epithelial ovarian cancer. *Nat Genet.* 47(2):164-71, 2015. PMC4445140.

35. Kabisch M, Lorenzo Bermejo J, Dünnebie T, Ying S, Michailidou K, Bolla MK, Wang Q, Dennis J, Shah M, Perkins BJ, Czene K, Darabi H, Eriksson M, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lambrechts D, Neven P, Peeters S, Weltens C, Couch FJ, Olson JE, Wang X, Purrington K, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Peto J, Dos-Santos-Silva I, Johnson N, Fletcher O, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Schmidt MK, Broeks A, Cornelissen S, Hogervorst FB, Li J, Brand JS, Humphreys K, Guénel P, Truong T, Menegaux F, Sanchez M, Burwinkel B, Marmé F, Yang R, Bugert P, González-Neira A, Benitez J, Pilar Zamora M, Arias Perez JI, Cox A, Cross SS, Reed MW, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N; kConFab Investigators; Australian Ovarian Cancer Study Group, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindblom A, Margolin S, Hooning MJ, Hollestelle A, Kriege M, Koppert LB, Hopper JL, Southey MC, Tsimiklis H, Apicella C, Slettedahl S, Toland AE, Vachon C, Yannoukakos D, Giles GG, Milne RL, McLean C, Fasching PA, Ruebner M, Ekici AB, Beckmann MW, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Ashworth A, Orr N, Schoemaker MJ, Swerdlow A, García-Closas M, Figueroa J, Chanock SJ, Lissowska J, Goldberg MS, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Brauch H, Brüning T, Ko YD; GENICA Network, Radice P, Peterlongo P, Scuvera G, Fortuzzi S, Bogdanova N, Dörk T, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Devilee P, Tollenaar RA, Seynaeve C, Van Asperen CJ, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Zheng W, Shrubsole MJ, Cai Q, Torres D, Anton-Culver H, Kristensen V, Bacot F, Tessier DC, Vincent D, Luccarini C, Baynes C, Ahmed S, Maranian M, Simard J, Chenevix-Trench G, Hall P, Pharoah PD, Dunning AM, Easton DF, Hamann U. Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. *Carcinogenesis.* 36(2):256-71, 2015. PMC4335262.
36. Blanco I, Kuchenbaecker K, Cuadras D, Wang X, Barrowdale D, de Garibay GR, Librado P, Sánchez-Gracia A, Rozas J, Bonifaci N, McGuffog L, Pankratz VS, Islam A, Mateo F, Berenguer A, Petit A, Català I, Brunet J, Feliubadaló L, Tornero E, Benítez J, Osorio A, Cajal TR, Nevanlinna H, Aittomäki K, Arun BK, Toland AE, Karlan BY, Walsh C, Lester J, Greene MH, Mai PL, Nussbaum RL, Andrulis IL, Domchek SM, Nathanson KL, Rebbeck TR, Barkardottir RB, Jakubowska A, Lubinski J, Durda K, Jaworska-Bieniek K, Claes K, Van Maerken T, Díez O, Hansen TV, Jønson L, Gerdes AM, Ejlersen B, de la Hoya M, Caldés T, Dunning AM, Oliver C, Fineberg E, Cook M, Peock S, McCann E, Murray A, Jacobs C, Pichert G, Lalloo F, Chu C, Dorkins H, Paterson J, Ong KR, Teixeira MR; Teixeira, Hogervorst FB, van der Hout AH, Seynaeve C, van der Luijt RB, Ligtenberg MJ, Devilee P, Wijnen JT, Rookus MA, Meijers-Heijboer HE, Blok MJ, van den Ouweland AM, Aalfs CM, Rodriguez GC, Phillips KA, Piedmonte M, Nerenstone SR, Bae-Jump VL, O'Malley DM, Ratner ES, Schmutzler RK, Wappenschmidt B, Rhiem K, Engel C, Meindl A, Ditsch N, Arnold N, Plendl HJ, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Gehrig A, Bojesen A, Pedersen IS, Sunde L, Jensen UB, Thomassen

M, Kruse TA, Foretova L, Peterlongo P, Bernard L, Peissel B, Scuvera G, Manoukian S, Radice P, Ottini L, Montagna M, Agata S, Maugard C, Simard J, Soucy P, Berger A, Fink-Retter A, Singer CF, Rappaport C, Geschwantler-Kaulich D, Tea MK, Pfeiler G; BCFR, John EM, Miron A, Neuhausen SL, Terry MB, Chung WK, Daly MB, Goldgar DE, Janavicius R, Dorfling CM, van Rensburg EJ, Fostira F, Konstantopoulou I, Garber J, Godwin AK, Olah E, Narod SA, Rennert G, Paluch SS, Laitman Y, Friedman E; SWE-BRCA, Liljegren A, Rantala J, Stenmark-Askmalm M, Loman N, Imyanitov EN, Hamann U; kConFab Investigators, Spurdle AB, Healey S, Weitzel JN, Herzog J, Margileth D, Gorrini C, Esteller M, Gómez A, Sayols S, Vidal E, Heyn H; GEMO, Stoppa-Lyonnet D, Léoné M, Barjhoux L, Fassy-Colcombet M, de Pauw A, Lasset C, Ferrer SF, Castera L, Berthet P, Cornelis F, Bignon YJ, Damiola F, Mazoyer S, Sinilnikova OM, Maxwell CA, Vijai J, Robson M, Kauff N, Corines MJ, Villano D, Cunningham J, Lee A, Lindor N, Lázaro C, Easton DF, Offit K, Chenevix-Trench G, Couch FJ, Antoniou AC, Pujana MA. Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS One*. 10(4):e0120020, 2015. PMC4382299.

37. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL; CIMBA Consortium, Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H, Stenmark-Askmalm M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther SA, Domchek SM, Arun BK, Lu KH, Mitchell G, Karlan BY, Walsh C, Lester J, Godwin AK, Pathak H, Ross E, Daly MB, Whittemore AS, John EM, Miron A, Terry MB, Chung WK, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Ejlersen B, Gerdes AM, Hansen Tv, Ramón y Cajal T, Osorio A, Benitez J, Godino J, Tejada MI, Duran M, Weitzel JN, Bobolis KA, Sand SR, Fontaine A, Savarese A, Pasini B, Peissel B, Bonanni B, Zaffaroni D, Vignolo-Lutati F, Scuvera G, Giannini G, Bernard L, Genuardi M, Radice P, Dolcetti R, Manoukian S, Pensotti V, Gismondi V, Yannoukakos D, Fostira F, Garber J, Torres D, Rashid MU, Hamann U, Peock S, Frost D, Platte R, Evans DG, Eeles R, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Izatt L, Adlard J, Donaldson A, Ellis S, Sharma P, Schmutzler RK, Wappenschmidt B, Becker A, Rhiem K, Hahnen E, Engel C, Meindl A, Engert S, Ditsch N, Arnold N, Plendl HJ, Mundhenke C, Niederacher D, Fleisch M, Sutter C, Bartram CR, Dikow N, Wang-Gohrke S, Gadzicki D, Steinemann D, Kast K, Beer M, Varon-Mateeva R, Gehrig A, Weber BH, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Houdayer C, Belotti M, Gauthier-Villars M, Damiola F, Boutry-Kryza N, Lasset C, Sobol H, Peyrat JP, Muller D, Fricker JP, Collonge-Rame MA, Mortemousque I, Nogues C, Rouleau E, Isaacs C, De Paepe A, Poppe B, Claes K, De Leeneer K, Piedmonte M, Rodriguez G, Wakely K, Boggess J, Blank SV, Basil J, Azodi M, Phillips KA, Caldes T, de la Hoya M, Romero A, Nevanlinna H, Aittomäki K, van der Hout AH, Hogervorst FB, Verhoef S, Collée JM, Seynaeve C, Oosterwijk JC, Gille JJ, Wijnen JT, Garcia EB, Kets CM, Ausems MG, Aalfs CM, Devilee P, Mensenkamp AR, Kwong A, Olah E, Papp J, Diez O, Lázaro C, Darder E, Blanco I, Salinas M, Jakubowska A, Lubinski J, Gronwald J, Jaworska-Bieniek K, Durda K, Sukiennicki G, Huzarski T, Byrski T, Cybulski C,

Toloczko-Grabarek A, Złowocka-Perłowska E, Menkiszak J, Arason A, Barkardottir RB, Simard J, Laframboise R, Montagna M, Agata S, Alducci E, Peixoto A, Teixeira MR, Spurdle AB, Lee MH, Park SK, Kim SW, Friebel TM, Couch FJ, Lindor NM, Pankratz VS, Guidugli L, Wang X, Tischkowitz M, Foretova L, Vijai J, Offit K, Robson M, Rau-Murthy R, Kauff N, Fink-Retter A, Singer CF, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, Berger A, Greene MH, Mai PL, Imyanitov EN, Toland AE, Senter L, Bojesen A, Pedersen IS, Skytte AB, Sunde L, Thomassen M, Moeller ST, Kruse TA, Jensen UB, Caligo MA, Aretini P, Teo SH, Selkirk CG, Hulick PJ, Andrulis I. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA*. 313(13):1347-61, 2015.

38. Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A, Dennis J, Kuchenbaecker KB, Soucy P, Terry MB, Chung WK, Goldgar DE, Buys SS; BCFR, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Gerdes AM, Ejlersen B, Nielsen FC, Hansen TV, Osorio A, Benitez J, Andrés-Conejero R, Segota E, Weitzel JN, Thelander M, Peterlongo P, Radice P, Pensotti V, Dolcetti R, Bonanni B, Peissel B, Zaffaroni D, Scuvera G, Manoukian S, Varesco L, Capone GL, Papi L, Ottini L, Yannoukakos D, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brady A, Brewer C, Foo C, Evans DG, Frost D, Eccles D; EMBRACE, Douglas F, Cook J, Adlard J, Barwell J, Walker L, Izatt L, Side LE, Kennedy MJ, Tischkowitz M, Rogers MT, Porteous ME, Morrison PJ, Platte R, Eeles R, Davidson R, Hodgson S, Cole T, Godwin AK, Isaacs C, Claes K, De Leeneer K, Meindl A, Gehrig A, Wappenschmidt B, Sutter C, Engel C, Niederacher D, Steinemann D, Plendl H, Kast K, Rhiem K, Ditsch N, Arnold N, Varon-Mateeva R, Schmutzler RK, Preisler-Adams S, Markov NB, Wang-Gohrke S, de Pauw A, Lefol C, Lasset C, Leroux D, Rouleau E, Damiola F; GEMO Study Collaborators, Dreyfus H, Barjhoux L, Golmard L, Uhrhammer N, Bonadona V, Sornin V, Bignon YJ, Carter J, Van Le L, Piedmonte M, DiSilvestro PA, de la Hoya M, Caldes T, Nevanlinna H, Aittomäki K, Jager A, van den Ouweland AM, Kets CM, Aalfs CM, van Leeuwen FE, Hogervorst FB, Meijers-Heijboer HE; HEBON, Oosterwijk JC, van Roozendaal KE, Rookus MA, Devilee P, van der Luijt RB, Olah E, Diez O, Teulé A, Lazaro C, Blanco I, Del Valle J, Jakubowska A, Sukiennicki G, Gronwald J, Lubinski J, Durda K, Jaworska-Bieniek K, Agnarsson BA, Maugard C, Amadori A, Montagna M, Teixeira MR, Spurdle AB, Foulkes W, Olswold C, Lindor N, Pankratz VS, Szabo CI, Lincoln A, Jacobs L, Corines M, Robson M, Vijai J, Berger A, Fink-Retter A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Greene MH, Mai PL, Rennert G, Imyanitov EN, Mulligan AM, Glendon G, Andrulis IL, Tchatchou S, Toland AE, Pedersen IS, Thomassen M, Kruse TA, Jensen UB, Caligo MA, Friedman E, Zidan J, Laitman Y, Lindblom A, Melin B, Arver B, Loman N, Rosenquist R, Olopade OI, Nussbaum RL, Ramus SJ, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK, Mitchell G, Karlan BY, Lester J, Orsulic S, Stoppa-Lyonnet D, Thomas G, Simard J, Couch FJ, Offit K, Easton DF, Chenevix-Trench G, Antoniou AC, Mazoyer S, Phelan CM, Sinilnikova OM, Cox DG. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Res*. 17(1):51, 2015.

39. Brand JS, Li J, Humphreys K, Karlsson R, Eriksson M, Ivansson E, Hall P, Czene K. Identification of two novel mammographic density loci at 6Q25.1. *Breast Cancer Res.* 17(1):75, 2015. PMC4501298.
40. Lei J, Rudolph A, Moysich KB, Rafiq S, Behrens S, Goode EL, Pharoah PP, Seibold P, Fasching PA, Andrulis IL, Kristensen VN, Couch FJ, Hamann U, Hooning MJ, Nevanlinna H, Eilber U, Bolla MK, Dennis J, Wang Q, Lindblom A, Mannermaa A, Lambrechts D, García-Closas M, Hall P, Chenevix-Trench G, Shah M, Luben R, Haeberle L, Ekici AB, Beckmann MW, Knight JA, Glendon G, Tchatchou S, Alnæs GI, Borresen-Dale AL, Nord S, Olson JE, Hallberg E, Vachon C, Torres D, Ulmer HU, Rüdiger T, Jager A, van Deurzen CH, Tilanus-Linthorst MM, Muranen TA, Aittomäki K, Blomqvist C, Margolin S, Kosma VM, Hartikainen JM, Kataja V, Hatse S, Wildiers H, Smeets A, Figueroa J, Chanock SJ, Lissowska J, Li J, Humphreys K, Phillips KA; kConFab Investigators, Linn S, Cornelissen S, van den Broek SA, Kang D, Choi JY, Park SK, Yoo KY, Hsiung CN, Wu PE, Hou MF, Shen CY, Teo SH, Taib NA, Yip CH, Ho GF, Matsuo K, Ito H, Iwata H, Tajima K, Dunning AM, Benitez J, Czene K, Sucheston LE, Maishman T, Tapper WJ, Eccles D, Easton DF, Schmidt MK, Chang-Claude J. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. *Breast Cancer Res.* 17:18, 2015. PMC4374346.
41. Palomba G, Loi A, Porcu E, Cossu A, Zara I, Budroni M, Dei M, Lai S, Mulas A, Olmeo N, Ionta MT, Atzori F, Cuccuru G, Pitzalis M, Zoledziwska M, Olla N, Lovicu M, Pisano M, Abecasis GR, Uda M, Tanda F, Michailidou K, Easton DF, Chanock SJ, Hoover RN, Hunter DJ, Schlessinger D, Sanna S, Crisponi L, Palmieri G. Genome-wide association study of susceptibility loci for breast cancer in Sardinian population. *BMC Cancer.* 15:383, 2015. PMC4434540.
42. Fagerholm R, Schmidt MK, Khan S, Rafiq S, Tapper W, Aittomäki K, Greco D, Heikkinen T, Muranen TA, Fasching PA, Janni W, Weinshilboum R, Loehberg CR, Hopper JL, Southey MC, Keeman R, Lindblom A, Margolin S, Mannermaa A, Kataja V, Chenevix-Trench G; kConFab Investigators, Lambrechts D, Wildiers H, Chang-Claude J, Seibold P, Couch FJ, Olson JE, Andrulis IL, Knight JA, García-Closas M, Figueroa J, Hooning MJ, Jager A, Shah M, Perkins BJ, Luben R, Hamann U, Kabisch M, Czene K, Hall P, Easton DF, Pharoah PD, Liu J, Eccles D, Blomqvist C, Nevanlinna H. The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. *Oncotarget.* 6(10):7390-7407, 2015. PMC4480688.
43. Orr N, Dudbridge F, Dryden N, Maguire S, Novo D, Perrakis E, Johnson N, Ghossaini M, Hopper JL, Southey MC, Apicella C, Stone J, Schmidt MK, Brooks A, Van't Veer LJ, Hogervorst FB, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Gibson L, Aitken Z, Warren H, Sawyer E, Tomlinson I, Kerin MJ, Miller N, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Guénel P, Truong T, Cordina-Duverger E, Sanchez M, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Benitez J, Zamora MP, Arias Perez JJ, Menéndez P, Anton-Culver H, Neuhausen SL, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Hamann U, Brauch H, Justenhoven C, Brüning T, Ko YD, Nevanlinna H,

Aittomäki K, Blomqvist C, Khan S, Bogdanova N, Dörk T, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Chenevix-Trench G, Beesley J, Lambrechts D, Moisse M, Floris G, Beuselinck B, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Radice P, Peterlongo P, Peissel B, Pensotti V, Couch FJ, Olson JE, Slettedahl S, Vachon C, Giles GG, Milne RL, McLean C, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Simard J, Goldberg MS, Labrèche F, Dumont M, Kristensen V, Alnæs GG, Nord S, Borresen-Dale AL, Zheng W, Deming-Halverson S, Shrubsole M, Long J, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Devilee P, Tollenaar RA, Seynaeve CM, Van Asperen CJ, Garcia-Closas M, Figueroa J, Chanock SJ, Lissowska J, Czene K, Darabi H, Eriksson M, Klevebring D, Hoening MJ, Hollestelle A, van Deurzen CH, Kriege M, Hall P, Li J, Liu J, Humphreys K, Cox A, Cross SS, Reed MW, Pharoah PD, Dunning AM, Shah M, Perkins BJ, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Ashworth A, Swerdlow A, Jones M, Schoemaker MJ, Meindl A, Schmutzler RK, Olswold C, Slager S, Toland AE, Yannoukakos D, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsarn P, Matsuo K, Ito H, Iwata H, Ishiguro J, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Teo SH, Yip CH, Kang P, Ikram MK, Shu XO, Lu W, Gao YT, Cai H, Kang D, Choi JY, Park SK, Noh DY, Hartman M, Miao H, Lim WY, Lee SC, Sangrairang S, Gaborieau V, Brennan P, McKay J, Wu PE, Hou MF, Yu JC, Shen CY, Blot W, Cai Q, Signorello LB, Luccarini C, Bayes C, Ahmed S, Maranian M, Healey CS, González-Neira A, Pita G, Alonso MR, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, Hunter DJ, Lindstrom S, Dennis J, Michailidou K, Bolla MK, Easton DF, dos Santos Silva I, Fletcher O, Peto J; GENICA Network; kConFab Investigators; Australian Ovarian Cancer Study Group. Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. *Hum Mol Genet.* 24(10):2966-84, 2015. PMC4406292.

44. Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, Arnold N, Arun BK, Arver B, Ashworth A; Australian Ovarian Cancer Study Group, Baglietto L, Balleine R, Bandera EV, Barrowdale D, Bean YT, Beckmann L, Beckmann MW, Benitez J, Berger A, Berger R, Beuselinck B, Bisogna M, Bjorge L, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Brand JS, Brauch H; Breast Cancer Family Register, Brenner H, Brinton L, Brooks-Wilson A, Bruinsma F, Brunet J, Brüning T, Budzilowska A, Bunker CH, Burwinkel B, Butzow R, Buys SS, Caligo MA, Campbell I, Carter J, Chang-Claude J, Chanock SJ, Claes KB, Collée JM, Cook LS, Couch FJ, Cox A, Cramer D, Cross SS, Cunningham JM, Cybulski C, Czene K, Damiola F, Dansonka-Mieszkowska A, Darabi H, de la Hoya M, deFazio A, Dennis J, Devilee P, Dicks EM, Diez O, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Silva ID, du Bois A, Dumont M, Dunning AM, Duran M, Easton DF, Eccles D, Edwards RP, Ehrencrona H, Ejlersen B, Ekici AB, Ellis SD; EMBRACE, Engel C, Eriksson M, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Fontaine A, Fortuzzi S, Fostira F, Fridley BL, Friebel T, Friedman E, Friel G, Frost D, Garber J, García-Closas M, Gayther SA; GEMO Study Collaborators; GENICA Network, Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goodman MT, Gore M, Greene MH, Grip M,

Gronwald J, Gschwantler Kaulich D, Guénel P, Guzman SR, Haeberle L, Haiman CA, Hall P, Halverson SL, Hamann U, Hansen TV, Harter P, Hartikainen JM, Healey S; HEBON, Hein A, Heitz F, Henderson BE, Herzog J, T Hildebrandt MA, Høgdall CK, Høgdall E, Hogervorst FB, Hopper JL, Humphreys K, Huzarski T, Imyanitov EN, Isaacs C, Jakubowska A, Janavicius R, Jaworska K, Jensen A, Jensen UB, Johnson N, Jukkola-Vuorinen A, Kabisch M, Karlan BY, Kataja V, Kauff N; KConFab Investigators, Kelemen LE, Kerin MJ, Kiemeny LA, Kjaer SK, Knight JA, Knol-Bout JP, Konstantopoulou I, Kosma VM, Krakstad C, Kristensen V, Kuchenbaecker KB, Kupryjanczyk J, Laitman Y, Lambrechts D, Lambrechts S, Larson MC, Lasa A, Laurent-Puig P, Lazaro C, Le ND, Le Marchand L, Leminen A, Lester J, Levine DA, Li J, Liang D, Lindblom A, Lindor N, Lissowska J, Long J, Lu KH, Lubinski J, Lundvall L, Lurie G, Mai PL, Mannermaa A, Margolin S, Mariette F, Marme F, Martens JW, Massuger LF, Maugard C, Mazoyer S, McGuffog L, McGuire V, McLean C, McNeish I, Meindl A, Menegaux F, Menéndez P, Menkiszak J, Menon U, Mensenkamp AR, Miller N, Milne RL, Modugno F, Montagna M, Moysich KB, Müller H, Mulligan AM, Muranen TA, Narod SA, Nathanson KL, Ness RB, Neuhausen SL, Nevanlinna H, Neven P, Nielsen FC, Nielsen SF, Nordestgaard BG, Nussbaum RL, Odunsi K, Offit K, Olah E, Olopade OI, Olson JE, Olson SH, Oosterwijk JC, Orlow I, Orr N, Orsulic S, Osorio A, Ottini L, Paul J, Pearce CL, Pedersen IS, Peissel B, Pejovic T, Peltari LM, Perkins J, Permuth-Wey J, Peterlongo P, Peto J, Phelan CM, Phillips KA, Piedmonte M, Pike MC, Platte R, Plisiecka-Halasa J, Poole EM, Poppe B, Pylkäs K, Radice P, Ramus SJ, Rebbeck TR, Reed MW, Rennert G, Risch HA, Robson M, Rodriguez GC, Romero A, Rossing MA, Rothstein JH, Rudolph A, Runnebaum I, Salani R, Salvesen HB, Sawyer EJ, Schildkraut JM, Schmidt MK, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schrauder MG, Schumacher F, Schwaab I, Scuvera G, Sellers TA, Severi G, Seynaeve CM, Shah M, Shrubsole M, Siddiqui N, Sieh W, Simard J, Singer CF, Sinilnikova OM, Smeets D, Sohn C, Soller M, Song H, Soucy P, Southey MC, Stegmaier C, Stoppa-Lyonnet D, Sucheston L; SWE-BRCA, Swerdlow A, Tangen IL, Tea MK, Teixeira MR, Terry KL, Terry MB, Thomassen M, Thompson PJ, Tihomirova L, Tischkowitz M, Toland AE, Tollenaar RA, Tomlinson I, Torres D, Truong T, Tsimiklis H, Tung N, Tworoger SS, Tyrer JP, Vachon CM, Van 't Veer LJ, van Altena AM, Van Asperen CJ, van den Berg D, van den Ouweland AM, van Doorn HC, Van Nieuwenhuysen E, van Rensburg EJ, Vergote I, Verhoef S, Vierkant RA, Vijai J, Vitonis AF, von Wachenfeldt A, Walsh C, Wang Q, Wang-Gohrke S, Wappenschmidt B, Weischer M, Weitzel JN, Weltens C, Wentzensen N, Whittemore AS, Wilkens LR, Winqvist R, Wu AH, Wu X, Yang HP, Zaffaroni D, Pilar Zamora M, Zheng W, Ziogas A, Chenevix-Trench G, Pharoah PD, Rookus MA, Hooning MJ, Goode EL. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecol Oncol.* 2015. In press. PMC4630206.

45. Rudolph A, Milne RL, Truong T, Knight JA, Seibold P, Flesch-Janys D, Behrens S, Eilber U, Bolla MK, Wang Q, Dennis J, Dunning AM, Shah M, Munday HR, Darabi H, Eriksson M, Brand JS, Olson J, Vachon CM, Hallberg E, Castela JE, Carracedo A, Torres M, Li J, Humphreys K, Cordina-Duverger E, Menegaux F, Flyger H, Nordestgaard BG, Nielsen SF, Yesilyurt BT, Floris G, Leunen K, Engelhardt EG, Broeks A, Rutgers EJ, Glendon G, Mulligan AM, Cross S, Reed M, Gonzalez-Neira A, Arias Perez JJ, Provenzano E, Apicella C, Southey MC, Spurdle A; kConFab Investigators;

AOCS Group, Häberle L, Beckmann MW, Ekici AB, Dieffenbach AK, Arndt V, Stegmaier C, McLean C, Baglietto L, Chanock SJ, Lissowska J, Sherman ME, Brüning T, Hamann U, Ko YD, Orr N, Schoemaker M, Ashworth A, Kosma VM, Kataja V, Hartikainen JM, Mannermaa A, Swerdlow A; GENICA-Network, Giles GG, Brenner H, Fasching PA, Chenevix-Trench G, Hopper J, Benítez J, Cox A, Andrulis IL, Lambrechts D, Gago-Dominguez M, **Couch F**, Czene K, Bojesen SE, Easton DF, Schmidt MK, Guénel P, Hall P, Pharoah PD, Garcia-Closas M, Chang-Claude J. Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. *Int J Cancer*. 136(6):E685-96, 2015. PMC4289418.

46. Rudolph A, Fasching PA, Behrens S, Eilber U, Bolla MK, Wang Q, Thompson D, Czene K, Brand JS, Li J, Scott C, Pankratz VS, Brandt K, Hallberg E, Olson JE, Lee A, Beckmann MW, Ekici AB, Häberle L, Maskarinec G, Le Marchand L, Schumacher F, Milne RL, Knight JA, Apicella C, Southey MC, Kapuscinski MK, Hopper JL, Andrulis IL, Giles GG, Haiman CA, Khaw KT, Luben R, Hall P, Pharoah PD, Couch FJ, Easton DF, Dos-Santos-Silva I, Vachon C, Chang-Claude J. A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density. *Breast Cancer Res*. 17(1):110, 2015. PMC4537547.
47. Zhang B, Shu XO, Delahanty RJ, Zeng C, Michailidou K, Bolla MK, Wang Q, Dennis J, Wen W, Long J, Li C, Dunning AM, Chang-Claude J, Shah M, Perkins BJ, Czene K, Darabi H, Eriksson M, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lambrechts D, Neven P, Wildiers H, Floris G, Schmidt MK, Rookus MA, van den Hurk K, de Kort WL, Couch FJ, Olson JE, Hallberg E, Vachon C, Rudolph A, Seibold P, Flesch-Janys D, Peto J, Dos-Santos-Silva I, Fletcher O, Johnson N, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Li J, Humphreys K, Brand J, Guénel P, Truong T, Cordina-Duverger E, Menegaux F, Burwinkel B, Marme F, Yang R, Surowy H, Benitez J, Zamora MP, Perez JL, Cox A, Cross SS, Reed MW, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Chenevix-Trench G; kConFab Investigators, Australian Ovarian Study Group, Haiman CA, Henderson BE, Schumacher F, Marchand LL, Lindblom A, Margolin S, Hooning MJ, Martens JW, Tilanus-Linthorst MM, Collée JM, Hopper JL, Southey MC, Tsimiklis H, Apicella C, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Giles GG, Milne RL, McLean C, Fasching PA, Häberle L, Ekici AB, Beckmann MW, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Swerdlow AJ, Ashworth A, Orr N, Jones M, Figueroa J, Garcia-Closas M, Brinton L, Lissowska J, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Brauch H, Brüning T, Ko YD, Peterlongo P, Manoukian S, Bonanni B, Radice P, Bogdanova N, Antonenkova N, Dörk T, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Devilee P, Seynaeve C, Van Asperen CJ, Jakubowska A, Lubiński J, Jaworska-Bieniek K, Durda K, Hamann U, Torres D, Schmutzler RK, Neuhausen SL, Anton-Culver H, Kristensen VN, Grenaker Alnæs GI; DRIVE Project, Pierce BL, Kraft P, Peters U, Lindstrom S, Seminara D, Burgess S, Ahsan H, Whittemore AS, John EM, Gammon MD, Malone KE, Tessier DC, Vincent D, Bacot F, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, González-Neira A, Pita G, Alonso MR, Álvarez N, Herrero D, Pharoah PD, Simard J, Hall P, Hunter DJ, Easton DF, Zheng W. Height and

Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. *J Natl Cancer Inst.* 107(11), 2015. PMC4643630.

48. Jamshidi M, Fagerholm R, Khan S, Aittomäki K, Czene K, Darabi H, Li J, Andrulis IL, Chang-Claude J, Devilee P, Fasching PA, Michailidou K, Bolla MK, Dennis J, Wang Q, Guo Q, Rhenius V, Cornelissen S, Rudolph A, Knight JA, Loehberg CR, Burwinkel B, Marme F, Hopper JL, Southey MC, Bojesen SE, Flyger H, Brenner H, Holleczeck B, Margolin S, Mannermaa A, Kosma VM, Investigators K, Van Dyck L, Nevelsteen I, Couch FJ, Olson JE, Giles GG, McLean C, Haiman CA, Henderson BE, Winqvist R, Pylkäs K, Tollenaar RA, García-Closas M, Figueroa J, Hooning MJ, Martens JW, Cox A, Cross SS, Simard J, Dunning AM, Easton DF, Pharoah PD, Hall P, Blomqvist C, Schmidt MK, Nevanlinna H. SNP-SNP interaction analysis of NF- κ B signaling pathway on breast cancer survival. *Oncotarget.* 6(35):37979-94, 2015.
49. Stone J, Thompson DJ, Dos Santos Silva I, Scott C, Tamimi RM, Lindstrom S, Kraft P, Hazra A, Li J, Eriksson L, Czene K, Hall P, Jensen M, Cunningham J, Olson JE, Purrington K, **Couch FJ**, Brown J, Leyland J, Warren RM, Luben RN, Khaw KT, Smith P, Wareham NJ, Jud SM, Heusinger K, Beckmann MW, Douglas JA, Shah KP, Chan HP, Helvie MA, Le Marchand L, Kolonel LN, Woolcott C, Maskarinec G, Haiman C, Giles GG, Baglietto L, Krishnan K, Southey MC, Apicella C, Andrulis IL, Knight JA, Ursin G, Alnaes GI, Kristensen VN, Borresen-Dale AL, Gram IT, Bolla MK, Wang Q, Michailidou K, Dennis J, Simard J, Paroah P, Dunning AM, Easton DF, Fasching PA, Pankratz VS, Hopper JL, Vachon CM. Novel associations between common breast cancer susceptibility variants and risk-predicting mammographic density measures. *Cancer Res.* 75(12):2457-67, 2015. PMC4470785
50. Guo X, Long J, Zeng C, Michailidou K, Ghoussaini M, Bolla MK, Wang Q, Milne RL, Shu XO, Cai Q, Beesley J, Kar SP, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Beeghly-Fadiel A, Benitez J, Blot W, Bogdanova N, Bojesen SE, Brauch H, Brenner H, Brinton L, Brooks A, Brüning T, Burwinkel B, Cai H, Canisius S, Chang-Claude J, Choi JY, Couch FJ, Cox A, Cross SS, Czene K, Darabi H, Devilee P, Droit A, Dörk T, Fasching PA, Fletcher O, Flyger H, Fostira F, Gaborieau V, García-Closas M, Giles GG, Grip M, Guénel P, Haiman CA, Hamann U, Hartman M, Hollestelle A, Hopper JL, Hsiung CN, Ito H, Jakubowska A, Johnson N, Kabisch M, Kang D, Khan S, Knight JA, Kosma VM, Lambrechts D, Marchand LL, Li J, Lindblom A, Lophatananon A, Lubinski J, Mannermaa A, Manoukian S, Margolin S, Marme F, Matsuo K, McLean CA, Meindl A, Muir K, Neuhausen SL, Nevanlinna H, Nord S, Olson JE, Orr N, Peterlongo P, Putti TC, Rudolph A, Sangrajrang S, Sawyer EJ, Schmidt MK, Schmutzler RK, Shen CY, Shi J, Shrubsole MJ, Southey MC, Swerdlow A, Teo SH, Thienpont B, Toland AE, Tollenaar RA, Tomlinson IP, Truong T, Tseng CC, van den Ouweland A, Wen W, Winqvist R, Wu A, Yip CH, Zamora MP, Zheng Y, Hall P, Pharoah PD, Simard J, Chenevix-Trench G; kConFab Investigators, Dunning AM, Easton DF, Zheng W. Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. *Cancer Epidemiol Biomarkers Prev.* 2015 Sep 9. PMC4633342.

51. Day FR, Ruth KS, Thompson DJ, Lunetta KL, Pervjakova N, Chasman DI, Stolk L, Finucane HK, Sulem P, Bulik-Sullivan B, Esko T, Johnson AD, Elks CE, Franceschini N, He C, Altmaier E, Brody JA, Franke LL, Huffman JE, Keller MF, McArdle PF, Nutile T, Porcu E, Robino A, Rose LM, Schick UM, Smith JA, Teumer A, Traglia M, Vuckovic D, Yao J, Zhao W, Albrecht E, Amin N, Corre T, Hottenga JJ, Mangino M, Smith AV, Tanaka T, Abecasis GR, Andrulis IL, Anton-Culver H, Antoniou AC, Arndt V, Arnold AM, Barbieri C, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bernstein L, Bielski SJ, Blomqvist C, Boerwinkle E, Bogdanova NV, Bojesen SE, Bolla MK, Borresen-Dale AL, Boutin TS, Brauch H, Brenner H, Brüning T, Burwinkel B, Campbell A, Campbell H, Chanock SJ, Chapman JR, Chen YD, Chenevix-Trench G, Couch FJ, Coviello AD, Cox A, Czene K, Darabi H, De Vivo I, Demerath EW, Dennis J, Devilee P, Dörk T, Dos-Santos-Silva I, Dunning AM, Eicher JD, Fasching PA, Faul JD, Figueroa J, Flesch-Janys D, Gandin I, Garcia ME, García-Closas M, Giles GG, Grotto GG, Goldberg MS, González-Neira A, Goodarzi MO, Grove ML, Gudbjartsson DF, Guénel P, Guo X, Haiman CA, Hall P, Hamann U, Henderson BE, Hocking LJ, Hofman A, Homuth G, Hooning MJ, Hopper JL, Hu FB, Huang J, Humphreys K, Hunter DJ, Jakubowska A, Jones SE, Kabisch M, Karasik D, Knight JA, Kolcic I, Kooperberg C, Kosma VM, Kriebel J, Kristensen V, Lambrechts D, Langenberg C, Li J, Li X, Lindström S, Liu Y, Luan J, Lubinski J, Mägi R, Mannermaa A, Manz J, Margolin S, Marten J, Martin NG, Masciullo C, Meindl A, Michailidou K, Mihailov E, Milani L, Milne RL, Müller-Nurasyid M, Nalls M, Neale BM, Nevanlinna H, Neven P, Newman AB, Nordestgaard BG, Olson JE, Padmanabhan S, Peterlongo P, Peters U, Petersmann A, Peto J, Pharoah PD, Pirastu NN, Pirie A, Pistis G, Polasek O, Porteous D, Psaty BM, Pyrkäs K, Radice P, Raffel LJ, Rivadeneira F, Rudan I, Rudolph A, Ruggiero D, Sala CF, Sanna S, Sawyer EJ, Schlessinger D, Schmidt MK, Schmidt F, Schmutzler RK, Schoemaker MJ, Scott RA, Seynaeve CM, Simard J, Sorice R, Southey MC, Stöckl D, Strauch K, Swerdlow A, Taylor KD, Thorsteinsdottir U, Toland AE, Tomlinson I, Truong T, Tryggvadottir L, Turner ST, Vozzi D, Wang Q, Wellons M, Willemsen G, Wilson JF, Winqvist R, Wolffenbuttel BB, Wright AF, Yannoukakos D, Zemunik T, Zheng W, Zygmont M, Bergmann S, Boomsma DI, Buring JE, Ferrucci L, Montgomery GW, Gudnason V, Spector TD, van Duijn CM, Alizadeh BZ, Ciullo M, Crisponi L, Easton DF, Gasparini PP, Gieger C, Harris TB, Hayward C, Kardia SL, Kraft P, McKnight B, Metspalu A, Morrison AC, Reiner AP, Ridker PM, Rotter JI, Toniolo D, Uitterlinden AG, Ulivi S, Völzke H, Wareham NJ, Weir DR, Yerges-Armstrong LM; PRACTICAL Consortium; kConFab Investigators; AOCs Investigators; Generation Scotland; EPIC-InterAct Consortium; LifeLines Cohort Study, Price AL, Stefansson K, Visser JA, Ong KK, Chang-Claude J, Murabito JM, Perry JR, Murray A. Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. *Nat Genet.* 47(11)1294-303, 2015. PMC4661791.
52. Thompson DJ, O'Mara TA, Glubb DM, Painter JN, Cheng T, Folkard E, Doody D, Dennis J, Webb PM, Gorman M, Martin L, Hodgson S, Michailidou K, Tyrer JP, Maranian MJ, Hall P, Czene K, Darabi H, Li J, Fasching PA, Hein A, Beckmann MW, Ekici AB, Dörk T, Hillemanns P, Dürst M, Runnebaum I, Zhao H, Depreeuw J, Schrauwen S, Amant F, Goode EL, Fridley BL, Dowdy SC, Winham SJ, Salvesen HB, Trovik J, Njolstad TS, Werner HM, Ashton K, Proietto T, Otton G, Carvajal-Carmona L,

Tham E, Liu T, Mints M, Scott RJ, McEvoy M, Attia J, Holliday EG, Montgomery GW, Martin NG, Nyholt DR, Henders AK, Hopper JL, Traficante N, Ruebner M, Swerdlow AJ, Burwinkel B, Brenner H, Meindl A, Brauch H, Lindblom A, Lambrechts D, Chang-Claude J, Couch F, Giles G, Kristensen VN, Cox A, Bolla MK, Wang Q, Bojesen SE, Shah M, Luben R, Khaw KT, Pharoah PD, Dunning AM, Tomlinson I, Dowsett M, Easton DF, Spurdle AB. CYP19A1 fine-mapping and Mendelian randomisation: estradiol is causal for endometrial cancer. *Endocr Relat Cancer*. 23(2):77-91, 2016. PMC4697192.

53. Seibold P, Schmezer P, Behrens S, Michailidou K, Bolla MK, Wang Q, Flesch-Janys D, Nevanlinna H, Fagerholm R, Aittomäki K, Blomqvist C, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Lambrechts D, Wildiers H, Kristensen V, Alnæs GG, Nord S, Borresen-Dale AL, Hoening MJ, Hollestelle A, Jager A, Seynaeve C, Li J, Liu J, Humphreys K, Dunning AM, Rhenius V, Shah M, Kabisch M, Torres D, Ulmer HU, Hamann U, Schildkraut JM, Purrington KS, Couch FJ, Hall P, Pharoah P, Easton DF, Schmidt MK, Chang-Claude J, Popanda O. A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. *BMC Cancer*. 15(1):978, 2015. PMC4682235.
54. Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D; EMBRACE, McGuffog L, Ellis S, Feng B, Buys SS, Hopper JL, Southey MC, Tesoriero A; kConFab Investigators, James PA, Bruinsma F, Campbell IG; Australia Ovarian Cancer Study Group, Broeks A, Schmidt MK, Hogervorst FB; HEBON, Beckman MW, Fasching PA, Fletcher O, Johnson N, Sawyer EJ, Riboli E, Banerjee S, Menon U, Tomlinson I, Burwinkel B, Hamann U, Marme F, Rudolph A, Janavicius R, Tihomirova L, Tung N, Garber J, Cramer D, Terry KL, Poole EM, Tworoger SS, Dorfling CM, van Rensburg EJ, Godwin AK, Guénel P, Truong T; GEMO Study Collaborators, Stoppa-Lyonnet D, Damiola F, Mazoyer S, Sinilnikova OM, Isaacs C, Maugard C, Bojesen SE, Flyger H, Gerdes AM, Hansen TV, Jensen A, Kjaer SK, Hogdall C, Hogdall E, Pedersen IS, Thomassen M, Benitez J, González-Neira A, Osorio A, Hoya Mde L, Segura PP, Diez O, Lazaro C, Brunet J, Anton-Culver H, Eun Jung L, John EM, Neuhausen SL, Ding YC, Castillo D, Weitzel JN, Ganz PA, Nussbaum RL, Chan SB, Karlan BY, Lester J, Wu A, Gayther S, Ramus SJ, Sieh W, Whittemore AS, Monteiro AN, Phelan CM, Terry MB, Piedmonte M, Offit K, Robson M, Levine D, Moysich KB, Cannioto R, Olson SH, Daly MB, Nathanson KL, Domchek SM, Lu KH, Liang D, Hildebrandt MA, Ness R, Modugno F, Pearce L, Goodman MT, Thompson PJ, Brenner H, Butterbach K, Meindl A, Hahnen E, Wappenschmidt B, Brauch H, Brüning T, Blomqvist C, Khan S, Nevanlinna H, Pelttari LM, Aittomäki K, Butzow R, Bogdanova NV, Dörk T, Lindblom A, Margolin S, Rantala J, Kosma VM, Mannermaa A, Lambrechts D, Neven P, Claes KB, Maerken TV, Chang-Claude J, Flesch-Janys D, Heitz F, Varon-Mateeva R, Peterlongo P, Radice P, Viel A, Barile M, Peissel B, Manoukian S, Montagna M, Oliani C, Peixoto A, Teixeira MR, Collavoli A, Hallberg E, Olson JE, Goode EL, Hart SN, Shimelis H, Cunningham JM, Giles GG, Milne RL, Healey S, Tucker K, Haiman CA, Henderson BE, Goldberg MS, Tischkowitz M, Simard J, Soucy P, Eccles DM, Le N, Borresen-Dale AL, Kristensen V, Salvesen HB, Bjorge L, Bandera EV, Risch H, Zheng W, Beeghly-Fadiel A, Cai H, Pylkäs K, Tollenaar RA, Ouweland AM, Andrulis IL, Knight JA; OCGN, Narod S, Devilee P, Winqvist R, Figueroa J,

Greene MH, Mai PL, Loud JT, García-Closas M, Schoemaker MJ, Czene K, Darabi H, McNeish I, Siddiqui N, Glasspool R, Kwong A, Park SK, Teo SH, Yoon SY, Matsuo K, Hosono S, Woo YL, Gao YT, Foretova L, Singer CF, Rappaport-Feurhauser C, Friedman E, Laitman Y, Rennert G, Imyanitov EN, Hulick PJ, Olopade OI, Senter L, Olah E, Doherty JA, Schildkraut J, Koppert LB, Kiemeny LA, Massuger LF, Cook LS, Pejovic T, Li J, Borg A, Öfverholm A, Rossing MA, Wentzensen N, Henriksson K, Cox A, Cross SS, Pasini BJ, Shah M, Kabisch M, Torres D, Jakubowska A, Lubinski J, Gronwald J, Agnarsson BA, Kupryjanczyk J, Moes-Sosnowska J, Fostira F, Konstantopoulou I, Slager S, Jones M; PRostate cancer AssoCiation group To Investigate Cancer Associated aLterations in the genome, Antoniou AC, Berchuck A, Swerdlow A, Chenevix-Trench G, Dunning AM, Pharoah PD, Hall P, Easton DF, Couch FJ, Spurdle AB, Goldgar DE. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *J Natl Cancer Inst.* 108(2), 2015.

55. Davies NM, Gaunt TR, Lewis SJ, Holly J, Donovan JL, Hamdy FC, Kemp JP, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Pandha H; PRACTICAL consortium, Lathrop M, Smith GD, Martin RM. The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. *Cancer Causes Control.* 26(11):1603-16, 2015. PMC4596899.
56. Lei J, Rudolph A, Moysich KB, Behrens S, Goode EL, Bolla MK, Dennis J, Dunning AM, Easton DF, Wang Q, Benitez J, Hopper JL, Southey MC, Schmidt MK, Broeks A, Fasching PA, Haerle L, Peto J, Dos-Santos-Silva I, Sawyer EJ, Tomlinson I, Burwinkel B, Marmé F, Guénel P, Truong T, Bojesen SE, Flyger H, Nielsen SF, Nordestgaard BG, González-Neira A, Menéndez P, Anton-Culver H, Neuhausen SL, Brenner H, Arndt V, Meindl A, Schmutzler RK, Brauch H, Hamann U, Nevanlinna H, Fagerholm R, Dörk T, Bogdanova NV, Mannermaa A, Hartikainen JM; Australian Ovarian Study Group; kConFab Investigators, Van Dijk L, Smeets A, Flesch-Janys D, Eilber U, Radice P, Peterlongo P, **Couch FJ**, Hallberg E, Giles GG, Milne RL, Haiman CA, Schumacher F, Simard J, Goldberg MS, Kristensen V, Borresen-Dale AL, Zheng W, Beeghly-Fadiel A, Winqvist R, Grip M, Andrulis IL, Glendon G, García-Closas M, Figueroa J, Czene K, Brand JS, Darabi H, Eriksson M, Hall P, Li J, Cox A, Cross SS, Pharoah PD, Shah M, Kabisch M, Torres D, Jakubowska A, Lubinski J, Ademuyiwa F, Ambrosone CB, Swerdlow A, Jones M, Chang-Claude J. Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. *Hum Genet.* 135(1):137-54, 2016. PMC4698282.
57. Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, Ramus SJ, Nussbaum RL, Olopade OI, Rantala J, Yoon SY, Caligo MA, Spagnesi L, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Toland AE, Senter L, Andrulis IL,

Glendon G, Hulick PJ, Imyanitov EN, Greene MH, Mai PL, Singer CF, Rappaport-Fuerhauser C, Kramer G, Vijai J, Offit K, Robson M, Lincoln A, Jacobs L, Machackova E, Foretova L, Navratilova M, Vasickova P, Couch FJ, Hallberg E, Ruddy KJ, Sharma P, Kim SW; kConFab Investigators, Teixeira MR, Pinto P, Montagna M, Matricardi L, Arason A, Johannsson OT, Barkardottir RB, Jakubowska A, Lubinski J, Izquierdo A, Pujana MA, Balmaña J, Diez O, Ivady G, Papp J, Olah E, Kwong A; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Nevanlinna H, Aittomäki K, Perez Segura P, Caldes T, Van Maerken T, Poppe B, Claes KB, Isaacs C, Elan C, Lasset C, Stoppa-Lyonnet D, Barjhoux L, Belotti M, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Kast K, Arnold N, Varon-Mateeva R, Wand D, Godwin AK, Evans DG, Frost D, Perkins J, Adlard J, Izatt L, Platte R, Eeles R, Ellis S; EMBRACE, Hamann U, Garber J, Fostira F, Fountzilas G, Pasini B, Giannini G, Rizzolo P, Russo A, Cortesi L, Papi L, Varesco L, Palli D, Zanna I, Savarese A, Radice P, Manoukian S, Peissel B, Barile M, Bonanni B, Viel A, Pensotti V, Tommasi S, Peterlongo P, Weitzel JN, Osorio A, Benitez J, McGuffog L, Healey S, Gerdes AM, Ejlertsen B, Hansen TV, Steele L, Ding YC, Tung N, Janavicius R, Goldgar DE, Buys SS, Daly MB, Bane A, Terry MB, John EM, Southey M, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Res.* 18(1):15, 2016. PMC4746828.

58. Petridis C, Brook MN, Shah V, Kohut K, Gorman P, Caneppele M, Levi D, Papouli E, Orr N, Cox A, Cross SS, Dos-Santos-Silva I, Peto J, Swerdlow A, Schoemaker MJ, Bolla MK, Wang Q, Dennis J, Michailidou K, Benitez J, González-Neira A, Tessier DC, Vincent D, Li J, Figueroa J, Kristensen V, Borresen-Dale AL, Soucy P, Simard J, Milne RL, Giles GG, Margolin S, Lindblom A, Brüning T, Brauch H, Southey MC, Hopper JL, Dörk T, Bogdanova NV, Kabisch M, Hamann U, Schmutzler RK, Meindl A, Brenner H, Arndt V, Winqvist R, Pylkäs K, Fasching PA, Beckmann MW, Lubinski J, Jakubowska A, Mulligan AM, Andrulis IL, Tollenaar RA, Devilee P, Le Marchand L, Haiman CA, Mannermaa A, Kosma VM, Radice P, Peterlongo P, Marme F, Burwinkel B, van Deurzen CH, Hollestelle A, Miller N, Kerin MJ, Lambrechts D, Floris G, Wesseling J, Flyger H, Bojesen SE, Yao S, Ambrosone CB, Chenevix-Trench G, Truong T, Guénel P, Rudolph A, Chang-Claude J, Nevanlinna H, Blomqvist C, Czene K, Brand JS, Olson JE, Couch FJ, Dunning AM, Hall P, Easton DF, Pharoah PD, Pinder SE, Schmidt MK, Tomlinson I, Roylance R, García-Closas M, Sawyer EJ. Genetic predisposition to ductal carcinoma in situ of the breast. *Breast Cancer Res.* 18(1):22, 2016. PMC4756509.
59. Easton DF, Lesueur F, Decker B, Michailidou K, Li J, Allen J, Luccarini C, Pooley KA, Shah M, Bolla MK, Wang Q, Dennis J, Ahmad J, Thompson ER, Damiola F, Pertesi M, Voegelé C, Mebirouk N, Robinot N, Durand G, Forey N, Luben RN, Ahmed S, Aittomäki K, Anton-Culver H, Arndt V; Australian Ovarian Cancer Study Group, Baynes C, Beckman MW, Benitez J, Van Den Berg D, Blot WJ, Bogdanova NV, Bojesen SE, Brenner H, Chang-Claude J, Chia KS, Choi JY, Conroy DM, Cox A, Cross SS, Czene K, Darabi H, Devilee P, Eriksson M, Fasching PA, Figueroa J, Flyger H, Fostira F, García-Closas M, Giles GG, Glendon G, González-Neira A, Guénel P, Haiman CA, Hall P, Hart SN, Hartman M, Hoening MJ, Hsiung CN, Ito H, Jakubowska A, James PA, John EM, Johnson N, Jones M, Kabisch M, Kang D; kConFab Investigators, Kosma VM,

Kristensen V, Lambrechts D, Li N; Lifepool Investigators, Lindblom A, Long J, Lophatananon A, Lubinski J, Mannermaa A, Manoukian S, Margolin S, Matsuo K, Meindl A, Mitchell G, Muir K; NBCS Investigators, Nevelsteen I, van den Ouweland A, Peterlongo P, Phuah SY, Pylkäs K, Rowley SM, Sangrajrang S, Schmutzler RK, Shen CY, Shu XO, Southey MC, Surowy H, Swerdlow A, Teo SH, Tollenaar RA, Tomlinson I, Torres D, Truong T, Vachon C, Verhoef S, Wong-Brown M, Zheng W, Zheng Y, Nevanlinna H, Scott RJ, Andrulis IL, Wu AH, Hopper JL, Couch FJ, Winqvist R, Burwinkel B, Sawyer EJ, Schmidt MK, Rudolph A, Dörk T, Brauch H, Hamann U, Neuhausen SL, Milne RL, Fletcher O, Pharoah PD, Campbell IG, Dunning AM, Le Calvez-Kelm F, Goldgar DE, Tavtigian SV, Chenevix-Trench G. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. *J Med Genet.* 53(5):298-309, 2016. PMC4938802

60. **Couch FJ**, Kuchenbaecker KB, Michailidou K, Mendoza-Fandino GA, Nord S, Lilyquist J, Olswold C, Hallberg E, Agata S, Ahsan H, Aittomäki K, Ambrosone C, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Barile M, Barkardottir RB, Barrowdale D, Beckmann L, Beckmann MW, Benitez J, Blank SV, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldes T, Caligo MA, Canzian F, Carpenter J, Chang-Claude J, Chanock SJ, Chung WK, Claes KB, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Damiola F, Darabi H, de la Hoya M, Devilee P, Diez O, Ding YC, Dolcetti R, Domchek SM, Dorfling CM, Dos-Santos-Silva I, Dumont M, Dunning AM, Eccles DM, Ehrencrona H, Ekici AB, Eliassen H, Ellis S, Fasching PA, Figueroa J, Flesch-Janys D, Försti A, Fostira F, Foulkes WD, Friebel T, Friedman E, Frost D, Gabrielson M, Gammon MD, Ganz PA, Gapstur SM, Garber J, Gaudet MM, Gayther SA, Gerdes AM, Ghoussaini M, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Gronwald J, Guénel P, Gunter M, Haeberle L, Haiman CA, Hamann U, Hansen TV, Hart S, Healey S, Heikkinen T, Henderson BE, Herzog J, Hogervorst FB, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Humphreys K, Hunter DJ, Huzarski T, Imyanitov EN, Isaacs C, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Jones M, Kabisch M, Kar S, Karlan BY, Khan S, Khaw KT, Kibriya MG, Knight JA, Ko YD, Konstantopoulou I, Kosma VM, Kristensen V, Kwong A, Laitman Y, Lambrechts D, Lazaro C, Lee E, Le Marchand L, Lester J, Lindblom A, Lindor N, Lindstrom S, Liu J, Long J, Lubinski J, Mai PL, Makalic E, Malone KE, Mannermaa A, Manoukian S, Margolin S, Marme F, Martens JW, McGuffog L, Meindl A, Miller A, Milne RL, Miron P, Montagna M, Mazoyer S, Mulligan AM, Muranen TA, Nathanson KL, Neuhausen SL, Nevanlinna H, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olopade OI, Olson JE, Osorio A, Park SK, Peeters PH, Peissel B, Peterlongo P, Peto J, Phelan CM, Pilarski R, Poppe B, Pylkäs K, Radice P, Rahman N, Rantala J, Rappaport C, Rennert G, Richardson A, Robson M, Romieu I, Rudolph A, Rutgers EJ, Sanchez MJ, Santella RM, Sawyer EJ, Schmidt DF, Schmidt MK, Schmutzler RK, Schumacher F, Scott R, Senter L, Sharma P, Simard J, Singer CF, Sinilnikova OM, Soucy P, Southey M, Steinemann D, Stenmark-Askmal M, Stoppa-Lyonnet D, Swerdlow A, Szabo CI, Tamimi R, Tapper W, Teixeira MR, Teo SH, Terry MB, Thomassen M, Thompson D, Tihomirova L, Toland AE, Tollenaar RA, Tomlinson I, Truong T, Tsimiklis H, Teulé A, Tumino R, Tung N, Turnbull C, Ursin G, van Deurzen CH, van Rensburg EJ, Varon-Mateeva R, Wang Z, Wang-Gohrke S,

Weiderpass E, Weitzel JN, Whittemore A, Wildiers H, Winqvist R, Yang XR, Yannoukakos D, Yao S, Zamora MP, Zheng W, Hall P, Kraft P, Vachon C, Slager S, Chenevix-Trench G, Pharoah PD, Monteiro AA, García-Closas M, Easton DF, Antoniou AC. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nat Commun.* 7:11375. 2016. PMC4853421..

61. Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E, Dicks E, Barrowdale D, Sinnott-Armstrong NA, Sallari RC, Hillman KM, Kaufmann S, Sivakumaran H, Marjaneh MM, Lee JS, Hills M, Jarosz M, Drury S, Canisius S, Bolla MK, Dennis J, Wang Q, Hopper JL, Southey MC, Brooks A, Schmidt MK, Lophatananon A, Muir K, Beckmann MW, Fasching PA, Dos-Santos-Silva I, Peto J, Sawyer EJ, Tomlinson I, Burwinkel B, Marme F, Guénel P, Truong T, Bojesen SE, Flyger H, González-Neira A, Perez JL, Anton-Culver H, Eun Jung L, Arndt V, Brenner H, Meindl A, Schmutzler RK, Brauch H, Hamann U, Aittomäki K, Blomqvist C, Ito H, Matsuo K, Bogdanova N, Dörk T, Lindblom A, Margolin S, Kosma VM, Mannermaa A, Tseng CC, Wu AH, Lambrechts D, Wildiers H, Chang-Claude J, Rudolph A, Peterlongo P, Radice P, Olson JE, Giles GG, Milne RL, Haiman CA, Henderson BE, Goldberg MS, Teo SH, Yip CH, Nord S, Borresen-Dale AL, Kristensen V, Long J, Zheng W, Pylkäs K, Winqvist R, Andrulis IL, Knight JA, Devilee P, Seynaeve C, Figueroa J, Sherman ME, Czene K, Darabi H, Hollestelle A, van den Ouweland AM, Humphreys K, Gao YT, Shu XO, Cox A, Cross SS, Blot W, Cai Q, Ghoussaini M, Perkins BJ, Shah M, Choi JY, Kang D, Lee SC, Hartman M, Kabisch M, Torres D, Jakubowska A, Lubinski J, Brennan P, Sangrajrang S, Ambrosone CB, Toland AE, Shen CY, Wu PE, Orr N, Swerdlow A, McGuffog L, Healey S, Lee A, Kapuscinski M, John EM, Terry MB, Daly MB, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ejlersen B, Hansen TV, Osorio A, Benitez J, Rando R, Weitzel JN, Bonanni B, Peissel B, Manoukian S, Papi L, Ottini L, Konstantopoulou I, Apostolou P, Gar65ber J, Rashid MU, Frost D; EMBRACE, Izatt L, Ellis S, Godwin AK, Arnold N, Niederacher D, Rhiem K, Bogdanova-Markov N, Sagne C, Stoppa-Lyonnet D, Damiola F; GEMO Study Collaborators, Sinilnikova OM, Mazoyer S, Isaacs C, Claes KB, De Leeneer K, de la Hoya M, Caldes T, Nevanlinna H, Khan S, Mensenkamp AR; HEBON, Hoening MJ, Rookus MA, Kwong A, Olah E, Diez O, Brunet J, Pujana MA, Gronwald J, Huzarski T, Barkardottir RB, Laframboise R, Soucy P, Montagna M, Agata S, Teixeira MR; kConFab Investigators, Park SK, Lindor N, **Couch FJ**, Tischkowitz M, Foretova L, Vijai J, Offit K, Singer CF, Rappaport C, Phelan CM, Greene MH, Mai PL, Rennert G, Imyanitov EN, Hulick PJ, Phillips KA, Piedmonte M, Mulligan AM, Glendon G, Bojesen A, Thomassen M, Caligo MA, Yoon SY, Friedman E, Laitman Y, Borg A, von Wachenfeldt A, Ehrencrona H, Rantala J, Olopade OI, Ganz PA, Nussbaum RL, Gayther SA, Nathanson KL, Domchek SM, Arun BK, Mitchell G, Karlan BY, Lester J, Maskarinec G, Woolcott C, Scott C, Stone J, Apicella C, Tamimi R, Luben R, Khaw KT, Helland Å, Haakensen V, Dowsett M, Pharoah PD, Simard J, Hall P, García-Closas M, Vachon C, Chenevix-Trench G, Antoniou AC, Easton DF, Edwards SL. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nat Genet.* 48(4):374-86, 2016. PMC4938803.

62. Shi J, Zhang Y, Zheng W, Michailidou K, Ghoussaini M, Bolla MK, Wang Q, Dennis J, Lush M, Milne RL, Shu XO, Beesley J, Kar S, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Zhao Z, Guo X, Benitez J, Beeghly-Fadiel A, Blot W, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Brinton L, Brooks A, Brüning T, Burwinkel B, Cai H, Canisius S, Chang-Claude J, Choi JY, Couch FJ, Cox A, Cross SS, Czene K, Darabi H, Devilee P, Droit A, Dork T, Fasching PA, Fletcher O, Flyger H, Fostira F, Gaborieau V, García-Closas M, Giles GG, Grip M, Guenel P, Haiman CA, Hamann U, Hartman M, Miao H, Hollestelle A, Hopper JL, Hsiung CN, Investigators K, Ito H, Jakubowska A, Johnson N, Torres D, Kabisch M, Kang D, Khan S, Knight JA, Kosma VM, Lambrechts D, Li J, Lindblom A, Lophatananon A, Lubinski J, Mannermaa A, Manoukian S, Le Marchand L, Margolin S, Marme F, Matsuo K, McLean C, Meindl A, Muir K, Neuhausen SL, Nevanlinna H, Nord S, Børresen-Dale AL, Olson JE, Orr N, van den Ouweland AM, Peterlongo P, Choudary Putti T, Rudolph A, Sangrajrang S, Sawyer EJ, Schmidt MK, Schmutzler RK, Shen CY, Hou MF, Shrubsole MJ, Southey MC, Swerdlow A, Hwang Teo S, Thienpont B, Toland AE, Tollenaar RA, Tomlinson I, Truong T, Tseng CC, Wen W, Winqvist R, Wu AH, Har Yip C, Zamora PM, Zheng Y, Floris G, Cheng CY, Hooning MJ, Martens JW, Seynaeve C, Kristensen VN, Hall P, Pharoah PD, Simard J, Chenevix-Trench G, Dunning AM, Antoniou AC, Easton DF, Cai Q, Long J. Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. *Int J Cancer*. 139(6):1303-17, 2016.
63. Cheng TH, Thompson DJ, O'Mara TA, Painter JN, Glubb DM, Flach S, Lewis A, French JD, Freeman-Mills L, Church D, Gorman M, Martin L; National Study of Endometrial Cancer Genetics Group (NSEC), Hodgson S, Webb PM; Australian National Endometrial Cancer Study Group (ANEC), Attia J, Holliday EG, McEvoy M, Scott RJ, Henders AK, Martin NG, Montgomery GW, Nyholt DR, Ahmed S, Healey CS, Shah M, Dennis J, Fasching PA, Beckmann MW, Hein A, Ekici AB, Hall P, Czene K, Darabi H, Li J, Dörk T, Dürst M, Hillemanns P, Runnebaum I, Amant F, Schrauwen S, Zhao H, Lambrechts D, Depreeuw J, Dowdy SC, Goode EL, Fridley BL, Winham SJ, Njølstad TS, Salvesen HB, Trovik J, Werner HM, Ashton K, Otton G, Proietto T, Liu T, Mints M, Tham E; RENDOCAS; CHIBCHA Consortium, Li MJ, Yip SH, Wang J, Bolla MK, Michailidou K, Wang Q, Tyrer JP, Dunlop M, Houlston R, Palles C, Hopper JL; AOC Group, Peto J, Swerdlow AJ, Burwinkel B, Brenner H, Meindl A, Brauch H, Lindblom A, Chang-Claude J, Couch FJ, Giles GG, Kristensen VN, Cox A, Cunningham JM, Pharoah PD, Dunning AM, Edwards SL, Easton DF, Tomlinson I, Spurdle AB. Five endometrial cancer risk loci identified through genome-wide association analysis. *Nat Genet*. 48(6):667-74, 2016. PMC4907351

3. Invited Articles: Nothing to Report.

4. Abstracts: Nothing to Report

7. Inventions, Patents, and Licenses:

Nothing to report.

8. Reportable Outcomes:

Products related scientific advance

A total of 27 genetic modifiers of ovarian cancer risk among BRCA1 mutation carriers have been identified.

A modifier locus on chromosome 4q32 specifically influences risks of ovarian cancer among BRCA1 mutation carriers and not among the general population or BRCA2 mutation carriers.

Risk loci associated with specific subtypes of ovarian cancer have been identified, suggesting unique etiological pathways for the histological subtypes of ovarian cancer.

The ovarian cancer risk loci explain 6.4% of the excess familial relative risk of epithelial ovarian cancer in the general population.

Personalized ovarian cancer risk prediction models for BRCA1 carriers developed using the identified risk loci identify BRCA1 mutation carriers with absolute ovarian cancer risks by age 80 ranging from 28% to 63%.

Position dependent risks of ovarian cancer for different BRCA1 and BRCA2 mutations have been determined that can be used in clinical risk prediction models.

9. Other Achievements:

Nothing to report.

10. References:

1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG and Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet.* 72(5):1117-30, 2003. PMC1180265.
2. Antoniou AC, Sinilnikova OM, Simard J, Leone M, Dumont M, Neuhausen SL, Struwing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ, Rebbeck TR, Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J, Narod SA, Tomlinson G, Olopade OI, Godwin A, Isaacs C, Jakubowska A, Lubinski J, Gronwald J, Gorski B, Byrski T, Huzarski T, Peock S, Cook M, Baynes C, Murray A, Rogers M, Daly PA, Dorkins H, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Niederacher D, Deissler H, Spurdle AB, Chen X, Waddell N, Cloonan N, Kirchhoff T, Offit K, Friedman E, Kaufmann B, Laitman Y, Galore G, Rennert G,

- Lejbkiewicz F, Raskin L, Andrulis IL, Ilyushik E, Ozcelik H, Devilee P, Vreeswijk MP, Greene MH, Prindiville SA, Osorio A, Benitez J, Zikan M, Szabo CI, Kilpivaara O, Nevanlinna H, Hamann U, Durocher F, Arason A, Couch FJ, Easton DF and Chenevix-Trench G. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. *Am J Hum Genet.* 81(6):1186-200, 2007. PMC2276351.
3. Ramus SJ, Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Sinilnikova OM, Healey S, Barrowdale D, Lee A, Thomassen M, Gerdes AM, Kruse TA, Jensen UB, Skytte AB, Caligo MA, Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmal M, Melin B, Domchek SM, Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J, Jaworska K, Durda K, Zlowocka E, Gronwald J, Huzarski T, Byrski T, Cybulski C, Toloczko-Grabarek A, Osorio A, Benitez J, Duran M, Tejada MI, Hamann U, Rookus M, van Leeuwen FE, Aalfs CM, Meijers-Heijboer HE, van Asperen CJ, van Roozendaal KE, Hoogerbrugge N, Collee JM, Kriege M, van der Luijt RB, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Jacobs C, Eeles R, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Paterson J, Douglas F, Brewer C, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Pathak H, Godwin AK, Stoppa-Lyonnet D, Caux-Moncoutier V, de Pauw A, Gauthier-Villars M, Mazoyer S, Leone M, Calender A, Lasset C, Bonadona V, Hardouin A, Berthet P, Bignon YJ, Uhrhammer N, Faivre L, Loustalot C, Buys S, Daly M, Miron A, Terry MB, Chung WK, John EM, Southey M, Goldgar D, Singer CF, Tea MK, Pfeiler G, Fink-Retter A, Hansen T, Ejlersen B, Johannsson OT, Offit K, Kirchhoff T, Gaudet MM, Vijai J, Robson M, Piedmonte M, Phillips KA, Van Le L, Hoffman JS, Ewart Toland A, Montagna M, Tognazzo S, Ilyanov E, Issacs C, Janavicius R, Lazaro C, Blanco I, Tornero E, Navarro M, Moysich KB, Karlan BY, Gross J, Olah E, Vaszko T, Teo SH, Ganz PA, Beattie MS, Dorfling CM, van Rensburg EJ, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Schafer D, Caldes T, de la Hoya M, Nevanlinna H, Aittomaki K, Plante M, Spurdle AB, Neuhausen SL, Ding YC, Wang X, Lindor N, Fredericksen Z, Pankratz VS, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Bonanni B, Bernard L, Dolcetti R, Papi L, Ottini L, Radice P, Greene MH, Mai PL, Andrulis IL, Glendon G, Ozcelik H, Pharoah PD, Gayther SA, Simard J, Easton DF, Couch FJ and Chenevix-Trench G. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Hum Mutat.* 33(4):690-702, 2012. PMC3458423.
 4. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Chen YA, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Antonenkova N, Antoniou AC, Armasu SM, Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ, Cicek MS, Coetzee GA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dork T, du Bois A, Durst M, Easton DF, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher DA, Flanagan JM, Garcia-Closas M, Gentry-Maharaj A, Giles GG, Glasspool RM, Gonzalez-Bosquet J, Goodman MT, Gore M, Gorski B, Gronwald J, Hall P, Halle MK, Harter P, Heitz F, Hillemanns P, Hoatlin M, Hogdall CK, Hogdall E, Hosono S, Jakubowska A, Jensen A,

Jim H, Kalli KR, Karlan BY, Kaye SB, Kelemen LE, Kiemeny LA, Kikkawa F, Konecny GE, Krakstad C, Kjaer SK, Kupryjanczyk J, Lambrechts D, Lambrechts S, Lancaster JM, Le ND, Leminen A, Levine DA, Liang D, Lim BK, Lin J, Lissowska J, Lu KH, Lubinski J, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson SH, Orlow I, Paul J, Pearce CL, Pejovic T, Peltari LM, Pike MC, Poole EM, Raska P, Renner SP, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shridhar V, Shu XO, Shvetsov YB, Sieh W, Song H, Southey MC, Spiewankiewicz B, Stram D, Sutphen R, Teo SH, Terry KL, Tessier DC, Thompson PJ, Tworoger SS, van Altena AM, Vergote I, Vierkant RA, Vincent D, Vitonis AF, Wang-Gohrke S, Palmieri Weber R, Wentzensen N, Whittemore AS, Wik E, Wilkens LR, Winterhoff B, Woo YL, Wu AH, Xiang YB, Yang HP, Zheng W, Ziogas A, Zulkifli F, Phelan CM, Iversen E, Schildkraut JM, Berchuck A, Fridley BL, Goode EL, Pharoah PD, Monteiro AN, Sellers TA and Gayther SA. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nat Commun.* 4:1627, 2013. PMC3709460.

5. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF and Goldgar DE. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). *Breast Cancer Res.* 9(2):104, 2007. PMC1868919.
6. Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, Wang X, Kirchhoff T, McGuffog L, Barrowdale D, Lee A, Healey S, Sinilnikova OM, Andrulis IL, Ozcelik H, Mulligan AM, Thomassen M, Gerdes AM, Jensen UB, Skytte AB, Kruse TA, Caligo MA, von Wachenfeldt A, Barbany-Bustinza G, Loman N, Soller M, Ehrencrona H, Karlsson P, Nathanson KL, Rebbeck TR, Domchek SM, Jakubowska A, Lubinski J, Jaworska K, Durda K, Zlowocka E, Huzarski T, Byrski T, Gronwald J, Cybulski C, Gorski B, Osorio A, Duran M, Tejada MI, Benitez J, Hamann U, Hogervorst FB, van Os TA, van Leeuwen FE, Meijers-Heijboer HE, Wijnen J, Blok MJ, Kets M, Hooning MJ, Oldenburg RA, Ausems MG, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Jacobs C, Eeles RA, Adlard J, Davidson R, Eccles DM, Cole T, Cook J, Paterson J, Brewer C, Douglas F, Hodgson SV, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Side LE, Bove B, Godwin AK, Stoppa-Lyonnet D, Fassy-Colcombet M, Castera L, Cornelis F, Mazoyer S, Leone M, Boutry-Kryza N, Bressac-de Paillerets B, Caron O, Pujol P, Coupier I, Delnatte C, Akloul L, Lynch HT, Snyder CL, Buys SS, Daly MB, Terry M, Chung WK, John EM, Miron A, Southey MC, Hopper JL, Goldgar DE, Singer CF, Rappaport C, Tea MK, Fink-Retter A, Hansen TV, Nielsen FC, Arason A, Vijai J, Shah S, Sarrel K, Robson ME, Piedmonte M, Phillips K, Basil J, Rubinstein WS, Boggess J, Wakeley K, Ewart-Toland A, Montagna M, Agata S, Imyanitov EN, Isaacs C, Janavicius R, Lazaro C, Blanco I, Feliubadalo L, Brunet J, Gayther SA, Pharoah PP, Odunsi KO, Karlan BY, Walsh CS, Olah E, Teo SH, Ganz PA, Beattie MS, van Rensburg EJ, Dorfling CM, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Heinritz W, Caldes T, de la Hoya M, Muranen TA, Nevanlinna H, Tischkowitz MD, Spurdle AB, Neuhausen SL, Ding YC, Lindor NM, Fredericksen Z, Pankratz VS, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Bernard L, Viel

- A, Giannini G, Varesco L, Radice P, Greene MH, Mai PL, Easton DF, Chenevix-Trench G, Offit K and Simard J. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiol Biomarkers Prev.* 21(4):645-57, 2012. PMC3319317.
7. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, Bacot F, Vincent D, Hogervorst FB, Peock S, Stoppa-Lyonnet D, Jakubowska A, Radice P, Schmutzler RK, Domchek SM, Piedmonte M, Singer CF, Friedman E, Thomassen M, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Greene MH, Karlan BY, Garber J, Phelan CM, Weitzel JN, Montagna M, Olah E, Andrulis IL, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Nevanlinna H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, Hamann U, Ramus SJ, Toland AE, Caligo MA, Olopade OI, Tung N, Claes K, Beattie MS, Southey MC, Ilyanov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez O, Balmana J, Barkardottir RB, Arun BK, Rennert G, Teo SH, Ganz PA, Campbell I, van der Hout AH, van Deurzen CH, Seynaeve C, Gomez Garcia EB, van Leeuwen FE, Meijers-Heijboer HE, Gille JJ, Ausems MG, Blok MJ, Ligtenberg MJ, Rookus MA, Devilee P, Verhoef S, van Os TA, Wijnen JT, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Izatt L, Eeles RA, Adlard J, Eccles DM, Cook J, Brewer C, Douglas F, Hodgson S, Morrison PJ, Side LE, Donaldson A, Houghton C, Rogers MT, Dorkins H, Eason J, Gregory H, McCann E, Murray A, Calender A, Hardouin A, Berthet P, Delnatte C, Nogues C, Lasset C, Houdayer C, Leroux D, Rouleau E, Prieur F, Damiola F, Sobol H, Coupier I, Venat-Bouvet L, Castera L, Gauthier-Villars M, Leone M, Pujol P, Mazoyer S, Bignon YJ, Zlowocka-Perlowska E, Gronwald J, Lubinski J, Durda K, Jaworska K, Huzarski T, Spurdle AB, Viel A, Peissel B, Bonanni B, Melloni G, Ottini L, Papi L, Varesco L, Tibiletti MG, Peterlongo P, Volorio S, Manoukian S, Pensotti V, Arnold N, Engel C, Deissler H, Gadzicki D, Gehrig A, Kast K, Rhiem K, Meindl A, Niederacher D, Ditsch N, Plendl H, Preisler-Adams S, Engert S, Sutter C, Varon-Mateeva R, Wappenschmidt B, Weber BH, Arver B, Stenmark-Askmal M, Loman N, Rosenquist R, Einbeigi Z, Nathanson KL, Rebbeck TR, Blank SV, Cohn DE, Rodriguez GC, Small L, Friedlander M, Bae-Jump VL, Fink-Retter A, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, Lindor NM, Kaufman B, Shimon Paluch S, Laitman Y, Skytte AB, Gerdes AM, Pedersen IS, Moeller ST, Kruse TA, Jensen UB, Vijai J, Sarrel K, Robson M, Kauff N, Mulligan AM, Glendon G, Ozcelik H, Ejlersen B, Nielsen FC, Jonson L, Andersen MK, Ding YC, Steele L, Foretova L, Teule A, Lazaro C, Brunet J, Pujana MA, Mai PL, Loud JT, Walsh C, Lester J, Orsulic S, Narod SA, Herzog J, Sand SR, Tognazzo S, Agata S, Vaszko T, Weaver J, Stavropoulou AV, Buys SS, Romero A, de la Hoya M, Aittomaki K, Muranen TA, Duran M, Chung WK, Lasa A, Dorfling CM, Miron A, Benitez J, Senter L, Huo D, Chan SB, Sokolenko AP, Chiquette J, Tihomirova L, Friebel TM, Agnarsson BA, Lu KH, Lejbkiewicz F, James PA, Hall P, Dunning AM, Tessier D, Cunningham J, Slager SL, Wang C, Hart S, Stevens K, Simard J, Pastinen T, Pankratz VS, Offit K, Easton DF, Chenevix-Trench G and Antoniou AC. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genet.* 9(3):e1003212, 2013. PMC3609646.
 8. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, Coetzee S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van

Rensburg EJ, Neuhausen SL, Ding YC, Hansen TV, Jonson L, Gerdes AM, Ejlertsen B, Barrowdale D, Dennis J, Benitez J, Osorio A, Garcia MJ, Komenaka I, Weitzel JN, Ganschow P, Peterlongo P, Bernard L, Viel A, Bonanni B, Peissel B, Manoukian S, Radice P, Papi L, Ottini L, Fostira F, Konstantopoulou I, Garber J, Frost D, Perkins J, Platte R, Ellis S, Godwin AK, Schmutzler RK, Meindl A, Engel C, Sutter C, Sinilnikova OM, Damiola F, Mazoyer S, Stoppa-Lyonnet D, Claes K, De Leeneer K, Kirk J, Rodriguez GC, Piedmonte M, O'Malley DM, de la Hoya M, Caldes T, Aittomaki K, Nevanlinna H, Collee JM, Rookus MA, Oosterwijk JC, Tihomirova L, Tung N, Hamann U, Isacacs C, Tischkowitz M, Imyanitov EN, Caligo MA, Campbell IG, Hogervorst FB, Olah E, Diez O, Blanco I, Brunet J, Lazaro C, Pujana MA, Jakubowska A, Gronwald J, Lubinski J, Sukiennicki G, Barkardottir RB, Plante M, Simard J, Soucy P, Montagna M, Tognazzo S, Teixeira MR, Pankratz VS, Wang X, Lindor N, Szabo CI, Kauff N, Vijai J, Aghajanian CA, Pfeiler G, Berger A, Singer CF, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Tchatchou S, Andrulis IL, Glendon G, Toland AE, Jensen UB, Kruse TA, Thomassen M, Bojesen A, Zidan J, Friedman E, Laitman Y, Soller M, Liljegren A, Arver B, Einbeigi Z, Stenmark-Askmal M, Olopade OI, Nussbaum RL, Rebbeck TR, Nathanson KL, Domchek SM, Lu KH, Karlan BY, Walsh C, Lester J, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambrechts S, Dicks E, Doherty JA, Wicklund KG, Rossing MA, Rudolph A, Chang-Claude J, Wang-Gohrke S, Eilber U, Moysich KB, Odunsi K, Sucheston L, Lele S, Wilkens LR, Goodman MT, Thompson PJ, Shvetsov YB, Runnebaum IB, Durst M, Hillemanns P, Dork T, Antonenkova N, Bogdanova N, Leminen A, Pelttari LM, Butzow R, Modugno F, Kelley JL, Edwards RP, Ness RB, du Bois A, Heitz F, Schwaab I, Harter P, Matsuo K, Hosono S, Orsulic S, Jensen A, Kjaer SK, Hogdall E, Hasmad HN, Azmi MA, Teo SH, Woo YL, Fridley BL, Goode EL, Cunningham JM, Vierkant RA, Bruinsma F, Giles GG, Liang D, Hildebrandt MA, Wu X, Levine DA, Bisogna M, Berchuck A, Iversen ES, Schildkraut JM, Concannon P, Weber RP, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Orlow I, Olson SH, Krakstad C, Salvesen HB, Tangen IL, Bjorge L, van Altena AM, Aben KK, Kiemeny LA, Massuger LF, Kellar M, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Cybulski C, Yang H, Lissowska J, Brinton LA, Wentzensen N, Hogdall C, Lundvall L, Nedergaard L, Baker H, Song H, Eccles D, McNeish I, Paul J, Carty K, Siddiqui N, Glasspool R, Whittemore AS, Rothstein JH, McGuire V, Sieh W, Ji BT, Zheng W, Shu XO, Gao YT, Rosen B, Risch HA, McLaughlin JR, Narod SA, Monteiro AN, Chen A, Lin HY, Permuth-Wey J, Sellers TA, Tsai YY, Chen Z, Ziogas A, Anton-Culver H, Gentry-Maharaj A, Menon U, Harrington P, Lee AW, Wu AH, Pearce CL, Coetzee G, Pike MC, Dansonka-Mieszkowska A, Timorek A, Rzepecka IK, Kupryjanczyk J, Freedman M, Noushmehr H, Easton DF, Offit K, Couch FJ, Gayther S, Pharoah PP, Antoniou AC and Chenevix-Trench G. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nat Genet.* 47(2):164-71, 2015. PMC4445140.

9. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL, Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H, Stenmark-Askmal M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther SA, Domchek SM, Arun BK, Lu KH, Mitchell G, Karlan BY, Walsh C, Lester J, Godwin AK, Pathak H, Ross E, Daly MB, Whittemore AS, John EM, Miron A, Terry MB, Chung WK, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Ejlertsen B,

Gerdes AM, Hansen T, Ramon y Cajal T, Osorio A, Benitez J, Godino J, Tejada MI, Duran M, Weitzel JN, Bobolis KA, Sand SR, Fontaine A, Savarese A, Pasini B, Peissel B, Bonanni B, Zaffaroni D, Vignolo-Lutati F, Scuvera G, Giannini G, Bernard L, Genuardi M, Radice P, Dolcetti R, Manoukian S, Pensotti V, Gismonti V, Yannoukakos D, Fostira F, Garber J, Torres D, Rashid MU, Hamann U, Peock S, Frost D, Platte R, Evans DG, Eeles R, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Izatt L, Adlard J, Donaldson A, Ellis S, Sharma P, Schmutzler RK, Wappenschmidt B, Becker A, Rhiem K, Hahnen E, Engel C, Meindl A, Engert S, Ditsch N, Arnold N, Plendl HJ, Mundhenke C, Niederacher D, Fleisch M, Sutter C, Bartram CR, Dikow N, Wang-Gohrke S, Gadzicki D, Steinemann D, Kast K, Beer M, Varon-Mateeva R, Gehrig A, Weber BH, Stoppa-Lyonnet D, Houdayer C, Belotti M, Gauthier-Villars M, Damiola F, Boutry-Kryza N, Lasset C, Sobol H, Peyrat JP, Muller D, Fricker JP, Collonge-Rame MA, Mortemousque I, Nogues C, Rouleau E, Isaacs C, De Paepe A, Poppe B, Claes K, De Leeneer K, Piedmonte M, Rodriguez G, Wakely K, Boggess J, Blank SV, Basil J, Azodi M, Phillips KA, Caldes T, de la Hoya M, Romero A, Nevanlinna H, Aittomaki K, van der Hout AH, Hogervorst FB, Verhoef S, Collee JM, Seynaeve C, Oosterwijk JC, Gille JJ, Wijnen JT, Gomez Garcia EB, Kets CM, Ausems MG, Aalfs CM, Devilee P, Mensenkamp AR, Kwong A, Olah E, Papp J, Diez O, Lazaro C, Darder E, Blanco I, Salinas M, Jakubowska A, Lubinski J, Gronwald J, Jaworska-Bieniek K, Durda K, Sukiennicki G, Huzarski T, Byrski T, Cybulski C, Toloczko-Grabarek A, Zlowocka-Perlowska E, Menkiszak J, Arason A, Barkardottir RB, Simard J, Laframboise R, Montagna M, Agata S, Alducci E, Peixoto A, Teixeira MR, Spurdle AB, Lee MH, Park SK, Kim SW, Friebel TM, Couch FJ, Lindor NM, Pankratz VS, Guidugli L, Wang X, Tischkowitz M, Foretova L, Vijai J, Offit K, Robson M, Rau-Murthy R, Kauff N, Fink-Retter A, Singer CF, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, Berger A, Greene MH, Mai PL, Imyanitov EN, Toland AE, Senter L, Bojesen A, Pedersen IS, Skytte AB, Sunde L, Thomassen M, Moeller ST, Kruse TA, Jensen UB, Caligo MA, Aretini P, Teo SH, Selkirk CG, Hulick PJ and Andrulis I. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *Jama*. 313(13):1347-61, 2015. PMC4537700.

11. Appendices

The Appendices consist of copies of each of the publications originating from our group which are referenced in this report.

Ramus et al., 2012

Couch et al., 2012

Couch et al., 2013

Permuth-Wey et al., 2013

Kuchenbaecker et al., 2015

Rebbeck et al., 2015

Ovarian Cancer Susceptibility Alleles and Risk of Ovarian Cancer in *BRCA1* and *BRCA2* Mutation Carriers

Susan J. Ramus,^{1†} Antonis C. Antoniou,^{2†*} Karoline B. Kuchenbaecker,² Penny Soucy,³ Jonathan Beesley,⁴ Xiaoping Chen,⁴ Lesley McGuffog,² Olga M. Sinilnikova,^{5,6} Sue Healey,⁴ Daniel Barrowdale,² Andrew Lee,² Mads Thomassen,⁷ Anne-Marie Gerdes,⁸ Torben A. Kruse,⁷ Uffe Birk Jensen,⁹ Anne-Bine Skytte,¹⁰ Maria A. Caligo,¹¹ Annelie Liljegren,¹² Annika Lindblom,¹³ Håkan Olsson,¹⁴ Ulf Kristoffersson,¹⁵ Marie Stenmark-Askmal,¹⁶ Beatrice Melin,¹⁷ SWE-BCRA,¹⁸ Susan M. Domchek,¹⁹ Katherine L. Nathanson,¹⁹ Timothy R. Rebbeck,¹⁹ Anna Jakubowska,²⁰ Jan Lubinski,²⁰ Katarzyna Jaworska,^{20,21} Katarzyna Durda,²⁰ Elżbieta Złowocka,²⁰ Jacek Gronwald,²⁰ Tomasz Huzarski,²⁰ Tomasz Byrski,²⁰ Cezary Cybulski,²⁰ Aleksandra Toloczko-Grabarek,²⁰ Ana Osorio,²² Javier Benitez,²² Mercedes Duran,²³ Maria-Isabel Tejada,²⁴ Ute Hamann,²⁵ Matti Rookus,²⁶ Flora E. van Leeuwen,²⁷ Cora M. Aalfs,²⁸ Hanne E.J. Meijers-Heijboer,²⁹ Christi J. van Asperen,³⁰ K.E.P. van Roozendaal,³¹ Nicoline Hoogerbrugge,³² J. Margriet Collée,³³ Mieke Krieger,³³ Rob B. van der Luit,³⁴ HEBON,³⁵ EMBRACE,³⁶ Susan Peock,³⁶ Debra Frost,³⁶ Steve D. Ellis,³⁶ Radka Platte,³⁶ Elena Fineberg,³⁶ D. Gareth Evans,³⁷ Fiona Laloo,³⁷ Chris Jacobs,³⁸ Ros Eeles,³⁹ Julian Adlard,⁴⁰ Rosemarie Davidson,⁴¹ Diana Eccles,⁴² Trevor Cole,⁴³ Jackie Cook,⁴⁴ Joan Paterson,⁴⁵ Fiona Douglas,⁴⁶ Carole Brewer,⁴⁷ Shirley Hodgson,⁴⁸ Patrick J. Morrison,⁴⁹ Lisa Walker,⁵⁰ Mary E. Porteous,⁵¹ M. John Kennedy,⁵² Harsh Pathak,⁵³ Andrew K. Godwin,⁵³ Dominique Stoppa-Lyonnet,^{54–56} Virginie Caux-Moncoutier,⁵⁴ Antoine de Pauw,⁵⁴ Marion Gauthier-Villars,⁵⁴ Sylvie Mazoyer,⁶ Mélanie Léoné,⁵ Alain Calender,⁵ Christine Lasset,^{57,58} Valérie Bonadona,^{57,58} Agnès Hardouin,⁵⁹ Pascaline Berthet,⁵⁹ Yves-Jean Bignon,⁶⁰ Nancy Uhrhammer,⁶⁰ Laurence Faivre,^{61,62} Catherine Loustalot,⁶² GEMO,⁶³ Sandra Buys,⁶⁴ Mary Daly,⁶⁵ Alex Miron,⁶⁶ Mary Beth Terry,⁶⁷ Wendy K. Chung,⁶⁷ Esther M. John,⁶⁸ Melissa Southey,⁶⁹ David Goldgar,⁷⁰ Christian F. Singer,⁷¹ Muy-Kheng Tea,⁷¹ Georg Pfeiler,⁷¹ Anneliese Fink-Retter,⁷¹ Thomas v. O. Hansen,⁷² Bent Ejlersen,⁷³ Oskar Th. Johannsson,⁷⁴ Kenneth Offit,⁷⁵ Tomas Kirchhoff,⁷⁶ Mia M. Gaudet,⁷⁷ Joseph Vijai,⁷⁸ Mark Robson,⁷⁹ Marion Piedmonte,⁸⁰ Kelly-Anne Phillips,⁸¹ Linda Van Le,⁸² James S. Hoffman,⁸³ Amanda Ewart Toland,⁸⁴ Marco Montagna,⁸⁵ Silvia Tognazzo,⁸⁵ Evgeny Ilyanov,⁸⁶ Claudine Isaacs,⁸⁷ Ramunas Janavicius,⁸⁸ Conxi Lazaro,⁸⁹ Ignacio Blanco,⁹⁰ Eva Tornero,⁸⁹ Matilde Navarro,⁹⁰ Kirsten B. Moysich,⁹¹ Beth Y. Karlan,⁹² Jenny Gross,⁹² Edith Olah,⁹³ Tibor Vaszko,⁹³ Soo-Hwang Teo,⁹⁴ Patricia A. Ganz,⁹⁵ Mary S. Beattie,⁹⁶ Cecelia M. Dorfling,⁹⁷ Elizabeth J. van Rensburg,⁹⁷ Orland Diez,⁹⁸ Ava Kwong,⁹⁹ Rita K. Schmutzler,¹⁰⁰ Barbara Wappenschmidt,¹⁰⁰ Christoph Engel,¹⁰¹ Alfons Meindl,¹⁰² Nina Ditsch,¹⁰³ Norbert Arnold,¹⁰⁴ Simone Heidemann,¹⁰⁵ Dieter Niederacher,¹⁰⁶ Sabine Preisler-Adams,¹⁰⁷ Dorotea Gadzik,¹⁰⁸ Raymonda Varon-Mateeva,¹⁰⁹ Helmut Deissler,¹¹⁰ Andrea Gehrig,¹¹¹ Christian Sutter,¹¹² Karin Kast,¹¹³ Britta Fiebig,¹¹⁴ Dieter Schäfer,¹¹⁵ Trinidad Caldes,¹¹⁶ Miguel de la Hoya,¹¹⁶ Heli Nevanlinna,¹¹⁷ Kristiina Aittomäki,¹¹⁸ Marie Plante,¹¹⁹ Amanda B. Spurdle,⁴ kConFab,¹²⁰ Susan L. Neuhausen,¹²¹ Yuan Chun Ding,¹²¹ Xianshu Wang,¹²² Noralane Lindor,¹²³ Zachary Fredericksen,¹²⁴ V. Shane Pankratz,¹²⁴ Paolo Peterlongo,^{125,126} Siranoush Manoukian,¹²⁷ Bernard Peissel,¹²⁷ Daniela Zaffaroni,¹²⁷ Bernardo Bonanni,¹²⁸ Boris Bernard,^{129,130} Riccardo Dolcetti,¹³¹ Laura Papi,¹³² Laura Ottini,¹³³ Paolo Radice,^{125,126} Mark H. Greene,¹³⁴ Phuong L. Mai,¹³⁴ Irene L. Andrulis,¹³⁵ Gord Glendon,¹³⁶ Hilmi Ozcelik,¹³⁵ OCGN,¹³⁶ Paul D.P. Pharoah,¹³⁷ Simon A. Gayther,¹ Jacques Simard,³ Douglas F. Easton,² Fergus J. Couch,¹²² and Georgia Chenevix-Trench,⁴ on behalf of the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

¹Department of Preventive Medicine, Keck School of Medicine, University of Southern California, California; ²Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; ³Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Québec City, Canada; ⁴Genetics and Population Health Division, Queensland Institute of Medical Research, Herston, Australia; ⁵Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Centre Hospitalier Universitaire de Lyon / Centre Léon Bérard, Lyon, France; ⁶INSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France; ⁷Department of Clinical Genetics, Odense University Hospital, Odense, Denmark; ⁸Department of Clinical Genetics, Rigshospitalet and Copenhagen University, Copenhagen, Denmark; ⁹Department of Clinical Genetics, Skejby Hospital, Aarhus, Denmark; ¹⁰Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark; ¹¹Section of Genetic Oncology, Department of Laboratory Medicine, University and University Hospital of Pisa, Pisa, Italy; ¹²Department of Oncology, Karolinska University Hospital, Stockholm, Sweden; ¹³Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden; ¹⁴Department of Oncology, Lund University Hospital, Lund, Sweden; ¹⁵Department of Clinical Genetics, Lund University Hospital, Lund, Sweden; ¹⁶Division of Clinical Genetics, Department of Clinical and Experimental Medicine,

This article was originally published online on 14 February 2012. Due to an error at the publisher, the list of authors and affiliations was truncated. The full author and affiliation lists were restored, and other corrections were made to the references as per journal style, on 13 April 2012.

Additional Supporting Information may be found in the online version of this article.

[†]Contributed equally to the study.

*Correspondence to: Antonis C. Antoniou, Cancer Research UK Senior Cancer Research Fellow, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge, CB1 8RN, United Kingdom. E-mail: a.antoniou@srl.cam.ac.uk

Linköping University, Linköping, Sweden;¹⁷ Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden;¹⁸ Swedish Breast Cancer Study, Stockholm, Sweden;¹⁹ Abramson Cancer Center, and Perelman School of Medicine, Philadelphia, University of Pennsylvania;²⁰ Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland;²¹ Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, Poland;²² Human Genetics Group, Spanish National Cancer Centre (CNIO), Madrid, Spain, and Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain;²³ Institute of Biology and Molecular Genetics, University of Valladolid, Valladolid, Spain;²⁴ Molecular Genetics Laboratory, Cruces Hospital Barakaldo, Bizkaia, Spain;²⁵ Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany;²⁶ Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands;²⁷ Department of Epidemiology, Division of Psychosocial Research & Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands;²⁸ Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands;²⁹ Department of Clinical Genetics, VU Medical Center, Amsterdam, The Netherlands;³⁰ Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands;³¹ Department of Clinical Genomics, MUMC, Maastricht, The Netherlands;³² Hereditary Cancer Clinic, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands;³³ Department of Medical Oncology, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The Netherlands;³⁴ Department of Medical Genetics, University Medical Center Utrecht, The Netherlands;³⁵ Hereditary Breast Ovarian Cancer Group, Amsterdam, The Netherlands;³⁶ Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom;³⁷ Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation, Manchester, United Kingdom;³⁸ Clinical Genetics, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom;³⁹ Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom;⁴⁰ Yorkshire Regional Genetics Service, Leeds, United Kingdom;⁴¹ Ferguson-Smith Centre for Clinical Genetics, Yorkhill Hospitals, Glasgow, United Kingdom;⁴² University of Southampton Faculty of Medicine, Southampton University Hospitals NHS Trust, Southampton, United Kingdom;⁴³ West Midlands Regional Genetics Service, Birmingham Women's Hospital Healthcare NHS Trust, Edgbaston, Birmingham, United Kingdom;⁴⁴ Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, United Kingdom;⁴⁵ Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom;⁴⁶ Institute of Genetic Medicine, Centre for Life, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom;⁴⁷ Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom;⁴⁸ Medical Genetics Unit, St George's, University of London, London, United Kingdom;⁴⁹ Northern Ireland Regional Genetics Centre, Belfast Health and Social Care Trust, and Department of Medical Genetics, Queens University Belfast, Belfast, United Kingdom;⁵⁰ Oxford Regional Genetics Service, Churchill Hospital, Oxford, United Kingdom;⁵¹ South East of Scotland Regional Genetics Service, Western General Hospital, Edinburgh, United Kingdom;⁵² Academic Unit of Clinical and Molecular Oncology, Trinity College Dublin and St James's Hospital, Dublin, Ireland;⁵³ Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas;⁵⁴ Service de Génétique Oncologique, Institut Curie, Paris, France;⁵⁵ Unité INSERM U830, Institut Curie, Paris, France;⁵⁶ Université Paris Descartes, Faculté de Médecine, Paris, France;⁵⁷ Université Lyon 1, CNRS UMR5558, Lyon, France;⁵⁸ Unité de Prévention et d'Epidémiologie Génétique, Centre Léon Bérard, Lyon, France;⁵⁹ Centre François Baclesse, Caen, France;⁶⁰ Département d'Oncogénétique, Centre Jean Perrin, Université d'Auvergne, Auvergne, France;⁶¹ Centre de Génétique, CHU Dijon, Université de Bourgogne, Dijon, France;⁶² Centre Georges François Leclerc, Dijon, France;⁶³ GEMO study: Cancer Genetics Network "Groupe Génétique et Cancer", Fédération Nationale des Centres de Lutte Contre le Cancer, Paris, France;⁶⁴ Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City;⁶⁵ Fox Chase Cancer Center, Philadelphia, Pennsylvania;⁶⁶ Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts;⁶⁷ Department of Epidemiology, Columbia University, New York, NY;⁶⁸ Department of Epidemiology, Cancer Prevention Institute of California, Fremont, California;⁶⁹ Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Melbourne, Australia;⁷⁰ Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah;⁷¹ Department of OB/GYN and Comprehensive Cancer Center, Medical University of Austria, Vienna, Austria;⁷² Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;⁷³ Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;⁷⁴ Department of Oncology, Landspítali University Hospital, Reykjavik, Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland;⁷⁵ Clinical Cancer Genetics Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY;⁷⁶ Department of Environmental Medicine, NYU Cancer Institute, New York University School of Medicine, New York, NY;⁷⁷ Epidemiology Research Program, American Cancer Society, Atlanta, Georgia;⁷⁸ Clinical Cancer Genetics Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY;⁷⁹ Memorial Sloan-Kettering Cancer Center, New York, NY;⁸⁰ Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY;⁸¹ Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Australia;⁸² Gynecologic Oncology Group, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina;⁸³ The Hospital of Central Connecticut, New Britain, Connecticut;⁸⁴ Division of Human Cancer Genetics, Departments of Internal Medicine and Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio;⁸⁵ Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV - IRCCS, Padua, Italy;⁸⁶ Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, St.-Petersburg, Russia;⁸⁷ Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC;⁸⁸ Vilnius University Hospital Santariskiu Clinics, Hematology, Oncology and Transfusion Medicine Center, Department of Molecular and Regenerative Medicine; State Research Institute Inovative Medicine Center, Vilnius, Lithuania;⁸⁹ Molecular Diagnostic Unit, Hereditari Cancer Program, IDIBELL-Catalan Institute of Oncology, Catalan, Spain;⁹⁰ Genetic Counseling Unit, Hereditari Cancer Program, IDIBELL-Catalan Institute of Oncology, Catalan, Spain;⁹¹ Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York;⁹² Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California;⁹³ Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary;⁹⁴ Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Malaysia and University Malaya Cancer Research Institute, University Malaya, Kuala Lumpur, Malaysia;⁹⁵ UCLA Schools of Medicine and Public Health, Division of Cancer Prevention & Control Research, Jonsson Comprehensive Cancer Center, Los Angeles, California;⁹⁶ University of California, San Francisco, Departments of Medicine, Epidemiology, and Biostatistics, San Francisco, California;

⁹⁷Cancer Genetics Laboratory, Department of Genetics, University of Pretoria, Pretoria, South Africa; ⁹⁸Oncogenetics Laboratory, Vall d'Hebron Institute of Oncology (VHIO); University Hospital Vall d'Hebron, Barcelona, Spain; ⁹⁹The Hong Kong Hereditary Breast Cancer Family Registry; Cancer Genetics Center, Hong Kong Sanatorium and Hospital, Hong Kong; Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong; ¹⁰⁰Centre of Familial Breast and Ovarian Cancer, Department of Gynaecology and Obstetrics and Centre for Integrated Oncology (CIO), University Hospital of Cologne, Cologne, Germany; ¹⁰¹Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany; ¹⁰²Department of Gynaecology and Obstetrics, Division of Tumor Genetics, Klinikum rechts der Isar, Technical University Munich, Munich, Germany; ¹⁰³Department of Gynaecology and Obstetrics, Ludwig-Maximilian University Munich, Munich, Germany; ¹⁰⁴Department of Gynaecology and Obstetrics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany; ¹⁰⁵Institute of Human Genetics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany; ¹⁰⁶Department of Gynaecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; ¹⁰⁷Institute of Human Genetics, University of Münster, Münster, Germany; ¹⁰⁸Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany; ¹⁰⁹Institute of Human Genetics, Campus Virchow Klinikum, Charité Berlin, Germany; ¹¹⁰Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany; ¹¹¹Centre of Familial Breast and Ovarian Cancer, Department of Medical Genetics, Institute of Human Genetics, University Würzburg, Würzburg, Germany; ¹¹²Institute of Human Genetics, Department of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany; ¹¹³Department of Gynaecology and Obstetrics, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany; ¹¹⁴Institute of Human Genetics, University Regensburg, Regensburg, Germany; ¹¹⁵Institute of Human Genetics, University Hospital Frankfurt a.M., Frankfurt, Germany; ¹¹⁶Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid, Spain; ¹¹⁷Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; ¹¹⁸Department of Clinical Genetics, Helsinki University Central Hospital, Helsinki, Finland; ¹¹⁹Gynaecologic Oncology Service, Centre Hospitalier Universitaire de Québec (CHUQ), Côte du Palais, Québec, Canada; ¹²⁰Kathleen Cuninghame Consortium for Research into Familial Breast Cancer–Peter MacCallum Cancer Center, Melbourne, Australia; ¹²¹Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California; ¹²²Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; ¹²³Department of Medical Genetics, Mayo Clinic, Rochester, Minnesota; ¹²⁴Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota; ¹²⁵Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predicted Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy; ¹²⁶IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy; ¹²⁷Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy; ¹²⁸Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia (IEO), Milan, Italy; ¹²⁹Department of Experimental Oncology, Istituto Europeo di Oncologia, Milan, Italy; ¹³⁰Consortium for Genomics Technology (Cogentech), Milan, Italy; ¹³¹Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, IRCCS, Aviano (PN), Italy; ¹³²Medical Genetics Unit, Department of Clinical Physiopathology, University of Florence, Firenze, Italy; ¹³³Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy; ¹³⁴Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland; ¹³⁵Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario M5G 1×5, Cancer Care Ontario, Departments of Molecular Genetics and Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada; ¹³⁶Ontario Cancer Genetics Network: Cancer Care Ontario, Ontario, Canada; ¹³⁷Department of Oncology, University of Cambridge, Cambridge, United Kingdom

Communicated by Stephen J. Chanock

Received 20 September 2011; accepted revised manuscript 14 December 2011.

Published online 17 January 2012 in Wiley Online Library (www.wiley.com/humanmutation). DOI: 10.1002/humu.22025

ABSTRACT: Germline mutations in *BRCA1* and *BRCA2* are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of ovarian cancer risk for *BRCA1* and *BRCA2* mutation carriers. Four single-nucleotide polymorphisms (SNPs), rs10088218 (at 8q24), rs2665390 (at 3q25), rs717852 (at 2q31), and rs9303542 (at 17q21), were genotyped in 12,599 *BRCA1* and 7,132 *BRCA2* carriers, including 2,678 ovarian cancer cases. Associations were evaluated within a retrospective cohort approach. All four loci were associated with ovarian cancer risk in *BRCA2* carriers; rs10088218 per-allele hazard ratio (HR) = 0.81 (95% CI: 0.67–0.98) P-trend = 0.033, rs2665390 HR = 1.48 (95% CI: 1.21–1.83) P-trend = 1.8×10^{-4} , rs717852 HR = 1.25 (95% CI: 1.10–1.42) P-trend = 6.6×10^{-4} , rs9303542 HR = 1.16 (95% CI: 1.02–1.33) P-trend = 0.026. Two loci were associated with ovarian cancer risk in *BRCA1* carriers; rs10088218 per-allele HR = 0.89 (95% CI: 0.81–

0.99) P-trend = 0.029, rs2665390 HR = 1.25 (95% CI: 1.10–1.42) P-trend = 6.1×10^{-4} . The HR estimates for the remaining loci were consistent with odds ratio estimates for the general population. The identification of multiple loci modifying ovarian cancer risk may be useful for counseling women with *BRCA1* and *BRCA2* mutations regarding their risk of ovarian cancer.

Hum Mutat 33:690–702, 2012. © 2012 Wiley Periodicals, Inc.

KEY WORDS: ovarian cancer; *BRCA1*; *BRCA2*; association; SNP

Introduction

Pathogenic mutations in the *BRCA1* (MIM# 113705) and *BRCA2* (MIM# 600185) genes confer high risks of ovarian and breast cancer [Miki et al., 1994; Wooster et al., 1995]. Breast cancer risks by age 70 have been estimated to range between 40% and 87% for *BRCA1* and 40–84% for *BRCA2* mutation carriers, whereas

ovarian cancer risk estimates range between 16–68% and 11–27% for *BRCA1* and *BRCA2* mutation carriers, respectively [Antoniou et al., 2003; Antoniou et al., 2008; Begg et al., 2008; Chen et al., 2006; Ford et al., 1998; Hopper et al., 1999; Milne et al., 2008; Simchoni et al., 2006; Struwing et al., 1997; Thompson et al., 2001; Thompson et al., 2002]. Recent genome-wide association studies (GWAS) have identified common alleles associated with risk of breast, ovarian, and other cancers [reviewed Easton and Eeles, 2008; McCarthy and Hirschhorn, 2008; Song et al., 2009]. These common variants are plausible candidates for modifiers of disease risk for mutation carriers. The Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA) has provided convincing evidence that variants identified through GWAS of breast cancer are also associated with the risk of developing breast cancer for *BRCA1* and/or *BRCA2* mutation carriers [Antoniou et al., 2008a; Antoniou et al., 2009; Antoniou et al., 2010b; Antoniou et al., 2011].

Similarly, CIMBA has investigated the influence of ovarian cancer GWAS variants on ovarian cancer risk in *BRCA1* and *BRCA2* carriers. The first ovarian cancer susceptibility locus identified by a GWAS was rs3814113 at 9p22.2. The minor C allele was associated with a decreased risk of ovarian cancer (odds ratio (OR) = 0.82, 95% confidence interval (CI): 0.79–0.86, $P = 5.1 \times 10^{-19}$) [Song et al., 2009]. A previous CIMBA study showed that the minor allele of rs3814113 was also associated with a reduced risk of ovarian cancer for both *BRCA1* and *BRCA2* carriers (HR = 0.78 for both *BRCA1* and *BRCA2* mutation carriers) [Ramus et al., 2011].

A breast cancer GWAS in *BRCA1* mutation carriers found that locus 19p13 is associated with breast cancer risk for *BRCA1* mutation carriers. Two alleles on 19p13, rs8170C>T and rs2363956G>T, showed independent associations with breast cancer risk [Antoniou et al., 2010a]. Analysis of the associations of these SNPs with ovarian cancer risk in 843 ovarian cancer cases showed no evidence that this locus modifies ovarian cancer risk for *BRCA1* mutation carriers. However, the same two alleles were identified at the same time as ovarian cancer susceptibility alleles in a population-based ovarian cancer GWAS - rs8170 (OR = 1.12, 95% CI: 1.07–1.17, P-trend = 3.6×10^{-6} , serous OR = 1.18, 95% CI: 1.12–1.25, P-trend = 2.7×10^{-9}) and rs2363956 (OR = 1.1, 95% CI: 1.06–1.15, P-trend = 1.2×10^{-7} , serous OR = 1.16, 95% CI: 1.11–1.21, P-trend = 3.8×10^{-11}) [Bolton et al., 2010]. Subsequent genotyping of SNPs rs8170 and rs67397200 (an SNP correlated with both rs8170 and rs2363956 and identified via imputation), in a larger series of *BRCA1* and *BRCA2* mutation carriers from CIMBA, confirmed that both SNPs are associated with breast cancer risk. This analysis, which included 1,399 *BRCA1* ovarian cancer cases and 428 *BRCA2* ovarian cancer cases, also found that the 19p13 SNPs were associated with ovarian cancer risk in both *BRCA1* and *BRCA2* carriers in an analysis of the simultaneous breast and ovarian cancer associations in *BRCA1* carriers [Couch et al., in press].

Four additional ovarian cancer susceptibility loci were identified in a GWAS of more than 10,000 cases and 17,000 controls: rs2072590G>T (2q31) OR = 1.16 (95% CI: 1.12–1.21) P-trend = 4.5×10^{-14} , rs2665390T>C (3q25) OR = 1.19 (95% CI: 1.11–1.27) P-trend = 3.2×10^{-7} , rs10088218G>A (8q24) OR = 0.84 (95% CI: 0.80–0.89) P-trend = 3.2×10^{-9} , and rs9303542A>G (17q21) OR = 1.11 (95% CI: 1.06–1.16) P-trend = 1.4×10^{-6} [Goode et al., 2010]. All these associations were stronger for serous ovarian cancer, the most common histology observed in BRCA-related ovarian cancer, than for all histologies. To investigate whether these SNPs are associated with risk of ovarian and breast cancer for mutation carriers, we genotyped these SNPs (or, in the case of rs2072590, a surrogate SNP, rs717852A>G, $r^2 = 0.96$) for 12,599 *BRCA1* and 7,132 *BRCA2* mutation carriers from 40 studies that were part of CIMBA.

Materials and Methods

Subjects

All subjects were female carriers of pathogenic mutations in *BRCA1* or *BRCA2* from 40 studies from Europe, North America, South Africa, and Australia (Supp. Table S1). Pathogenic mutations were defined as protein-truncating mutations or mutations listed on the Breast Cancer Information Core (BIC) <http://research.nhgri.nih.gov/bic/> as described previously [Antoniou et al., 2007]. All subjects were 18 years or older at recruitment. The majority of carriers (>97%) were recruited through cancer genetics clinics offering genetic testing, and enrolled into national or regional studies. Some carriers were identified by population-based sampling of cases, and some by community recruitment. Only women of self-reported white, European ancestry were included in the analysis. Subjects were excluded if they were from a country other than the country in which the study is conducted, or if they carried mutations in both genes. If a woman was enrolled in two different studies, only one of the samples was included in the analysis. These duplicate samples were identified by dates of birth and diagnosis and from available genotyping data. Subject information included year of birth; age at last follow-up; ages at breast and/or ovarian cancer diagnosis; and age at bilateral prophylactic mastectomy or oophorectomy. Related subjects were identified through a unique family identifier. *BRCA1* mutations were classified based on their predicted functional consequence. Class 1 was comprised of loss of function mutations subject to nonsense-mediated decay whereas class 2 mutations were those expected to generate a stable protein (details described previously [Antoniou et al., 2008a]). Subjects participated in clinical or research studies at the host institutions under ethically-approved protocols. Further details about CIMBA are described elsewhere [Chenevix-Trench et al., 2007].

Genotyping

The DNA samples from 12,599 *BRCA1* and 7,132 *BRCA2* carriers from 40 studies were genotyped for SNPs rs10088218 (8q24), rs2665390 (3q25), rs717852 (2q31), and rs9303542 (17q21) using the iPLEX (Sequenom, San Diego, CA) Mass Array platform (Supp. Table S1) at four genotyping centers. We used a correlated SNP ($r^2 = 0.96$), rs717852, to replace a failed assay for rs2072590. All genotyping data were subjected to a standard set of quality control criteria. Samples from affected and unaffected subjects were randomly arrayed within plates. No template controls were included on every 384-well plate and at least 2% of the samples were tested in duplicate. Samples were excluded if they consistently failed genotyping, defined as a pass rate of < 80% for all SNPs in this genotyping round. For a study to be included in the analysis, the genotype data were required to attain or exceed a call-rate threshold of 95% and a concordance between duplicates of 98%. We also evaluated the deviation from Hardy-Weinberg equilibrium (HWE) for unrelated subjects. For none of these studies was HWE rejected at a predefined threshold of $P = 0.001$. An additional quality control criterion was consistent results for 95 DNA samples from a standard test plate (Coriell Institute, Camden, NJ) genotyped at all centers. If the genotyping was inconsistent for more than one sample in the test plate, the study was excluded. A total of 19,731 carriers with genotype data were eligible for inclusion in the analysis (12,599 *BRCA1* and 7,132 *BRCA2* carriers) (Supp. Table S1). Three studies failed quality control for rs717852 and one for rs2665390.

Table 1. Summary Characteristics for the 19,731 Eligible *BRCA1* and *BRCA2* Carriers^a Used in the Analysis

Characteristic	<i>BRCA1</i>		<i>BRCA2</i>	
	Unaffected	Ovarian cancer	Unaffected	Ovarian cancer
Number	10,535	2,064	6,518	614
Person-years follow-up	459,178	104,942	304,789	34,605
Median age at censor (IQR)	42 (35–50)	50 (45–56)	45 (38–55)	56 (49–63)
Age at censor, N (%)				
< 30	1,536 (14.6)	93 (4.5)	796 (12.2)	24 (3.9)
30–39	2,945 (28.0)	171 (8.3)	1,402 (21.5)	15 (2.4)
40–49	3,375 (32.0)	760 (36.8)	2,017 (31.0)	129 (21.0)
50–59	1,721 (16.3)	707 (34.8)	1,297 (19.9)	217 (35.3)
60–69	656 (6.2)	269 (13.0)	667 (10.2)	175 (28.5)
70+	302 (2.9)	64 (3.1)	339 (5.2)	54 (8.8)
Year of birth, N (%)				
<1920	50 (0.5)	8 (0.4)	56 (0.9)	11 (1.8)
1920–1929	204 (1.9)	123 (6.0)	199 (3.1)	67 (10.9)
1930–1939	548 (5.2)	337 (16.3)	499 (7.7)	163 (26.6)
1940–1949	1,495 (14.2)	678 (32.9)	1,122 (17.2)	323 (52.8)
1950–1959	2,757 (26.2)	641 (31.1)	1,736 (26.6)	115 (18.7)
1960–1969	3,113 (29.6)	256 (12.4)	1,747 (26.8)	23 (3.8)
1970+	2,368 (22.5)	21 (1.0)	1,159 (17.8)	3 (0.5)
Mutation class, N (%)				
Class 1 ^b	6,460 (61.3)	1,481 (71.8)	6,058 (92.9)	576 (93.8)
Class 2 ^b	3,294 (31.3)	459 (22.2)	163 (2.5)	9 (1.5)
Other	781 (7.4)	124 (6.0)	297 (4.6)	29 (4.7)

^a Carriers of self-reported white European ancestry only.

^b See methods for definitions.

IQR, interquartile range.

Statistical Analysis

The primary aim of this study was to evaluate the association between each genotype and ovarian cancer risk. The primary end-point was therefore the age at diagnosis of ovarian cancer. For this purpose, individuals were censored at the age of the ovarian cancer diagnosis, or risk-reducing salpingo-oophorectomy (RRSO) or the age at last observation. Breast cancer was not considered as a censoring event in this analysis, and mutation carriers who developed ovarian cancer after a breast cancer diagnosis were considered as affected in the ovarian cancer analysis. To address the fact that mutation carriers were not sampled at random with respect to their disease phenotype, analysis was conducted by modeling the retrospective likelihood of the observed genotypes conditional on the disease phenotypes as previously described [Antoniou et al., 2007; Barnes et al., In Press]. This method has been shown to provide unbiased estimates of the risk ratios within the present sampling frame [Barnes et al., In Press]. The effect of each SNP was modeled either as a per-allele hazard ratio (HR) (multiplicative model) or as separate HRs for heterozygotes and homozygotes, and these were estimated on the logarithmic scale. The HRs were assumed to be independent of age (i.e., we used a Cox proportional-hazards model). The assumption of proportional hazards was tested by adding a “genotype x age” interaction term to the model in order to fit models in which the HR changed with age. Analyses were carried out with the pedigree-analysis software MENDEL [Lange et al., 1988] and details of this approach have been described previously [Antoniou et al., 2007; Barnes et al., In Press]. We examined between study/country heterogeneity by comparing the models that allowed for study-specific log HRs against models in which the same log HR was assumed to apply to all studies.

To investigate whether our results were influenced by any of our assumptions, we performed additional sensitivity analyses. If any of the SNPs were associated with disease survival, the inclusion of prevalent cases may influence the HR estimates. We therefore repeated our analysis by excluding mutation carriers diagnosed more

than 5 years prior to the age at recruitment into the study. We also examined whether SNP associations differed by type of *BRCA1* mutations as described above.

The associations of these SNPs with breast cancer risk were assessed within a competing risk analysis framework [Barnes et al., In Press; Ramus et al., 2011] by estimating HRs simultaneously for breast and ovarian cancers. In this model, each individual was at risk of developing either breast or ovarian cancer, and the probabilities of developing each disease were assumed to be independent conditional on the underlying genotype. A different censoring process was used in this case, whereby individuals were followed up to the age of the first breast or ovarian cancer diagnosis and were considered to have developed the corresponding disease. No follow-up was considered after the first cancer diagnosis. Individuals were censored for breast cancer at the age of bilateral prophylactic mastectomy and for ovarian cancer at the age of bilateral oophorectomy and in such circumstances were assumed to be unaffected for the corresponding disease. The remaining individuals were censored at the age at last observation and were assumed to be unaffected for both diseases.

To ensure a sufficiently large number of mutation carriers within each stratum, we grouped studies from the same country. All analyses were stratified and used calendar year and cohort-specific cancer incidences for *BRCA1* and *BRCA2* [Antoniou et al., 2008b]. For sensitivity analyses, strata with small numbers of mutation carriers were grouped. We used a robust variance-estimation approach to allow for the nonindependence among related carriers [Boos, 1992].

Results

In total, 12,599 *BRCA1* and 7,132 *BRCA2* carriers were eligible for analysis of associations between ovarian cancer risk and rs10088218 (8q24), rs2665390 (3q25), rs717852 (2q31), and rs9303542 (17q21). The primary analysis included 2,678 mutation carriers who were followed up to the age at diagnosis of invasive ovarian cancer (cases) and 17,053 carriers who were censored as unaffected (Table 1).

Table 2. SNP Genotype Distributions and Associations with Ovarian Cancer Risk

Mutation	Genotype	Unaffected N (%)	Affected ^a N (%)	HR	95% CI	P-value
8q24–rs10088218 <i>BRCA1</i>	GG	7,978 (76.1)	1,574 (76.3)	1		
	AG	2,325 (22.2)	461 (22.4)	0.93	0.83–1.05	
	AA	176 (1.7)	27 (1.3)	0.61	0.41–0.91	
	2-df test					0.032
	per allele			0.89	0.81–0.99	0.029
<i>BRCA2</i>	GG	4,865 (74.7)	485 (79.0)	1		
	AG	1,537 (23.6)	116 (18.9)	0.73	0.59–0.91	
	AA	113 (1.7)	13 (2.1)	1.12	0.61–2.04	
	2-df test					0.014
	per allele			0.81	0.67–0.98	0.033
3q25–rs2665390 <i>BRCA1</i>	TT	8,242 (85.6)	1,623 (83.1)	1		
	TC	1,330 (13.8)	314 (16.1)	1.25	1.08–1.44	
	CC	58 (0.6)	17 (0.9)	1.57	0.91–2.69	
	2-df test					2.7×10^{-3}
	per allele			1.25	1.10–1.42	6.1×10^{-4}
<i>BRCA2</i>	TT	5,226 (85.3)	449 (78.6)	1		
	TC	862 (14.1)	118 (20.7)	1.58	1.26–1.98	
	CC	38 (0.6)	4 (0.7)	1.20	0.34–4.19	
	2-df test					3.2×10^{-4}
	per allele			1.48	1.21–1.83	1.8×10^{-4}
2q31–rs717852 <i>BRCA1</i>	TT	4,134 (47.0)	863 (45.3)	1		
	CT	3,807 (43.2)	862 (45.3)	1.11	0.99–1.23	
	CC	864 (9.8)	179 (9.4)	1.06	0.88–1.27	
	2-df test					0.18
	per allele			1.06	0.98–1.14	0.16
<i>BRCA2</i>	TT	3,029 (48.6)	245 (42.0)	1		
	CT	2,645 (42.4)	272 (46.6)	1.30	1.08–1.56	
	CC	558 (9.0)	67 (11.5)	1.51	1.13–2.01	
	2-df test					3.2×10^{-3}
	per allele			1.25	1.10–1.42	6.6×10^{-4}
17q21–rs9303542 <i>BRCA1</i>	TT	5,695 (54.2)	1,076 (52.3)	1		
	TC	4,085 (38.9)	826 (40.1)	1.08	0.98–1.20	
	CC	729 (6.9)	157 (7.6)	1.15	0.95–1.40	
	2-df test					0.17
	per allele			1.08	1.00–1.17	0.06
<i>BRCA2</i>	TT	3,445 (53.0)	296 (48.3)	1		
	TC	2,593 (39.9)	264 (43.1)	1.19	1.00–1.42	
	CC	462 (7.1)	53 (8.7)	1.31	0.95–1.81	
	2-df test					0.082
	per allele			1.16	1.02–1.33	0.026

^aOvarian cancer.

Analysis restricted to mutation carriers of white European ancestry.

The minor allele of rs2665390 (3q25) was associated with a significantly increased risk of ovarian cancer for both *BRCA1* carriers (per-allele HR = 1.25, 95% CI: 1.10–1.42, P-trend = 6.1×10^{-4}) and *BRCA2* carriers (per allele HR = 1.48, 95% CI: 1.21–1.83, P-trend = 1.8×10^{-4}) (Table 2). The minor allele of rs10088218 (8q24) was associated with a significantly decreased risk of ovarian cancer for both *BRCA1* carriers (per-allele HR = 0.89, 95% CI: 0.81–0.99, P-trend = 0.029), and *BRCA2* carriers (per allele HR = 0.81, 95% CI: 0.67–0.98, P-trend = 0.033). The two remaining SNPs, rs717852 (2q31) and rs9303542 (17q21), were associated with ovarian cancer risk for *BRCA2* carriers (rs717852-per allele HR = 1.25, 95% CI: 1.10–1.42, P-trend = 6.6×10^{-4} ; rs9303542-per allele HR = 1.16, 95% CI: 1.02–1.33, P-trend = 0.026). The estimated HRs in *BRCA1* carriers for these two SNPs were also >1 but not significantly different from 1, nor did they differ significantly from the HRs in *BRCA2* carriers. There was no evidence that the HRs varied by age for either *BRCA1* or *BRCA2* mutation carriers (*BRCA1*-rs10088218 $P = 0.34$, rs2665390 $P = 0.24$, rs717852 $P = 0.09$, rs9303542 $P =$

0.58; *BRCA2*-rs10088218 $P = 0.66$, rs2665390 $P = 0.95$, rs717852 $P = 0.88$, rs9303542 $P = 0.67$). The country-specific HRs are shown in Figure 1. There was no evidence of heterogeneity in HRs across the studies/countries (*BRCA1*-rs10088218 $P = 0.27$, rs2665390 $P = 0.59$, rs717852 $P = 0.60$, rs9303542 $P = 0.10$; *BRCA2*-rs10088218 $P = 0.16$, rs2665390 $P = 0.32$, rs717852 $P = 0.75$, rs9303542 $P = 0.49$).

To determine if any survival bias was introduced by including long-term survivors, we excluded all ovarian cancer cases recruited 5 or more years after diagnosis (Supp. Table S2). All HR estimates were similar to those from the primary analysis although only three were significant in the reduced sample set.



We examined the associations between the SNPs and ovarian cancer risk by the *BRCA1* mutation-type based on the predicted functional consequence (Supp. Table S2). We found no evidence of a difference in the per-allele HR by *BRCA1* mutation type for rs10088218 (8q24) (P for difference in HR = 0.99). For rs2665390 (3q25) the estimated HR for class 1 mutations was somewhat higher (per-allele HR = 1.34 [95% CI: 1.15–1.56] P-trend = 2.2×10^{-4})

a) *BRCA1*

b) *BRCA2*



rs10088218

8q24





rs717852

2q31



rs2665390

3q25



rs9303542

17q21





Figure 1. Forest plots of study-specific HRs for ovarian cancer risk in (a) *BRCA1* mutation carriers, (b) *BRCA2* mutation carriers. Country-specific per-allele HR estimates for the SNPs rs10088218 (8q24), rs2665390 (3q25), rs717852 (2q31), and rs9303542 (17q21) in *BRCA1* and *BRCA2* mutation carriers. The area of the square is proportional to the inverse of the variance of the estimate. Horizontal lines indicate 95% confidence intervals. Diamonds indicate the summary HR estimates for all of the CIMBA. For *BRCA2*, some of the smaller studies have been combined with others from the same country. GE/AT/HU denotes the stratum for Germany, Austria, and Hungary. NL/SA denotes the stratum for the Netherlands and South Africa.

Table 3. Competing Risk Analysis

					Breast cancer			Ovarian cancer		
		Unaffected N (%)	Breast cancer N (%)	Ovarian cancer N (%)	HR	95% C.I.	P-value	HR	95% C.I.	P-value
8q24—rs10088218										
BRCA1	GG	3,661 (77.0)	4,772 (75.5)	1,119 (76.4)	1			1		
	AG	1,025 (21.5)	1,431 (22.6)	330 (22.5)	1.03	0.94–1.11		0.96	0.83–1.11	
	AA	70 (1.5)	117 (1.9)	16 (1.1)	1.08	0.84–1.38		0.55	0.32–0.94	
	2-df test						0.72			0.083
	per allele				1.03	0.96–1.10	0.44	0.91	0.80–1.03	0.13
BRCA2	GG	2,123 (73.9)	2,861 (75.3)	366 (80.6)	1			1		
	AG	699 (24.3)	877 (23.1)	77 (17.0)	0.91	0.82–1.02		0.60	0.46–0.78	
	AA	53 (1.8)	62 (1.6)	11 (2.4)	0.85	0.61–1.18		1.17	0.60–2.27	
	2-df test						0.17			7.7 × 10 ^{−4}
	per allele				0.92	0.84–1.00	0.061	0.72	0.57–0.91	5.7 × 10 ^{−3}
3q25—rs2665390										
BRCA1	TT	3,716 (85.2)	4,995 (85.7)	1,151 (82.8)	1			1		
	TC	614 (14.1)	801 (13.7)	229 (16.4)	1.00	0.90–1.11		1.27	1.06–1.51	
	CC	31 (0.7)	33 (0.6)	11 (0.8)	0.80	0.53–1.19		1.22	0.62–2.41	
	2-df test						0.54			0.028
	per allele				0.98	0.89–1.08	0.70	1.23	1.06–1.44	8.5 × 10 ^{−3}
BRCA2	TT	2,282 (85.5)	3,067 (85.1)	326 (76.8)	1			1		
	TC	368 (13.8)	517 (14.4)	95 (22.5)	1.02	0.89–1.16		1.75	1.34–2.27	
	CC	19 (0.7)	20 (0.6)	3 (0.7)	0.72	0.39–1.35		1.02	0.21–5.10	
	2-df test						0.57			1.6 × 10 ^{−4}
	per allele				0.99	0.87–1.12	0.82	1.59	1.25–2.02	1.9 × 10 ^{−4}
2q31—rs717852										
BRCA1	TT	1,817 (47.3)	2,576 (46.5)	606 (45.5)	1			1		
	CT	1,667 (43.5)	2,400 (43.3)	602 (45.1)	1.01	0.94–1.09		1.10	0.96–1.25	
	CC	356 (9.3)	562 (10.2)	125 (9.4)	1.13	0.99–1.29		1.10	0.87–1.40	
	2-df test						0.18			0.32
	per allele				1.04	0.99–1.10	0.14	1.08	0.98–1.19	0.15
BRCA2	TT	1,345 (49.8)	1,752 (47.5)	177 (41.4)	1			1		
	CT	1,112 (41.2)	1,603 (43.5)	202 (47.2)	1.08	0.98–1.19		1.39	1.11–1.74	
	CC	244 (9.0)	331 (9.0)	50 (11.5)	1.03	0.87–1.21		1.60	1.13–2.26	
	2-df test						0.30			3.8 × 10 ^{−3}
	per allele				1.04	0.97–1.12	0.30	1.31	1.12–1.53	8.5 × 10 ^{−4}
17q21—rs9303542										
BRCA1	TT	2,537 (53.1)	3,470 (54.8)	764 (52.3)	1			1		
	TC	1,891 (39.6)	2,434 (38.5)	586 (40.1)	0.98	0.91–1.05		1.08	0.95–1.23	
	CC	349 (7.3)	426 (6.7)	111 (7.6)	0.95	0.82–1.09		1.10	0.87–1.40	
	2-df test						0.70			0.44
	per allele				0.98	0.92–1.03	0.41	1.06	0.97–1.17	0.22
BRCA2	TT	1,517 (52.8)	2,012 (53.1)	212 (46.7)	1			1		
	TC	1,136 (39.6)	1,520 (40.1)	203 (44.9)	0.98	0.89–1.08		1.26	1.02–1.55	
	CC	218 (7.6)	259 (6.8)	38 (8.4)	0.87	0.73–1.05		1.17	0.79–1.74	
	2-df test						0.35			0.099
	per allele				0.96	0.89–1.03	0.22	1.16	0.99–1.35	0.075

Associations with breast and ovarian cancer risk for *BRCA1* and *BRCA2* mutation carriers. Analysis restricted to mutation carriers of European ancestry.

compared to class 2 mutations (HR = 1.08 (95% CI: 0.78–1.36), P-trend = 0.85), but the difference in HRs was not significant ($P = 0.06$). Similar patterns in the HRs between class 1 and class 2 mutations were seen for rs9303542 (17q21) and rs717852 (2q31), but none of the differences were significant ($P = 0.20$ and $P = 0.36$, respectively).

To determine whether these four SNPs were also associated with breast cancer risk for *BRCA1* and *BRCA2* mutation carriers, we performed an analysis in which we estimated HRs for breast and ovarian cancer simultaneously within a bivariate outcome model (Table 3). There was no evidence of association between these SNPs and breast cancer risk for mutation carriers. The estimated HRs for ovarian cancer risk under this analysis were similar to those estimated in the main analysis. However, some of the results were no longer significant due to the fact that mutation carriers diagnosed with ovarian cancer after a breast cancer diagnosis are censored at breast cancer, which results in a reduced number of ovarian cancer cases. The 3q25 SNP, rs2665390, was significantly associated with ovarian cancer risk for both *BRCA1* and *BRCA2* carriers (per-allele

HR = 1.23, 95% CI: 1.06–1.44, P-trend = 8.5×10^{-3} and per-allele HR = 1.59, 95% CI: 1.25–2.02, P-trend = 1.9×10^{-4} , respectively). As in the primary analysis, rs717852 (2q31) was only associated with an increased ovarian cancer risk in *BRCA2* carriers (HR = 1.31, 95% CI: 1.12–1.53, P-trend = 8.5×10^{-4}). The magnitude of the association between SNP rs10088218 (8q24) and ovarian cancer risk in *BRCA2* carriers was somewhat larger than in the primary analysis (HR = 0.72, 95% CI: 0.57–0.91, P-trend = 5.7×10^{-3}).

Discussion

Recent studies have shown that common genetic variants identified from ovarian cancer GWAS are associated with susceptibility to ovarian cancer for *BRCA1* and/or *BRCA2* mutation carriers [Couch et al., in press; Ramus et al., 2011]. In the present study, we genotyped four SNPs, rs10088218 (8q24), rs2665390 (3q25), rs717852 (2q31), and rs9303542 (17q21) that were found to be associated with ovarian cancer in women from the general population. We found

that all SNPs were associated with ovarian cancer risk for *BRCA2* mutation carriers. There was significant evidence that two of the SNPs (rs10088218 at 8q24 and rs2665390 at 3q25) were also associated with ovarian cancer risk for *BRCA1* mutation carriers. For the remaining two SNPs at 2q31 and 17q21, the associations with ovarian cancer risk in *BRCA1* mutations did not reach statistical significance. However, the estimated HRs were still consistent with both the estimated HRs in *BRCA2* carriers, and the estimated ORs in the general population. Thus these data, combined with those for the previously detected ovarian cancer risk SNPs at 9p22.2 [Ramus et al., 2011] and 19p13 [Couch et al., in press], indicate that all six known common susceptibility loci for ovarian cancer, are also associated with the ovarian cancer risk in *BRCA1* and *BRCA2* carriers, and moreover that the relative risk of ovarian cancer is generally similar to that in the general population.

In the general population, the magnitude of the associations with ovarian cancer risk were stronger for cases with the serous histological subtype for rs2072590 (2q31) $P_{\text{heterogeneity}} = 2.9 \times 10^{-4}$, rs10088218 (8q24) $P_{\text{heterogeneity}} = 1.1 \times 10^{-7}$, and rs2665390 (3q25) $P_{\text{heterogeneity}} = 0.02$ [Goode et al., 2010]. However, we were not able to assess this interaction in the *BRCA1* and *BRCA2* carriers, due to small numbers and incomplete pathology data for histological subtype.

When the data were analyzed within a competing risks framework, we observed no evidence that these SNPs were associated with breast cancer risk for *BRCA1* or *BRCA2* mutation carriers. None of the published breast cancer GWAS using women from the general population [Ahmed et al., 2009; Easton et al., 2007; Gold et al., 2008; Hunter et al., 2007; Thomas et al., 2009] have reported associations for these SNPs at the strict genome-wide levels of significance. These results indicate that, for both groups of mutation carriers and for the general population, the predominant association is with ovarian cancer risk and that the association with breast cancer risk, if any, is very weak.

The fine-mapping and functional follow-up of the risk alleles from the ovarian cancer GWAS are currently being performed. Therefore, the gene most likely to be driving the ovarian cancer risk in each region has not yet been identified but the closest genes to each SNP and the genes in the linkage disequilibrium block provide some insight to the potential candidates. The rs2665390 SNP is located at 3q25, and is intronic to the *TIPARP* gene, a member of the poly (ADP-ribose) polymerase (PARP) superfamily. *BRCA1-BRCA2*-deficient cells can use the *PARP1* alternative DNA repair mechanism to survive, and synthetic inhibition of *PARP1* has been developed as a new therapy for breast and ovarian cancer patients with mutations in these genes [Fong et al., 2009]. There are no other candidate genes within 200 kb of this SNP and the five other genes within the linkage disequilibrium block (*LEKR1*, *LOC730091*, *PA2G4P4*, *SSR3*, and *KCNAB1*) are not known to have functions that suggest a role in cancer [www.genecards.org; Safran et al., 2010].

The rs717852 SNP is located at 2q31 in a region containing a family of homeobox (*HOX*) genes; *HOXD10*, *HOXD11*, *HOXD12*, *HOXD13*, *HOXD3*, *HOXD4*, *HOXD8*, *HOXD9*, and *HOXD1*. *HOX* genes are involved in regulating embryogenesis and organogenesis and altered expression of *HOX* genes has been reported in many cancers [Buzzai and Licht, 2008; Shiraishi et al., 2002]. The other genes in this region, *KIAA1715*, *EVX2*, and *MTX2*, do not have a reported role in cancer [www.genecards.org; Safran et al., 2010]. The ovarian cancer risk-associated SNP rs2072590 is downstream of *HOXD3* and upstream of *HOXD1*, and it tags SNPs in the *HOXD3* 3' untranslated region. The genotyped SNP rs717852 is intronic of *HOXD3*.

Common variants that confer susceptibility to multiple cancer phenotypes, including prostate, colorectal, breast, and bladder can-

cers have been identified in a 500-kb region of a gene desert at 8q24, approximately 200 kb 5' of *MYC* [Jia et al., 2009]. Functional studies have suggested that transcriptional regulation of *MYC* may explain these associations [Jia et al., 2009; Pomerantz et al., 2009]. In contrast, rs10088218 is >700 kb 3' of *MYC*. Variants in this region may also be capable of distant regulation of *MYC*. However, *PVT1*, a noncoding RNA which is an *MYC* protein target, is another plausible candidate in this region. *PVT1* is amplified in breast and ovarian tumors, and is overexpressed in transformed cells [Guan et al., 2007]. A prostate cancer risk variant at the 8q24 locus, located 0.5 Mb upstream of the *PVT1* gene has recently been shown to be associated with increased expression of the *PVT1* gene rather than affecting *MYC* expression [Meyer et al., 2011].

The final SNP, rs9303542 at 17q21, is intronic to *SKAP1*, a src kinase-associated phosphoprotein, which regulates mitotic progression [Fang et al., 2009]. *SKAP1* has been shown to suppress activation of *RAS* and *RAF1* genes that may have a role in the early-stage development of ovarian cancer [Kosco et al., 2008]. The region also contains 10 *HOXB* genes and, as described earlier, altered expression of *HOX* genes has been reported in many cancers. Of the other 12 genes in this region, the only ones with a suggested role in cancer are, *PRAC*, encoding a small nuclear protein which is a prostate cancer susceptibility candidate, *CBX1*, which may play an important role in the epigenetic control of chromatin structure and gene expression, and *CDK5RAP3* that may be involved in cell proliferation [www.genecards.org; Safran et al., 2010].

We have previously demonstrated that common risk alleles for breast cancer increase the risk of breast cancer to a similar relative extent in *BRCA1* and *BRCA2* carriers (once estrogen receptor status is taken into account). These results demonstrate that the same holds true for ovarian cancer loci identified through GWAS, and provides a general model in which common susceptibility loci and *BRCA1* and *BRCA2* mutations interact multiplicatively on the risk of developing ovarian cancer [Wacholder et al., 2011]. Although the HR conferred by each locus is modest, the HRs are much larger in combination. These translate to small differences in absolute risk between different genotypes for the vast majority of women at low risk of this disease, but the absolute risk differences for mutation carriers will be much greater. As more genetic modifiers of ovarian cancer risk are identified, in the future, such information combined with other risk factors such as parity and oral contraceptive use could be incorporated into risk prediction algorithms such as BOADICEA [Antoniou et al., 2008b]. This could enable the stratification of mutation carriers into different ovarian cancer risk categories and could potentially be used for guiding the clinical management of mutation carriers with respect to screening or prophylactic surgery.

Acknowledgments

This work was supported by Cancer Research UK grants C12292/A11174 and C1287/A10118, NHMRC grants to GCT, and grants from the NIH (CA128978), and the U.S. Department of Defense Ovarian Cancer Idea award (W81XWH-10-1-0341) to FJC. The research leading to these results has received funding from the European Community's Seventh Framework Programme No. 223175 (HEALTH-F2-2009-223175); European Community's Seventh Framework Programme under grant agreement No. 223175 (HEALTH-F2-2009-223175). ACA is a CR-UK Senior Cancer Research Fellow, DFE is CR-UK Principal Research Fellow, GCT is a NHMRC Senior Principal Research Fellow and JS is Chairholder of the Canada Research Chair in Oncogenetics. This work was supported by the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program (grant number CRN_87521); and the Canadian Breast Cancer Research Alliance (grant number 019511)

Breast Cancer Family Registry (BCFR): was supported by the National Cancer Institute, National Institutes of Health under RFA-CA-06-503 and through cooperative agreements with members of the Breast Cancer Family Registry and Principal Investigators, including Cancer Care Ontario (U01 CA69467), Columbia University (U01 CA69398), Fox Chase Cancer Center (U01 CA69631), Huntsman Cancer Institute (U01 CA69446), Northern California Cancer Center (U01 CA69417), University of Melbourne (U01 CA69638), and Research Triangle Institute Informatics Support Center (RFP No. N02PC45022-46). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR.

BRCA-gene mutations and breast cancer in South African women (BMBSA): was supported by grants from the Cancer Association of South Africa (CANSA) to Elizabeth J. van Rensburg.

Copenhagen Breast Cancer Study (CBCS): was supported by the Neye Foundation.

Spanish National Cancer Center (CNIO). This study was partially supported by Fundación Mutua Madrileña, Asociación Española Contra el Cáncer, the Spanish Ministry of Science and Innovation FIS PI08/1120 and Cancer Network RD06/0020/1060. Funded in part by the Basque Foundation for Health Innovation and Research (BIOEF: BIO07/CA/006).

CONSORZIO Studi Italiani Tumori Ereditari Alla Mammella (CONSIT TEAM) was supported by grants from Associazione Italiana per la Ricerca sul Cancro (4017) and by funds from Italian citizens who allocated the $5 \times 1,000$ share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects " $5 \times 1,000$ ") to PP. Supported by grants from Ministero della Salute ("Progetto Tevere"—Linea 1 RC D/08/02B—"Progetto Tumori Femminili"—F/08/0PZ—Linea 1 RC CORR/08) to SM. Supported by grants from Associazione Italiana per la Ricerca sul Cancro (8713) to LO. Supported by grants from Fondazione Italiana per la Ricerca sul Cancro (Special Project "Hereditary tumors"), Ministero della Salute (RFPS-2006-3-340203, Extraordinary National Cancer Program 2006 "Alleanza contro il Cancro", and "Progetto Tumori Femminili") and Ministero dell'Università e Ricerca (RBLAO3-BETH) to PR.

Deutsches Krebsforschungszentrum (DKFZ) study: was supported by the DKFZ.

Epidemiological study of BRCA1 & BRCA2 mutation carriers (EMBRACE) was supported by Cancer Research UK Grants (C1287/A10118 and C1287/A11990). D. Gareth Evans and Fiona Laloo are supported by an NIHR grant to the Biomedical Research Centre, Manchester. The Investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Ros Eeles, Elizabeth Bancroft, and Lucia D'Mello were also supported by Cancer Research UK Grant (C5047/A8385).

Fox Chase Cancer Center (FCCC): was supported by the National Institutes of Health (U01 CA69631, 5U01 CA113916, R01 CA140323 to A.K.G.); the Ovarian Cancer Research Fund, and the Eileen Stein Jacoby Fund. The author acknowledges support from The University of Kansas Cancer Center and the Kansas Bioscience Authority Eminent Scholar Program. A.K.G. is the Chancellors Distinguished Chair in Biomedical Sciences endowed Professor. The German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC): was supported by a grant of the German Cancer Aid (grant 109076) and by the Centre of Molecular Medicine Cologne (CMMC).

Genetic Modifiers of cancer risk in BRCA1/2 mutation carriers (GEMO) study (Cancer Genetics Network "Groupe Génétique et Cancer", Fédération Nationale des Centres de Lutte Contre le Cancer, France) was supported by the Ligue Nationale Contre le Cancer; Association for International Cancer Research Grant (AICR-07-0454); and the Association "Le cancer du sein, parlons-en!" Award.

Georgetown. CI received support from the Familial Cancer Registry at Georgetown University (NIH/NCI grant P30-CA051008), the Cancer Genetics Network (HHSN261200744000C), and Swing For the Cure.

Gynecologic Oncology Group (GOG): KAP is the Cancer Council Victoria, Colebatch Clinical Research Fellow.

The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON). The HEBON study is supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756 and the ZonMW grant 91109024.

Hospital Clinico San Carlos (HCSC): was supported by The National Institute of Health Carlos III (RTICC 06/0020/0021).

Helsinki Breast Cancer Study (HEBCS): was supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (132473), the Finnish Cancer Society, and the Sigrid Juselius Foundation.

The Hong Kong Hereditary Breast Cancer Family Registry (HRBCF): thanks the Dr. Ellen Li Charitable Foundation and Kuok Foundation for grant support.

Hungarian Breast and Ovarian Cancer Study (HUNBOCS) was supported by Hungarian Research Grant KTIA-OTKA CK-80745 to Edith Olah.

International Hereditary Cancer Center (IHCC): was supported by the State Committee for Scientific Research (PBZ_KBN_122/P05/2004). Katarzyna Jaworska is a fellow of International PhD program, Postgraduate School of Molecular Medicine, Warsaw Medical University, supported by the Polish Foundation of Science.

Iceland Landspítali-University Hospital (ILUH): The ILUH group was supported by a grant from the Icelandic Association "Walking for Breast Cancer Research" and by the Landspítali University Hospital Research Fund.

Istituto Oncologico Veneto Hereditary Breast and Ovarian Cancer Study (IOVHBOCS) was supported by Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR), and "Ministero della Salute" ("Progetto Tumori Femminili and grant numbers RFPS 2006-5-341353, ACC2/R6.9").

Kathleen Cuninghame Consortium for Research into Familial Breast Cancer (KCONFAB) was supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC), and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. ABS is a Senior Research Fellow of the NHMRC.

The research of the MAGIC consortium at the University of Pennsylvania was funded by RO1-CA083855 and RO1-CA102776 to TRR.

Mayo Clinic Study (MAYO) was supported by the National Institutes of Health (R01 CA128978 and P50 CA116201); the Komen race for the cure (KG081527); the Breast Cancer Research Foundation and the U.S. Department of Defense Ovarian Cancer Idea award (W81XWH-10-1-0341). Memorial Sloan Kettering Cancer Center (MSKCC) was supported by the Breast Cancer Research Foundation and the Lomangino Family Research Fund.

National Cancer Institute (NCI): was supported by the Intramural Research Program of the US National Cancer Institute at the National Institutes of Health, and by support services contracts NO2-CP-11019-50 and NO2-CP-65504 with Westat, Inc, Rockville, MD to PLM and MHG.

N.N. Petrov Institute of Oncology (NNPIO): was supported by the Russian Foundation for Basic Research (grant numbers 10-04-92601, 10-04-92110, 11-04-00227), the Federal Agency for Science and Innovations (contract 16.512.11.2237), the Commission of the European Communities (grant number PITN-GA-2009-238132), and through a Royal Society International Joint grant (JP090615).

Ontario Cancer Genetics Network (OCGN): was supported by Cancer Care Ontario, Canada (ILA); and the National Cancer Institute, National Institutes of Health under RFA-CA-06-503 and through cooperative agreements with members of the Breast Cancer Family Registry and PIs. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the CFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the CFR.

The Ohio State University Clinical Cancer Genetics (OSUCCG): was supported by the Ohio State University Comprehensive Cancer Center.

Pisa Breast Cancer Study (PBCS): was supported by Fondazione Cassa di Risparmio di Pisa Grant n.122/07 and grant 2010 from ITT (Istituto Toscano Tumori).

Swedish Breast Cancer Study (SWE-BRCA): was supported by the Swedish Cancer Society.

Beckman Research Institute City of Hope (BRICOH) was supported by the National Institutes of Health (R01 CA74415 to SLN and YCD) University of

California, Los Angeles (UCLA) was supported by funding from the Jonsson Comprehensive Cancer Center Foundation.

University of California San Francisco (UCSF): was supported by the Clinical and Translational Science Institute at the University of California, San Francisco (to MSB).

UK and Gilda Radner Familial Ovarian Cancer Registries (UKGRFOCR): UKFOCR was supported by a project grant from CRUK to PP. We would like to acknowledge the Roswell Park Alliance Foundation for their continued support of the Gilda Radner Ovarian Family Cancer Registry.

University of Pennsylvania (UPENN) was supported by Breast Cancer Research Foundation (BRCF) to KLN and Komen Foundation for the Cure to SMD.

Women's Cancer Program (WCP): was supported in part by the American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN).

Breast Cancer Family Registry (BCFR): Samples from the FCCC, HCI, and NCCC were processed and distributed by the Coriell Institute for Medical Research.

Baltic Familial Breast Ovarian Cancer Consortium (BFBOCC): A special acknowledgement for Laima Tihomirova (Latvian Biomedical Research and Study Center, Riga, Latvia) for providing samples and data for joint Lithuanian-Latvian BFBOCC study.

Spanish National Cancer Center (CNIO) and the Spanish Consortium: thanks R.M. Alonso, G. Pita, and R.M. Milne for their assistance. We also thank IBGM-CSIC, Universidad de Valladolid, and Junta de Castilla y León. CONSORZIO Studi Italiani Tumori Ereditari Alla Mammella (CONSTIT TEAM): thanks Gaia Roversi, Elisa Cattaneo, and Marco A. Pierotti of the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Monica Barile of the Istituto Europeo di Oncologia, Milan, Italy and the personnel of the Cancer Genetic Testing laboratory at the IFOM-IEO Campus, Milan, Italy. Epidemiological study of BRCA1 & BRCA2 mutation carriers (EMBRACE): Douglas F. Easton is the PI of the study. EMBRACE Collaborating Centers are: Coordinating Centre, Cambridge: Susan Peock, Debra Frost, Steve D. Ellis, Elena Fineberg, Radka Platte. North of Scotland Regional Genetics Service, Aberdeen: Zosia Miedzybrodzka, Helen Gregory. Northern Ireland Regional Genetics Service, Belfast: Patrick Morrison, Lisa Jeffers. West Midlands Regional Clinical Genetics Service, Birmingham: Trevor Cole, Kai-ren Ong, Jonathan Hoffman. South West Regional Genetics Service, Bristol: Alan Donaldson, Margaret James. East Anglian Regional Genetics Service, Cambridge: Joan Paterson, Sarah Downing, Amy Taylor. Medical Genetics Services for Wales, Cardiff: Alexandra Murray, Mark T. Rogers, Emma McCann. St James's Hospital, Dublin & National Centre for Medical Genetics, Dublin: M. John Kennedy, David Barton. South East of Scotland Regional Genetics Service, Edinburgh: Mary Porteous, Sarah Drummond. Peninsula Clinical Genetics Service, Exeter: Carole Brewer, Emma Kivuva, Anne Searle, Selina Goodman, Kathryn Hill. West of Scotland Regional Genetics Service, Glasgow: Rosemarie Davidson, Victoria Murday, Nicola Bradshaw, Lesley Snadden, Mark Longmuir, Catherine Watt, Sarah Gibson, Eshika Haque, Ed Tobias, Alexis Duncan. South East Thames Regional Genetics Service, Guy's Hospital London: Louise Izatt, Chris Jacobs, Caroline Langman, Anna Whaite. North West Thames Regional Genetics Service, Harrow: Huw Dorkins. Leicestershire Clinical Genetics Service, Leicester: Julian Barwell. Yorkshire Regional Genetics Service, Leeds: Julian Adlard, Gemma Serra-Feliu. Cheshire & Merseyside Clinical Genetics Service, Liverpool: Ian Ellis, Catherine Houghton. Manchester Regional Genetics Service, Manchester: D Gareth Evans, Fiona Laloo, Jane Taylor. North East Thames Regional Genetics Service, NE Thames, London: Lucy Side, Alison Male, Cheryl Berlin. Nottingham Centre for Medical Genetics, Nottingham: Jacqueline Eason, Rebecca Collier. Northern Clinical Genetics Service, Newcastle: Fiona Douglas, Oonagh Claber, Irene Jobson. Oxford Regional Genetics Service, Oxford: Lisa Walker, Diane McLeod, Dorothy Halliday, Sarah Durell, Barbara Stayner. The Institute of Cancer Research and Royal Marsden NHS Foundation Trust: Ros Eeles, Susan Shanley, Nazneen Rahman, Richard Houlston, Elizabeth Bancroft, Lucia D'Mello, Elizabeth Page, Audrey Arden-Jones, Kelly Kohut, Jennifer Wiggins, Elena Castro, Anita Mitra, Lisa Robertson. North Trent Clinical Genetics Service, Sheffield: Jackie Cook, Oliver Quarrell, Cathryn Bardsley. South West Thames Regional Genetics Service, London: Shirley Hodgson, Sheila Goff, Glen Brice, Lizzie Winchester, Charlotte Eddy, Vishakha Tripathi, Virginia Attard. Wessex Clinical

Genetics Service, Princess Anne Hospital, Southampton: Diana Eccles, Anneke Lucassen, Gillian Crawford, Donna McBride, Sarah Smalley.

Fox Chase Cancer Center (FCCC): thanks Ms. JoEllen Weaver and Dr. Betsy Bove for their technical support.

The German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC): thanks all the families for providing samples for this study and the German Cancer Aid for establishing the GC-HBOC and their longstanding patronage.

Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO): thanks all the GEMO collaborating groups for their contribution to this study. GEMO Collaborating Centers are: Coordinating Centers, Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Centre Hospitalier Universitaire de Lyon / Centre Léon Bérard, & Equipe « Génétique du cancer du sein », Centre de Recherche en Cancérologie de Lyon: Olga Sinilnikova, Sylvie Mazoyer, Laure Barjhoux, Carole Verny-Pierre, Sophie Giraud, Mélanie Léone; and Service de Génétique Oncologique, Institut Curie, Paris: Dominique Stoppa-Lyonnet, Marion Gauthier-Villars, Bruno Buecher, Claude Houdayer, Virginie Moncoutier, Muriel Belotti, Carole Tirapo, Antoine de Pauw. Institut Gustave Roussy, Villejuif: Brigitte Bressac-de-Paillerets, Audrey Remenieras, Véronique Byrde, Olivier Caron, Gilbert Lenoir. Centre Jean Perrin, Clermont-Ferrand: Yves-Jean Bignon, Nancy Uhrhammer. Centre Léon Bérard, Lyon: Christine Lasset, Valérie Bonadona. Centre François Baclesse, Caen: Agnès Hardouin, Pascaline Berthet. Institut Paoli Calmettes, Marseille: Hagay Sobol, Violaine Bourdon, Tetsuro Noguchi, François Eisinger. Groupe Hospitalier Pitié-Salpêtrière, Paris: Florence Coulet, Chrystelle Colas, Florent Soubrier. CHU de Arnaud-de-Villeneuve, Montpellier: Isabelle Coupier, Pascal Pujol. Centre Oscar Lambret, Lille: Jean-Philippe Peyrat, Joëlle Fournier, Françoise Révillon, Philippe Vennin, Claude Adenis. Hôpital René Huguenin/Institut Curie, St Cloud: Etienne Rouleau, Rosette Lidereau, Liliane Demange, Catherine Nogues. Centre Paul Strauss, Strasbourg: Danièle Muller, Jean-Pierre Fricker. Institut Bergonié, Bordeaux: Emmanuelle Barouk-Simonet, Françoise Bonnet, Virginie Bubié, Nicolas Sevenet, Michel Longy. Institut Claudius Regaud, Toulouse: Christine Toulas, Rosine Guimbaud, Laurence Gladieff, Viviane Feillel. CHU de Grenoble: Dominique Leroux, Hélène Dreyfus, Christine Reischung, Magalie Peysselon. CHU de Dijon: Fanny Coron, Laurence Faivre. CHU de St-Etienne: Fabienne Prieur, Marine Lebrun, Caroline Kientz. Hôtel Dieu Centre Hospitalier, Chambéry: Sandra Fert Ferrer. Centre Antoine Lacassagne, Nice: Marc Frénay. CHU de Limoges: Laurence Vénat-Bouvet. CHU de Nantes: Capucine Delnatte. CHU Bretonneau, Tours: Isabelle Mortemousque. Creighton University, Omaha, USA: Henry T. Lynch, Carrie L. Snyder.

Gynecologic Oncology Group (GOG): We thank the investigators of the Australia New Zealand Gynaecological Oncology Group (ANZGOG).

Helsinki Breast Cancer Study (HEBCS): thanks Dr. Carl Blomqvist, Tuomas Heikkinen, and Taru Muranen for their help with the patient data and samples.

The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON): HEBON Collaborating Centers: Coordinating center: Netherlands Cancer Institute, Amsterdam, NL: F.B.L. Hogervorst, S. Verhoef, M. Verheus, L.J. van 't Veer, F.E. van Leeuwen, M.A. Rookus; Erasmus Medical Center, Rotterdam, NL: M. Collée, A.M.W. van den Ouweland, A. Jager, M.J. Hoening, M.M.A. Tilanus-Linthorst, C. Seynaeve; Leiden University Medical Center, NL, Leiden: C.J. van Asperen, J.T. Wijnen, M.P. Vreeswijk, R.A. Tollenaar, P. Devilee; Radboud University Nijmegen Medical Center, Nijmegen, NL: M.J. Ligtenberg, N. Hoogerbrugge; University Medical Center Utrecht, Utrecht, NL: M.G. Ausems, R.B. van der Luijt; Amsterdam Medical Center, NL: C.M. Aalfs, T.A. van Os; VU University Medical Center, Amsterdam, NL: J.J.P. Gille, Q. Waisfisz, H.E.J. Meijers-Heijboer; University Hospital Maastricht, Maastricht, NL: E.B. Gomez-Garcia, C.E. van Roozendaal, Marinus J. Blok, B. Caanen; University Medical Center Groningen University, NL: J.C. Oosterwijk, A.H. van der Hout, M.J. Mourits; The Netherlands Foundation for the detection of hereditary tumours, Leiden, NL: H.F. Vasen.

The Hong Kong Hereditary Breast Cancer Family Registry (HRBCP) wish to thank the Hong Kong Sanatorium and Hospital Molecular Pathology Laboratory staff for their technical support and the nurses, research assistants, doctors, and genetic counselors who have assisted in patient recruitment.

Interdisciplinary Health Research International Team Breast Cancer Susceptibility (INHERIT BRCA): We would like to thank Stéphane Dubois, Dr Martine Dumont, Martine Tranchant (Cancer Genomics Laboratory, CRCHUQ) for sample management and skillful technical assistance, Sylvie Desjardins and Marc-André Rodrigue (Plateforme de séquençage et de génotypage des génome du CRCHUL/CHUQ) for iPLEX genotyping and Pascal Belleau for data quality control analyses.

Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer (KCONFAB): thanks Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (funded 2001–2009 by NHMRC and currently by the National Breast Cancer Foundation and Cancer Australia #628333) for their contributions to this resource, and the many families who contribute to kConFab.

Memorial Sloan-Kettering Cancer Center (MSKCC): On behalf of the MSKCC study, we acknowledge the Starr Cancer Consortium, the Breast Cancer Research Foundation, the Norman and Carol Stone Cancer Research Initiative, the Kate and Robert Niehaus Clinical Cancer Research Initiative, the Lymphoma Foundation, and the Sabin Family Research Initiative.

Ontario Cancer Genetics Network (OCGN): thanks Mona Gill, Lucine Collins, Nalan Gokgoz, Teresa Selander, Nayana Weerasooriya, and members of the Ontario Cancer Genetics Network for their contributions to the study. The Ohio State University Clinical Cancer Genetics (OSUCCG): thanks the Human Cancer Genetics Sample bank for sample preparation and Leigha Senter and Kevin Sweet for ascertainment of study participants and collection of phenotype data.

Swedish Breast Cancer Study (SWE-BRCA): SWE-BRCA collaborators: Per Karlsson, Margareta Nordling, Annika Bergman, and Zakaria Einbeigi, Gothenburg, Sahlgrenska University Hospital; Marie Stenmark-Askmal and Sigrun Liedgren, Linköping University Hospital; Åke Borg, Niklas Loman, Håkan Olsson, Maria Soller, Helena Jernström, Katja Harbst and Karin Henriksson, Lund University Hospital; Annika Lindblom, Brita Arver, Anna von Wachenfeldt, Annelie Liljegren, Gisela Barbany-Bustanza and Johanna Rantala, Stockholm, Karolinska University Hospital; Beatrice Melin, Henrik Grönberg, Eva-Lena Stattin and Monica Emanuelsson, Umeå University Hospital; Hans Ehrencrona, Richard Rosenquist, and Niklas Dahl, Uppsala University Hospital.

Beckman Research Institute of City of Hope was supported by the National Institutes of Health (R01 CA74415 to SLN)) and the Morris and Horowitz Families Endowment.

University of California, Los Angeles (UCLA): thanks Ms. Joyce Seldon for her genetic counselling services, and Ms. Lorna Kwan for database management.

University of California San Francisco (UCSF): thanks Ms. Salina Chan for her database support and management and to Ms. Beth Crawford for her genetic counseling services.

UK and Gilda Radner Familial Ovarian Cancer Registries (UKGRFOCR): UKFOCR thanks Carole Pye, Patricia Harrington and Eva Wozniak for family recruitment and technical support. GRFOCR would like to acknowledge Lara Sucheston (Department of Cancer Prevention and Control) and Kunle Odunsi (Departments Gynecologic Oncology and Immunology).

ACA is a CR-UK Senior Cancer Research Fellow, DFE is CR-UK Principal Research Fellow, GCT is a NHMRC Senior Principal Research Fellow and. JS is Chairholder of the Canada Research Chair in Oncogenetics.

References

Ahmed S, Thomas G, Ghoussaini M, Healey CS, Humphreys MK, Platte R, Morrison J, Maranian M, Pooley KA, Luben R, Eccles D, Evans DG, and many others. 2009. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. *Nat Genet* 41:585–590.

Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, and many others. 2003. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet* 72:1117–1130.

Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C, Ganz PA, and many others. 2010b. Common breast cancer susceptibility alleles and the risk of breast cancer

for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Res* 70:9742–9754.

Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, and many others. 2008b. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. *Brit J Cancer* 98:1457–1466.

Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, Lee A, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, and many others. 2011. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Hum Mol Genet* 20:3304–3321. Advanced access published on 18 May 2011.

Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H, Heikkinen T, Simard J, Spurdle AB, Beesley J, Chen X; Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer, Neuhausen SL, Ding YC, and many others. 2009. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Hum Mol Genet* 18:4442–4456.

Antoniou AC, Sinilnikova OM, Simard J, Léoné M, Dumont M, Neuhausen SL, Struwing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, and many others. 2007. RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. *Am J Hum Genet* 81:1186–1200.

Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Hofmann W, Sutter C, and many others. 2008a. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Am J Hum Genet* 82:937–948.

Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T, Ghoussaini M, Barrowdale D; EMBRACE, and many others. 2010a. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nat Genet* 42:885–892.

Barnes DR, Lee A, EMBRACE Investigators, kConFab Investigators, Easton DF, Antoniou AC. Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations. *Genet Epidemiol* In press.

Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF, Anton-Culver H, Capanu M, Liang X, Hummer AJ, Sima C, Bernstein JL. 2008. Variation of breast cancer risk among BRCA1/2 carriers. *JAMA* 299:194–201.

Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, and many others. 2010. Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nat Genet* 42:880–884.

Boos D.D. 1992. On generalised score tests. *Am Stat* 46:327–333.

Buzzai M, Licht JD. 2008. New molecular concepts and targets in acute myeloid leukemia. *Curr Opin Hematol* 15:82–87.

Chen S, Iversen ES, Friebe T, Finkelstein D, Weber BL, Eisen A, Peterson LE, Schildkraut JM, Isaacs C, Peshkin BN, Corio C, Leondaridis L, Tomlinson G, Dutson D, Kerber R, Amos CI, Strong LC, Berry DA, Euhus DM, Parmigiani G. 2006. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. *J Clin Oncol* 24:863–871.

Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE; CIMBA. 2007. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). *Breast Cancer Res* 9:104 (doi:10.1186/bcr1670).

Couch FJ, Gaudet MM, Antoniou AA, Ramus SJ, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, Wang X, Kirchhoff T, McGuffog L, Barrowdale D, and many others. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers *Cancer Epi Bio Prevent* (In Press).

Easton DF, Eccles RA. 2008. Genome-wide association studies in cancer. *Hum Mol Genet* 17:R109–R115.

Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struwing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, and many others. 2007. Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature* 447:1087–1093.

Fang L, Seki A, Fang G. 2009. SKAP associates with kinetochores and promotes the metaphase-to-anaphase transition. *Cell Cycle* 8:2819–2827.

Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. 2009. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med* 361:123–134.

Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struwing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, and the Breast Cancer Linkage Consortium. 1998. Genetic heterogeneity and penetrance analysis of the BRCA1 and

- BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. *Am J Hum Genet* 62:676–689.
- Gold B, Kirchhoff T, Stefanov S, Lautenberger J, Viale A, Garber J, Friedman E, Narod S, Olshen AB, Gregersen P, Kosarin K, Olsh A, Bergeron J, Ellis NA, Klein RJ, Clark AG, Norton L, Dean M, Boyd J, Offit K. 2008. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. *Proc Natl Acad Sci USA* 105:4340–4345.
- Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, and many others. 2010. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. *Nat Genet* 42:874–879.
- Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, Kallinger SE, Carlson JW, Ginzinger DG, Celniker SE, Mills GB, Huntsman DG, Gray JW. 2007. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. *Clin Cancer Res* 13:5745–5755.
- Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, Easton DF, Venter DJ. 1999. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. *Cancer Epidemiol Biomarkers Prev* 8:741–747.
- Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, and many others. 2007. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. *Nat Genet* 39:870–874.
- Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, Reich D, Yan C, Khalid O, Kantoff P, Oh W, Manak JR, Berman BP, Henderson BE, Frenkel B, Haiman CA, Freedman M, Tanay A, Coetzee GA. 2009. Functional enhancers at the gene-poor 8q24 cancer-linked locus. *PLoS Genet* 5:e1000597. Epub 2009 Aug 14.
- Kosco KA, Cerignoli F, Williams S, Abraham RT, Mustelin T. 2008. SKAP55 modulates T cell antigen receptor-induced activation of the Ras-Erk-AP1 pathway by binding RasGRP1. *Mol Immunol* 45:510–522.
- Lange K, Weeks D, Boehnke M. 1988. Programs for Pedigree Analysis: MENDEL, FISHER, and dGENE. *Genet Epidemiol* 5:471–472.
- McCarthy MI, Hirschhorn JN. 2008. Genome-wide association studies: past, present and future. *Hum Mol Genet* 17:R100–R101.
- Meyer KB, Maia AT, O'Reilly M, Ghousaini M, Prathalingam R, Porter-Gill P, Amb S, Prokunina-Olsson L, Carroll J, Ponder BA. A Functional Variant at a Prostate Cancer Predisposition Locus at 8q24 Is Associated with PVT1 Expression. *PLoS Genet* 2011 7:e1002165. doi: 10.1371/journal.pgen.1002165. Epub 2011 Jul 21.
- Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, and many others. 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 266:66–71.
- Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Díez O, Alonso MC, Lazaro C, Blanco I, Sánchez-de-Abaio A, Caldés T, and many others. 2008. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. *Clin Cancer Res* 14:2861–2869.
- Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, Verzi MP, Doddapaneni H, Beckwith CA, Chan JA, Hills A, Davis M, Yao K, Kehoe SM, Lenz HJ, Haiman CA, Yan C, Henderson BE, Frenkel B, Barretina J, Bass A, Tabernero J, Baselga J, Regan MM, Manak JR, Shivdasani R, Coetzee GA, Freedman ML. 2009. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. *Nat Genet* 41:882–884.
- Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PD, Sinilnikova OM, Beesley J, Chen X, McGuffog L, Healey S, Couch FJ, Wang X, Fredericksen Z, and many others. 2011. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 103:105–116.
- Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, Nativ N, Bahir I, Doniger T, Krug H, Sirotta-Madi A, Olender T, Golan Y, Stelzer G, Harel A, Lancet D. 2010. GeneCards Version 3: the human gene integrator database 2010; doi: 10.1093/database/baq020 Database (Oxford). 2010 Aug 5;2010:baq020. Print 2010.
- Shiraishi M, Sekiguchi A, Oates AJ, Terry MJ, Miyamoto Y. 2002. HOX gene clusters are hotspots of de novo methylation in CpG islands of human lung adenocarcinomas. *Oncogene* 21:3659–3662.
- Simchoni S, Friedman E, Kaufman B, Gershoni-Baruch R, Orr-Urtreger A, Kedarn-Barnes I, Shiri-Sverdlov R, Dagan E, Tsabari S, Shohat M, Catane R, King MC, Lahad A, Levy-Lahad E. 2006. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. *Proc Natl Acad Sci USA* 103:3770–3774.
- Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, Dörk T, Goode EL, and many others. 2009. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. *Nat Genet* 41:996–1000.
- Struwing JP, Hartge P, Wacholder S. 1997. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. *N Engl J Med* 336:1401–1408.
- Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, Hankinson SE, Hutchinson A, Wang Z, Yu K, Chatterjee N, Garcia-Closas M, and many others. 2009. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). *Nat Genet* 41:579–584.
- Thompson D, Easton D, Breast Cancer Linkage Consortium. 2002. Variation in BRCA1 cancer risks by mutation position. *Cancer Epidemiol Biomarkers Prev* 11:329–336.
- Thompson D, Easton D, the BCLC. 2001. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. *Am J Hum Genet* 68:410–419.
- Wacholder S, Han SS, Weinberg CR. 2011. Inference from a multiplicative model of joint genetic effects on ovarian cancer risk. *J Natl Cancer Inst* 103:82–83.
- Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. 1995. Identification of the breast cancer susceptibility gene BRCA2. *Nature* 378:789–792.

Research Article

Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in *BRCA1* and *BRCA2* Mutation Carriers

Fergus J. Couch¹, Mia M. Gaudet⁴, Antonis C. Antoniou⁵, Susan J. Ramus⁸, Karoline B. Kuchenbaecker⁵, Penny Soucy¹¹, Jonathan Beesley¹⁴, Xiaoqing Chen¹⁴, Xianshu Wang¹, Tomas Kirchhoff¹⁵, Lesley McGuffog⁵, Daniel Barrowdale⁵, Andrew Lee⁵, Sue Healey¹⁴, Olga M. Sinilnikova^{17,18}, Irene L. Andrulis^{20,21,22,23} for OCGN; Hilmi Ozcelik^{21,22}, Anna Marie Mulligan^{21,22,24}, Mads Thomassen²⁵, Anne-Marie Gerdes²⁶, Uffe Birk Jensen²⁷, Anne-Bine Skytte²⁸, Torben A. Kruse²⁵, Maria A. Caligo²⁹, Anna von Wachenfeldt³⁰, Gisela Barbany-Bustinza³¹, Niklas Loman³², Maria Soller³³, Hans Ehrencrona³⁴, Per Karlsson³⁵ for SWE-BRCA; Katherine L. Nathanson³⁶, Timothy R. Rebbeck³⁷, Susan M. Domchek³⁶, Ania Jakubowska⁴⁰, Jan Lubinski⁴⁰, Katarzyna Jaworska^{40,41}, Katarzyna Durda⁴⁰, Elzbieta Złowocka⁴⁰, Tomasz Huzarski⁴⁰, Tomasz Byrski⁴⁰, Jacek Gronwald⁴⁰, Cezary Cybulski⁴⁰, Bohdan Górski⁴⁰, Ana Osorio⁴², Mercedes Durán⁴⁵, María Isabel Tejada⁴⁶, Javier Benitez^{42,43}, Ute Hamann⁴⁷; Frans B.L. Hogervorst⁴⁹ for HEBON; Theo A. van Os⁵¹, Flora E. van Leeuwen⁵⁰, Hanne E.J. Meijers-Heijboer⁵², Juul Wijnen⁵³, Marinus J. Blok⁵⁴, Marleen Kets⁵⁵, Maartje J. Hoening⁵⁶, Rogier A. Oldenburg⁵⁷, Margreet G.E.M. Ausems⁵⁸, Susan Peock⁵, Debra Frost⁵, Steve D. Ellis⁵, Radka Platte⁵, Elena Fineberg⁵, D. Gareth Evans⁵⁹, Chris Jacobs⁶⁰, Rosalind A. Eeles⁶³, Julian Adlard⁶⁴, Rosemarie Davidson⁶⁵, Diana M. Eccles⁶⁶, Trevor Cole⁶⁷, Jackie Cook⁶⁸, Joan Paterson⁷, Carole Brewer⁶⁹, Fiona Douglas⁷⁰, Shirley V. Hodgson⁶¹, Patrick J. Morrison⁷¹, Lisa Walker⁷², Mary E. Porteous⁷³, M. John Kennedy⁷⁴, Lucy E. Side⁶² for EMBRACE; Betsy Bove³⁸, Andrew K. Godwin⁷⁵, Dominique Stoppa-Lyonnet^{19,76,77,78} for GEMO Study Collaborators, Marion Fassy-Colcombet⁷⁸, Laurent Castera⁷⁸, François Cornelis^{79,80,81}, Sylvie Mazoyer¹⁸, Mélanie Léoné¹⁷, Nadia Boutry-Kryza¹⁷, Brigitte Bressac-de Paillerets⁸², Olivier Caron⁸³, Pascal Pujol⁸⁴, Isabelle Coupier⁸⁴, Capucine Delnatte⁸⁵, Linda Akloul⁸⁵, Henry T. Lynch⁸⁶, Carrie L. Snyder⁸⁶, Sandra S. Buys⁸⁷, Mary B. Daly³⁹, MaryBeth Terry¹⁶, Wendy K. Chung¹⁶, Esther M. John⁸⁹, Alexander Miron⁹⁰, Melissa C. Southey⁹¹, John L. Hopper⁹², David E. Goldgar⁸⁸, Christian F. Singer⁹⁴, Christine Rappaport⁹⁴, Muy-Kheng M. Tea⁹⁴, Anneliese Fink-Retter⁹⁴, Thomas V.O. Hansen⁹⁵, Finn C. Nielsen⁹⁵, Aðalgeir Arason^{96,97}, Joseph Vijai¹⁵, Sohela Shah¹⁵, Kara Sarrel¹⁵, Mark E. Robson¹⁵, Marion Piedmonte⁹⁸, Kelly Phillips⁹³, Jack Basil¹⁰⁰, Wendy S. Rubinstein^{101,102}, John Boggess¹⁰³, Katie Wakeley¹⁰⁴, Amanda Ewart-Toland¹⁰⁵, Marco Montagna¹⁰⁶, Simona Agata¹⁰⁶, Evgeny N. Imyanitov¹⁰⁷, Claudine Isaacs¹⁰⁸, Ramunas Janavicius¹⁰⁹, Conxi Lazaro¹¹⁰, Ignacio Blanco¹¹¹, Lidia Feliubadalo¹¹⁰, Joan Brunet¹¹¹, Simon A. Gayther⁸, Paul P.D. Pharoah⁶, Kunle O. Odunsi⁹⁹, Beth Y. Karlan⁹, Christine S. Walsh⁹, Edith Olah¹¹³, Soo Hwang Teo¹¹⁴, Patricia A. Ganz¹⁰, Mary S. Beattie¹¹⁵, Elizabeth J. van Rensburg¹¹⁶, Cecelia M. Dorfling¹¹⁶, Orland Diez¹¹², Ava Kwong¹¹⁷, Rita K. Schmutzler¹¹⁸, Barbara Wappenschmidt¹¹⁸, Christoph Engel¹¹⁹, Alfons Meindl¹²¹, Nina Ditsch¹²², Norbert Arnold¹²³, Simone Heidemann¹²⁴, Dieter Niederacher¹²⁵, Sabine Preisler-Adams¹²⁶, Dorothea Gadzicki¹²⁷, Raymonda Varon-Mateeva¹²⁸, Helmut Deissler¹²⁹, Andrea Gehrig¹³⁰, Christian Sutter⁴⁸, Karin Kast¹³¹, Britta Fiebig¹³², Wolfram Heinritz¹²⁰, Trinidad Caldes⁴⁴, Miguel de la Hoya⁴⁴, Taru A. Murañen¹³³, Heli Nevanlinna¹³³, Marc D. Tischkowitz^{12,13}, Amanda B. Spurdle¹⁴, Susan L. Neuhausen¹³⁴, Yuan Chun Ding¹³⁴, Noralane M. Lindor², Zachary Fredericksen³, V. Shane Pankratz³, Paolo Peterlongo¹³⁵, Siranoush Manoukian¹³⁶, Bernard Peissel¹³⁶, Daniela Zaffaroni¹³⁶, Monica Barile¹³⁷, Loris Bernard¹³⁸, Alessandra Viel¹³⁹, Giuseppe Giannini¹⁴⁰, Liliana Varesco¹⁴¹, Paolo Radice¹³⁵, Mark H. Greene¹⁴², Phuong L. Mai¹⁴², Douglas F. Easton⁵, Georgia Chenevix-Trench¹⁴ for kConFab investigators; Kenneth Offit¹⁵, and Jacques Simard¹¹ on behalf of the Consortium of Investigators of Modifiers of BRCA1/2

Authors' Affiliations: Departments of ¹Laboratory Medicine and Pathology, ²Medical Genetics, and ³Health Sciences Research, Mayo Clinic, Rochester, Minnesota; ⁴Epidemiology Research Program, American Cancer Society, Atlanta, Georgia; ⁵Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, ⁶Department of Oncology, University of Cambridge; ⁷Department of Clinical Genetics, East Anglian Regional Genetics Service, Addenbrookes Hospital, Cambridge, United Kingdom; ⁸Department of Preventive Medicine, Keck School of Medicine, University of Southern California; ⁹Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center; ¹⁰Department of Health Services, UCLA School of Public Health, Los Angeles, California; ¹¹Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Québec City, Québec; ¹²Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill University; ¹³Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada; ¹⁴Department of Genetics, Queensland Institute of Medical Research, Herston, Queensland, Australia; ¹⁵Clinical Cancer Genetics Laboratory, Memorial Sloan Kettering Cancer Center; ¹⁶Department of Epidemiology, Columbia University, New York; ¹⁷Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Centre Hospitalier Universitaire de Lyon/Centre Léon Bérard; ¹⁸INSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon; ¹⁹GEMO Study Collaborators: Cancer Genetics Network "Groupe Génétique et Cancer", Fédération Nationale des Centres de Lutte Contre le Cancer, Lyon, France; Departments of ²⁰Molecular Genetics and ²¹Laboratory Medicine and Pathobiology, ²²Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Cancer Care Ontario, University of Toronto, ²³Ontario Cancer Genetics Network: Cancer Care Ontario; ²⁴Department of Laboratory Medicine, and the Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada; ²⁵Department of Clinical Genetics, Odense University Hospital, Odense; ²⁶Department of Clinical Genetics, Rigshospitalet, København; ²⁷Department of Clinical Genetics, Skejby Hospital, Århus; ²⁸Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark; ²⁹Section of Genetic Oncology, University Hospital

of Pisa, Pisa, Italy; Departments of ³⁰Oncology and ³¹Clinical Genetics, Karolinska University Hospital, Stockholm; Departments of ³²Oncology and ³³Clinical Genetics, Lund University Hospital, Lund; ³⁴Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala; ³⁵Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden; Departments of ³⁶Medicine and ³⁷Biostatistics and Epidemiology, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania; ³⁸Clinical Molecular Genetics Laboratory, ³⁹Fox Chase Cancer Center, Philadelphia, Pennsylvania; ⁴⁰Department of Genetics and Pathology, Pomeranian Medical University, Szczecin; ⁴¹Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, Poland; ⁴²Human Genetics Group, ⁴³Genotyping Unit, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, and Spanish Network on Rare Diseases (CIBERER); ⁴⁴Molecular Oncology Laboratory, Hospital Clinico San Carlos, Madrid; ⁴⁵Institute of Biology and Molecular Genetics, Universidad de Valladolid (IBGM-UVA), Valladolid; ⁴⁶Molecular Genetics Laboratory (Department of Biochemistry), Cruces Hospital Barakaldo, Bizkaia, Spain; ⁴⁷Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ); ⁴⁸Institute of Human Genetics, Division of Molecular Genetics, University Heidelberg, Germany; ⁴⁹Family Cancer Clinic, ⁵⁰Department of Epidemiology, Head, Division of Psychosocial Research & Epidemiology, Netherlands Cancer Institute; ⁵¹Department of Clinical Genetics, Academic Medical Center; ⁵²Department of Clinical Genetics, VU Medical Center, Amsterdam; ⁵³Department of Human Genetics & Department of Clinical Genetics, Leiden University Medical Center, Leiden; ⁵⁴Department of Genetics and Cell Biology, University Medical Center, Maastricht; ⁵⁵Hereditary Cancer Clinic, Radboud University Nijmegen Medical Center, Nijmegen; Departments of ⁵⁶Medical Oncology and ⁵⁷Clinical Genetics, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam; ⁵⁸Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands; ⁵⁹Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester; ⁶⁰Clinical Genetics, Guy's and St. Thomas' NHS Foundation Trust; ⁶¹Medical Genetics Unit, St George's, University of London; ⁶²North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Trust; ⁶³Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London; ⁶⁴Yorkshire Regional Genetics Service, Leeds; ⁶⁵Ferguson-Smith Centre for Clinical Genetics, Yorkhill Hospitals, Glasgow; ⁶⁶University of Southampton Faculty of Medicine, Southampton University Hospitals NHS Trust, Southampton; ⁶⁷West Midlands Regional Genetics Service, Birmingham Women's Hospital Healthcare NHS Trust, Edgbaston, Birmingham; ⁶⁸Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield; ⁶⁹Department of Clinical Genetics, Royal Devon & Exeter Hospital, Exeter; ⁷⁰Institute of Genetic Medicine, Centre for Life, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne; ⁷¹Northern Ireland Regional Genetics Centre, Belfast Health and Social Care Trust, and Department of Medical Genetics, Queens University Belfast, Belfast; ⁷²Oxford Regional Genetics Service, Churchill Hospital, Oxford; ⁷³South East of Scotland Regional Genetics Service, Western General Hospital, Edinburgh, United Kingdom; ⁷⁴Academic Unit of Clinical and Molecular Oncology, Trinity College Dublin and St James's Hospital, Dublin, Ireland; ⁷⁵Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City; ⁷⁶Service de Génétique Oncologique, ⁷⁷Unité INSERM U830, Institut Curie; ⁷⁸Université Paris Descartes, Faculté de Médecine; ⁷⁹Genetic Unit, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, Paris; ⁸⁰Sud-Francilien Hospital, Evry-Corbeil; ⁸¹University Hospital, Clermont-Ferrand; ⁸²Genetics Department, ⁸³Consultation de Génétique, Département de Médecine, Institut de Cancérologie Gustave Roussy, Villejuif; ⁸⁴Unité d'Oncogénétique, CHU Arnaud de Villeneuve, Montpellier; ⁸⁵Service Oncologie Médicale, Centre René Gauducheau, Nantes, France; ⁸⁶Department of Preventive Medicine, Creighton University, Omaha, Nebraska; ⁸⁷Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah; ⁸⁸Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah; ⁸⁹Department of Epidemiology, Cancer Prevention Institute of California, Fremont, California; ⁹⁰Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts; ⁹¹Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne; ⁹²Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, ⁹³Division of Cancer Medicine, Peter MacCallum Cancer Centre; and Department of Medicine, St Vincent's Hospital, The University of Melbourne, Melbourne, Victoria, Australia; ⁹⁴Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; ⁹⁵Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; ⁹⁶Department of Pathology, Landspítali University Hospital; ⁹⁷Faculty of Medicine, University of Iceland, Reykjavik, Iceland; ⁹⁸Gynecologic Oncology Group Statistical and Data Center, ⁹⁹Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York; ¹⁰⁰Good Samaritan Hospital, Department of Obstetrics and Gynecology, GOG affiliate, Cincinnati, Ohio; ¹⁰¹Center for Medical Genetics, NorthShore University Health System, Evanston; ¹⁰²Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, Illinois; ¹⁰³University of North Carolina, Chapel Hill, North Carolina; ¹⁰⁴Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital, South Weymouth, Massachusetts; ¹⁰⁵Departments of Molecular Virology, Immunology & Medical Genetics and Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio; ¹⁰⁶Istituto Oncologico Veneto IOV - IRCCS, Immunology and Molecular Oncology Unit, Padua, Italy; ¹⁰⁷Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, St.-Petersburg, Russia; ¹⁰⁸Fisher Center for Familial Cancer Research, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia; ¹⁰⁹Department of Molecular and Regenerative Medicine, Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania; ¹¹⁰Molecular Diagnostic Unit, ¹¹¹Genetic Counseling Unit, Hereditary Cancer Program, IDIBELL-Catalan Institute of Oncology; ¹¹²Molecular Medicine and Genetics Program, Vall d'Hebron University Hospital, Oncogenetics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; ¹¹³Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary; ¹¹⁴Breast Cancer Research Unit, University Malaya Cancer Research Institute, University Malaya; and Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Subang Jaya, Malaysia; ¹¹⁵Department of Medicine, Epidemiology and Biostatistics, University of California, San Francisco, California; ¹¹⁶Cancer Genetics Laboratory, Department of Genetics, University of Pretoria, Pretoria, South Africa; ¹¹⁷Hong Kong Hereditary Breast Cancer Family Registry and Cancer Genetics Center, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong; ¹¹⁸Centre of Familial Breast and Ovarian Cancer, Department of Gynaecology and Obstetrics and Centre for Integrated Oncology (CIO), University Hospital of Cologne, Cologne; ¹¹⁹Institute for Medical Informatics, Statistics and Epidemiology, ¹²⁰Institute of Human Genetics, University Leipzig, Leipzig; ¹²¹Department of Gynaecology and Obstetrics, Division of Tumor Genetics, Klinikum rechts der Isar, Technical University Munich; ¹²²Department of Gynaecology and Obstetrics, Ludwig-Maximilians University Munich, Munich; ¹²³Department of Gynaecology and Obstetrics, ¹²⁴Institute of Human Genetics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel; ¹²⁵Department of Gynaecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine University, Düsseldorf; ¹²⁶Institute of Human Genetics, University of Münster, Münster; ¹²⁷Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover; ¹²⁸Institute of Human Genetics, Campus Virchow Klinikum, Berlin; ¹²⁹Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm; ¹³⁰Centre of Familial Breast and Ovarian Cancer, Department of Medical Genetics, Institute of Human Genetics, University Würzburg, Würzburg; ¹³¹Department of Gynaecology and Obstetrics, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden; ¹³²Institute of Human Genetics, University Regensburg, Regensburg, Germany; ¹³³Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Biomedicum Helsinki, Helsinki, Finland; ¹³⁴Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California; ¹³⁵Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predicted Medicine, and IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, ¹³⁶Unit of Medical Genetics, Department of Preventive and Predicted Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT); ¹³⁷Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia (IEO); ¹³⁸Department of Experimental Oncology, Istituto Europeo di Oncologia, and Consortium for Genomics Technology (Cogentech), Milan; ¹³⁹Unit of Experimental Oncology 1, Centro di Riferimento Oncologico, IRCCS, Aviano (PN); ¹⁴⁰Department of Experimental Medicine, University La Sapienza, Rome; ¹⁴¹Unit of Hereditary Cancer, Department of Epidemiology, Prevention and Special Functions, Istituto Nazionale per la Ricerca sul Cancro (IST), Genoa, Italy; and ¹⁴²Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland

Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (<http://cebp.aacrjournals.org>).

F.J. Couch and M.M. Gaudet contributed equally as primary authors.

K. Offit and J. Simard contributed equally as senior authors.

T.R. Rebbeck is the Editor-in-Chief of *Cancer Epidemiology, Biomarkers & Prevention*.

Corresponding Author: Fergus J. Couch, Mayo Clinic, Stabile 2-42, 200 First Street SW, Rochester, MN 55905. Phone: 507-284-3623; Fax: 507-538-1937; E-mail: couch.fergus@mayo.edu

doi: 10.1158/1055-9965.EPI-11-0888

©2012 American Association for Cancer Research.

Abstract

Background: Genome-wide association studies (GWAS) identified variants at 19p13.1 and ZNF365 (10q21.2) as risk factors for breast cancer among *BRCA1* and *BRCA2* mutation carriers, respectively. We explored associations with ovarian cancer and with breast cancer by tumor histopathology for these variants in mutation carriers from the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA).

Methods: Genotyping data for 12,599 *BRCA1* and 7,132 *BRCA2* mutation carriers from 40 studies were combined.

Results: We confirmed associations between rs8170 at 19p13.1 and breast cancer risk for *BRCA1* mutation carriers [HR, 1.17; 95% confidence interval (CI), 1.07–1.27; $P = 7.42 \times 10^{-4}$] and between rs16917302 at ZNF365 (HR, 0.84; 95% CI, 0.73–0.97; $P = 0.017$) but not rs311499 at 20q13.3 (HR, 1.11; 95% CI, 0.94–1.31; $P = 0.22$) and breast cancer risk for *BRCA2* mutation carriers. Analyses based on tumor histopathology showed that 19p13 variants were predominantly associated with estrogen receptor (ER)-negative breast cancer for both *BRCA1* and *BRCA2* mutation carriers, whereas rs16917302 at ZNF365 was mainly associated with ER-positive breast cancer for both *BRCA1* and *BRCA2* mutation carriers. We also found for the first time that rs67397200 at 19p13.1 was associated with an increased risk of ovarian cancer for *BRCA1* (HR, 1.16; 95% CI, 1.05–1.29; $P = 3.8 \times 10^{-4}$) and *BRCA2* mutation carriers (HR, 1.30; 95% CI, 1.10–1.52; $P = 1.8 \times 10^{-3}$).

Conclusions: 19p13.1 and ZNF365 are susceptibility loci for ovarian cancer and ER subtypes of breast cancer among *BRCA1* and *BRCA2* mutation carriers.

Impact: These findings can lead to an improved understanding of tumor development and may prove useful for breast and ovarian cancer risk prediction for *BRCA1* and *BRCA2* mutation carriers. *Cancer Epidemiol Biomarkers Prev*; 21(4); 645–57. ©2012 AACR.

Introduction

Genome-wide association studies (GWAS) have been used to identify several loci containing common variants that are associated ($P < 1.0 \times 10^{-7}$) with breast cancer risk in the general population. Variants from 12 of these loci have also been investigated as modifiers of cancer risk in *BRCA1* and *BRCA2* mutation carriers (1–3). While only variants in *CASP8*, *TOX3*, 2q35, and 6q25.1 have been associated with breast cancer risk in *BRCA1* mutation carriers, variants in *FGFR2*, *TNRC9/TOX3*, *MAP3K1*, *LSP1*, 2q35, *SLC4A7/NEK10*, 5p12, and 1p11.2 loci have been associated with breast cancer in *BRCA2* mutation carriers (1–3). This is consistent with the known associations between these single-nucleotide polymorphisms (SNP) and estrogen receptor (ER) status of breast cancers in the general population (4).

Most recently, a GWAS of *BRCA1* mutation carriers conducted through CIMBA identified 5 SNPs on 19p13 that were associated with breast cancer risk for *BRCA1* mutation carriers (5). Two of these showed independent associations: rs8170 [HR, 1.26; 95% confidence interval (CI), 1.17–1.35; $P_{\text{trend}} = 2.3 \times 10^{-9}$] and rs2363956 (HR, 0.84; 95% CI, 0.80–0.89; $P_{\text{trend}} = 5.5 \times 10^{-9}$). Imputation analysis of the 19p13 region, using 1000 Genomes Project data, identified several correlated SNPs with more significant associations than rs8170 and rs2363956. The 19p13.1 locus was also found to be associated with ER-negative breast cancer (rs8170: OR, 1.21; $P = 0.003$) and triple-negative breast cancer [tumors lacking expression of ER, progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2); rs8170: OR, 1.28; $P =$

1.2×10^{-6}] in the general population (5). In addition, the 19p13.1 locus has been associated with ovarian cancer in the general population (rs8170: OR, 1.12; $P = 3.6 \times 10^{-6}$; ref. 6) but was not found to be associated with ovarian cancer in *BRCA1* mutation carriers (rs8170: HR, 1.07; $P = 0.33$; ref. 5). A separate GWAS in *BRCA2* mutation carriers identified 2 breast cancer susceptibility alleles [rs16917302 at ZNF365 (10q21.2): HR, 0.75; 95% CI, 0.66–0.86; $P = 3.8 \times 10^{-5}$; and rs311499 at 20q13.3: HR, 0.72; 95% CI, 0.61–0.85; $P = 6.6 \times 10^{-5}$; ref. 7]. A weakly correlated SNP at the ZNF365 locus (rs10995190) has also been associated with breast cancer overall (OR, 0.83; $P = 5.1 \times 10^{-15}$) and ER-positive ($P = 4.1 \times 10^{-6}$) but not ER-negative breast cancer in the general population (8).

Here, we genotyped more than 12,000 *BRCA1* and 7,000 *BRCA2* mutation carriers from the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA), for the previously genotyped variant at 19p13.1, rs8170, and one of the imputed SNPs that was found to have a stronger association with breast cancer risk for *BRCA1* mutation carriers (rs67397200). We also genotyped SNPs at ZNF365 (rs16917302) and 20q13.3 (rs311499) in an effort to verify these loci as risk factors for ovarian cancer and to further validate these loci as risk factors for breast cancer in *BRCA1* and *BRCA2* mutation carriers.

Materials and Methods

Subjects

All mutation carriers participated in clinical or research studies at the host institutions under ethically approved protocols and provided written informed consent.

Subjects were *BRCA1* and *BRCA2* mutation carriers recruited by 40 study centers in 22 countries and assembled through the CIMBA initiative (Supplementary Table S1). The majority were recruited through cancer genetics clinics and enrolled into national or regional studies. Others were identified in research studies of high-risk families, by population-based sampling of cases and some by community recruitment. Eligibility to participate in CIMBA is restricted to female carriers of pathogenic *BRCA1* or *BRCA2* mutations, defined by generally recognized criteria (Breast Cancer Information Core), who were 18 years old or older at recruitment. Information collected included the year of birth; mutation description (including nucleotide position and base change); age at last follow-up; ages at breast and ovarian cancer diagnoses; and age or date at bilateral prophylactic mastectomy. Information was also available on the country of residence. Related individuals were identified through a unique family identifier. Women with pathogenic mutations in both *BRCA1* and *BRCA2* were excluded from the current analysis. The primary analysis was restricted to women self-reported as "white European." Overlap of carriers between studies was evaluated by comparing the year of birth, exact mutation description, the reported ages, and previous SNP genotype data available within the CIMBA database. Duplicated mutation carriers were included only once in the analysis.

Genotyping

rs311499 at 20q13.3, rs16917302 at *ZNF365*, and both rs8170 and rs67397200 at 19p13.1 were genotyped using the iPLEX Mass Array platform at 4 genotyping centers as part of a larger study of 24 candidate SNPs. All centers included at least 2% duplicate samples and a random mixture of affected and unaffected carriers on each plate. Samples that failed for 5 or more of the SNPs genotyped were excluded from the analysis. Studies with an SNP call rate of <95% were excluded from the analysis of the SNP. The concordance between duplicates had to be at least 98%. To assess the accuracy of genotyping across genotyping centers, all centers genotyped 95 DNA samples from a standard test plate (Coriell Institute, Camden, NJ) for all SNPs. Genotyping centers with more than one concordance failure on the test plate for an SNP were excluded for analyses of that SNP. Deviation from Hardy-Weinberg equilibrium (HWE) was assessed for unrelated subjects separately for each SNP and study. The observed genotype frequencies were not significantly different from those expected under HWE for any of the SNPs and studies. After the above exclusions, a total of 19,731 unique mutation carriers (12,599 *BRCA1* and 7,132 *BRCA2*) from 40 studies had an observed genotype for at least one SNP (Supplementary Table S1).

Tumor pathology data collection

Tumor pathology data were collected from patient pathology reports, medical records, pathology review data, tumor registry records, and results from tissue

microarrays. ER status was identified as negative or positive, with immunohistochemistry scoring data and methodology provided when available. Most studies applied a cutoff point of >10% tumor cells stained positive for ER-positive status. For a small number of cases, where other scoring methods based on the proportion and intensity of staining were applied (Allred score, Remmele score, and H-score), widely accepted cutoff points were used. Consistency checks were conducted to validate receptor data against supplementary scoring information if provided.

Statistical analysis

The aim of the primary analysis was to evaluate the association between each genotype and breast cancer risk. We conducted the analysis by modeling the retrospective likelihood of the observed genotypes conditional on the disease phenotypes as previously described (9). The phenotype of each individual was defined by age at diagnosis of breast cancer or age at last follow-up. Individuals were censored at the earliest of age of first breast cancer diagnosis, ovarian cancer diagnosis, bilateral prophylactic mastectomy, or age at last observation. Mutation carriers censored at ovarian cancer diagnosis were considered unaffected in the analysis of breast cancer. The effect of each SNP was modeled either as a per-allele HR (multiplicative model) or as separate HRs for heterozygotes and homozygotes. We used a Cox proportional hazards model and tested the assumption of proportional hazards by adding a "genotype \times age" interaction term to fit models in which the HR changed with age. We examined heterogeneity across studies by comparing models that allowed for study-specific log HRs against models in which the same log HR was assumed to apply to all studies. All analyses were stratified by country of residence and applied cohort-specific breast cancer incidence rates for *BRCA1* and *BRCA2* (10). A robust variance-estimation approach was used to adjust for the nonindependence among related carriers.

To evaluate the evidence of replication for each of the SNPs, analyses were restricted to mutation carriers who had not been used in any of the previous *BRCA1* and *BRCA2* studies. The number of new samples used in each of the SNP analyses is shown in Supplementary Table S2. In addition, analyses were conducted using all available *BRCA1* and *BRCA2* carriers. The combined effects of the SNPs on breast cancer risk were evaluated by fitting retrospective likelihood models while allowing for linkage disequilibrium between the loci. To test for potential effects of survival bias, prevalent cases, defined as mutation carriers diagnosed more than 5 years prior to the age at recruitment, were excluded. Associations with specific functional class of mutation were also assessed. Class 1 mutations are predicted to undergo nonsense-mediated RNA decay resulting in reduced levels of mutant transcript, whereas class 2 mutations are predicted to generate stable mutant proteins (11). The associations with breast cancer subtypes defined by the ER status of the tumors in *BRCA1* and *BRCA2* mutation carriers were assessed by an

extension of the retrospective likelihood approach that models the simultaneous effect of each SNP on more than one tumor subtype (12). Associations with ovarian cancer risk were evaluated within a competing risk analysis framework (13) by estimating HRs simultaneously for breast and ovarian cancers. Because each mutation carrier was at risk of breast and ovarian cancer, we assumed that the probabilities of developing each disease were independent conditional on the underlying genotype. In this analysis, individuals were followed to the age of the first breast or ovarian cancer diagnosis and were considered to have developed the corresponding disease. Individuals were censored for breast cancer at the age of bilateral prophylactic mastectomy and for ovarian cancer at the age of bilateral oophorectomy and were assumed to be unaffected for the corresponding disease. The remaining individuals were censored at the age at last observation and were assumed to be unaffected for both diseases.

Results

After quality control exclusions, genotype data from 12,599 *BRCA1* and 7,132 *BRCA2* mutation carriers includ-

ing 5,408 *BRCA1* and 3,780 *BRCA2* mutation carriers not studied in the original GWAS were available for analysis. Of the *BRCA1* mutation carriers, 6,390 were affected with breast cancer and 6,209 were considered unaffected in the breast cancer analysis (censored at bilateral prophylactic mastectomy, ovarian cancer, or age at last follow up). Similarly, among the *BRCA2* mutation carriers, 3,810 were affected with breast cancer and 3,322 were unaffected. The characteristics of these mutation carriers are shown in Table 1 and the origins of the samples are summarized in Supplementary Table S1.

The associations between breast cancer risk in *BRCA1* and *BRCA2* mutation carriers and the minor alleles of rs8170 and rs67397200 (19p13.1), rs16917302 (*ZNF365*), and rs311499 (20q13.33) are summarized in Table 2. The minor allele of rs8170 at 19p13.1 was strongly associated with risk of breast cancer in *BRCA1* mutation carriers (HR, 1.20; 95% CI, 1.13–1.28; $P = 8.7 \times 10^{-9}$) but not *BRCA2* mutation carriers. This result for 12,599 *BRCA1* mutation carriers was consistent with the original finding in the *BRCA1* GWAS using 8,363 *BRCA1* mutation carriers (HR, 1.26; 95% CI, 1.17–1.35; $P = 2.3 \times 10^{-9}$). A separate analysis

Table 1. Summary characteristics for the 19,731 eligible *BRCA1* and *BRCA2* mutation carriers used in the analysis

Characteristic	<i>BRCA1</i>		<i>BRCA2</i>	
	Unaffected	Breast cancer	Unaffected	Breast cancer
Number	6,209	6,390	3,322	3,810
Person-years follow-up	264,903	263,068	147,053	168,201
Median age at Censure (IQR)	42 (34–50)	40 (34–47)	43 (34–53)	43 (37–50)
Age at censure, <i>n</i> (%)				
<30	1,189 (19.2)	691 (10.8)	611 (18.4)	306 (8.0)
30–39	1,661 (26.8)	2,445 (38.3)	834 (25.1)	1,141 (30.0)
40–49	1,765 (28.4)	2,191 (34.3)	865 (26.0)	1,394 (36.6)
50–59	1,058 (17.0)	812 (12.7)	566 (17.0)	687 (18.0)
60–69	380 (6.1)	198 (3.1)	302 (9.1)	226 (5.9)
70+	156 (2.5)	53 (0.8)	144 (4.3)	56 (1.5)
Year of birth, <i>n</i> (%)				
<1920	28 (0.5)	30 (0.5)	23 (0.7)	44 (1.2)
1920–1929	131 (2.1)	196 (3.1)	99 (3.0)	167 (4.4)
1930–1939	369 (5.9)	516 (8.1)	232 (7.0)	430 (11.3)
1940–1949	832 (13.4)	1,341 (21.0)	458 (13.8)	896 (23.5)
1950–1959	1,409 (22.7)	1,989 (31.1)	691 (20.8)	1,160 (30.5)
1960–1969	1,703 (27.4)	1,666 (26.1)	902 (27.2)	868 (22.8)
1970+	1,737 (28.0)	652 (10.2)	917 (27.6)	245 (6.4)
Mutation class, <i>n</i> (%)				
Class 1 ^a	4,063 (65.4)	3,878 (60.7)	3,114 (93.7)	3,520 (92.4)
Class 2 ^a	1,780 (28.7)	1,973 (30.9)	72 (2.2)	100 (2.6)
Other	366 (5.9)	539 (8.4)	136 (4.1)	190 (5.0)

NOTE: Carriers of self reported European ancestry only.

Abbreviation: IQR, interquartile range.

^aSee Materials and Methods for definitions.

Table 2. Evaluation of associations between SNPs and breast cancer risk among *BRCA1* and *BRCA2* mutation carriers of European ancestry

SNP/mutation	Genotype	Unaffected, N (%)	Affected, ^a N (%)	HR (95% CI)	P
rs8170—19p13.1					
BRCA 1	GG	3,870 (67.5)	3,755 (63.3)	1.00	8.7 × 10 ^{−9}
	AG	1,689 (29.4)	1,950 (32.9)	1.22 (1.14–1.31)	
	AA	178 (3.1)	227 (3.8)	1.35 (1.13–1.62)	
	Per-allele			1.20 (1.13–1.28)	
BRCA 2	GG	2,047 (66.3)	2,501 (68.2)	1.00	0.67
	AG	931 (30.2)	1,026 (28.0)	0.93 (0.84–1.03)	
	AA	108 (3.5)	138 (3.8)	1.16 (0.89–1.52)	
	Per-allele			0.98 (0.90–1.07)	
rs67397200—19p13.1					
BRCA 1	CC	2,536 (51.0)	2,455 (46.0)	1.00	2.4 × 10 ^{−8}
	GC	2,022 (40.6)	2,397 (44.9)	1.24 (1.16–1.34)	
	GG	415 (8.4)	487 (9.1)	1.25 (1.10–1.43)	
	Per-allele			1.17 (1.11–1.23)	
BRCA 2	CC	1,553 (49.8)	1,871 (50.7)	1.00	0.97
	GC	1,302 (41.7)	1,494 (40.5)	0.95 (0.87–1.04)	
	GG	265 (8.5)	323 (8.8)	1.07 (0.91–1.27)	
	Per-allele			1.00 (0.93–1.07)	
rs311499—20q13.3					
BRCA 1	GG	5,346 (86.2)	5,484 (85.9)	1.00	0.94
	AG	816 (13.2)	873 (13.7)	1.03 (0.94–1.13)	
	AA	41 (0.7)	28 (0.4)	0.67 (0.42–1.08)	
	Per-allele			1.00 (0.91–1.09)	
BRCA 2	GG	2,873 (86.6)	3,312 (87.0)	1.00	0.36
	AG	429 (13.0)	475 (12.5)	0.94 (0.82–1.07)	
	AA	16 (0.5)	21 (0.6)	0.97 (0.60–1.57)	
	Per-allele			0.95 (0.84–1.07)	
rs16917302—10q21.2					
BRCA 1	AA	4,913 (79.3)	5,084 (79.7)	1.00	0.27
	CA	1,216 (19.6)	1,222 (19.2)	0.96 (0.88–1.01)	
	CC	71 (1.1)	73 (1.1)	0.94 (0.69–1.27)	
	Per-allele			0.96 (0.89–1.03)	
BRCA 2	AA	2,583 (77.9)	3,101 (81.5)	1.00	7.0 × 10 ^{−4}
	CA	691 (20.8)	674 (17.7)	0.82 (0.74–0.92)	
	CC	41 (1.2)	32 (0.8)	0.78 (0.49–1.23)	
	Per-allele			0.83 (0.75–0.93)	

^aBreast cancer.

restricted to carriers not used in the *BRCA1* GWAS also confirmed the association (HR, 1.17; 95% CI, 1.07–1.27; $P = 7.42 \times 10^{-4}$; Supplementary Table S2). Similarly, rs67397200 at 19p13.1, which was imputed in the *BRCA1* GWAS, was strongly associated with breast cancer risk in *BRCA1* carriers (HR, 1.17; 95% CI, 1.11–1.23; $P = 2.4 \times 10^{-8}$; Table 2). There was no evidence of heterogeneity in the HRs across studies for *BRCA1* mutation carriers (Fig. 1). However, there was evidence that the per-allele HRs in *BRCA1* mutation carriers for rs8170 ($P = 0.015$) and rs67397200 ($P = 0.007$) at 19p13.1 decreased with increasing age of diagnosis of breast cancer. Because rs8170 and rs67397200 are located in the same region of 19p13.1 ($r^2 =$

0.58), we conducted an analysis for the joint effects of these SNPs on breast cancer risk in *BRCA1* mutation carriers ($n = 10,173$). When accounting for haplotype structure, rs67397200 remained significant (P for inclusion = 2.75×10^{-3}) and was retained in the model, whereas rs8170 was excluded (P for inclusion = 0.18). rs8170 and rs67397200 were not associated with breast cancer risk for *BRCA2* mutation carriers (Table 2).

Among SNPs identified from the original *BRCA2* GWAS, an analysis of genotype data from 7,132 *BRCA2* mutation carriers confirmed that rs16917302 at the *ZNF365* locus was associated with a decreased risk of breast cancer (HR, 0.83; 95% CI, 0.75–0.93; $P = 7.0 \times 10^{-4}$).




Figure 1. Forest plots of the associations by country of residence of *BRCA1* and *BRCA2* mutation carriers with breast cancer risk overall. A–C, squares indicate the country-specific per-allele HR estimates for SNPs (A) rs8170 for *BRCA1* mutation carriers, (B) rs67397200 for *BRCA1* mutation carriers, and (C) rs16917302 for *BRCA2* mutation carriers. The area of the square is proportional to the inverse of the variance of the estimate. Horizontal lines indicate 95% CIs.

The association also replicated in the additional carriers, not previously included in the *BRCA2* GWAS (HR, 0.84; 95% CI, 0.73–0.97; $P = 0.017$; Supplementary Table S2). In contrast, rs311499 from 20q13.3, which was associated with breast cancer risk in the *BRCA2* GWAS (HR, 0.72; 95% CI, 0.61–0.85; $P = 6.6 \times 10^{-5}$; ref. 7), was not associated with risk of breast cancer in the *BRCA2* carriers in the overall analysis (HR, 0.95; 95% CI, 0.84–1.07; $P = 0.36$; Table 2), nor the replication study (HR, 1.11; 95% CI, 0.94–1.31; $P = 0.22$; Supplementary Table S2). There was no evidence for heterogeneity in the HRs across studies for *BRCA2* mutation carriers (Fig. 1). HRs for rs16917302 and rs311499 did not vary by age at diagnosis.

To determine whether the inclusion of long-term survivors influenced the results, we repeated our analyses of the 4 SNPs, excluding *BRCA1* and *BRCA2* mutation carriers diagnosed with breast cancer more than 5 years before recruitment (prevalent cases). The strength of the associations for rs16917302 at *ZNF365* (per-allele HR, 0.85) for *BRCA2* mutation carriers and for rs8170 (per-allele HR, 1.19) and rs67397200 at 19p13.1 (per-allele HR, 1.16) for *BRCA1* mutation carriers were essentially unchanged (Supplementary Table S3). There was no influence of mutation type for *BRCA1* mutation carriers on breast cancer risk in the associations between mutations conferring susceptibility to nonsense-mediated RNA decay (NMD; class 1) and missense or truncating mutations not triggering NMD (class 2) for any of the SNPs (Supplementary Table S4).

Breast tumors in *BRCA1* mutation carriers are predominantly ER-negative (14) and rs8170 from 19p13.1 is strongly associated with ER-negative but not ER-positive breast cancer in the general population (5). Because of these previous findings, we evaluated whether rs8170 and rs67397200 at 19p13.1, as well as rs311499 at 20q13.3 and

rs16917302 at *ZNF365*, were differentially associated with ER-positive and/or ER-negative tumor status in *BRCA1* and *BRCA2* mutation carriers. Although the stratified results suggested a slightly stronger association for the 19p13.1 rs67397200 SNP with ER-negative disease than with ER-positive disease in *BRCA1* mutation carriers (per-allele ER-negative HR, 1.22; 95% CI, 1.14–1.30; $P = 4.4 \times 10^{-9}$; per-allele ER-positive HR, 1.14; 95% CI, 1.01–1.30; $P = 0.040$), the difference was not significant ($P = 0.41$; Table 3). rs67397200, however, was associated with ER-negative disease (per-allele HR, 1.29; 95% CI, 1.11–1.49; $P = 8.7 \times 10^{-4}$) but not ER-positive disease (per-allele HR, 0.92; 95% CI, 0.85–1.01; $P = 0.074$) in *BRCA2* mutation carriers ($P_{\text{heterogeneity}} = 1.5 \times 10^{-4}$; Table 3). The lack of association with rs311499 at 20q13.3 did not vary by ER status in *BRCA1* or *BRCA2* mutation carriers. For *BRCA2* mutation carriers, the minor allele of rs16917302 at *ZNF365* was inversely associated with both ER-positive (per-allele HR, 0.86; 95% CI, 0.75–0.97; $P = 0.016$) and ER-negative tumors (per-allele HR, 0.79; 95% CI, 0.62–1.00; $P = 0.048$; $P_{\text{heterogeneity}} = 0.56$; Table 3). However, in *BRCA1* mutation carriers, rs16917302 was associated with ER-positive (per-allele ER-positive HR, 0.77; 95% CI, 0.62–0.95; $P = 0.016$) but not ER-negative status ($P_{\text{heterogeneity}} = 0.028$; Table 3).

BRCA1 and *BRCA2* mutations are associated with elevated risk of ovarian cancer. In this CIMBA study, 1,465 *BRCA1* mutation carriers and 453 *BRCA2* mutation carriers who developed ovarian cancer were also genotyped for the 4 SNPs under study. To assess the influence of these SNPs on ovarian cancer risk in *BRCA1* and *BRCA2* mutation carriers, we used a competing risk analysis that evaluated the associations with breast and ovarian cancer risk simultaneously. While previous studies did not detect an association between rs8170 at 19p13.1 and ovarian cancer in *BRCA1* or *BRCA2* mutation carriers (5), in this

Table 3. Associations between SNPs and breast cancer risk by ER status of breast cancer cases among women with *BRCA1* and *BRCA2* mutations

SNP/mutation	Unaffected, N	Affected ^a (N)		ER ⁺		ER [−]		Case P_{het} ^b
		ER [−]	ER ⁺	HR (95% CI)	P_{trend}	HR (95% CI)	P_{trend}	P_{trend}
rs8170—19p13.1								
BRCA1	4,483	1,820	541	1.12 (0.96–1.29)	0.15	1.23 (1.14–1.33)	2.0×10^{-7}	0.26
BRCA2	2,738	401	1,343	0.94 (0.85–1.05)	0.26	1.18 (0.99–1.40)	0.058	0.026
rs67397200—19p13.1								
BRCA1	4,486	1,821	542	1.14 (1.01–1.30)	0.040	1.22 (1.14–1.30)	4.4×10^{-9}	0.41
BRCA2	2,733	401	1,349	0.92 (0.85–1.01)	0.074	1.29 (1.11–1.49)	8.7×10^{-4}	1.5×10^{-4}
rs311499—20q13.3								
BRCA1	4,898	1,890	559	1.07 (0.87–1.31)	0.51	0.95 (0.85–1.06)	0.35	0.31
BRCA2	2,930	406	1,372	0.95 (0.82–1.09)	0.48	0.83 (0.63–1.10)	0.19	0.40
rs16917302--10q21.2								
BRCA1	4,897	1,888	558	0.77 (0.62–0.95)	0.016	1.01 (0.92–1.11)	0.85	0.028
BRCA2	2,927	406	1,372	0.86 (0.75–0.97)	0.016	0.79 (0.62–1.00)	0.048	0.56

^aBreast cancer^b P value for heterogeneity in the associations with ER-positive and ER-negative breast cancer.

competing risk analysis with larger numbers of *BRCA1* and *BRCA2* mutation carriers, rs8170 was significantly associated with ovarian cancer risk in both *BRCA1* (HR, 1.15; 95% CI, 1.03–1.29; $P = 0.015$) and *BRCA2* (HR, 1.34; 95% CI, 1.12–1.62; $P = 1.9 \times 10^{-3}$) mutation carriers (Table 4). Similarly rs67397200 at 19p13.1 was associated with ovarian cancer risk in both *BRCA1* (HR, 1.16; 95% CI, 1.05–1.29; $P = 3.8 \times 10^{-4}$) and *BRCA2* (HR, 1.30; 95% CI, 1.10–1.52; $P = 1.8 \times 10^{-3}$) mutation carriers (Table 4). rs311499 at 20q13.3 and rs16917302 at *ZNF365* were not associated with ovarian cancer risk for either *BRCA1* or *BRCA2* mutation carriers (Table 4).

Discussion

GWAS of *BRCA1* and *BRCA2* mutation carriers previously identified variants at 19p13.1, *ZNF365*, and 20q13.3 as candidate breast cancer risk modifiers (5, 7). In this study, we further evaluated associations between variants at these loci and both breast and ovarian cancer in *BRCA1* and *BRCA2* mutation carriers. For the first time, we found that both rs8170 and the previously imputed rs67397200 at 19p13.1 were strongly associated with ovarian cancer in both *BRCA1* and *BRCA2* mutation carriers. In addition, we found that rs8170 and rs67397200 at 19p13.1 were associated with breast cancer risk for *BRCA1* and rs16917302 at *ZNF365* was associated with breast cancer in *BRCA2* mutation carriers in this replication study using an independent set of mutation carriers and in the combined analyses of data from the original study and the replication study. In contrast, rs311499 at 20q13.3 showed no association with breast cancer in the replication study. We also report for the first time that the *BRCA1* GWAS SNP rs67397200 is associated with ER-negative breast cancer in

BRCA2 mutation carriers and that the *BRCA2* GWAS SNP rs16917302 is associated with ER-positive disease in *BRCA1* mutation carriers.

The GWAS for breast cancer in *BRCA1* mutation carriers originally identified significant associations between variants at the 19p13.1 locus and risk of breast cancer. Five SNPs including rs8170 from a 39-kb region were associated with risk of disease. In an analysis of joint effects of these SNPs on breast cancer risk, the best model included rs8170 or rs4808611 and rs8100241 or rs2363956 (P for inclusion = 7.7×10^{-5} and $P = 6.7 \times 10^{-5}$ for rs8170 and rs8100241, respectively; ref. 5), suggesting that the associations were driven by a single causative variant partially correlated with all 5 SNPs. Imputation of additional SNPs in the region from the 1000 Genome Project identified 8 perfectly correlated SNPs within a 13-kb region that were more significantly associated with breast cancer risk. Of these, we chose rs67397200, which has an $r^2 = 0.58$ with rs8170 and $r^2 = 0.37$ with rs8100241/rs2363956, for further genotyping in an effort to determine whether this SNP (or 1 of the 7 other highly correlated SNPs) exhibited stronger associations with breast cancer. In an analysis of rs8170 in 11,669 and rs67397200 in 10,312 *BRCA1* mutation carriers, we observed similarly strong associations with breast cancer for *BRCA1* mutation carriers. In a joint analysis of rs8170 and rs67397200, allowing for haplotype structure, only rs67397200 remained significant. We were unable to genotype some of the original GWAS SNPs (rs2363956/rs8100241) in the present study and, as a consequence, could not evaluate the joint associations with rs67397200. It is therefore still unclear whether rs67397200 accounts solely for the association signal. The 35-kb region containing rs8170 and rs67397200 includes the *ABHD8*

Table 4. Associations with SNPs and breast and ovarian cancer risk using a competing risk analysis model among *BRCA1* and *BRCA2* mutation carriers of European ancestry

SNP/mutation	Genotype	Unaffected, N (%)	Breast cancer, N (%)	Ovarian cancer, N (%)	Breast cancer		Ovarian cancer	
					HR (95% CI)	P	HR (95% CI)	P
rs8170—19p13.1								
BRCA1	GG	2,972 (67.9)	3,730 (63.3)	923 (66.0)	1.00		1.00	
	AG	1,269 (29.0)	1,936 (32.9)	434 (31.0)	1.26 (1.17–1.36)		1.23 (1.08–1.42)	
	AA	139 (3.2)	224 (3.8)	42 (3.0)	1.34 (1.10–1.63)		1.04 (0.72–1.50)	
	Per-allele				1.22 (1.14–1.30)	2.1 × 10 ^{−9}	1.15 (1.03–1.29)	0.015
BRCA2	GG	1,788 (67.0)	2,494 (68.2)	266 (62.2)	1.00		1.00	
	AG	796 (29.9)	1,024 (28.0)	137 (32.0)	0.95 (0.85–1.05)		1.17 (0.93–1.47)	
	AA	83 (3.1)	138 (3.8)	25 (5.8)	1.37 (1.05–1.80)		2.72 (1.65–4.48)	
	Per-allele				1.02 (0.94–1.12)	0.62	1.34 (1.12–1.62)	1.9 × 10 ^{−3}
rs67397200—19p13.1								
BRCA1	CC	1,903 (51.5)	2,436 (46.0)	652 (49.7)	1.00		1.00	
	GC	1,498 (40.5)	2,381 (44.9)	540 (41.2)	1.28 (1.18–1.38)		1.16 (1.01–1.33)	
	GG	298 (8.1)	484 (9.1)	120 (9.2)	1.33 (1.16–1.53)		1.36 (1.07–1.73)	
	Per-allele				1.20 (1.13–1.27)	4.5 × 10 ^{−10}	1.16 (1.05–1.29)	3.8 × 10 ^{−4}
BRCA2	CC	1,363 (50.5)	1,866 (50.7)	194 (45.2)	1.00		1.00	
	GC	1,123 (41.6)	1,489 (40.5)	184 (42.9)	0.96 (0.87–1.06)		1.15 (0.92–1.44)	
	GG	214 (7.9)	323 (8.8)	51 (11.9)	1.18 (0.99–1.41)		1.95 (1.37–2.77)	
	Per-allele				1.03 (0.96–1.11)	0.39	1.30 (1.10–1.52)	1.8 × 10 ^{−3}
rs311499—20q13.3								
BRCA1	GG	4,115 (86.0)	5,442 (85.9)	1,273 (86.9)	1.00		1.00	
	AG	637 (13.3)	869 (13.7)	183 (12.5)	1.01 (0.92–1.12)		0.88 (0.74–1.05)	
	AA	32 (0.7)	28 (0.4)	9 (0.6)	0.70 (0.42–1.17)		1.16 (0.47–2.87)	
	Per-allele				0.99 (0.90–1.08)	0.77	0.91 (0.77–1.07)	0.25
BRCA2	GG	2,492 (86.7)	3,303 (87.0)	390 (86.1)	1.00		1.00	
	AG	372 (12.9)	474 (12.5)	58 (12.8)	0.93 (0.82–1.07)		0.92 (0.68–1.26)	
	AA	11 (0.4)	21 (0.6)	5 (1.1)	1.09 (0.68–1.74)		2.23 (0.80–6.22)	
	Per-allele				0.95 (0.84–1.08)	0.44	1.02 (0.76–1.37)	0.88
rs16917302—10q21.2								
BRCA1	AA	3,784 (79.2)	5,044 (79.7)	1,169 (79.8)	1.00		1.00	
	CA	937 (19.6)	1,216 (19.2)	285 (19.5)	0.96 (0.88–1.04)		0.97 (0.84–1.13)	
	CC	60 (1.3)	73 (1.2)	11 (0.8)	0.86 (0.62–1.19)		0.47 (0.25–0.92)	
	Per-allele				0.95 (0.88–1.03)	0.21	0.92 (0.80–1.05)	0.20
BRCA2	AA	2,237 (77.9)	3,094 (81.5)	353 (78.1)	1.00		1.00	
	CA	601 (20.9)	671 (17.7)	93 (20.6)	0.81 (0.72–0.92)		0.93 (0.72–1.21)	
	CC	35 (1.2)	32 (0.8)	6 (1.3)	0.80 (0.50–1.30)		1.21 (0.46–3.18)	
	Per-allele				0.83 (0.74–0.92)	5.8 × 10 ^{−4}	0.96 (0.76–1.22)	0.76

(abhydrolase domain containing 8), *ANKLE1* (ankyrin repeat and LEM domain containing 1), and *C19orf62* genes. *C19orf62*, encodes MERIT40 (mediator of Rap80 interactions and targeting 40 kD), a BRCA1-interacting protein that forms a complex with BRCA1–BARD1, Abraxas1, RAP80, BRCC36, and BRCC45 and is required for recruitment and retention of the BRCA1–BARD1 ubiquitin ligase at sites of DNA damage (15). Because alterations in MERIT40 expression or function may modify BRCA1 activity, variants in the *C19orf62* locus are attractive candidate breast cancer risk modifiers. However, as rs67397200 and the 7 other imputed SNPs that showed the most significant associations with breast cancer risk in *BRCA1* mutation carriers, are located at the 3' end of *ANKLE1* near *ABHD8*, it is also possible that one of these genes rather than *C19orf62* is influenced by the underlying causative variants in this region. Further comprehensive genotyping of other common variants and/or rare SNPs from this locus and detailed functional studies will be required to resolve this issue.

Our GWAS for breast cancer in *BRCA2* mutation carriers previously identified strong associations between rs16917302 in the *ZNF365* (dbGENE ID: 22891) locus and breast cancer (7). We have now replicated this association for *BRCA2* mutation carriers. rs16917302 is located within intron 4 of *ZNF365* and is unique to isoform C, the longest of the 4 isoforms created by alternative splicing sites (16). In independent studies, rs10995195 in *ZNF365*, which is 27 kb upstream from and only weakly correlated ($r^2 = 0.1$) with rs16917302, has been associated with breast cancer risk (8) and with mammographic density (17) in the general population. In addition, a cluster of SNPs located 154 kb from rs16917302 in isoform D of *ZNF365* has been associated with Crohn disease (18–20), and the region has also been implicated in family-based linkage analyses with uric acid nephrolithiasis (21) and hypotrichosis (22). It is unclear whether there is genetic or biologic linkage between these seemingly disparate phenotypes. Further fine mapping of the *ZNF365* region and functional analyses will be needed to identify the causative variants for each phenotype and to understand the downstream biologic effects.

Likewise, rs311499 at 20q13.3 was associated with breast cancer risk in *BRCA2* mutation carriers in the *BRCA2* GWAS (per-allele HR, 0.72; 95% CI, 0.61–0.85; $P = 6.6 \times 10^{-5}$). However, this association was not confirmed in the replication study described above (HR, 1.11; 95% CI, 0.94–1.31; $P = 0.22$) or in the combined analysis of the discovery and replication stages (HR, 0.95; 95% CI, 0.84–1.07; $P = 0.36$). This result was not unexpected because the association between rs311499 and breast cancer did not reach significance ($P < 0.05$) in stage II of the *BRCA2* GWAS (HR, 0.86; 95% CI, 0.67–1.06; $P = 0.13$; ref. 7).

To further characterize the influence of the 19p13.1 and *ZNF365* loci on breast cancer risk, we assessed the strength of association with ER-negative and ER-positive breast cancer in *BRCA1* and *BRCA2* mutation car-

riers. As reported above, rs67397200 at 19p13.1 was associated with both ER-negative and ER-positive breast cancer in *BRCA1* mutation carriers, whereas rs8170 at 19p13.1 was only associated with ER-negative disease. Interestingly, rs67397200 and rs8170 were also associated with ER-negative breast cancer but not ER-positive breast cancer in *BRCA2* mutation carriers. This is consistent with our previous finding that rs8170 at 19p13.1 is more strongly associated with ER-negative than ER-positive breast cancer in the general population (5). Given that the majority of *BRCA1* breast tumors exhibit a basal breast cancer phenotype (14), it remains to be determined whether ER-positive basal cases account for the mild association with ER-positive disease in *BRCA1* mutation carriers.

In contrast, we found that rs16917302 in the *ZNF365* locus was associated with both ER-positive and ER-negative disease in *BRCA2* mutation carriers. This was consistent with associations for both ER-positive and ER-negative breast cancer in a recent GWAS of breast cancer cases with a family history of the disease (8). In contrast, among *BRCA1* mutation carriers, the association with breast cancer risk was restricted to ER-positive cases. This suggests that refinement of phenotype, perhaps in specific subpopulations, may result in detection of previously hidden associations.

Ovarian cancer is an important component of the cancer phenotype in both *BRCA1* and *BRCA2* mutation carriers. Because breast and ovarian cancer can occur in the same mutation carriers, it has been suggested that susceptibility SNPs common to breast and ovarian cancer may exist in these populations. However, to date, none of the SNPs associated with breast cancer risk in *BRCA1* or *BRCA2* mutation carriers have been associated with ovarian cancer risk. Similarly, SNPs in the *BCN2* locus that are associated with ovarian cancer risk in *BRCA1* and *BRCA2* mutation carriers are not associated with breast cancer risk (13). Furthermore, in the general population, only SNPs in the 8q24 locus are known to influence both breast and ovarian cancer, and these appear to be independent disease-specific effects (23). Thus, the recent finding that SNPs at 19p13.1 were associated with breast cancer in *BRCA1* mutation carriers (5) and also with ovarian cancer in the general population (6) raised the possibility that a locus with common influences on breast and ovarian cancer does exist. However, the *BRCA1* GWAS failed to detect any association for 19p13.1 SNPs with ovarian cancer among *BRCA1* mutation carriers (843 ovarian cases; HR, 1.07; 95% CI, 0.93–1.24; $P = 0.33$; ref. 5). Here, we reevaluated associations between 19p13.1 SNPs and ovarian cancer using larger numbers of *BRCA1* ($n = 1,312$) and *BRCA2* ($n = 429$) carriers diagnosed with ovarian cancer. rs67397200 at 19p13.1 was associated with ovarian cancer risk in both *BRCA1* (HR, 1.16; 95% CI, 1.05–1.29; $P = 3.8 \times 10^{-4}$) and *BRCA2* (HR, 1.30; 95% CI, 1.10–1.52; $P = 1.8 \times 10^{-3}$) mutation carriers. The magnitude of the effect on ovarian cancer risk in *BRCA1* carriers (HR = 1.16) was similar to that observed for breast cancer. This is

the first locus found to influence both breast and ovarian cancer risk in either *BRCA1* or *BRCA2* mutation carriers.

Including the SNPs from the present study, 6 loci are now known to modify the risk of breast cancer for *BRCA1* mutation carriers [*CASP8*, *TOX3*, 2q35, 6q25.1, 19p13, and *ZNF365* (ER-positive disease only); refs. 1–3, 5, 10, 24] and 10 loci are known to modify the risk of breast cancer for *BRCA2* mutation carriers [*FGFR2*, *TOX3*, *MAP3K1*, *LSP1*, 2q35, *SLC4A7*, 5p12, *ZNF365*, 1p11.2, and 19p13.1 (ER-negative only); refs. 5, 7, 10, 24]. Taken together, these SNPs result in large variation in the absolute risk of breast cancer for *BRCA1* and *BRCA2* mutation carriers and may further improve our ability to provide individualized risks of breast cancer for *BRCA1* and *BRCA2* mutation carriers.

Disclosure of Potential Conflicts of Interest

The Editor-in-Chief of *Cancer Epidemiology, Biomarkers & Prevention* is an author of this article. In keeping with the AACR's Editorial Policy, the manuscript was peer reviewed and a member of the AACR's Publications Committee rendered the decision concerning acceptability. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government or the BCFR. No potential conflicts of interest are disclosed.

Acknowledgments

The authors thank all the individuals who took part in these studies and all the researchers, clinicians, technicians, and administrative staff who have enabled this work to be carried out. In particular, we thank (BFOCC) Laima Tikhomirova, (CBCS) Bent Ejler Jensen, (CNIO) R.M. Alonso, G. Pita, and R.M. Milne, the Molecular Genetics Laboratory from Hospital de Cruces, (CONSIT) Marco A. Pierotti, Gaia Roversi, Elisa Cattaneo, Carla B. Ripamonti, and Marilena Morganti (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), Bernardo Bonanni (Istituto Europeo di Oncologia, Milan, Italy); (EMBRACE) Cambridge, UK: S. Peock, D. Frost, S.D. Ellis, E. Fineberg, and R. Platte. North of Scotland Regional Genetics Service, Aberdeen, UK: Zosia Miedzybrodzka and Helen Gregory. Northern Ireland Regional Genetics Service, Belfast, UK: P.J. Morrison and Lisa Jeffers. West Midlands Regional Clinical Genetics Service, Birmingham, UK: T. Cole, Kai-ren Ong, and Jonathan Hoffman. South West Regional Genetics Service, Bristol, UK: Alan Donaldson and Margaret James. East Anglian Regional Genetics Service, Cambridge, UK: J. Paterson, Sarah Downing, and Amy Taylor. Medical Genetics Services for Wales, Cardiff, UK: Alexandra Murray, Mark T. Rogers, and Emma McCann. St James's Hospital, Dublin & National Centre for Medical Genetics, Dublin, Ireland: M.J. Kennedy and David Barton. South East of Scotland Regional Genetics Service, Edinburgh, UK: M.E. Porteous and Sarah Drummond. Peninsula Clinical Genetics Service, Exeter, UK: C. Brewer, Emma Kivuva, Anne Searle, Selina Goodman, and Kathryn Hill. West of Scotland Regional Genetics Service, Glasgow, UK: R. Davidson, Victoria Murday, Nicola Bradshaw, Lesley Snadden, Mark Longmuir, Catherine Watt, Sarah Gibson, Eshika Haque, Ed Tobias, and Alexis Duncan. South East Thames Regional Genetics Service, Guy's Hospital, London, UK: Louise Izatt, C. Jacobs, Caroline Langman, and Anna Whaite. North West Thames Regional Genetics Service, Harrow, UK: Huw Dorkins. Leicestershire Clinical Genetics Service, Leicester, UK: Julian Barwell. Yorkshire Regional Genetics Service, Leeds, UK: J. Adlard and Gemma Serra-Feliu. Cheshire & Merseyside Clinical Genetics Service, Liverpool, UK: Ian Ellis and Catherine Houghton. Manchester Regional Genetics Service, Manchester, UK: D.G. Evans, Fiona Laloo, and Jane Taylor. North East Thames Regional Genetics Service, NE Thames, London, UK: L.E. Side, Alison Male, and Cheryl Berlin. Nottingham Centre for Medical Genetics, Nottingham, UK: Jacqueline Eason and Rebecca Collier. Northern Clinical Genetics Service, Newcastle, UK: F. Douglas, Oonagh Claber, and Irene Jobson. Oxford Regional Genetics Service, Oxford, UK: L. Walker, Diane McLeod, Dorothy Halliday, Sarah Durrell, and Barbara Stayner. The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK: R.A. Eeles, Susan Shanley, Nazneen Rahman, Richard Houlston, Elizabeth Bancroft, Lucia D'Mello, Elizabeth Page, Audrey Ardern-Jones, Kelly

Kohut, Jennifer Wiggins, Elena Castro, Anita Mitra, and Lisa Robertson. North Trent Clinical Genetics Service, Sheffield, UK: J. Cook, Oliver Quarrell, and Cathryn Bardsley. South West Thames Regional Genetics Service, London, UK: S.V. Hodgson, Sheila Goff, Glen Brice, Lizzie Winchester, Charlotte Eddy, Vishakha Tripathi, and Virginia Attard. Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK: D.M. Eccles, Anneke Lucassen, Gillian Crawford, Donna McBride, and Sarah Smalley (EMBRACE); (GOG) the investigators of the Australia New Zealand Gynaecological Oncology Group (ANZGOG); (GEMO) Coordinating Centres, Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Centre Hospitalier Universitaire de Lyon/Centre Léon Bérard, & Equipe «Génétique du cancer du sein», Centre de Recherche en Cancérologie de Lyon, Lyon, France: O.M. Sinilnikova, S. Mazoyer, Laure Barhieux, Carole Verny-Pierre, Sophie Giraud, and Mélanie Léone; and Service de Génétique Oncologique, Institut Curie, Paris, France: D. Stoppa-Lyonnet, Marion Gauthier-Villars, Bruno Buecher, Claude Houdayer, Virginie Moncoutier, Muriel Belotti, Carole Tirapo, and Antoine de Pauw. Institut Gustave Roussy, Villejuif, France: B. Bressac-de-Paillerets, Audrey Remenieras, Véronique Byrde, O. Caron, and Gilbert Lenoir. Centre Jean Perrin, Clermont-Ferrand, France: Yves-Jean Bignon and Nancy Uhrhammer. Centre Léon Bérard, Lyon, France: Christine Lasset and Valérie Bonadona. Centre François Baclesse, Caen, France: Agnès Hardouin and Pascaline Berthet. Institut Paoli Calmettes, Marseille, France: Hagay Sobol, Violaine Bourdon, Tetsuro Noguchi, and François Eisinger. Groupe Hospitalier Pitié-Salpêtrière, Paris, France: Florence Coulet, Chrystelle Colas, and Florent Soubrier. CHU de Arnaud-de-Villeneuve, Montpellier, France: I. Coupier and P. Pujol. Centre Oscar Lambret, Lille, France: Jean-Philippe Peyrat, Joëlle Fournier, Françoise Révillon, Philippe Venin, and Claude Adenis. Hôpital René Huguenin/Institut Curie, St Cloud, MN: Etienne Rouleau, Rosette Lidereau, Liliane Demange, and Catherine Nogues. Centre Paul Strauss, Strasbourg, France: Danièle Muller and Jean-Pierre Fricker. Institut Bergonié, Bordeaux, France: Emmanuelle Barouk-Simonet, Françoise Bonnet, Virginie Bubien, Nicolas Sevenet, and Michel Longy. Institut Claudius Regaud, Toulouse, France: Christine Toulas, Rosine Guimbaud, Laurence Gladieff, and Viviane Feillel. CHU de Grenoble, France: Dominique Leroux, Hélène Dreyfus, Christine Rebuschung, and Magalie Peysselon. CHU de Dijon: Fanny Coron and Laurence Faivre. CHU de St-Etienne: Fabienne Prieur, Marine Lebrun, and Caroline Kientz. Hôtel Dieu Centre Hospitalier, Chambéry: Sandra Fert Ferrer. Centre Antoine Lacassagne, Nice, France: Marc Frénay. CHU de Limoges: Laurence Vénat-Bouvet. CHU de Nantes: Capucine Delnatte. CHU Bretonneau, Tours, France: Isabelle Mortemousque. Creighton University, Omaha, NE: H.T. Lynch, C.L. Snyder; (HCSC) Red Temática de Investigación Corporativa en Cáncer (ISCIII); (HEBCS) Kristiina Aittomäki, Kirsimari Aaltonen, and Carl Blomqvist and Tuomas Heikkinen and research nurse Irja Erkkilä; (HEBON) Netherlands Cancer Institute, Amsterdam, the Netherlands: F.B.L. Hogervorst, S. Verhoef, M. Verheus, L.J. van't Veer, F.E. van Leeuwen, and M.A. Rookus; Erasmus Medical Center, Rotterdam, the Netherlands: M. Collée, A.M.W. van den Ouweland, A. Jager, M.J. Hoening, M.M.A. Tilanus-Linthorst, and C. Seynaeve; Leiden University Medical Center, Leiden, the Netherlands: C.J. van Asperen, J.T. Wijnen, M.P. Vreeswijk, R.A. Tollenaar, and P. Devilee; Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands: M.J. Ligtenberg and N. Hoogerbrugge; University Medical Center Utrecht, Utrecht, the Netherlands: M.G. Ausems and R.B. van der Luijt; Amsterdam Medical Center, the Netherlands: C.M. Aalfs and T.A. van Os; VU University Medical Center, Amsterdam, the Netherlands: J.J.P. Gille, Q. Waisfisz, and H.E.J. Meijers-Heijboer; University Hospital Maastricht, Maastricht, the Netherlands: E.B. Gomez-Garcia, C.E. van Roozendaal, Marinus J. Blok, and B. Caanen; University Medical Center Groningen University, the Netherlands: J.C. Oosterwijk, A.H. van der Hout, and M.J. Mourits; The Netherlands Foundation for the detection of hereditary tumours, Leiden, the Netherlands: H.F. Vasen; (INHERIT) Stéphane Dubois, Martine Dumont, Martine Tranchant (Cancer Genomics Laboratory, CRCHUQ), and Sylvie Desjardins and Marc-André Rodrigue (Plateforme de séquençage et de génotypage des génomes du CRCHUL/CHUQ); (kConFab) Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study; (KUMC) JoEllen Weaver; (OCGN) Teresa Selander, Nayana Weerasooriya, and members of the Ontario Cancer Genetics Network; (OSU-CCG) Leigha Senter and Kevin Sweet and the Ohio State University Human Genetics Sample Bank; (SEABASS) Cancer Research Initiatives Foundation (Malaysia), University Malaya (Malaysia), National University Hospital (Singapore), University Kebangsaan Malaysia (Malaysia), Hospital Kuala Lumpur (Malaysia), and Putrajaya Hospital (Malaysia); (SWE-BRCA) P. Karlsson, Margareta Nordling, Annika Bergman, and Zakaria Einbeigi, Gothenburg, Sahlgrenska University Hospital, Marie Stenmark-Askmal and Sigrun Liedgren, Linköping University Hospital, Åke Borg, N. Loman, Håkan Olsson, M. Soller, Helena Jernström, Katja

Harbst, and Karin Henriksson, Lund University Hospital; Annika Lindblom, Brita Arver, A. von Wachenfeldt, Annelie Liljegren, G. Barbany-Bustinza, and Johanna Rantala, Stockholm, Karolinska University Hospital; Beatrice Melin, Henrik Grönberg, Eva-Lena Stattin, and Monica Emanuelsson, Umeå University Hospital; H. Ehrencrona, Richard Rosenquist, and Niklas Dahl, Uppsala University Hospital; (UKGRFOCR) Roswell Park Alliance Foundation for their continued support of the Gilda Radner Ovarian Family Cancer Registry, Carole Pye, Patricia Harrington, Eva Wozniak, Kirsten Moysich, and Lara Sucheston.

Grant Support

This research was supported by NIH grant CA128978, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a U.S. Department of Defence Ovarian Cancer Idea award (W81XWH-10-1-0341), and grants from the Breast Cancer Research Foundation and the Komen Foundation for the Cure. This work was also supported by Cancer Research UK (CR-UK) grants C12292/A11174 and C1287/A10118. The research leading to these results has received funding from the European Community's Seventh Framework Programme under grant agreement no. 223175 (HEALTH-F2-2009-223175). Support was also provided by the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program and by the Canadian Breast Cancer Research Alliance-grant #019511. A.C. Antoniou is a CR-UK Senior Cancer Research Fellow. D.F. Easton is CR-UK Principal Research Fellow. G. Chenevix-Trench is a NHMRC Senior Principal Research Fellow. BFBOCC was supported by the Research Council of Lithuania grant LIG-19/2010 to R. Janavicius. BMBSA was supported by grants from the Cancer Association of South Africa (CANSA) to E.J. van Rensburg. BCFR was supported by the National Cancer Institute, NIH under RFA-CA-06-503 and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR) and Principal Investigators, including Cancer Care Ontario (U01 CA69467), Columbia University (U01 CA69398), Fox Chase Cancer Center (U01 CA69631), Huntsman Cancer Institute (U01 CA69446), Cancer Prevention Institute of California (formerly the Northern California Cancer Center; U01 CA69417), University of Melbourne (U01 CA69638), and Research Triangle Institute Informatics Support Center (RFP No. N02PC45022-46). CBCS was supported by The Neye Foundation. CNIO was partially supported by Fundación Mutua Madrileña, Asociación Española Contra el Cáncer, the Spanish Ministry of Science and Innovation (FIS PI08 1120), and the Basque Foundation for Health Innovation and Research (BIOEF): BIO07/CA/006. CONSTIT TEAM was supported by grants from Ministero della Salute (Extraordinary National Cancer Program 2006 "Alleanza contro il Cancro" to L. Varesco and P. Radice, and "Progetto Tumori Femminili" to P. Radice), Ministero dell'Università e Ricerca (RBLAO3-BETH to P. Radice), Fondazione Italiana per la Ricerca sul Cancro (Special Project "Hereditary tumors" to P. Radice), Associazione Italiana per la Ricerca sul Cancro (4017 to P. Pujol), and by funds from Italian citizens who allocated the 5 × 1,000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects "5 × 1000"). The DKFZ study was supported by funds from the DKFZ. EMBRACE was supported by CR-UK Grants C1287/A10118 and C1287/A11990. D.G. Evans and Fiona Laloo were supported by an NIHR grant to the Biomedical Research Centre, Manchester, UK. The Investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust were supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. R.A. Eeles, Elizabeth Bancroft, and Lucia D'Mello were supported by CR-UK Grant C5047/A8385. GC-HBOC was supported by a grant of the German Cancer Aid (grant 109076) and by the Centre of Molecular Medicine Cologne (CMMC). The GEMO study was supported by the Ligue National Contre le Cancer; Association for International Cancer Research Grant (AICR-07-0454); and the Association "Le cancer du sein, parlons-en!" Award. The Georgetown study was supported by the Familial Cancer Registry at Georgetown University (NIH/NCI grant P30-CA051008), the Cancer Genetics Network

(HHSN261200744000C), and Swing Fore the Cure. GOG was supported through funding provided by both intramural (Clinical Genetics Branch, DCEG) and extramural (Community Oncology and Prevention Trials Program—COPTRG) NCI programs. K. Phillips is the Cancer Council Victoria, Colebatch Clinical Research Fellow. HEBCS was supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (132473), the Finnish Cancer Society, and the Sigrid Juselius Foundation. The HEBON study was supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756, and the ZonMW grant 91109024. HUNBOCS was supported by the Hungarian Research Grant KTIA-OTKA CK-80745. ICO was supported by Asociación Española Contra el Cáncer, Spanish Health Research Fund; Carlos III Health Institute; Catalan Health Institute and Autonomous Government of Catalonia; contract grant numbers ISCIII-RETIC RD06/0020/1051, PI10/01422, PI10/31488, and 2009SGR290. IHCC was supported by a Polish Foundation of Science award to K. Jaworska, a fellow of International PhD program, Postgraduate School of Molecular Medicine, Warsaw Medical University. ILUH was supported by the Icelandic Association "Walking for Breast Cancer Research" and by the Landspítali University Hospital Research Fund. INHERIT was supported with J. Simard, Chairholder of the Canada Research Chair in Oncogenetics. IOVHBOCS was supported by Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR), and "Ministero della Salute" ("Progetto Tumori Femminili and grant numbers RFP5 2006-5-341353, ACC2/R6.9"). kConFab was supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC), and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, and the Cancer Foundation of Western Australia. The kConFab Clinical Follow-Up Study was funded by the NHMRC [145684, 288704, 454508]. A.-B. Skytte is supported by a NHMRC Senior Research Fellowship. A.K. Godwin was funded by U01CA69631, 5U01CA113916, and the Eileen Stein Jacoby Fund while at FCCC. The author acknowledges support from The University of Kansas Cancer Center and the Kansas Bioscience Authority Eminent Scholar Program. A.K. Godwin is the Chancellors Distinguished Chair in Biomedical Sciences endowed Professor. The McGill study was supported by the Jewish General Hospital Weekend to End Breast Cancer. M. Thomassen holds a Fonds de la Recherche en Santé du Québec clinician-scientist award. The MSKCC study was supported by the Starr Cancer Consortium, the Breast Cancer Research Foundation, the Norman and Carol Stone Cancer Research Initiative, the Kate and Robert Niehaus Clinical Cancer Research Initiative, the Lymphoma Foundation, and the Sabin Family Research Initiative. The NCI study was supported by the Intramural Research Program of the U.S. National Cancer Institute and by support services contracts N02-CP-11019-50 and N02-CP-65504 with Westat, Inc. NNPIO was supported by the Russian Federation for Basic Research (grants 10-04-92601, 10-04-92110, 11-04-00227) and the Federal Agency for Science and Innovations (contract 16.512.11.2237). OCGN was supported by Cancer Care Ontario and the U.S. National Cancer Institute, NIH under RFA # CA-06-503 and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR) and Principal Investigators. OSU-CCG was supported by the Ohio State University Comprehensive Cancer Center. PBCS was supported by an Istituto Toscano Tumori grant to M.A. Caligo. SEABASS was supported by CARIF and University Malaya. The UCSF study was supported by the Helen Diller Family Comprehensive Cancer Center at UCSF, the Avon Foundation, and the Center for Translational and Policy Research in Personalized Medicine (TRANSPERS), NIH/NCI P01 CA130818-02A1. UKFOCR was supported by a project grant from CRUK to P.P.D. Pharoah. The UPENN study was supported Komen Foundation for the Cure to S.M. Domchek, the Breast Cancer Research Foundation to K.L. Nathanson, and NIH grants R01-CA083855 and R01-CA102776 to T.R. Rebbeck. WCRI was supported by the American Cancer Society Clinical Research Professorship #SIOP-06-258-06-COUN.

Received September 16, 2011; revised November 15, 2011; accepted December 20, 2011; published OnlineFirst February 21, 2012.

References

1. Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Res* 2010;70:9742–54.
2. Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, et al. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Hum Mol Genet* 2011;20:3304–21.
3. Engel C, Versmold B, Wappenschmidt B, Simard J, Easton DF, Peock S, et al. Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiol Biomarkers Prev* 2010;19:2859–68.

4. Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS, et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. *Hum Mol Genet* 2011;20:3289–303.
5. Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nat Genet* 2010;42:885–92.
6. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nat Genet* 2010;42:880–4.
7. Gaudet MM, Kirchhoff T, Green T, Vijai J, Korn JM, Guiducci C, et al. Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. *PLoS Genet* 2010;6:e1001183.
8. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. *Nat Genet* 2010;42:504–7.
9. Antoniou AC, Sinilnikova OM, Simard J, Leone M, Dumont M, Neuhausen SL, et al. RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. *Am J Hum Genet* 2007;81:1186–200.
10. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. *Br J Cancer* 2008;98:1457–66.
11. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S. The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. *Hum Mol Genet* 2002;11:2805–14.
12. Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D, Nevanlinna H, et al. Common breast cancer susceptibility alleles are associated with tumor subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Res* 2011;13:R110.
13. Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PD, Sinilnikova OM, Beesley J, et al. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 2010;103:105–16.
14. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. *J Clin Oncol* 2002;20:2310–8.
15. Shao G, Patterson-Fortin J, Messick TE, Feng D, Shanbhag N, Wang Y, et al. MERIT40 controls BRCA1-Rap80 complex integrity and recruitment to DNA double-strand breaks. *Genes Dev* 2009;23:740–54.
16. Gianfrancesco F, Esposito T, Casu G, Maninchedda G, Roberto R, Pirastu M. Emergence of Talanin protein associated with human uric acid nephrolithiasis in the Hominidae lineage. *Gene* 2004;339:131–8.
17. Lindstrom S, Vachon CM, Li J, Varghese J, Thompson D, Warren R, et al. Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. *Nat Genet* 2011;43:185–7.
18. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. *Nat Genet* 2007;39:596–604.
19. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 2007;447:661–78.
20. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. *Nat Genet* 2008;40:955–62.
21. Gianfrancesco F, Esposito T, Ombra MN, Forabosco P, Maninchedda G, Fattorini M, et al. Identification of a novel gene and a common variant associated with uric acid nephrolithiasis in a Sardinian genetic isolate. *Am J Hum Genet* 2003;72:1479–91.
22. Naz G, Ali G, Naqvi SK, Azeem Z, Ahmad W. Mapping of a novel autosomal recessive hypotrichosis locus on chromosome 10q11.23–22.3. *Hum Genet* 2010;127:395–401.
23. Ghousaini M, Song H, Koessler T, Al Olama AA, Kote-Jarai Z, Driver KE, et al. Multiple loci with different cancer specificities within the 8q24 gene desert. *J Natl Cancer Inst* 2008;100:962–6.
24. Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H, Heikkinen T, et al. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Hum Mol Genet* 2009;18:4442–56.

Cancer Epidemiology, Biomarkers & Prevention

Common Variants at the 19p13.1 and *ZNF365* Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in *BRCA1* and *BRCA2* Mutation Carriers

Fergus J. Couch, Mia M. Gaudet, Antonis C. Antoniou, et al.

Cancer Epidemiol Biomarkers Prev 2012;21:645-657. Published OnlineFirst February 20, 2012.

Updated version	Access the most recent version of this article at: doi: 10.1158/1055-9965.EPI-11-0888
Supplementary Material	Access the most recent supplemental material at: http://cebp.aacrjournals.org/content/suppl/2012/03/28/1055-9965.EPI-11-0888.DC1.html

Cited articles	This article cites 24 articles, 9 of which you can access for free at: http://cebp.aacrjournals.org/content/21/4/645.full.html#ref-list-1
Citing articles	This article has been cited by 3 HighWire-hosted articles. Access the articles at: http://cebp.aacrjournals.org/content/21/4/645.full.html#related-urls

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org .

Genome-Wide Association Study in *BRCA1* Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

Fergus J. Couch^{1,9*}, Xianshu Wang², Lesley McGuffog³, Andrew Lee³, Curtis Olsword⁴, Karoline B. Kuchenbaecker³, Penny Soucy⁵, Zachary Fredericksen⁴, Daniel Barrowdale³, Joe Dennis³, Mia M. Gaudet⁶, Ed Dicks³, Matthew Kosel⁴, Sue Healey⁷, Olga M. Sinilnikova^{8,9}, Adam Lee¹⁰, François Bacot¹¹, Daniel Vincent¹¹, Frans B. L. Hogervorst¹², Susan Peock³, Dominique Stoppa-Lyonnet^{13,14,15}, Anna Jakubowska¹⁶, kConFab Investigators¹⁷, Paolo Radice^{18,19}, Rita Katharina Schmutzler²⁰, SWE-BRCA²¹, Susan M. Domchek²², Marion Piedmonte²³, Christian F. Singer²⁴, Eitan Friedman²⁵, Mads Thomassen²⁶, Ontario Cancer Genetics Network²⁷, Thomas V. O. Hansen²⁸, Susan L. Neuhausen²⁹, Csilla I. Szabo³⁰, Ignacio Blanco³¹, Mark H. Greene³², Beth Y. Karlan³³, Judy Garber³⁴, Catherine M. Phelan³⁵, Jeffrey N. Weitzel³⁶, Marco Montagna³⁷, Edith Olah³⁸, Irene L. Andrulis³⁹, Andrew K. Godwin⁴⁰, Drakoulis Yannoukakos⁴¹, David E. Goldgar⁴², Trinidad Caldes⁴³, Heli Nevanlinna⁴⁴, Ana Osorio⁴⁵, Mary Beth Terry⁴⁶, Mary B. Daly⁴⁷, Elizabeth J. van Rensburg⁴⁸, Ute Hamann⁴⁹, Susan J. Ramus⁵⁰, Amanda Ewart Toland⁵¹, Maria A. Caligo⁵², Olufunmilayo I. Olopade⁵³, Nadine Tung⁵⁴, Kathleen Claes⁵⁵, Mary S. Beattie⁵⁶, Melissa C. Southey⁵⁷, Evgeny N. Imyanitov⁵⁸, Marc Tischkowitz⁵⁹, Ramunas Janavicius⁶⁰, Esther M. John⁶¹, Ava Kwong⁶², Orland Diez⁶³, Judith Balmaña⁶⁴, Rosa B. Barkardottir⁶⁵, Banu K. Arun⁶⁶, Gad Rennert⁶⁷, Soo-Hwang Teo⁶⁸, Patricia A. Ganz⁶⁹, Ian Campbell⁷⁰, Annemarie H. van der Hout⁷¹, Carolien H. M. van Deurzen⁷², Caroline Seynaeve⁷³, Encarna B. Gómez García⁷⁴, Flora E. van Leeuwen⁷⁵, Hanne E. J. Meijers-Heijboer⁷⁶, Johannes J. P. Gille⁷⁶, Margreet G. E. M. Ausems⁷⁷, Marinus J. Blok⁷⁸, Marjolijn J. L. Ligtenberg⁷⁹, Matti A. Rookus⁷⁵, Peter Devilee⁸⁰, Senno Verhoef¹², Theo A. M. van Os⁸¹, Juul T. Wijnen⁸², HEBON⁸³, EMBRACE³, Debra Frost³, Steve Ellis³, Elena Fineberg³, Radka Platte³, D. Gareth Evans⁸⁴, Louise Izatt⁸⁵, Rosalind A. Eeles⁸⁶, Julian Adlard⁸⁷, Diana M. Eccles⁸⁸, Jackie Cook⁸⁹, Carole Brewer⁹⁰, Fiona Douglas⁹¹, Shirley Hodgson⁹², Patrick J. Morrison⁹³, Lucy E. Side⁹⁴, Alan Donaldson⁹⁵, Catherine Houghton⁹⁶, Mark T. Rogers⁹⁷, Huw Dorkins⁹⁸, Jacqueline Eason⁹⁹, Helen Gregory¹⁰⁰, Emma McCann¹⁰¹, Alex Murray¹⁰², Alain Calender⁸, Agnès Hardouin¹⁰³, Pascaline Berthet¹⁰³, Capucine Delnatte¹⁰⁴, Catherine Nogues¹⁰⁵, Christine Lasset^{106,107}, Claude Houdayer^{13,15}, Dominique Leroux^{108,109}, Etienne Rouleau¹¹⁰, Fabienne Prieur¹¹¹, Francesca Damiola⁹, Hagay Sobol¹¹², Isabelle Coupier^{113,114}, Laurence Venat-Bouvet¹¹⁵, Laurent Castera¹³, Marion Gauthier-Villars¹³, Mélanie Léoné⁸, Pascal Pujol^{113,116}, Sylvie Mazoyer⁹, Yves-Jean Bignon¹¹⁷, GEMO Study Collaborators¹¹⁸, Elzbieta Złowocka-Perłowska¹⁶, Jacek Gronwald¹⁶, Jan Lubinski¹⁶, Katarzyna Durda¹⁶, Katarzyna Jaworska^{16,119}, Tomasz Huzarski¹⁶, Amanda B. Spurdle⁷, Alessandra Viel¹²⁰, Bernard Peissel¹²¹, Bernardo Bonanni¹²², Giulia Melloni¹²¹, Laura Ottini¹²³, Laura Papi¹²⁴, Liliana Varesco¹²⁵, Maria Grazia Tibiletti¹²⁶, Paolo Peterlongo^{18,19}, Sara Volorio¹²⁷, Siranoush Manoukian¹²¹, Valeria Pensotti¹²⁷, Norbert Arnold¹²⁸, Christoph Engel¹²⁹, Helmut Deissler¹³⁰, Dorothea Gadzicki¹³¹, Andrea Gehrig¹³², Karin Kast¹³³, Kerstin Rhiem²⁰, Alfons Meindl¹³⁴, Dieter Niederacher¹³⁵, Nina Ditsch¹³⁶, Hansjoerg Plendl¹³⁷, Sabine Preisler-Adams¹³⁸, Stefanie Engert¹³⁴, Christian Sutter¹³⁹, Raymonda Varon-Mateeva¹⁴⁰, Barbara Wappenschmidt²⁰, Bernhard H. F. Weber¹⁴¹, Brita Arver¹⁴², Marie Stenmark-Askmal¹⁴³, Niklas Loman¹⁴⁴, Richard Rosenquist¹⁴⁵, Zakaria Einbeigi¹⁴⁶, Katherine L. Nathanson¹⁴⁷, Timothy R. Rebbeck¹⁴⁸, Stephanie V. Blank¹⁴⁹, David E. Cohn¹⁵⁰, Gustavo C. Rodriguez¹⁵¹, Laurie Small¹⁵², Michael Friedlander¹⁵³, Victoria L. Bae-Jump¹⁵⁴, Anneliese Fink-Retter²⁴, Christine Rappaport²⁴, Daphne Gschwantler-Kaulich²⁴, Georg Pfeiler²⁴, Muy-Kheng Tea²⁴, Noralane M. Lindor¹⁵⁵, Bella Kaufman²⁵, Shani Shimon Paluch²⁵, Yael Laitman²⁵, Anne-Bine Skytte¹⁵⁶, Anne-Marie Gerdes¹⁵⁷, Inge Sokilde Pedersen¹⁵⁸, Sanne Traasdahl Moeller²⁶, Torben A. Kruse²⁶, Uffe Birk Jensen¹⁵⁹, Joseph Vijai¹⁶⁰, Kara Sarrel¹⁶⁰,

Mark Robson¹⁶⁰, Noah Kauff¹⁶⁰, Anna Marie Mulligan^{161,162}, Gord Glendon²⁷, Hilmi Ozelik^{39,161}, Bent Ejlersen¹⁶³, Finn C. Nielsen²⁸, Lars Jønson²⁸, Mette K. Andersen¹⁶⁴, Yuan Chun Ding²⁹, Linda Steele²⁹, Lenka Foretova¹⁶⁵, Alex Teulé³¹, Conxi Lazaro¹⁶⁶, Joan Brunet¹⁶⁷, Miquel Angel Pujana¹⁶⁸, Phuong L. Mai³², Jennifer T. Loud³², Christine Walsh³³, Jenny Lester³³, Sandra Orsulic³³, Steven A. Narod¹⁶⁹, Josef Herzog³⁶, Sharon R. Sand³⁶, Silvia Tognazzo³⁷, Simona Agata³⁷, Tibor Vaszko³⁸, Joellen Weaver¹⁷⁰, Alexandra V. Stavropoulou⁴¹, Saundra S. Buys¹⁷¹, Atocha Romero⁴³, Miguel de la Hoya⁴³, Kristiina Aittomäki¹⁷², Taru A. Muranen⁴⁴, Mercedes Duran¹⁷³, Wendy K. Chung¹⁷⁴, Adriana Lasa¹⁷⁵, Cecilia M. Dorfling⁴⁸, Alexander Miron¹⁷⁶, BCFR¹⁷⁷, Javier Benitez¹⁷⁸, Leigha Senter¹⁷⁹, Dezheng Huo⁵³, Salina B. Chan¹⁸⁰, Anna P. Sokolenko⁵⁸, Jocelyne Chiquette¹⁸¹, Laima Tihomirova¹⁸², Tara M. Friebe¹⁸³, Bjarni A. Agnarsson¹⁸⁴, Karen H. Lu⁶⁶, Flavio Lejbkowitz¹⁸⁵, Paul A. James¹⁸⁶, Per Hall¹⁸⁷, Alison M. Dunning¹⁸⁸, Daniel Tessier¹¹, Julie Cunningham¹, Susan L. Slager⁴, Chen Wang⁴, Steven Hart⁴, Kristen Stevens¹, Jacques Simard⁵, Tomi Pastinen¹⁸⁹, Vernon S. Pankratz⁴, Kenneth Offit¹⁶⁰, Douglas F. Easton³⁹, Georgia Chenevix-Trench⁷⁹, Antonis C. Antoniou^{3*} on behalf of CIMBA

1 Department of Laboratory Medicine and Pathology, and Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America, **2** Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America, **3** Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom, **4** Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America, **5** Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Québec City, Canada, **6** Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, United States of America, **7** Genetics Department, Queensland Institute of Medical Research, Brisbane, Australia, **8** Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon—Centre Léon Bérard, Lyon, France, **9** INSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France, **10** Department of Molecular Pharmacology and Experimental Therapeutics (MPET), Mayo Clinic, Rochester, Minnesota, United States of America, **11** Centre d'Innovation Génomique Québec et Université McGill, Montreal, Canada, **12** Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, The Netherlands, **13** Institut Curie, Department of Tumour Biology, Paris, France, **14** Institut Curie, INSERM U830, Paris, France, **15** Université Paris Descartes, Sorbonne Paris Cité, Paris, France, **16** Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland, **17** Kathleen Cuninghams Consortium for Research into Familial Breast Cancer—Peter MacCallum Cancer Center, Melbourne, Australia, **18** Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy, **19** IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy, **20** Centre of Familial Breast and Ovarian Cancer, Department of Gynaecology and Obstetrics and Centre for Integrated Oncology (CIO), Center for Molecular Medicine Cologne (CMCC), University Hospital of Cologne, Cologne, Germany, **21** Department of Oncology, Lund University, Lund, Sweden, **22** Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, **23** Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, New York, United States of America, **24** Department of Obstetrics and Gynecology, and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria, **25** Sheba Medical Center, Tel Aviv, Israel, **26** Department of Clinical Genetics, Odense University Hospital, Odense, Denmark, **27** Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada, **28** Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, **29** Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California, United States of America, **30** Center for Translational Cancer Research, Department of Biological Sciences, University of Delaware, Newark, Delaware, United States of America, **31** Genetic Counseling Unit, Hereditary Cancer Program, IDIBELL—Catalan Institute of Oncology, Barcelona, Spain, **32** Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States of America, **33** Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America, **34** Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, **35** Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, United States of America, **36** Clinical Cancer Genetics (for the City of Hope Clinical Cancer Genetics Community Research Network), City of Hope, Duarte, California, United States of America, **37** Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV—IRCCS, Padua, Italy, **38** Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary, **39** Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, **40** Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, United States of America, **41** Molecular Diagnostics Laboratory, IRRP, National Centre for Scientific Research Demokritos, Aghia Paraskevi Attikis, Athens, Greece, **42** Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah, United States of America, **43** Molecular Oncology Laboratory, Hospital Clinico San Carlos, IdISSC, Madrid, Spain, **44** Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland, **45** Human Genetics Group, Spanish National Cancer Centre (CNIO), and Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain, **46** Department of Epidemiology, Columbia University, New York, New York, United States of America, **47** Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America, **48** Department of Genetics, University of Pretoria, Pretoria, South Africa, **49** Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany, **50** Department of Preventive Medicine, Keck School of Medicine, University of Southern California, California, United States of America, **51** Division of Human Cancer Genetics, Departments of Internal Medicine and Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States of America, **52** Section of Genetic Oncology, Department of Laboratory Medicine, University of Pisa and University Hospital of Pisa, Pisa, Italy, **53** Center for Clinical Cancer Genetics and Global Health, University of Chicago Medical Center, Chicago, Illinois, United States of America, **54** Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America, **55** Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium, **56** Departments of Medicine, Epidemiology, and Biostatistics, University of California San Francisco, San Francisco, California, United States of America, **57** Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Parkville, Australia, **58** N. N. Petrov Institute of Oncology, St. Petersburg, Russia, **59** Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill University, Montreal, Quebec, Canada, **60** Vilnius University Hospital Santariskiu Clinics, Hematology, Oncology and Transfusion Medicine Center, Department of Molecular and Regenerative Medicine, Vilnius, Lithuania, **61** Department of Epidemiology, Cancer Prevention Institute of California, Fremont, California, United States of America, **62** The Hong Kong Hereditary Breast Cancer Family Registry, Cancer Genetics Center, Hong Kong Sanatorium and Hospital, Hong Kong, China, **63** Oncogenetics Laboratory, University Hospital Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, **64** Department of Medical Oncology, University Hospital, Vall d'Hebron, Barcelona, Spain, **65** Department of Pathology, Landspítali University Hospital and BMC, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, **66** Department of Breast Medical Oncology and Clinical Cancer Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, **67** Clalit National Israeli Cancer Control Center and Department of Community Medicine and Epidemiology, Carmel

Medical Center and B. Rappaport Faculty of Medicine, Haifa, Israel, **68** Cancer Research Initiatives Foundation, Sime Darby Medical Centre and University Malaya Cancer Research Institute, University of Malaya, Kuala Lumpur, Malaysia, **69** UCLA Schools of Medicine and Public Health, Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center, Los Angeles, California, United States of America, **70** VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia, **71** Department of Genetics, University Medical Center, Groningen University, Groningen, The Netherlands, **72** Department of Pathology, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The Netherlands, **73** Department of Medical Oncology, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The Netherlands, **74** Department of Clinical Genetics and GROW, School for Oncology and Developmental Biology, MUMC, Maastricht, The Netherlands, **75** Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands, **76** Department of Clinical Genetics, VU University Medical Centre, Amsterdam, The Netherlands, **77** Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands, **78** Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands, **79** Department of Human Genetics and Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, **80** Department of Human Genetics and Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands, **81** Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands, **82** Department of Human Genetics and Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands, **83** The Hereditary Breast and Ovarian Cancer Research Group Netherlands, Netherlands Cancer Institute, Amsterdam, The Netherlands, **84** Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, **85** Clinical Genetics, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom, **86** Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom, **87** Yorkshire Regional Genetics Service, Leeds, United Kingdom, **88** University of Southampton Faculty of Medicine, Southampton University Hospitals NHS Trust, Southampton, United Kingdom, **89** Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, United Kingdom, **90** Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom, **91** Institute of Genetic Medicine, Centre for Life, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom, **92** Department of Clinical Genetics, St George's University of London, London, United Kingdom, **93** Northern Ireland Regional Genetics Centre, Belfast Health and Social Care Trust, and Department of Medical Genetics, Queens University Belfast, Belfast, United Kingdom, **94** North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Trust and Institute for Womens Health, University College London, London, United Kingdom, **95** Clinical Genetics Department, St Michael's Hospital, Bristol, United Kingdom, **96** Cheshire and Merseyside Clinical Genetics Service, Liverpool Women's NHS Foundation Trust, Liverpool, United Kingdom, **97** All Wales Medical Genetics Services, University Hospital of Wales, Cardiff, United Kingdom, **98** North West Thames Regional Genetics Service, Kennedy-Galton Centre, Harrow, United Kingdom, **99** Nottingham Clinical Genetics Service, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, **100** North of Scotland Regional Genetics Service, NHS Grampian and University of Aberdeen, Foresterhill, Aberdeen, United Kingdom, **101** All Wales Medical Genetics Services, Glan Clwyd Hospital, Rhyl, United Kingdom, **102** All Wales Medical Genetics Services, Singleton Hospital, Swansea, United Kingdom, **103** Centre François Baclesse, Caen, France, **104** Centre René Gauducheau, Nantes, France, **105** Oncogénétique Clinique, Hôpital René Huguenin/Institut Curie, Saint-Cloud, France, **106** Unité de Prévention et d'Epidémiologie Génétique, Centre Léon Bérard, Lyon, France, **107** Université Lyon 1, CNRS UMR5558, Lyon, France, **108** Department of Genetics, Centre Hospitalier Universitaire de Grenoble, Grenoble, France, **109** Institut Albert Bonniot, Université de Grenoble, Grenoble, France, **110** Laboratoire d'Oncogénétique, Hôpital René Huguenin, Institut Curie, Saint-Cloud, France, **111** Service de Génétique Clinique Chromosomique et Moléculaire, Centre Hospitalier Universitaire de St Etienne, St Etienne, France, **112** Département Oncologie Génétique, Prévention et Dépistage, INSERM CIC-P9502, Institut Paoli-Calmettes/Université d'Aix-Marseille II, Marseille, France, **113** Unité d'Oncogénétique, CHU Arnaud de Villeneuve, Montpellier, France, **114** Unité d'Oncogénétique, CRLCC Val d'Aurelle, Montpellier, France, **115** Department of Medical Oncology, Centre Hospitalier Universitaire Dupuytren, Limoges, France, **116** INSERM 896, CRCM Val d'Aurelle, Montpellier, France, **117** Département d'Oncogénétique, Centre Jean Perrin, Université de Clermont-Ferrand, Clermont-Ferrand, France, **118** National Cancer Genetics Network, UNICANCER Genetic Group, Centre de Recherche en Cancérologie de Lyon and Institut Curie Paris, Paris, France, **119** Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, Poland, **120** Division of Experimental Oncology 1, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy, **121** Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy, **122** Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, Milan, Italy, **123** Department of Molecular Medicine, Sapienza University, Rome, Italy, **124** Unit of Medical Genetics, Department of Clinical Physiopathology, University of Florence, Firenze, Italy, **125** Unit of Hereditary Cancer, Department of Epidemiology, Prevention and Special Functions, IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, **126** UO Anatomia Patologica, Ospedale di Circolo-Università dell'Insubria, Varese, Italy, **127** IFOM, Fondazione Istituto FIRC di Oncologia Molecolare and Cogentech Cancer Genetic Test Laboratory, Milan, Italy, **128** University Hospital of Schleswig-Holstein/University Kiel, Kiel, Germany, **129** Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany, **130** University Hospital Ulm, Ulm, Germany, **131** Hannover Medical School, Hanover, Germany, **132** Institute of Human Genetics, University of Würzburg, Würzburg, Germany, **133** Department of Gynaecology and Obstetrics, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany, **134** Department of Gynaecology and Obstetrics, Division of Tumor Genetics, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany, **135** Department of Obstetrics and Gynaecology, University Medical Center Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany, **136** Department of Gynaecology and Obstetrics, University of Munich, Munich, Germany, **137** Institute of Human Genetics, University Hospital of Schleswig-Holstein, University of Kiel, Kiel, Germany, **138** Institute of Human Genetics, Münster, Germany, **139** Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany, **140** Institute of Medical and Human Genetics, Berlin, Germany, **141** Institute of Human Genetics, University of Regensburg, Regensburg, Germany, **142** Department of Oncology and Pathology, Karolinska University Hospital, Stockholm, Sweden, **143** Division of Clinical Genetics, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, **144** Department of Oncology, Lund University Hospital, Lund, Sweden, **145** Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden, **146** Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden, **147** Abramson Cancer Center and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, **148** Abramson Cancer Center and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, **149** NYU Women's Cancer Program, New York University School of Medicine, New York, New York, United States of America, **150** Ohio State University, Columbus Cancer Council, Columbus, Ohio, United States of America, **151** Division of Gynecologic Oncology, North Shore University Health System, University of Chicago, Evanston, Illinois, United States of America, **152** Maine Medical Center, Maine Women's Surgery and Cancer Centre, Scarborough, Maine, United States of America, **153** ANZ GOTG Coordinating Centre, Australia New Zealand GOG, Camperdown, Australia, **154** The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, **155** Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America, **156** Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark, **157** Department of Clinical Genetics, Rigshospitalet, København, Denmark, **158** Section of Molecular Diagnostics, Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark, **159** Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark, **160** Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, **161** Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada, **162** Department of Laboratory Medicine, and the Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Canada, **163** Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, **164** Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, **165** Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic, **166** Molecular Diagnostic Unit, Hereditary Cancer Program, IDIBELL-Catalan Institute of Oncology, Barcelona, Spain, **167** Genetic Counseling Unit, Hereditary Cancer Program, IDIBGI-Catalan Institute of Oncology, Girona, Spain, **168** Translational Research Laboratory, Breast Cancer and Systems Biology Unit, IDIBELL-Catalan Institute of Oncology, Barcelona, Spain, **169** Women's College Research Institute, University of Toronto, Toronto, Canada, **170** Biosample Repository, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America, **171** Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, United States of America, **172** Department of Clinical Genetics, Helsinki University Central Hospital, Helsinki,

Finland, **173** Institute of Biology and Molecular Genetics, Universidad de Valladolid (IBGM–UVA), Valladolid, Spain, **174** Departments of Pediatrics and Medicine, Columbia University, New York, New York, United States of America, **175** Genetics Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, **176** Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, **177** Breast Cancer Family Registry, Cancer Prevention Institute of California, Fremont, California, United States of America, **178** Human Genetics Group and Genotyping Unit, Spanish National Cancer Centre (CNIO), and Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain, **179** Division of Human Genetics, Department of Internal Medicine, The Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States of America, **180** Cancer Risk Program, Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, California, United States of America, **181** Unité de Recherche en Santé des Populations, Centre des Maladies du Sein Deschênes-Fabia, Centre de Recherche FRSQ du Centre Hospitalier Affilié Universitaire de Québec, Québec, Canada, **182** Latvian Biomedical Research and Study Centre, Riga, Latvia, **183** University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, **184** Landspítali University Hospital and University of Iceland School of Medicine, Reykjavík, Iceland, **185** Clalit National Israeli Cancer Control Center and Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel, **186** Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Australia, **187** Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, **188** Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom, **189** Department of Human Genetics, McGill University and Génome Québec Innovation Centre, McGill University, Montréal, Canada

Abstract

BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 *BRCA1* carriers (of whom 5,920 were diagnosed with breast and 1,839 were diagnosed with ovarian cancer), with a further replication in an additional sample of 2,646 *BRCA1* carriers. We identified a novel breast cancer risk modifier locus at 1q32 for *BRCA1* carriers (rs2290854, $P = 2.7 \times 10^{-8}$, HR = 1.14, 95% CI: 1.09–1.20). In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, $P = 1.4 \times 10^{-8}$, HR = 1.27, 95% CI: 1.17–1.38) and 4q32.3 (rs4691139, $P = 3.4 \times 10^{-8}$, HR = 1.20, 95% CI: 1.17–1.38). The 4q32.3 locus was not associated with ovarian cancer risk in the general population or *BRCA2* carriers, suggesting a *BRCA1*-specific association. The 17q21.31 locus was also associated with ovarian cancer risk in 8,211 *BRCA2* carriers ($P = 2 \times 10^{-4}$). These loci may lead to an improved understanding of the etiology of breast and ovarian tumors in *BRCA1* carriers. Based on the joint distribution of the known *BRCA1* breast cancer risk-modifying loci, we estimated that the breast cancer lifetime risks for the 5% of *BRCA1* carriers at lowest risk are 28%–50% compared to 81%–100% for the 5% at highest risk. Similarly, based on the known ovarian cancer risk-modifying loci, the 5% of *BRCA1* carriers at lowest risk have an estimated lifetime risk of developing ovarian cancer of 28% or lower, whereas the 5% at highest risk will have a risk of 63% or higher. Such differences in risk may have important implications for risk prediction and clinical management for *BRCA1* carriers.

Citation: Couch FJ, Wang X, McGuffog L, Lee A, Olsowd C, et al. (2013) Genome-Wide Association Study in *BRCA1* Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. *PLoS Genet* 9(3): e1003212. doi:10.1371/journal.pgen.1003212

Editor: Kent W. Hunter, National Cancer Institute, United States of America

Received: September 7, 2012; **Accepted:** November 14, 2012; **Published:** March 27, 2013

Copyright: © 2013 Couch et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The study was supported by NIH grant CA128978, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a U.S. Department of Defense Ovarian Cancer Idea award (W81XWH-10-1-0341), grants from the Breast Cancer Research Foundation and the Komen Foundation for the Cure; Cancer Research UK grants C12292/A11174 and C1287/A10118; the European Commission's Seventh Framework Programme grant agreement 223175 (HEALTH-F2-2009-223175). Breast Cancer Family Registry Studies (BCFR): supported by the National Cancer Institute, National Institutes of Health under RFA # CA-06-503 and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR) and Principal Investigators, including Cancer Care Ontario (U01 CA69467), Cancer Prevention Institute of California (U01 CA69417), Columbia University (U01 CA69398), Fox Chase Cancer Center (U01 CA69631), Huntsman Cancer Institute (U01 CA69446), and University of Melbourne (U01 CA69638). The Australian BCFR was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia), and the Victorian Breast Cancer Research Consortium. Melissa C. Southey is a NHMRC Senior Research Fellow and a Victorian Breast Cancer Research Consortium Group Leader. Carriers at FCCC were also identified with support from National Institutes of Health grants P01 CA16094 and R01 CA22435. The New York BCFR was also supported by National Institutes of Health grants P30 CA13696 and P30 ES009089. The Utah BCFR was also supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH grant UL1 RR025764, and by Award Number P30 CA042014 from the National Cancer Institute. Baltic Familial Breast Ovarian Cancer Consortium (BFBOCC): BFBOCC is partly supported by Lithuania (BFBOCC-LT), Research Council of Lithuania grant LIG-19/2010, and Hereditary Cancer Association (Paveldimo vėžio asociacija). Latvia (BFBOCC-LV) is partly supported by LSC grant 10.0010.08 and in part by a grant from the ESF Nr.2009/0220/1DP/1.1.1.2.0/09/APIA/VIAA/016. BRCA-gene mutations and breast cancer in South African women (BMBSA): BMBSA was supported by grants from the Cancer Association of South Africa (CANSA) to Elizabeth J. van Rensburg. Beckman Research Institute of the City of Hope (BRICOH): Susan L. Neuhausen was partially supported by the Morris and Horowitz Families Endowed Professorship. BRICOH was supported by NIH R01CA74415 and NIH P30 CA033752. Copenhagen Breast Cancer Study (CBCS): The CBCS study was supported by the NEYE Foundation. Spanish National Cancer Centre (CNIO): This work was partially supported by Spanish Association against Cancer (AECC08), RTICC 06/0020/1060, FISPI08/1120, Mutua Madrileña Foundation (FMMA) and SAF2010-20493. City of Hope Cancer Center (COH): The City of Hope Clinical Cancer Genetics Community Research Network is supported by Award Number RC4A153828 (PI: Jeffrey N. Weitzel) from the National Cancer Institute and the Office of the Director, National Institutes of Health. CONSORZIO STUDI ITALIANI SUI TUMORI EREDITARI ALLA MAMMELLA (CONSIT TEAM): CONSIT TEAM was funded by grants from Fondazione Italiana per la Ricerca sul Cancro (Special Project "Hereditary tumors"), Italian Association for Cancer Research (AIRC, IG 8713), Italian Ministry of Health (Extraordinary National Cancer Program 2006, "Alleanza contro il Cancro" and "Progetto Tumori Femminili), Italian Ministry of Education, University and Research (Prin 2008) Centro di Ascolto Donne Operate al Seno (CAOS) association and by funds from Italian citizens who allocated the 5×1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects '5×1000'). German Cancer Research Center (DKFZ): The DKFZ study was supported by the DKFZ. The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON): HEBON is supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756, the NWO grant 91109024, the Pink Ribbon grant 110005, and the BBMRI grant CP46/NWO. Epidemiological study of *BRCA1* & *BRCA2* mutation carriers (EMBRACE): EMBRACE is supported by Cancer Research UK Grants C1287/A10118 and C1287/A11990. D. Gareth Evans and Fiona Lalloo are supported by an NIHR grant to the Biomedical Research Centre, Manchester. The Investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. Rosalind A. Eeles and Elizabeth Bancroft are supported by Cancer Research UK Grant C5047/A8385. Fox Chase Cancer Center (FCCC): The authors acknowledge support from The University of Kansas Cancer Center and the Kansas Bioscience Authority Eminent Scholar Program. Andrew K. Godwin was funded by 5U01CA113916, R01CA140323, and by the Chancellors Distinguished Chair in Biomedical Sciences

Professorship. German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC): The German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) is supported by the German Cancer Aid (grant no 109076, Rita K. Schmutzler) and by the Center for Molecular Medicine Cologne (CMMC). Genetic Modifiers of cancer risk in *BRCA1/2* mutation carriers (GEMO): The GEMO study was supported by the Ligue National Contre le Cancer; the Association "Le cancer du sein, parlons-en!" Award and the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program. Gynecologic Oncology Group (GOG): This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office and Tissue Bank (CA 27469), Statistical and Data Center (CA 37517), and GOG's Cancer Prevention and Control Committee (CA 101165). Drs. Mark H. Greene and Phuong L. Mai were supported by funding from the Intramural Research Program, NCI, NIH. Hospital Clinico San Carlos (HCSC): HCSC was supported by RETICC 06/0020/0021, FIS research grant 09/00859, Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness, and the European Regional Development Fund (ERDF). Helsinki Breast Cancer Study (HEBCS): The HEBCS was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (132473), the Finnish Cancer Society, the Nordic Cancer Union, and the Sigrid Juselius Foundation. Study of Genetic Mutations in Breast and Ovarian Cancer patients in Hong Kong and Asia (HRBCP): HRBCP is supported by The Hong Kong Hereditary Breast Cancer Family Registry and the Dr. Ellen Li Charitable Foundation, Hong Kong. Molecular Genetic Studies of Breast and Ovarian Cancer in Hungary (HUNBOCS): HUNBOCS was supported by Hungarian Research Grant KTIA-OTKA CK-80745 and the Norwegian EEA Financial Mechanism HU0115/NA/2008-3/ÖP-9. Institut Català d'Oncologia (ICO): The ICO study was supported by the Asociación Española Contra el Cáncer, Spanish Health Research Foundation, Ramón Areces Foundation, Carlos III Health Institute, Catalan Health Institute, and Autonomous Government of Catalonia and contract grant numbers: ISCIII-RETIC RD06/0020/1051, PI09/02483, PI10/01422, PI10/00748, 2009SGR290, and 2009SGR283. International Hereditary Cancer Centre (IHCC): Supported by the Polish Foundation of Science. Katarzyna Jaworska is a fellow of International PhD program, Postgraduate School of Molecular Medicine, Warsaw Medical University. Iceland Landsþítali-University Hospital (ILUH): The ILUH group was supported by the Icelandic Association "Walking for Breast Cancer Research" and by the Landsþítali University Hospital Research Fund. Interdisciplinary Health Research Internal Team Breast Cancer susceptibility (INHERIT): INHERIT work was supported by the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program, the Canadian Breast Cancer Research Alliance grant 019511 and the Ministry of Economic Development, Innovation and Export Trade grant PSR-SIIRI-701. Jacques Simard is Chairholder of the Canada Research Chair in Oncogenetics. Istituto Oncologico Veneto (IOVHBOCS): The IOVHBOCS study was supported by Ministero dell'Istruzione, dell'Università e della Ricerca and Ministero della Salute ("Progetto Tumori Femminili" and RFP5 2006-5-341353,ACC2/R6.9"). Kathleen Cuninghame Consortium for Research into Familial Breast Cancer (kConFab): kConFab is supported by grants from the National Breast Cancer Foundation and the National Health and Medical Research Council (NHMRC) and by the Queensland Cancer Fund; the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia; and the Cancer Foundation of Western Australia. Amanda B. Spurdle is an NHMRC Senior Research Fellow. The Clinical Follow Up Study was funded from 2001–2009 by NHMRC and currently by the National Breast Cancer Foundation and Cancer Australia #628333. Mayo Clinic (MAYO): MAYO is supported by NIH grant CA128978, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a U.S. Department of Defence Ovarian Cancer Idea award (W81XWH-10-1-0341) and grants from the Breast Cancer Research Foundation and the Komen Foundation for the Cure. McGill University (MCGILL): The McGill Study was supported by Jewish General Hospital Weekend to End Breast Cancer, Quebec Ministry of Economic Development, Innovation, and Export Trade. Memorial Sloan-Kettering Cancer Center (MSKCC): The MSKCC study was supported by Breast Cancer Research Foundation, Niehaus Clinical Cancer Genetics Initiative, Andrew Sabin Family Foundation, and Lymphoma Foundation. Modifier Study of Quantitative Effects on Disease (MODSQUAD): MODSQUAD was supported by the European Regional Development Fund and the State Budget of the Czech Republic (RECAMO, CZ.1.05/2.1.00/03.0101). Women's College Research Institute, Toronto (NAROD): NAROD was supported by NIH grant: 1R01 CA149429-01. National Cancer Institute (NCI): Drs. Mark H. Greene and Phuong L. Mai were supported by the Intramural Research Program of the US National Cancer Institute, NIH, and by support services contracts NO2-CP-11019-50 and NO2-CP-65504 with Westat, Rockville, MD. National Israeli Cancer Control Center (NICCC): NICCC is supported by Clalit Health Services in Israel. Some of its activities are supported by the Israel Cancer Association and the Breast Cancer Research Foundation (BCRF), NY. N. N. Petrov Institute of Oncology (NNPIO): The NNPIO study has been supported by the Russian Foundation for Basic Research (grants 11-04-00227, 12-04-00928, and 12-04-01490), the Federal Agency for Science and Innovations, Russia (contract 02.740.11.0780), and through a Royal Society International Joint grant (JP090615). The Ohio State University Comprehensive Cancer Center (OSU-CCG): OSUCCG is supported by the Ohio State University Comprehensive Cancer Center. South East Asian Breast Cancer Association Study (SEABASS): SEABASS is supported by the Ministry of Science, Technology and Innovation, Ministry of Higher Education (UM.C/HIR/MOHE/06) and Cancer Research Initiatives Foundation. Sheba Medical Centre (SMC): The SMC study was partially funded through a grant by the Israel Cancer Association and the funding for the Israeli Inherited Breast Cancer Consortium. Swedish Breast Cancer Study (SWE-BRCA): SWE-BRCA collaborators are supported by the Swedish Cancer Society. The University of Chicago Center for Clinical Cancer Genetics and Global Health (UCHICAGO): UCHICAGO is supported by grants from the US National Cancer Institute (NIH/NCI) and by the Ralph and Marion Falk Medical Research Trust, the Entertainment Industry Fund National Women's Cancer Research Alliance, and the Breast Cancer Research Foundation. University of California Los Angeles (UCLA): The UCLA study was supported by the Jonsson Comprehensive Cancer Center Foundation and the Breast Cancer Research Foundation. University of California San Francisco (UCSF): The UCSF study was supported by the UCSF Cancer Risk Program and the Helen Diller Family Comprehensive Cancer Center. United Kingdom Familial Ovarian Cancer Registries (UKFOCR): UKFOCR was supported by a project grant from CRUK to Paul Pharoah. University of Pennsylvania (UPENN): The UPENN study was supported by the National Institutes of Health (NIH) (R01-CA102776 and R01-CA083855), Breast Cancer Research Foundation, Rooney Family Foundation, Susan G. Komen Foundation for the Cure, and the Macdonald Family Foundation. Victorian Familial Cancer Trials Group (VFCTG): The VFCTG study was supported by the Victorian Cancer Agency, Cancer Australia, and National Breast Cancer Foundation. Women's Cancer Research Initiative (WCRI): The WCRI at the Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, is funded by the American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: couch.fergus@mayo.edu (Fergus J Couch); Antonis@srll.cam.ac.uk (Antonis C Antoniou)

‡ These authors contributed equally to this work.

Introduction

Breast and ovarian cancer risk estimates for *BRCA1* mutation carriers vary by the degree of family history of the disease, suggesting that other genetic factors modify cancer risks for this population [1–4]. Studies by the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA) have shown that a subset of common alleles influencing breast and ovarian cancer risk in the general population are also associated with cancer risk in *BRCA1* mutation carriers [5–11]. In particular, the breast cancer associations were limited to loci associated with estrogen receptor (ER)-negative breast cancer in the general population (6q25.1, 12p11 and *TOX3*) [8–11].

To systematically search for loci associated with breast or ovarian cancer risk for *BRCA1* carriers we previously conducted a

two-stage genome-wide association study (GWAS) [12]. The initial stage involved analysis of 555,616 SNPs in 2383 *BRCA1* mutation carriers (1,193 unaffected and 1,190 affected). After replication testing of 89 SNPs showing the strongest association, with 5,986 *BRCA1* mutation carriers, a locus on 19p13 was shown to be associated with breast cancer risk for *BRCA1* mutation carriers. The same locus was also associated with the risk of estrogen-receptor (ER) negative and triple negative (ER, Progesterone and HER2 negative) breast cancer in the general population [12,13].

The Collaborative Oncological Gene-environment Study (COGS) consortium recently developed a 211,155 SNP custom genotyping array (iCOGS) in order to provide cost-effective genotyping of common and rare genetic variants to identify novel loci that explain the residual genetic variance of breast, ovarian

Author Summary

BRCA1 mutation carriers have increased and variable risks of breast and ovarian cancer. To identify modifiers of breast and ovarian cancer risk in this population, a multi-stage GWAS of 14,351 *BRCA1* mutation carriers was performed. Loci 1q32 and *TCF7L2* at 10q25.3 were associated with breast cancer risk, and two loci at 4q32.2 and 17q21.31 were associated with ovarian cancer risk. The 4q32.3 ovarian cancer locus was not associated with ovarian cancer risk in the general population or in *BRCA2* carriers and is the first indication of a *BRCA1*-specific risk locus for either breast or ovarian cancer. Furthermore, modeling the influence of these modifiers on cumulative risk of breast and ovarian cancer in *BRCA1* mutation carriers for the first time showed that a wide range of individual absolute risks of each cancer can be estimated. These differences suggest that genetic risk modifiers may be incorporated into the clinical management of *BRCA1* mutation carriers.

and prostate cancers and fine-map known susceptibility loci. A total of 32,557 SNPs on the iCOGS array were selected on the basis of the *BRCA1* GWAS for the purpose of identifying breast and ovarian cancer risk modifiers for *BRCA1* mutation carriers. Genotype data from the iCOGS array were obtained for 11,705 samples from *BRCA1* carriers and the 17 most promising SNPs were then genotyped in an additional 2,646 *BRCA1* carriers. In this manuscript we report on the novel risk modifier loci identified by this multi-stage GWAS. No study has previously shown how the absolute risks of breast and ovarian cancer for *BRCA1* mutation carriers vary by the combined effects of risk modifying loci. Here we use the results from this study, in combination with previously identified modifiers, to obtain absolute risks of developing breast and ovarian cancer for *BRCA1* mutation carriers based on the joint distribution of all known genetic risk modifiers.

Materials and Methods

Ethics statement

All carriers participated in clinical or research studies at the host institutions, approved by local ethics committees.

Study subjects

BRCA1 mutation carriers were recruited by 45 study centers in 25 countries through CIMBA. The majority were recruited through cancer genetics clinics, and enrolled into national or regional studies. The remainder were identified by population-based sampling or community recruitment. Eligibility for CIMBA association studies was restricted to female carriers of pathogenic *BRCA1* mutations age 18 years or older at recruitment. Information collected included year of birth, mutation description, self-reported ethnic ancestry, age at last follow-up, ages at breast or ovarian cancer diagnoses, and age at bilateral prophylactic mastectomy and oophorectomy. Information on tumour characteristics, including ER-status of the breast cancers, was also collected. Related individuals were identified through a unique family identifier. Women were included in the analysis if they carried mutations that were pathogenic according to generally recognized criteria.

GWAS stage 1 samples. A total of 2,727 *BRCA1* mutation carriers were genotyped on the Illumina Infinium 610K array (Figure 1). Of these 1,426 diagnosed with a first breast cancer under age 40 were considered “affected” in the breast cancer

association analysis and 683 diagnosed with an ovarian cancer at any time were considered as “affected” in the ovarian cancer analysis. “Unaffected” in both analyses were over age 35 (Table S1) [12].

Replication study samples. All eligible *BRCA1* carriers from CIMBA with sufficient DNA were genotyped, including those used in Stage 1. In total, 13,310 samples from 45 centers in 25 countries were genotyped using the iCOGS array (Table S2). Among the 13,310 samples, those that were genotyped in the GWAS stage 1 SNP selection stage are referred to as “stage 1” samples, and the remainder are “stage 2” samples. An additional 2,646 *BRCA1* samples “stage 3” were genotyped on an iPLEX Mass Array of 17 SNPs from 12 loci selected after an interim analysis of iCOGS array data and were available for analysis after quality control (QC) (Figure 1). Carriers of pathogenic mutations in *BRCA2* were drawn from a parallel GWAS of genetic modifiers for *BRCA2* mutation carriers. *BRCA2* mutation carriers were recruited from CIMBA through 47 studies which were largely the same as the studies that contributed to the *BRCA1* GWAS with similar eligibility criteria. Samples from *BRCA2* mutation carriers were also genotyped using the iCOGS array. Details of this experiment are described elsewhere [14]. A total of 8,211 samples were available for analysis after QC.

iCOGS SNP array

The iCOGS array was designed in a collaboration among the Breast Cancer Association Consortium (BCAC), Ovarian Cancer Association Consortium (OCAC), the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) and CIMBA. The general aims for designing the iCOGS array were to replicate findings from GWAS for identifying variants associated with breast, ovarian or prostate cancer (including subtypes and SNPs potentially associated with disease outcome), to facilitate fine-mapping of regions of interest, and to genotype “candidate” SNPs of interest within the consortia, including rarer variants. Each consortium was given a share of the array: nominally 25% of the SNPs each for BCAC, PRACTICAL and OCAC; 17.5% for CIMBA; and 7.5% for SNPs of common interest between the consortia. The final design comprised 220,123 SNPs, of which 211,155 were successfully manufactured. A total of 32,557 SNPs on the iCOGS array were selected based on 8 separate analyses of stage 1 of the CIMBA *BRCA1* GWAS that included 2,727 *BRCA1* mutation carriers [12]. After imputation for all SNPs in HapMap Phase II (CEU) a total of 2,568,349 (imputation $r^2 > 0.30$) were available for analysis. Markers were evaluated for associations with: (1) breast cancer; (2) ovarian cancer; (3) breast cancer restricted to Class 1 mutations (loss-of-function mutations expected to result in a reduced transcript or protein level due to nonsense-mediated RNA decay); (4) breast cancer restricted to Class 2 mutations (mutations likely to generate stable proteins with potential residual or dominant negative function); (5) breast cancer by tumor ER-status; (6) breast cancer restricted to *BRCA1* 185delAG mutation carriers; (7) breast cancer restricted to *BRCA1* 5382insC mutation carriers; and (8) breast cancer by contrasting the genotype distributions in *BRCA1* mutation carriers, against the distribution in population-based controls. Analyses (1) and (2) were based on both imputed and observed genotypes, whereas the rest were based on only the observed genotypes. SNPs were ranked according to the 1 d.f. score-test for trend P-value (described below) and selected for inclusion based on nominal proportions of 61.5%, 20%, 2.5%, 2.5%, 2.5%, 0.5%, 0.5% and 10.0% for analyses (1) to (8). SNP duplications were not allowed and SNPs with a pairwise $r^2 \geq 0.90$ with a higher-ranking SNP were only allowed (up to a maximum




Figure 1. Study design for selection of the SNPs and genotyping of *BRCA1* samples. GWAS data from 2,727 *BRCA1* mutation carriers were analysed for associations with breast and ovarian cancer risk and 32,557 SNPs were selected for inclusion on the iCOGS array. A total of 11,705 *BRCA1* samples (after quality control (QC) checks) were genotyped on the 31,812 *BRCA1*-GWAS SNPs from the iCOGS array that passed QC. Of these samples, 2,387 had been genotyped at the SNP selection stage and are referred to as “stage 1” samples, whereas 9,318 samples were unique to the iCOGS study (“Stage 2” samples). Next, 17 SNPs that exhibited the most significant associations with breast and ovarian cancer were selected for genotyping in a third stage involving an additional 2,646 *BRCA1* samples (after QC). doi:10.1371/journal.pgen.1003212.g001

of 2) if the P-value for association was $<10^{-4}$ for analyses (1) and (2) and $<10^{-5}$ for other analyses. SNPs with poor Illumina design scores were replaced by the SNP with the highest r^2 (among SNPs with $r^2 > 0.80$ based on HapMap data) that had a good quality design score. The analysis of associations with breast and ovarian cancer risks presented here included all 32,557 SNPs on iCOGS that were selected on the basis of the *BRCA1* GWAS.

Genotyping and quality control

iCOGS genotyping. Genotyping was performed at Mayo Clinic. Genotypes for samples genotyped on the iCOGS array were called using Illumina’s GenCall algorithm (Text S1). A total of 13,510 samples were genotyped for 211,155 SNPs. The sample and SNP QC process is summarised in Table S3. Of the 13,510 samples, 578 did not fulfil eligibility criteria based on phenotypic

data and were excluded. A step-wise QC process was applied to the remaining samples and SNPs. Samples were excluded due to inferred gender errors, low call rates (<95%), low or high heterozygosity and sample duplications (cryptic and intended). Of the 211,155 markers genotyped, 9,913 were excluded due to Y-chromosome origin, low call rates (<95%), monomorphic SNPs, or SNPs with Hardy-Weinberg equilibrium (HWE) $P < 10^{-7}$ under a country-stratified test statistic [15] (Table S3). SNPs that gave discordant genotypes among known sample duplicates were also excluded. Multi-dimensional scaling was used to exclude individuals of non-European ancestry. We selected 37,149 weakly correlated autosomal SNPs (pair-wise $r^2 < 0.10$) to compute the genomic kinship between all pairs of *BRCA1* carriers, along with 197 HapMap samples (CHB, JPT, YRI and CEU). These were converted to distances and subjected to multidimensional scaling (Figure S1). Using the first two components, we calculated the proportion of European ancestry for each individual [12] and excluded samples with >22% non-European ancestry (Figure S1). A total of 11,705 samples and 201,242 SNPs were available for analysis, including 31,812 SNPs selected by the *BRCA1* GWAS. The genotyping cluster plots for all SNPs that demonstrated genome-wide significance level of association or are presented below, were checked manually for quality (Figure S2).

iPLEX analysis. The most significant SNPs from 4 loci associated with ovarian cancer and 8 loci associated with breast cancer were selected (17 SNPs in total) for stage 3 genotyping. Genotyping using the iPLEX Mass Array platform was performed at Mayo Clinic. CIMBA QC procedures were applied. Samples that failed for $\geq 20\%$ of the SNPs were excluded from the analysis. No SNPs failed HWE ($P < 0.01$). The concordance among duplicates was $\geq 98\%$. Mutation carriers of self-reported non-European ancestry were excluded. A total of 2,646 *BRCA1* samples were eligible for analysis after QC.

Statistical methods

The main analyses were focused on the evaluation of associations between each genotype and breast cancer or ovarian cancer risk separately. Analyses were carried out within a survival analysis framework. In the breast cancer analysis, the phenotype of each individual was defined by age at breast cancer diagnosis or age at last follow-up. Individuals were followed until the age of the first breast cancer diagnosis, ovarian cancer diagnosis, or bilateral prophylactic mastectomy, whichever occurred first; or last observation age. Mutation carriers censored at ovarian cancer diagnosis were considered unaffected. For the ovarian cancer analysis, the primary endpoint was the age at ovarian cancer diagnosis. Mutation carriers were followed until the age of ovarian cancer diagnosis, or risk-reducing salpingo-oophorectomy (RRSO) or age at last observation. In order to maximize the number of ovarian cancer cases, breast cancer was not considered as a censoring event in this analysis, and mutation carriers who developed ovarian cancer after a breast cancer diagnosis were considered as affected in the ovarian cancer analysis.

Association analysis. The majority of mutation carriers were sampled through families seen in genetic clinics. The first tested individual in a family is usually someone diagnosed with cancer at a relatively young age. Such study designs tend to lead to an over-sampling of affected individuals, and standard analytical methods like Cox regression may lead to biased estimates of the risk ratios [16,17]. To adjust for this potential bias the data were analyzed within a survival analysis framework, by modeling the retrospective likelihood of the observed genotypes conditional on the disease phenotypes. A detailed description of the retrospective likelihood approach has been published [17,18]. The associations

between genotype and breast cancer risk at both stages were assessed using the 1 d.f. score test statistic based on this retrospective likelihood [17,18]. To allow for the non-independence among related individuals, we accounted for the correlation between the genotypes by estimating the kinship coefficient for each pair of individuals using the available genomic data [16,19,20] and by robust variance estimation based on reported family membership [21]. We chose to present P-values based on the kinship adjusted score test as it utilises the degree of relationship between individuals. A genome-wide level of significance of 5×10^{-8} was used [22]. These analyses were performed in R using the GenABEL [23] libraries and custom-written functions in FORTRAN and Python.

To estimate the magnitude of the associations (HRs), the effect of each SNP was modeled either as a per-allele HR (multiplicative model) or as genotype-specific HRs, and were estimated on the log-scale by maximizing the retrospective likelihood. The retrospective likelihood was fitted using the pedigree-analysis software MENDEL [17,24]. As sample sizes varied substantially between contributing centers heterogeneity was examined at the country level. All analyses were stratified by country of residence and used calendar-year and cohort-specific breast cancer incidence rates for *BRCA1* [25]. Countries with small number of mutation carriers were combined with neighbouring countries to ensure sufficiently large numbers within each stratum (Table S2). USA and Canada were further stratified by reported Ashkenazi Jewish (AJ) ancestry due to large numbers of AJ carriers. In stage 3 analysis involving several countries with small numbers of mutation carriers, we assumed only 3 large strata (Europe, Australia, USA/Canada). The combined iCOGS stage and stage 3 analysis was also stratified by stage of the experiment. The analysis of associations by breast cancer ER-status was carried out by an extension of the retrospective likelihood approach to model the simultaneous effect of each SNP on more than one tumor subtype [26] (Text S1).

Competing risk analysis. The associations with breast and ovarian cancer risk simultaneously were assessed within a competing risk analysis framework [17] by estimating HRs simultaneously for breast and ovarian cancer risk. This analysis provides unbiased estimates of association with both diseases and more powerful tests of association in cases where an association exists between a variant and at least one of the diseases [17]. Each individual was assumed to be at risk of developing either breast or ovarian cancer, and the probabilities of developing each disease were assumed to be independent conditional on the underlying genotype. A different censoring process was used, whereby individuals were followed up to the age of the first breast or ovarian cancer diagnosis and were considered to have developed the corresponding disease. No follow-up was considered after the first cancer diagnosis. Individuals censored for breast cancer at the age of bilateral prophylactic mastectomy and for ovarian cancer at the age of RRSO were assumed to be unaffected for the corresponding disease. The remaining individuals were censored at the last observation age and were assumed to be unaffected for both diseases.

Imputation. For the SNP selection process, the MACH software was used to impute non-genotyped SNPs based on the phased haplotypes from HapMap Phase II (CEU, release 22). The IMPUTE2 software [27] was used to impute non-genotyped SNPs for samples genotyped on the iCOGS array (stage 1 and 2 only), based on the 1,000 Genomes haplotypes (January 2012 version). Associations between each marker and cancer risk were assessed using a similar score test to that used for the observed SNPs, but based on the posterior genotype probabilities at each imputed marker for each individual. In all analyses, we considered only SNPs with imputation information/accuracy $r^2 > 0.30$.

Absolute breast and ovarian cancer risks by combined SNP profile. We estimated the absolute risk of developing breast and ovarian cancer based on the joint distribution of all SNPs that were significantly associated with risk for *BRCA1* mutation carriers based on methods previously applied to *BRCA2* carriers [28]. We assumed that the average, age-specific breast and ovarian cancer incidences for *BRCA1* mutation carriers, over all modifying loci, agreed with published penetrance estimates for *BRCA1* [25]. The model assumed independence among the modifying loci and we used only the SNP with the strongest evidence of association from each region. We used only loci identified through the *BRCA1* GWAS that exhibited associations at a genome-wide significance level, and loci that were identified through population-based GWAS of breast or ovarian cancer risk, but were also associated with those risks for *BRCA1* mutation carriers. For each SNP, we used the per-allele HR and minor allele frequencies estimated from the present study. Genotype frequencies were obtained under the assumption of HWE.

Results

Samples from 11,705 *BRCA1* carriers from 45 centers in 25 countries yielded high-quality data for 201,242 SNPs on the iCOGS array. The array included 31,812 *BRCA1* GWAS SNPs, which were analyzed here for their associations with breast and ovarian cancer risk for *BRCA1* mutation carriers (Table S2). Of the 11,705 *BRCA1* mutation carriers, 2,387 samples had also been genotyped for stage 1 of the GWAS and 9,318 were unique to the stage 2 iCOGS study.

Breast cancer associations

When restricting analysis to stage 2 samples (4,681 unaffected, 4,637 affected), there was little evidence of inflation in the association test-statistic ($\lambda = 1.038$; Figure S3). Combined analysis of stage 1 and 2 samples (5,784 unaffected, 5,920 affected) revealed 66 SNPs in 28 regions with $P < 10^{-4}$ (Figure S4). These included variants from three loci (19p13, 6q25.1, 12p11) previously associated with breast cancer risk for *BRCA1* mutation carriers (Table 1). Further evaluation of 18 loci associated with breast cancer susceptibility in the general population found that only the *TOX3*, *LSP1*, 2q35 and *RAD51L1* loci were significantly associated with breast cancer for *BRCA1* carriers (Table 1, Table S4).

After excluding SNPs from the known loci, there were 39 SNPs in 25 regions with $P = 1.2 \times 10^{-6}$ – 1.0×10^{-4} . Twelve of these SNPs were genotyped by iPLEX in an additional 2,646 *BRCA1* carriers (1,252 unaffected, 1,394 affected, “stage 3” samples, Table S5). There was additional evidence of association with breast cancer risk for four SNPs at two loci ($P < 0.01$, Table 2). When all stages were combined, SNPs rs2290854 and rs6682208 ($r^2 = 0.84$) at 1q32, near *MDM4*, had combined *P*-values of association with breast cancer risk of 1.4×10^{-7} and 4×10^{-7} , respectively. SNPs rs11196174 and rs11196175 ($r^2 = 0.96$) at 10q25.3 (in *TCF7L2*) had combined *P*-values of 7.5×10^{-7} and 1.2×10^{-6} . Analysis within a competing risks framework, where associations with breast and ovarian cancer risks are evaluated simultaneously [17], revealed stronger associations with breast cancer risk for all 4 SNPs, but no associations with ovarian cancer (Table 3). In particular, we observed a genome-wide significant association between the minor allele of rs2290854 from 1q32 and breast cancer risk (per-allele HR: 1.14; 95%CI: 1.09–1.20; $p = 2.7 \times 10^{-8}$). Country-specific HR estimates for all SNPs are shown in Figure S5. Analyses stratified by *BRCA1* mutation class revealed no significant evidence of a difference in the associations of any of the SNPs by the predicted functional consequences of *BRCA1* mutations (Table S6). SNPs in the *MDM4* and *TCF7L2* loci were

associated with breast cancer risk for both class1 and class2 mutation carriers.

Both the 1q32 and 10q25.3 loci were primarily associated with ER-negative breast cancer for *BRCA1* (rs2290854: ER-negative HR = 1.16, 95%CI: 1.10–1.22, $P = 1.2 \times 10^{-7}$; rs11196174: HR = 1.14, 95%CI: 1.07–1.20, $P = 9.6 \times 10^{-6}$), although the differences between the ER-negative and ER-positive HRs were not significant (Table S7). Given that ER-negative breast cancers in *BRCA1* and *BRCA2* mutation carriers are phenotypically similar [29], we also evaluated associations between these SNPs and ER-negative breast cancer in 8,211 *BRCA2* mutation carriers. While the 10q25.3 SNPs were not associated with overall or ER-negative breast cancer risk for *BRCA2* carriers, the 1q32 SNPs were associated with ER-negative (rs2290854 HR = 1.16, 95%CI: 1.01–1.34, $P = 0.033$; rs6682208 HR = 1.19, 95%CI: 1.04–1.35, $P = 0.016$), but not ER-positive breast cancer (rs2290854 *P*-diff = 0.006; rs6682208 *P*-diff = 0.001). Combining the *BRCA1* and *BRCA2* samples provided strong evidence of association with ER-negative breast cancer (rs2290854: $P = 1.25 \times 10^{-8}$; rs6682208: $P = 2.5 \times 10^{-7}$).

The iCOGS array included additional SNPs from the 1q32 region that were not chosen based on the *BRCA1* GWAS. Of these non-*BRCA1* GWAS SNPs, only SNP rs4951407 was more significantly associated with risk than the *BRCA1*-GWAS selected SNPs ($P = 3.3 \times 10^{-6}$, HR = 1.12, 95%CI: 1.07–1.18, using stage 1 and stage 2 samples). The evidence of association with breast cancer risk was again stronger under the competing risks analysis (HR = 1.14, 95%CI: 1.08–1.20, $P = 6.1 \times 10^{-7}$). Backward multiple regression analysis, considering only the genotyped SNPs ($P < 0.01$), revealed that the most parsimonious model included only rs4951407. SNPs from the 1000 Genomes Project, were imputed for the stage 1 and stage 2 samples (Figure S6). Only imputed SNP rs12404974, located between *PIK3C2B* and *MDM4* ($r^2 = 0.77$ with rs4951407), was more significantly associated with breast cancer ($P = 2.7 \times 10^{-6}$) than any of the genotyped SNPs. None of the genotyped or imputed SNPs from 10q25.3 provided *P*-values smaller than those for rs11196174 and rs11196175 (Figure S7).

Ovarian cancer associations

Analyses of associations with ovarian cancer risk using the stage 2 samples (8,054 unaffected, 1,264 affected) revealed no evidence of inflation in the association test-statistic ($\lambda = 1.039$, Figure S3). In the combined analysis of stage 1 and 2 samples (9866 unaffected, 1839 affected), 62 SNPs in 17 regions were associated with ovarian cancer risk for *BRCA1* carriers at $P < 10^{-4}$ (Figure S3). These included SNPs in the 9p22 and 3q25 loci previously associated with ovarian cancer risk in both the general population and *BRCA1* carriers [6,7] (Table 1). Associations ($P < 0.01$) with ovarian cancer risk were also observed for SNPs in three other known ovarian cancer susceptibility loci (8q24, 17q21, 19p13), but not 2q31 (Table 1). For all loci except 9p22, SNPs were identified that displayed smaller *P*-values of association than previously published results [5–7].

After excluding SNPs from known ovarian cancer susceptibility regions, there were 48 SNPs in 15 regions with $P = 5 \times 10^{-7}$ to 10^{-4} . Five SNPs from four of these loci were genotyped in the stage 3 samples (2,204 unaffected, 442 with ovarian cancer). Three SNPs showed additional evidence of association with ovarian cancer risk ($P < 0.02$, Table 2; Table S5). In the combined stage 1–3 analyses, SNPs rs17631303 and rs183211 ($r^2 = 0.68$) on chromosome 17q21.31 had *P*-values for association of 1×10^{-8} and 3×10^{-8} respectively, and rs4691139 at 4q32.3 had a *P*-value of 3.4×10^{-8} (Table 2).

The minor alleles of rs17631303 (HR = 1.27, 95%CI: 1.17–1.38) and rs183211 (HR = 1.25, 95%CI: 1.16–1.35) at 17q21.31 were associated with increased ovarian cancer risk (Table 2). Analysis of

Table 1. Associations with breast or ovarian cancer risk for loci previously reported to be associated with cancer risk for *BRCA1* mutation carriers.

Locus	Previously published association in <i>BRCA1</i>				Strongest association in current set of 31,812 <i>BRCA1</i> GWAS SNPs				Association for published SNP in set of all iCOGS SNPs				
	SNP	all1/all2 (freq)	HR (95%CI)	P	SNP	all1/all2 (freq)	r ²	HR (95%CI)	P	Best tag SNP (r ²)	all1/all2 (freq)	HR (95%CI)	P
Loci previously associated with breast cancer risk for <i>BRCA1</i> carriers													
19p13	rs8170	G/A (0.17)	1.26 (1.17–1.35)	2.3×10 ^{−9}	rs8100241	G/A (0.52)	0.31	0.84 (0.80–0.88)	4.3×10 ^{−13}	rs8170 (1.0)	G/A (0.17)	1.22 (1.14–1.29)	4.8×10 ^{−10}
6q25.1	rs2046210	C/T (0.35)	1.17 (1.11–1.23)	4.5×10 ^{−9}	rs3734805	A/C (0.08)	0.25	1.28 (1.18–1.39)	5×10 ^{−9}	rs2046210* (1.0)	G/A (0.35)	1.15 (1.10–1.21)	2.8×10 ^{−8}
12p11	rs10771399	A/G (0.11)	0.87 (0.81–0.94)	3.2×10 ^{−4}	rs7957915	A/G (0.14)	0.85	0.85 (0.79–0.91)	8.1×10 ^{−6}	rs10771399*	A/G (0.11)	0.85 (0.79–0.92)	2.7×10 ^{−5}
TOX3	rs3803662	C/T (0.29)	1.09 (1.03–1.16)	0.0049	rs4784220	A/G (0.38)	0.52	1.08 (1.03–1.13)	0.0021	rs3803662*	G/A (0.29)	1.05 (1.00–1.11)	0.075
2q35	rs13387042 ^a	G/A (0.52)	1.02 (0.96–1.07)	0.57	rs13389571	A/G (0.05)	0.02	0.86 (0.77–0.96)	0.011	rs13387042*	A/G (0.48)	1.01 (0.96–1.06)	0.74
Known ovarian cancer susceptibility loci													
9p22	rs3814113	T/C (0.34)	0.78 (0.72–0.85)	4.8×10 ^{−9}	rs3814113	A/G (0.34)	1.00	0.77 (0.71–0.83)	5.9×10 ^{−11}	rs3814113 (1.0)	A/G (0.34)	0.77 (0.71–0.83)	5.9×10 ^{−11}
2q31	rs2072590	T/C (0.31)	1.06 (0.98–1.14)	0.16	rs1026032	A/G (0.26)	0.75	1.08 (0.99–1.17)	0.064	rs2072590* (1.0)	C/A (0.32)	1.05 (0.97–1.14)	0.20
8q24	rs10088218	G/A (0.13)	0.89 (0.81–0.99)	0.029	rs9918771	A/C (0.17)	0.31	0.86 (0.78–0.95)	0.0021	rs10088218 (1.0)	G/A (0.13)	0.86 (0.78–0.96)	0.0096
3q25	rs2665390	T/C (0.075)	1.25 (1.10–1.42)	2.7×10 ^{−3}	rs7651446	C/A (0.043)	0.71	1.46 (1.25–1.71)	6.6×10 ^{−6}	rs344008 (1.0)	G/A (0.075)	1.21 (1.07–1.38)	3.8×10 ^{−3}
17q21	rs9303542	T/C (0.26)	1.08 (1.00–1.17)	0.06	rs11651753	G/A (0.43)	0.36	1.14 (1.06–1.23)	4.6×10 ^{−4}	rs9303542* (1.0)	A/G (0.26)	1.12 (1.04–1.22)	8.0×10 ^{−3}
19p13 ^b	rs67397200	C/G (0.28)	1.16 (1.05–1.29)	3.8×10 ^{−4}	c19_pos17158477	G/C (0.038)	0.01	0.64 (0.49–0.83)	7.0×10 ^{−4}	rs67397200 (c19_pos17262404)	G/C (0.28)	1.12 (1.01–1.23)	0.027

Freq = frequency of allele 2 in unaffected *BRCA1* carriers.

HR = Per allele Hazard Ratio associated with allele 2, under a single disease risk model, unless specified.

r²: correlation between the SNP in the present study and the published SNP.*SNP not in *BRCA1* GWAS SNP allocation on iCOGS chip.^a: rs13387042 was previously found to be associated only under the 2-df model.^b: analysis under a competing risks model.

doi:10.1371/journal.pgen.1003212.t001

Table 2. Associations with breast and ovarian cancer risk for SNPs found to be associated with risk at all 3 stages of the experiment.

SNP, Chr, Position, Allele1/ Allele2	Stage	Number		Allele 2 Frequency		HR* (95% CI)			
		Unaffected	Affected	Unaffected	Affected	Per Allele	Heterozygote	Homozygote	P-trend
Breast Cancer									
rs2290854, 1q32, 202782648, G/A	Stage 1	1104	1283	0.30	0.34	1.19 (1.08–1.30)	1.28 (1.12–1.47)	1.31 (1.06–1.61)	4.2×10 ^{−4}
	Stage 2	4681	4637	0.31	0.33	1.09 (1.03–1.16)	1.10 (1.02–1.19)	1.18 (1.03–1.35)	0.003
	Stages1+2	5785	5920	0.31	0.33	1.12 (1.06–1.17)	1.15 (1.07–1.23)	1.21 (1.08–1.36)	1.7×10 ^{−5}
	Stage 3	1252	1393	0.30	0.33	1.19 (1.07–1.32)	1.24 (1.07–1.43)	1.36 (1.06–1.74)	0.0013
	Combined	7037	7313	0.31	0.33	1.13 (1.08–1.18)	1.16 (1.09–1.24)	1.24 (1.11–1.37)	1.4×10 ^{−7}
rs6682208, 1q32, 202832806, G/A	Stage 1	1104	1283	0.32	0.35	1.14 (1.04–1.25)	1.24 (1.09–1.42)	1.20 (0.98–1.47)	0.0070
	Stage 2	4681	4637	0.32	0.34	1.10 (1.04–1.17)	1.09 (1.01–1.19)	1.21 (1.06–1.38)	0.0014
	Stages1+2	5785	5920	0.32	0.34	1.11 (1.05–1.17)	1.13 (1.05–1.21)	1.21 (1.08–1.35)	5.4×10 ^{−5}
	Stage 3	1250	1394	0.30	0.34	1.19 (1.07–1.32)	1.31 (1.14–1.51)	1.28 (1.01–1.63)	8.6×10 ^{−4}
	Combined	7035	7314	0.32	0.34	1.12 (1.07–1.17)	1.16 (1.09–1.23)	1.22 (1.11–1.35)	4.3×10 ^{−7}
rs11196174, 10q25.3, 114724086, A/G	Stage 1	1103	1282	0.27	0.32	1.15 (1.05–1.27)	1.17 (1.03–1.34)	1.31 (1.05–1.63)	0.0038
	Stage 2	4681	4636	0.29	0.31	1.10 (1.04–1.17)	1.13 (1.04–1.23)	1.17 (1.01–1.35)	0.0017
	Stages1+2	5784	5918	0.28	0.31	1.12 (1.06–1.18)	1.14 (1.06–1.23)	1.21 (1.07–1.37)	3.1×10 ^{−5}
	Stage 3	1251	1393	0.28	0.31	1.16 (1.05–1.29)	1.08 (0.93–1.25)	1.46 (1.15–1.85)	0.0057
	Combined	7035	7311	0.28	0.31	1.13 (1.07–1.18)	1.13 (1.06–1.21)	1.26 (1.13–1.40)	7.5×10 ^{−7}
rs11196175, 10q25.3, 114726604, A/G	Stage 1	1101	1280	0.27	0.31	1.15 (1.05–1.27)	1.18 (1.03–1.35)	1.29 (1.03–1.62)	0.0043
	Stage 2	4674	4627	0.28	0.30	1.10 (1.03–1.17)	1.13 (1.04–1.22)	1.17 (1.01–1.35)	0.0020
	Stages1+2	5775	5907	0.28	0.30	1.12 (1.06–1.18)	1.14 (1.06–1.22)	1.21 (1.07–1.37)	3.9×10 ^{−5}
	Stage 3	1251	1394	0.27	0.31	1.16 (1.04–1.29)	1.06 (0.91–1.22)	1.48 (1.17–1.87)	0.0075
	Combined	7026	7301	0.28	0.31	1.12 (1.07–1.18)	1.12 (1.05–1.20)	1.26 (1.13–1.41)	1.2×10 ^{−6}
Ovarian Cancer									
rs17631303, 17q21, 40872185, A/G	Stage 1	1797	574	0.19	0.25	1.46 (1.22–1.74)	1.36 (1.01–1.68)	2.46 (1.53–3.96)	1.3×10 ^{−5}
	Stage 2	7996	1257	0.19	0.21	1.20 (1.07–1.35)	1.10 (0.96–1.26)	1.83 (1.34–2.48)	1.5×10 ^{−3}
	Stages1+2	9793	1831	0.19	0.22	1.27 (1.16–1.40)	1.15 (1.03–1.29)	2.03 (1.16–2.61)	3.0×10 ^{−7}
	Stage 3	2204	442	0.17	0.21	1.27 (1.07–1.51)	1.24 (0.99–1.56)	1.67 (1.07–2.62)	0.014
	Combined	11997	2273	0.19	0.22	1.27 (1.17–1.38)	1.17 (1.06–1.29)	1.95 (1.57–2.42)	1.4×10 ^{−8}
rs183211, 17q21, 42143493, G/A	Stage 1	1812	575	0.22	0.28	1.45 (1.23–1.71)	1.37 (1.11–1.69)	2.29 (1.53–3.41)	2.5×10 ^{−5}
	Stage 2	8054	1264	0.23	0.25	1.20 (1.07–1.33)	1.13 (0.99–1.28)	1.62 (1.22–2.14)	1.1×10 ^{−3}
	Stages1+2	9866	1839	0.23	0.26	1.25 (1.15–1.37)	1.16 (1.04–1.29)	1.83 (1.46–2.28)	5.7×10 ^{−7}
	Stage 3	2204	442	0.22	0.26	1.25 (1.06–1.48)	1.15 (0.92–1.44)	1.79 (1.21–2.67)	0.018
	Combined	12070	2281	0.23	0.26	1.25 (1.16–1.35)	1.16 (1.05–1.27)	1.82 (1.5–2.21)	3.1×10 ^{−8}
rs4691139, 4q32.3, 166128171, A/G	Stage 1	1812	575	0.47	0.53	1.24 (1.08–1.42)	1.46 (1.13–1.88)	1.55 (1.16–2.05)	3.6×10 ^{−3}
	Stage 2	8054	1264	0.48	0.52	1.18 (1.08–1.29)	1.29 (1.10–1.50)	1.40 (1.17–1.67)	1.3×10 ^{−4}
	Stages1+2	9866	1839	0.48	0.52	1.20 (1.11–1.29)	1.33 (1.17–1.52)	1.44 (1.24–1.67)	1.1×10 ^{−6}
	Stage 3	2204	441	0.47	0.52	1.20 (1.04–1.39)	1.19 (0.91–1.54)	1.44 (1.08–1.94)	9×10 ^{−3}
	Combined	12070	2280	0.48	0.52	1.20 (1.17–1.38)	1.30 (1.16–1.46)	1.44 (1.26–1.65)	3.4×10 ^{−8}

*HRs estimated under the single disease risk models.
doi:10.1371/journal.pgen.1003212.t002

the associations within a competing risks framework, revealed no association with breast cancer risk (Table 3). The ovarian cancer effect size was maintained in the competing risk analysis but the significance of the association was slightly weaker ($P = 2 \times 10^{-6}$ –

1×10^{-5}). This is expected because 663 ovarian cancer cases occurring after a primary breast cancer diagnosis were excluded for this analysis. The evidence of association was somewhat stronger under the genotype-specific model (2-df $P = 1.6 \times 10^{-9}$

Table 3. Analysis of associations with breast and ovarian cancer risk simultaneously (competing risks analysis) for SNPs found to be associated with breast or ovarian cancer.

SNP, Chr, Position, Allele1/Allele2	Unaffected (Allele2 Freq)	Ovarian Cancer (Allele2 Freq)	Breast Cancer (Allele2 Freq)	Ovarian Cancer		Breast Cancer	
				HR (95% CI)	P	HR (95% CI)	P
SNPs found to be associated with breast cancer risk.							
rs2290854, 1q32, 202782648, G/A	5473 (0.31)	1618 (0.31)	7259 (0.33)	1.08 (0.99–1.18)	0.08	1.14 (1.09–1.20)	2.7×10^{-8}
	5471 (0.32)	1618 (0.33)	7260 (0.34)	1.08 (1.00–1.18)	0.06	1.13 (1.08–1.19)	1.2×10^{-7}
	5471 (0.28)	1618 (0.29)	7257 (0.31)	1.07 (0.98–1.16)	0.16	1.14 (1.08–1.19)	3.2×10^{-7}
	5465 (0.28)	1615 (0.29)	7247 (0.31)	1.07 (0.97–1.16)	0.16	1.14 (1.08–1.19)	3.9×10^{-7}
SNPs found to be associated with ovarian cancer risk							
rs17631303, 17q21, 40872185, A/G	5445 (0.19)	1610 (0.22)	7215 (0.19)	1.26 (1.14–1.39)	1.0×10^{-5}	1.02 (0.96–1.08)	0.52
	5473 (0.23)	1618 (0.26)	7260 (0.23)	1.25 (1.14–1.38)	3.5×10^{-6}	1.02 (0.97–1.08)	0.42
	5473 (0.48)	1617 (0.53)	7269 (0.48)	1.21 (1.12–1.31)	2.8×10^{-6}	0.98 (0.93–1.02)	0.28

doi:10.1371/journal.pgen.1003212.t003

and $P = 2.6 \times 10^{-9}$ for rs17631303 and rs183211 respectively in all samples combined) with larger HR estimates for the rare homozygote genotypes than those expected under a multiplicative model (Table 2).

Previous studies of the known common ovarian cancer susceptibility alleles found significant associations with ovarian cancer for both *BRCA1* and *BRCA2* carriers [6,7]. Thus, we evaluated the associations between the 17q21.31 SNPs and ovarian cancer risk for *BRCA2* carriers using iCOGS genotype data (7580 unaffected and 631 affected). Both rs17631303 and rs183211 were associated with ovarian cancer risk for *BRCA2* carriers ($P = 1.98 \times 10^{-4}$ and 9.26×10^{-4}), with similar magnitude and direction of association as for *BRCA1* carriers. Combined analysis of *BRCA1* and *BRCA2* mutation carriers provided strong evidence of association ($P = 2.80 \times 10^{-10}$ and 2.01×10^{-9} , Table 4).

The combined analysis of stage 1 and 2 samples, and *BRCA2* carriers, identified seven SNPs on the iCOGS array (pairwise r^2 range: 0.68–1.00) from a 1.3 Mb (40.8–42.1 Mb, build 36.3) region of 17q21.31 that were strongly associated ($P < 1.27 \times 10^{-9}$) with ovarian cancer risk (Table 4, Figure 2). Stepwise-regression analysis based on observed genotype data retained only one of the seven SNPs in the model, but it was not possible to distinguish between the SNPs. Imputation through the 1000 Genomes Project, revealed several SNPs in 17q21.31 with stronger associations (Figure 2, Table S8) than the most significant genotyped SNP in the combined *BRCA1/2* analysis (rs169201, $P = 6.24 \times 10^{-11}$). The most significant SNP (rs140338099 (17-44034340), $P = 3 \times 10^{-12}$), located in *MAPT*, was highly correlated ($r^2 = 0.78$) with rs169201 in *NSF* (Figure 2). This locus appears to be distinct from a previously identified ovarian cancer susceptibility locus located >1 Mb distal on 17q21 (spanning 43.3–44.3 Mb, build 36.3) [30]. None of the SNPs in the novel region were strongly correlated with any of the SNPs in the 43.3–44.3 Mb region (maximum $r^2 = 0.07$, Figure S8). The most significantly associated SNP from the *BRCA1* GWAS from the 43.3–44.3 Mb locus was rs11651753 ($p = 4.6 \times 10^{-4}$) (Table 1) ($r^2 < 0.023$ with the seven most significant SNPs in the novel 17q21.31 region). An analysis of the joint associations of rs11651753 and rs17631303 from the two 17q21 loci with ovarian cancer risk for *BRCA1* carriers (Stage 1 and 2 samples) revealed that both SNPs remained significant in the model (P -for inclusion = 0.001 for rs11651753, 1.2×10^{-6} for rs17631303), further suggesting that the two regions are independently associated with ovarian cancer for *BRCA1* carriers.

The minor allele of rs4691139 at the novel 4q32.3 region was also associated with an increased ovarian cancer risk for *BRCA1* carriers (per-allele HR = 1.20, 95%CI:1.17–1.38, Table 2), but was not associated with breast cancer risk (Table 3). No other SNPs from the 4q32.3 region on the iCOGS array were more significantly associated with ovarian cancer for *BRCA1* carriers. Analysis of associations with variants identified through 1000 Genomes Project-based imputation of the Stage 1 and 2 samples, revealed 19 SNPs with stronger evidence of association ($P = 5.4 \times 10^{-7}$ to 1.1×10^{-6}) than rs4691139 (Figure S9). All were highly correlated (pairwise $r^2 > 0.89$) and the most significant (rs4588418) had $r^2 = 0.97$ with rs4691139. There was no evidence for association between rs4691139 and ovarian cancer risk for *BRCA2* carriers (HR = 1.08, 95%CI: 0.96–1.21, $P = 0.22$).

Absolute risks of developing breast and ovarian cancer

The current analyses suggest that 10 loci are now known to be associated with breast cancer risk for *BRCA1* mutation carriers: 1q32, 10q25.3, 19p13, 6q25.1, 12p11, *TOX3*, 2q35, *LSP1* and *RAD51L1* all reported here and *TERT* [31]. Similarly, seven loci are associated with ovarian cancer risk for *BRCA1* mutation

Table 4. Associations with SNPs at the novel 17q21 region with ovarian cancer risk for *BRCA1* and *BRCA2* mutation carriers.

SNP, Allele1/Allele2	<i>BRCA1</i> (Stage 1 & 2 samples)				<i>BRCA2</i>				<i>BRCA1 & BRCA2</i> samples combined	
	Unaffected (All2 freq)	Ovarian Cancer (All2 freq)	HR* (95%CI)	P-trend	Unaffected (All2 freq)	Ovarian Cancer (All2 freq)	HR* (95%CI)	P-trend	P-trend	P-trend
rs17631303, A/G	9793 (0.19)	1831 (0.22)	1.27 (1.16–1.40)	3.04×10^{-7}	7481 (0.19)	626 (0.24)	1.32 (1.15–1.52)	1.98×10^{-4}	2.80×10^{-10}	
rs2077606, G/A	9736 (0.19)	1810 (0.22)	1.27 (1.15–1.40)	5.51×10^{-7}	7421 (0.19)	613 (0.23)	1.31 (1.13–1.50)	5.60×10^{-4}	1.27×10^{-9}	
rs2532348, A/G	9511 (0.21)	1789 (0.24)	1.25 (1.14–1.37)	8.71×10^{-7}	7407 (0.23)	615 (0.28)	1.33 (1.17–1.51)	4.62×10^{-5}	2.49×10^{-10}	
rs183211, G/A	9866 (0.23)	1839 (0.26)	1.25 (1.15–1.37)	5.67×10^{-7}	7580 (0.25)	631 (0.30)	1.26 (1.11–1.43)	9.26×10^{-4}	2.01×10^{-9}	
rs169201, A/G	9865 (0.20)	1839 (0.23)	1.27 (1.15–1.37)	5.04×10^{-7}	7578 (0.21)	631 (0.26)	1.36 (1.19–1.55)	1.72×10^{-5}	6.24×10^{-11}	
rs199443, G/A	9849 (0.20)	1835 (0.23)	1.26 (1.15–1.39)	5.15×10^{-7}	7580 (0.21)	631 (0.26)	1.35 (1.18–1.54)	2.57×10^{-5}	8.87×10^{-11}	
rs199534, A/C	9865 (0.20)	1839 (0.23)	1.26 (1.15–1.39)	6.26×10^{-7}	7575 (0.21)	630 (0.26)	1.35 (1.18–1.55)	1.90×10^{-5}	8.57×10^{-11}	

*HRs estimated under the single disease risk model.
doi:10.1371/journal.pgen.1003212.t004

carriers: 9p22, 8q24, 3q25, 17q21, 19p13, 17q21.31 and 4q32.3. Figure S10 shows the range of combined HRs at different percentiles of the combined genotype distribution, based on the single SNP HR and minor allele estimates from Table 1, Table 2, and Table S4 and for TERT from Bojesen et al [31] and assuming that all SNPs interact multiplicatively. Relative to *BRCA1* mutation carriers at lowest risk, the median, 5th and 95th percentile breast cancer HRs were 3.40, 2.27, and 5.35 respectively. These translate to absolute risks of developing breast cancer by age 80 of 65%, 51% and 81% for those at median, 5th and 95th percentiles of the combined genotype distribution (Figure 3, Figure S10). Similarly, the median, 5th and 95th percentile combined HRs for ovarian cancer were 6.53, 3.75 and 11.12 respectively, relative to those at lowest ovarian cancer risk (Figure S10). These HRs translate to absolute risks of developing ovarian cancer of 44%, 28% and 63% by age 80 for the median, 5th and 95th percentile of the combined genotype distribution (Figure 3).

Discussion

In this study we analyzed data from 11,705 *BRCA1* mutation carriers from CIMBA who were genotyped using the iCOGS high-density custom array, which included 31,812 SNPs selected on the basis of a *BRCA1* GWAS. This study forms the large-scale replication stage of the first GWAS of breast and ovarian cancer risk modifiers for *BRCA1* mutation carriers. We have identified a novel locus at 1q32, containing the *MDM4* oncogene, that is associated with breast cancer risk for *BRCA1* mutation carriers ($P < 5 \times 10^{-8}$). A separate locus at 10q23.5, containing the *TCF7L2* gene, provided strong evidence of association with breast cancer risk for *BRCA1* carriers but did not reach a GWAS level of significance. We have also identified two novel loci associated with ovarian cancer for *BRCA1* mutation carriers at 17q21.31 and 4q32.2 ($P < 5 \times 10^{-8}$). We further confirmed associations with loci previously shown to be associated with breast or ovarian cancer risk for *BRCA1* mutation carriers. In most cases stronger associations were detected with either the same SNP reported previously (due to increased sample size) or other SNPs in the regions. Future fine mapping studies of these loci will aim to identify potentially causal variants for the observed associations.

Although the 10q25.3 locus did not reach the strict GWAS level of significance for association with breast cancer risk, the association was observed at all three independent stages of the experiment. Additional evidence for the involvement of this locus in breast cancer susceptibility comes from parallel studies of the Breast Cancer Association Consortium (BCAC). SNPs at 10q25.3 had also been independently selected for inclusion on the iCOGS array through population based GWAS of breast cancer. Analyses of those SNPs in BCAC iCOGS studies also found that SNPs at 10q25.3 were associated with breast cancer risk in the general population [32]. Thus, 10q25.3 is likely a breast cancer risk-modifying locus for *BRCA1* mutation carriers. The most significant SNPs at 10q25.3 were located in *TCF7L2*, a transcription factor that plays a key role in the Wnt signaling pathway and in glucose homeostasis, and is expressed in normal and malignant breast tissue (The Cancer Genome Atlas (TCGA)). Variation in the *TCF7L2* locus has previously been associated with Type 2 diabetes in a number of GWAS. The most significantly associated SNPs with Type 2 diabetes (rs7903146 and rs4506565) [22,33] were also associated with breast cancer risk for *BRCA1* mutation carriers in stage 1 and 2 analyses ($p = 3.7 \times 10^{-4}$ and $p = 2.5 \times 10^{-4}$ respectively); these SNPs were correlated with the most significant hit (rs11196174) for *BRCA1* breast cancer ($r^2 = 0.40$ and 0.37 based




Figure 2. Mapping of the 17q21 locus. *Top 3 panels:* P-values of association ($-\log_{10}$ scale) with ovarian cancer risk for genotyped and imputed SNPs (1000 Genomes Project CEU), by chromosome position (b.37) at the 17q21 region, for *BRCA1*, *BRCA2* mutation carriers and combined. Results based on the kinship-adjusted score test statistic (1 d.f.). *Fourth panel:* Genes in the region spanning (43.4–44.9 Mb, b.37) and the location of the most significant genotyped SNPs (in red font) and imputed SNPs (in black font). *Bottom panel:* Pairwise r^2 values for genotyped SNPs on iCOG array in the 17q21 region covering positions (43.4–44.9 Mb, b.37). doi:10.1371/journal.pgen.1003212.g002




Figure 3. Predicted breast and ovarian cancer absolute risks for *BRCA1* mutation carriers at the 5th, 10th, 90th, and 95th percentiles of the combined SNP profile distributions. The minimum, maximum and average risks are also shown. Predicted cancer risks are based on the associations of known breast or ovarian cancer susceptibility loci (identified through GWAS) with cancer risk for *BRCA1* mutation carriers and loci identified through the present study. Breast cancer risks based on the associations with: 1q32, 10q25.3, 19p13, 6q25.1, 12p11, *TOX3*, 2q35, *LSP1*, *RAD51L1* (based on HR and minor allele frequency estimates from Table 1, Table 2, and Table S4) and *TERT* [31]. Ovarian cancer risks based on the associations with: 9p22, 8q24, 3q25, 17q21, 19p13 (Table 1) and 17q21.31, 4q32.3 (Table 2). Only the top SNP from each region was chosen. Average breast and ovarian cancer risks were obtained from published data [25]. The methods for calculating the predicted risks have been described previously [28].

doi:10.1371/journal.pgen.1003212.g003

on stage 1 and 2 samples). This raises the possibility that variants in this locus influence breast cancer indirectly through effects on cellular metabolism.

We found that SNPs at 1q32 were primarily associated with ER-negative breast cancer risk for *BRCA1* mutation carriers. There was also evidence of association with ER-negative breast cancer for *BRCA2* mutation carriers. SNPs at the 1q32 region were independently selected for inclusion on iCOGS through GWAS of breast cancer in the general population by BCAC. In parallel analyses of iCOGS data by BCAC, 1q32 was found to be associated with ER-negative breast cancer [34] but not overall breast cancer risk [32]. Taken together, these results are in agreement with our findings and in line with the observation that the majority of *BRCA1* breast cancers are ER-negative. However, they are not in agreement with a previous smaller candidate-gene study that found an association between a correlated SNP in *MDM4* ($r^2 > 0.85$) and overall breast cancer risk [35]. The 1q32 locus includes the *MDM4* oncogene which plays a role in regulation of p53 and MDM2 and the apoptotic response to cell stress. *MDM4* is expressed in breast tissue and is amplified and overexpressed along with *LRRN2* and *PIK3C2B* in breast and other tumor types (TCGA) [36–38]. Although fine mapping will be

necessary to identify the functionally relevant SNPs in this locus, we found evidence of cis-regulatory variation impacting *MDM4* expression [39–41] (Text S1, Table S9, Figure S11), suggesting that common variation in the 1q32 locus may influence the risk of breast cancer through direct effects on *MDM4* expression.

Several correlated SNPs at 17q21.31 from the iCOGS array provided strong evidence of association with ovarian cancer risk in both *BRCA1* and *BRCA2* mutation carriers. A subsequent analysis of these SNPs, which were selected through the *BRCA1* GWAS, in case-control samples from the Ovarian Cancer Association Consortium (OCAC), revealed that the 17q21.31 locus is associated with ovarian cancer risk in the general population [Wey et al, personal communication]. Thus, 17q21.31 is likely a novel susceptibility locus for ovarian cancer in *BRCA1* mutation carriers. The most significant associations at 17q21.31 were clustered in a large region of strong linkage disequilibrium which has previously been identified as a “17q21.31 inversion” (~900 kb long) consisting of two haplotypes (termed H1 and H2) [42]. The minor allele of rs2532348 (MAF = 0.21), which tags H2, was associated with increased ovarian cancer risk for *BRCA1* mutation carriers (Table 4). The 1.3 Mb 17q21.31 locus contains 13 genes and several predicted pseudogenes (Figure 2), several of which are

expressed in normal ovarian surface epithelium and ovarian adenocarcinoma [43]. Variation in this region has been associated with Parkinson's disease (*MAPT*, *PLEKHM1*, *NSF*, *c17orf69*) progressive supranuclear palsy (*MAPT*), celiac disease (*WNT3*), bone mineral density (*CRHR1*) (NHGRI GWAS catalog) and intracranial volume [44]. Of the top hits for these phenotypes, SNP rs199533 in *NSF*, previously associated with Parkinson's disease [45] and rs9915547 associated with intracranial volume [44] were strongly associated with ovarian cancer ($P < 10^{-9}$ in *BRCA1/2* combined). Whether these phenotypes have shared causal variants in this locus remains to be elucidated. Further exploration of the functional relevance of the strongest hits in the 17q21.31 locus ($P < 10^{-8}$ in *BRCA1/2* combined) provided evidence that cis-regulatory variation alters expression of several genes at 17q21, including *PLEKHM1*, *c17orf69*, *ARHGAP27*, *MAPT*, *KANSL1* and *WNT3* [39,41] (Table S9, Figure S12), suggesting that ovarian cancer risk may be associated with altered expression of one or more genes in this region.

Our analyses revealed that a second novel locus at 4q32.3 was also associated with ovarian cancer risk for *BRCA1* mutation carriers ($P < 5 \times 10^{-8}$). However, we found no evidence of association for these SNPs with ovarian cancer risk for *BRCA2* mutation carriers using 8,211 CIMBA samples genotyped using the iCOGS array. Likewise, no evidence of association was found between rs4691139 at 4q32.3 and ovarian cancer risk in the general population based on data by OCAC data derived from 18,174 cases and 26,134 controls (odds ratio = 1.00, 95%CI: 0.97–1.04, $P = 0.76$) [46]. The confidence intervals rule out a comparable effect to that found in *BRCA1* carriers. Therefore, our findings may represent a *BRCA1*-specific association with ovarian cancer risk, the first of its kind. The 4q32.2 region contains several members of the *TRIM* (Tripartite motif containing) gene family, *c4orf39* and *TMEM192*. *TRIM60*, *c4orf39* and *TMEM192* are expressed in normal ovarian epithelium and/or ovarian tumors (TCGA).

In summary, we have identified a novel locus at 1q32 associated with breast cancer risk for *BRCA1* mutation carriers, which was also associated with ER-negative breast cancer for *BRCA2* carriers and in the general population. A separate locus at 10q23.5 provided strong evidence of association with breast cancer risk for *BRCA1* carriers. We have also identified 2 novel loci associated with ovarian cancer for *BRCA1* mutation carriers. Of these, the 4q32.2 locus was associated with ovarian cancer risk for *BRCA1* carriers but not for *BRCA2* carriers or in the general population. Additional functional characterisation of the loci will further improve our understanding of the biology of breast and ovarian cancer development in *BRCA1* carriers. Taken together with other identified genetic modifiers, 10 loci are now known to be associated with breast cancer risk for *BRCA1* mutation carriers (1q32, 10q25.3, 19p13, 6q25.1, 12p11, *TOX3*, 2q35, *LSP1*, *RAD51L1* and *TERT*) and seven loci are known to be associated with ovarian cancer risk for *BRCA1* mutation carriers (9p22, 8q24, 3q25, 17q21, 19p13 and 17q21.31, 4q32.3).

As *BRCA1* mutations confer high breast and ovarian cancer risks, the results from the present study, taken together with other identified genetic modifiers, demonstrate for the first time that they can result in large differences in the absolute risk of developing breast or ovarian cancer for *BRCA1* between genotypes. For example, the breast cancer lifetime risks for the 5% of *BRCA1* carriers at lowest risk are predicted to be 28–50% compared to 81–100% for the 5% at highest risk (Figure 3). Based on the distribution of ovarian cancer risk modifiers, the 5% of *BRCA1* mutation carriers at lowest risk will have a lifetime risk of developing ovarian cancer of 28% or lower whereas the 5% at

highest risk will have a lifetime risk of 63% or higher. Similarly, the breast cancer risk by age 40 is predicted to be 4–9% for the 5% of *BRCA1* carriers at lowest risk compared to 20–49% for the 5% at highest risk, whereas the ovarian cancer risk at age 50 ranges from 3–7% for the 5% at lowest risk and from 18–47% for the 5% at highest risk. The risks at all ages for the 10% at highest or lowest risk of breast and ovarian cancer are predicted to be similar to those for the highest and lowest 5%. Thus, at least 20% of *BRCA1* mutation carriers are predicted to have absolute risks of disease that are different from the average *BRCA1* carriers. These large differences in cancer risks may have practical implications for the clinical management of *BRCA1* mutation carriers, for example in deciding the timing of interventions. Such risks, in combination with other lifestyle and hormonal risk factors could be incorporated into cancer risk prediction algorithms for use by clinical genetics centers. These algorithms could then be used to inform the development of effective and consistent clinical recommendations for the clinical management of *BRCA1* mutation carriers.

Supporting Information

Figure S1 Multidimensional scaling of stage 1 and stage 2 (genotyped on iCOGS) samples. Panel A: Graphical representation of the first two components, for the *BRCA1* carriers, for subgroups defined by the common 185delAG (c.68_69delAG) *BRCA1* Jewish founder mutation, the 5382insC (c.5266dupC) Eastern European founder mutation and Hapap individuals (CEU: European; ASI: Includes CHB and JPT populations; YRI: African). Panel B: Red dots represent the samples with >22% non-European ancestry, excluded from the analysis. (PDF)

Figure S2 Genotyping cluster plots in the *BRCA1* samples for the key associated SNPs. (PDF)

Figure S3 Quantile-quantile plot for the kinship adjusted score test statistic for stage 2 samples (1 degree of freedom χ^2 trend test) for the associations with breast cancer (panel A) and ovarian cancer (panel B) risk for *BRCA1* mutation carriers. The $y = x$ line corresponds to the expected distribution, under the hypothesis of no inflation. Inflation was estimated using the values of the lowest 90% test statistics. (PDF)

Figure S4 P-values (on $-\log_{10}$ scale) by chromosomal position, for the associations of 31,812 *BRCA1* GWAS SNPs with breast (panel A) and ovarian (panel B) cancer risk for *BRCA1* mutation carriers in the combined stage 1 and stage 2 samples. Blue lines correspond to a P-value of 10^{-5} ; red lines correspond to P-value 5×10^{-8} . (PDF)

Figure S5 Forest plots of the associations by country of residence of *BRCA1* mutation carriers in the combined stage 1, stage 2 and stage 3 samples for SNPs found to be associated with breast and ovarian cancer risk for *BRCA1* mutation carriers. Squares indicate the country specific, per-allele HR estimates for the SNPs. The area of the square is proportional to the inverse of the variance of the estimate. Horizontal lines indicate 95% confidence intervals. There was some evidence of heterogeneity in country-specific HR estimates for the rs2290854 and rs6682208 SNP ($P = 0.04$ and 0.02 respectively, Figure S3), but after accounting for opposite effects of these SNPs in Finland/Denmark, there was no evidence of heterogeneity. There was some evidence of heterogeneity in the country-specific HRs for rs17631303 ($P_{\text{het}} = 0.004$, $df = 19$) but this was no longer present after excluding one country (Poland, P_{het}

het = 0.12, df = 18), or when restricting analyses to Stage 1 and 2 samples only (P-het = 0.09, df = 19). There was no evidence of heterogeneity for correlated SNP rs183211 (P-het = 0.10). There was no evidence of heterogeneity in the country-specific HRs for any of the other SNPs ($P > 0.68$).

(PDF)

Figure S6 *MDM4* regional association plot using *BRCA1* stage 1 and stage 2 samples. P-values for association ($-\log_{10}$ scale) with breast cancer risk for *BRCA1* mutation carriers for genotyped SNPs (diamond symbols \diamond) and SNPs imputed from the 1000 genomes project data (square symbols \square), by position (hg18) on chromosome 1. Red gradient represents r^2 value with the most significant genotyped SNP rs4951407. The blue peaks represent recombination rate in the region.

(PDF)

Figure S7 *TCF7L2* regional association plot using *BRCA1* stage 1 and stage 2 samples. P-values for association ($-\log_{10}$ scale) with breast cancer risk for *BRCA1* mutation carriers for genotyped SNPs (diamond symbols \diamond) and SNPs imputed from the 1000 genomes project data (square symbols \square), by position (hg18) on chromosome 1. Missing genotypes were replaced by imputed results. Red gradient represents r^2 value with the most significant genotyped SNP rs11196174. The blue peaks represent recombination rate in the region.

(PDF)

Figure S8 Linkage disequilibrium patterns between the SNPs in the novel (17q21.31) and previously identified regions on 17q21. SNPs in the novel region are uncorrelated with SNPs in the 43.3–44.3 Mb region (positions according to hg build 36.3).

(PDF)

Figure S9 4q32.3 regional association plot using *BRCA1* stage 1 and stage 2 samples. P-values for association ($-\log_{10}$ scale) with ovarian cancer risk for *BRCA1* mutation carriers for genotyped SNPs (diamond symbols \diamond) and imputed SNPs from the 1000 genomes project data (square symbols \square), by position (hg18) on chromosome 1. Red gradient represents r^2 value with the most significant genotyped SNP rs4691139. Blue peaks represent recombination rate in the region.

(PDF)

Figure S10 Combined Hazard Ratios (HR) for breast and ovarian cancer for *BRCA1* mutation carriers. (A) HR for Breast Cancer based on 10 loci associated with breast cancer risk for *BRCA1* mutation carriers. (B) Ovarian Cancer based on 7 loci associated with ovarian cancer risk for *BRCA1* mutation carriers. All HRs computed relative to the lowest risk category. The Y-axes translate the combined HRs into absolute risks of developing breast or ovarian cancer by age 80. The absolute risks and HRs at different percentiles of the combined genotype distribution are also marked. The combined HRs were obtained under the assumption that the loci interact multiplicatively.

(PDF)

Figure S11 Cis-eQTL and allelic expression (AE) analyses at *MDM4* locus. A) Cis-eQTLs for SNPs at *MDM4* locus using expression data from primary human osteoblasts (HOb). B) AE mapping for cis-regulatory variation in *MDM4* locus using primary skin fibroblasts. Coordinates (hg18) for locus shown on top; blue tracks indicate the $-\log_{10}$ (P value) of the association across all SNPs tested. The location of transcripts in this region is shown below.

(PDF)

Figure S12 Cis-eQTL and allelic expression (AE) analyses at chr17q21.31 locus. (Upper panel) Cis-eQTLs for SNPs at c17orf69 locus using expression data from primary human osteoblasts. Allelic expression mapping for cis-regulatory variation in *KANS1* (middle panel) and *WNT3* loci (lower panel) using a CEU population panel of lymphoblastoid cells. Coordinates (hg18) for loci are shown on top; blue tracks indicate the $-\log_{10}$ (P value) of the association across all SNPs tested. The location of transcripts in these regions are shown.

(PDF)

Table S1 Affected and unaffected *BRCA1* mutation carriers by study country in the breast and ovarian cancer analysis used in SNP selection for the iCOGS array.

(DOCX)

Table S2 Origin of *BRCA1* samples by Country and Stage used in the current analysis.

(DOCX)

Table S3 Sample and SNP quality control summary.

(DOCX)

Table S4 Associations with breast cancer risk for *BRCA1* mutation carriers, for known breast cancer susceptibility variants.

(DOCX)

Table S5 Associations with *BRCA1* breast or ovarian cancer risk for SNPs genotyped at stages 1, 2, and 3.

(DOCX)

Table S6 Analysis of breast cancer associations by *BRCA1* mutation class.

(DOCX)

Table S7 Associations with Breast Cancer ER status in *BRCA1* carriers for SNPs genotyped in stages 1–3.

(DOCX)

Table S8 Imputed SNPs at the novel 17q21 region with P-values less than the most significant genotyped SNP (rs169201).

(DOCX)

Table S9 SNPs associated ($P < 1 \times 10^{-5}$) with local expression and Allelic Imbalance.

(DOCX)

Text S1 Supplementary Methods.

(DOCX)

Acknowledgments

Antonios C. Antoniou is a Cancer Research–UK Senior Cancer Research Fellow. Douglas F. Easton is a Cancer Research UK Principal Research Fellow. Georgia Chenevix-Trench is an NHMRC Senior Principal Research Fellow.

iCOGS: CIMBA acknowledges the contributions of Kyriaki Michailidou, Jonathan Tyrer, and Ali Amin Al Olama to the iCOGS statistical analyses; Shahana Ahmed, Melanie J. Maranian, and Catherine S. Healey for their contributions to the iCOGS genotyping quality control process; and the staff of the genotyping unit in the Medical Genomics Facility at the Mayo Clinic under the supervision of Dr. Julie Cunningham.

Breast Cancer Family Registry (BCFR) Studies: Samples from the NC-BCFR were processed and distributed by the Coriell Institute for Medical Research. We wish to thank members and participants in the Breast Cancer Family Registry for their contributions to the study. The ABCFS would like to also thank Maggie Angelakos, Judi Maskiell, and Gillian Dite. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR.

Baltic Familial Breast Ovarian Cancer Consortium (BFBOCC): BFBOCC acknowledges Vilijus Rudaitis and Laimonas Griškevičius. BFBOCC-LV acknowledges oncologists Janis Eglitis, Anna Krilova and Aivars Stengrevics.

BRCA-gene mutations and breast cancer in South African women (BMBSA): BMBSA thanks the families who contributed to the BMBSA study.

Beckman Research Institute of the City of Hope (BRICOH): BRICOH thanks Greg Wilhoite and Marie Pinto for their work in participant enrollment and biospecimen and data management.

Copenhagen Breast Cancer Study (CBCS): CBCS thanks the Danish Breast Cancer Cooperative Group (DBCG) for clinical data.

Spanish National Cancer Centre (CNIO): CNIO thanks Alicia Barroso, Rosario Alonso and Guillermo Pita for their assistance.

CONsorzio Studi Italiani sui Tumori Ereditari Alla Mammella (CONSIT TEAM): CONSIT TEAM acknowledges Daniela Zaffaroni of the Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Monica Barile of Istituto Europeo di Oncologia (IEO), Milan, Riccardo Dolcetti of the Centro di Riferimento Oncologico (CRO) IRCCS, Aviano (PN), Maurizio Genuardi of University of Florence, Florence, Giuseppe Giannini of “La Sapienza” University, Rome, Adele Patrini of the Ospedale di Circolo-Università dell’Insubria, Varese, Antonella Savarese and Aline Martayain of the Istituto Nazionale Tumori Regina Elena (IRE), Rome and Stefania Tommasi of the Istituto Nazionale Tumori “Giovanni Paolo II”, Bari and the personnel of the CGT-lab at IFOM-IEO Campus, Milan, Italy.

Dana-Farber Cancer Institute (DFCI): DFCI thanks the study staff and participants.

The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON): HEBON recognizes Netherlands Cancer Institute, Amsterdam, NL: M.A. Rookus, F.B.L. Hogervorst, S. Verhoef, F.E. van Leeuwen, M.K. Schmidt, J. de Lange; Erasmus Medical Center, Rotterdam, NL: J.M. Collée, A.M.W. van den Ouweland, M.J. Hooning, C. Seynaeve; Leiden University Medical Center, NL: C.J. van Asperen, J.T. Wijnen, R.A. Tollenaar, P. Devilee, T.C.T.E.F. van Cronenburg; Radboud University Nijmegen Medical Center, NL: C.M. Kets, A.R. Mensenkamp; University Medical Center Utrecht, NL: M.G.E.M. Ausems, R.B. van der Luijt; Amsterdam Medical Center, NL: C.M. Aalfs, T.A.M. van Os; VU University Medical Center, Amsterdam, NL: J.J.P. Gille, Q. Waisfisz, H.E.J. Meijers-Heijboer; University Hospital Maastricht, NL: E.B. Gómez-García, M.J. Blok; University Medical Center Groningen, NL: J.C. Oosterwijk, H. van der Hout, M.J. Mourits, G.H. de Bock.

Epidemiological study of BRCA1 & BRCA2 mutation carriers (EMBRACE): Douglas F. Easton is the PI of the study. EMBRACE acknowledges the Coordinating Centre, Cambridge: Susan Peock, Debra Frost, Steve Ellis, Elena Fineberg, Radka Platte. North of Scotland Regional Genetics Service, Aberdeen: Zosia Miedzybrodzka, Helen Gregory. Northern Ireland Regional Genetics Service, Belfast: Patrick Morrison, Lisa Jeffers. West Midlands Regional Clinical Genetics Service, Birmingham: Trevor Cole, Kai-ren Ong, Jonathan Hoffman. South West Regional Genetics Service, Bristol: Alan Donaldson, Margaret James. East Anglian Regional Genetics Service, Cambridge: Marc Tischkowitz, Joan Paterson, Amy Taylor. Medical Genetics Services for Wales, Cardiff: Alexandra Murray, Mark T. Rogers, Emma McCann. St James’s Hospital, Dublin & National Centre for Medical Genetics, Dublin: M. John Kennedy, David Barton. South East of Scotland Regional Genetics Service, Edinburgh: Mary Porteous, Sarah Drummond. Peninsula Clinical Genetics Service, Exeter: Carole Brewer, Emma Kivuwa, Anne Searle, Selina Goodman, Kathryn Hill. West of Scotland Regional Genetics Service, Glasgow: Rosemarie Davidson, Victoria Murday, Nicola Bradshaw, Lesley Snadden, Mark Longmuir, Catherine Watt, Sarah Gibson, Eshika Haque, Ed Tobias, Alexis Duncan. South East Thames Regional Genetics Service, Guy’s Hospital London: Louise Izatt, Chris Jacobs, Caroline Langman. North West Thames Regional Genetics Service, Harrow: Huw Dorkins, Angela Brady, Athalie Melville, Kashmir Randhawa. Leicestershire Clinical Genetics Service, Leicester: Julian Barwell. Yorkshire Regional Genetics Service, Leeds: Julian Adlard, Gemma Serra-Feliu. Cheshire & Merseyside Clinical Genetics Service, Liverpool: Ian Ellis, Catherine Houghton. Manchester Regional Genetics Service, Manchester: D Gareth Evans, Fiona Laloo, Jane Taylor. North East Thames Regional Genetics Service, NE Thames, London: Lucy Side, Alison Male, Cheryl Berlin. Nottingham Centre for Medical Genetics,

Nottingham: Jacqueline Eason, Rebecca Collier. Northern Clinical Genetics Service, Newcastle: Fiona Douglas, Oonagh Claber, Irene Jobson. Oxford Regional Genetics Service, Oxford: Lisa Walker, Diane McLeod, Dorothy Halliday, Sarah Durell, Barbara Stayner. The Institute of Cancer Research and Royal Marsden NHS Foundation Trust: Rosalind A. Eeles, Susan Shanley, Nazneen Rahman, Richard Houlston, Astrid Stormorken, Elizabeth Bancroft, Elizabeth Page, Audrey Ardern-Jones, Kelly Kohut, Jennifer Wiggins, Elena Castro, Emma Killick, Sue Martin, Gillian Rea, Anjana Kulkarni. North Trent Clinical Genetics Service, Sheffield: Jackie Cook, Oliver Quarrell, Cathryn Bardsley. South West Thames Regional Genetics Service, London: Shirley Hodgson, Sheila Goff, Glen Brice, Lizzie Winchester, Charlotte Eddy, Vishakha Tripathi, Virginia Attard, Anna Lehmann. Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton: Diana Eccles, Anneke Lucassen, Gillian Crawford, Donna McBride, Sarah Smalley.

Fox Chase Cancer Center (FCCC): FCCC thanks Dr. Betsy Bove for her technical support.

German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC): GC-HBOC thanks all family members who participated in this study, Wolfram Heinritz, Center Leipzig, and Dieter Schäfer, Center Frankfurt, for providing DNA samples and Juliane Köhler for excellent technical assistance.

Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO): GEMO thanks all the GEMO collaborating groups for their contribution to this study. GEMO Collaborating Centers are: Coordinating Centres, Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon - Centre Léon Bérard, & Equipe «Génétique du cancer du sein», Centre de Recherche en Cancérologie de Lyon: Olga Similnikova, Sylvie Mazoyer, Francesca Damiola, Laure Barjhoux, Carole Vernet-Pierre, Sophie Giraud, Mélanie Léone; and Service de Génétique Oncologique, Institut Curie, Paris: Dominique Stoppa-Lyonnet, Marion Gauthier-Villars, Bruno Buecher, Claude Houdayer, Virginie Moncoutier, Muriel Belotti, Carole Tirapo, Antoine de Pauw. Institut Gustave Roussy, Villejuif: Brigitte Bressac-de-Paillerets, Olivier Caron. Centre Jean Perrin, Clermont-Ferrand: Yves-Jean Bignon, Nancy Uhrhammer. Centre Léon Bérard, Lyon: Christine Lasset, Valérie Bonadona, Sandrine Handallou. Centre François Baclesse, Caen: Agnès Hardouin, Pascaline Berthet. Institut Paoli Calmettes, Marseille: Hagay Sobol, Violaine Bourdon, Tetsuro Noguchi, Audrey Remenieras, François Eisinger. CHU Arnaud-de-Villeneuve, Montpellier: Isabelle Coupier, Pascal Pujol. Centre Oscar Lambret, Lille: Jean-Philippe Peyrat, Joëlle Fournier, Françoise Révillon, Philippe Vennin, Claude Adenis. Hôpital René Huguenin/Institut Curie, St Cloud: Etienne Rouleau, Rosette Lidereau, Liliane Demange, Catherine Nogues. Centre Paul Strauss, Strasbourg: Danièle Muller, Jean-Pierre Fricker. Institut Bergonié, Bordeaux: Emmanuelle Barouk-Simonet, Françoise Bonnet, Virginie Buben, Nicolas Sevenet, Michel Longy. Institut Claudius Regaud, Toulouse: Christine Toulas, Rosine Guimbaud, Laurence Gladiéff, Viviane Feillel. CHU Grenoble: Dominique Leroux, Hélène Dreyfus, Christine Rebischung, Magalie Peysselon. CHU Dijon: Fanny Coron, Laurence Faivre. CHU St-Etienne: Fabienne Prieur, Marine Lebrun, Caroline Kientz. Hôtel Dieu Centre Hospitalier, Chambéry: Sandra Fert Ferrer. Centre Antoine Lacassagne, Nice: Marc Frénay. CHU Limoges: Laurence Vénat-Bouvet. CHU Nantes: Capucine Delnatte. CHU Bretonneau, Tours: Isabelle Mortemousque. Groupe Hospitalier Pitié-Salpêtrière, Paris: Florence Coulet, Chrystelle Colas, Florent Soubrier. CHU Vandoeuvre-les-Nancy: Johanna Sokolowska, Myriam Bronner. Creighton University, Omaha, USA: Henry T. Lynch, Carrie L. Snyder.

GFAST: G-FAST acknowledges the contribution of Bruce Poppe and Anne De Paepe and the technical support of Ilse Coene en Brecht Crombez.

Hospital Clinico San Carlos (HCSC): HCSC acknowledges Alicia Tosar for her technical assistance.

Helsinki Breast Cancer Study (HEBCS): HEBCS thanks Carl Blomqvist, Kirsimari Aaltonen and RN Irja Erkkilä for their help with the HEBCS data and samples.

Study of Genetic Mutations in Breast and Ovarian Cancer patients in Hong Kong and Asia (HRBCP): HRBCP thanks Hong Kong Sanatorium and Hospital for their continual support.

Molecular Genetic Studies of Breast and Ovarian Cancer in Hungary (HUNBOCS): HUNBOCS thanks Hungarian Breast and Ovarian Cancer Study Group members (Janos Papp, Aniko Bozsik, Kristof

Arvai, Judit Franko, Maria Balogh, Gabriella Varga, Judit Ferenczi, Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary) and the clinicians and patients for their contributions to this study.

Interdisciplinary HEalth Research Internal Team BREast CAncer susceptibility (INHERIT): INHERIT thanks Dr Martine Dumont, Martine Tranchant for sample management and skillful technical assistance. J.S. is Chairholder of the Canada Research Chair in Oncogenetics.

Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab): kConFab thanks Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study for their contributions to this resource, and the many families who contribute to kConFab.

Modifier Study of Quantitative Effects on Disease (MOD-SQUAD): MODSQUAD acknowledges ModSQuAD members Csilla Szabo and Zohra Ali-Kahn Catts (University of Delaware, Newark, USA); Lenka Foretova and Eva Machackova (Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic); and Michal Zikan, Petr Pohlreich and Zdenek Kleibl (Oncogynecologic Center and Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic).

National Israeli Cancer Control Center (NICCC): NICCC thanks the NICCC National Familial Cancer Consultation Service team led by Sara Dishon, the laboratory team led by Dr. Flavio Lejbkowitz, and the research field operations team led by Dr. Mila Pinchev.

Ontario Cancer Genetics Network (OCGN): OCGN thanks the study staff and participants.

The Ohio State University Comprehensive Cancer Center (OSUCCG): OSU CCG acknowledges Kevin Sweet, Caroline Craven and Michelle O'Connor who were instrumental in accrual of study participants, ascertainment of medical records and database management. Samples were processed by the OSU Human Genetics Sample Bank.

South East Asian Breast Cancer Association Study (SEABASS): SEABASS thanks Yip Cheng Har, Nur Aishah Mohd Taib, Phuah Sze Yee, Norhashimah Hassan and all the research nurses, research assistants and doctors involved in the MyBrCa Study for assistance in patient recruitment, data collection and sample preparation. In addition, we thank Philip Iau, Sng Jen-Hwei and Sharifah Nor Akmal for contributing samples from the Singapore Breast Cancer Study and the HUKM-HKL Study respectively.

Sheba Medical Centre (SMC): SMC acknowledges the assistance of the Meirav Comprehensive breast cancer center team at the Sheba Medical Center for assistance in this study.

Swedish Breast Cancer Study (SWE-BRCA): SWE-BRCA Acknowledges SWE-BRCA collaborators from Lund University and University Hospital: Åke Borg, Håkan Olsson, Helena Jernström, Karin Henriksson, Katja Harbst, Maria Solter, Niklas Loman, Ulf Kristofferson; Gothenburg Sahlgrenska University Hospital: Anna Öfverholm, Margareta Nordling, Per Karlsson, Zakaria Einbeigi; Stockholm and Karolinska University Hospital: Anna von Wachenfeldt, Annelie Liljegren, Annika Lindblom, Brita Arver, Gisela Barbany Bustinza, Johanna Rantala; Umeå University Hospital: Beatrice Melin, Christina Edwindsdotter Ardnor, Monica Emanuelsson; Uppsala University: Hans Ehrencrona, Maritta Hellström Pigg, Richard Rosenquist; Linköping University Hospital: Marie Stenmark-Askmal, Sigrun Liedgren.

The University of Chicago Center for Clinical Cancer Genetics and Global Health (UCHICAGO): UCHICAGO thanks Cecilia Zvocec, Qun Niu, physicians, genetic counselors, research nurses and staff of the Cancer Risk Clinic for their contributions to this resource, and the many families who contribute to our program. OIO is an ACS Clinical Research Professor.

University of California Los Angeles (UCLA): UCLA thanks Joyce Seldon MSGC and Lorna Kwan, MPH for assembling the data for this study.

University of California San Francisco (UCSF): UCSF thanks Ms. Salina Chan for her data management and the following genetic counselors for participant recruitment: Beth Crawford, Nicola Stewart, Julie Mak, and Kate Lamvik.

United Kingdom Familial Ovarian Cancer Registries (UKFOCR): UKFOCR thanks Paul Pharoah, Simon Gayther, Carole Pye,

Patricia Harrington and Eva Wozniak for their contributions towards the UKFOCR.

Victorian Familial Cancer Trials Group (VFCTG): VFCTG thanks Sarah Sawyer and Rebecca Driessen for assembling this data and Ella Thompson for performing all DNA amplification.

Author Contributions

Conceived and designed the experiments: Fergus J Couch, Douglas F Easton, Georgia Chenevix-Trench, Kenneth Offit, Antonis C Antoniou. Performed the experiments: Fergus J Couch, Julie Cunningham, Xianshu Wang, Curtis Olsword, Matthew Kosel, Adam Lee, Mia M Gaudet, Kenneth Offit, François Bacot, Daniel Vincent, Daniel Tessier. Analyzed the data: Antonis C Antoniou, Karoline B Kuchenbaecker, Lesley McGuffog, Daniel Barrowdale, Andrew Lee, Joe Dennis, Ed Dicks, Vernon S Pankratz, Zachary Fredericksen, Curtis Olsword, Matthew Kosel. Contributed reagents/materials/analysis tools: Penny Soucy, Kristen Stevens, Jacques Simard, Tomi Pastinen, Sue Healey, Olga M Sinilnikova, Andrew Lee. Wrote the manuscript: Fergus J Couch, Douglas F Easton, Antonis C Antoniou. Collected data and samples and provided critical review of the manuscript: Fergus J Couch, Xianshu Wang, Lesley McGuffog, Curtis Olsword, Karoline B Kuchenbaecker, Penny Soucy, Zachary Fredericksen, Daniel Barrowdale, Joe Dennis, Mia M Gaudet, Ed Dicks, Matthew Kosel, Olga M Sinilnikova, François Bacot, Daniel Vincent, Frans BL Hogervorst, Susan Peock, Dominique Stoppa-Lyonnet, Anna Jakubowska, Paolo Radice, Rita Katharina Schmutzler, Susan M Domchek, Marion Piedmonte, Christian F Singer, Thomas v O Hansen, Susan L Neuhausen, Csilla I Szabo, Ignacio Blanco, Mark H Greene, Beth Y Karlan, Catherine M Phelan, Jeffrey N Weitzel, Marco Montagna, Edith Olah, Irene L Andrulis, Andrew K Godwin, Drakoulis Yannoukakos, David E Goldgar, Trinidad Caldes, Heli Nevanlinna, Ana Osorio, Mary Beth Terry, Mary B Daly, Elizabeth J van Rensburg, Ute Hamann, Susan J Ramus, Amanda Ewart Toland, Maria A Caligo, Olufunmilayo I Olopade, Nadine Tung, Kathleen Claes, Mary S Beattie, Melissa C Southey, Evgeny N Imyanitov, Ramunas Janavicius, Esther M John, Ava Kwong, Orland Diez, Rosa B Barkardottir, Banu K Arun, Gad Rennert, Soo-Hwang Teo, Patricia A Ganz, Annemarie H van der Hout, Carolien HM van Deurzen, Encarna B Gómez Garcia, Flora E van Leeuwen, Hanne EJ Meijers-Heijboer, Johannes JP Gille, Margreet GEM Ausems, Marinus J Blok, Marjolijn JL Ligtenberg, Matti A Rookus, Peter Devilee, Theo AM van Os, Juul T Wijnen, Debra Frost, Radka Platte, D Gareth Evans, Louise Izatt, Rosalind A Eeles, Julian Adlard, Diana M Eccles, Carole Brewer, Patrick J Morrison, Lucy E Side, Alan Donaldson, Mark T Rogers, Jacqueline Eason, Helen Gregory, Emma McCann, Alain Calender, Agnès Hardouin, Pascaline Berthet, Capucine Delnatte, Catherine Nogues, Dominique Leroux, Etienne Rouleau, Fabienne Prieur, Hagay Sobol, Laurence Venat-Bouvet, Laurent Castera, Marion Gauthier-Villars, Mélanie Léoné, Yves-Jean Bignon, Elżbieta Złowocka-Perłowska, Katarzyna Durda, Katarzyna Jaworska, Tomasz Huzarski, Alessandra Viel, Bernard Peissel, Bernardo Bonanni, Giulia Melloni, Laura Ottini, Laura Papi, Liliana Varesco, Maria Grazia Tibiletti, Valeria Pensotti, Norbert Arnold, Christoph Engel, Dorothea Gadzicki, Andrea Gehrig, Karin Kast, Kerstin Rhiem, Dieter Niederacher, Nina Ditsch, Hansjoerg Plendl, Sabine Preisler-Adams, Raymonda Varon-Mateeva, Barbara Wappenschmidt, Bernhard H F Weber, Brita Arver, Marie Stenmark-Askmal, Richard Rosenquist, Zakaria Einbeigi, Katherine L Nathanson, Timothy R Rebbeck, Stephanie V Blank, David E Cohn, Gustavo C Rodriguez, Michael Friedlander, Victoria L Bae-Jump, Anneliese Fink-Retter, Christine Rappaport, Daphne Gschwanner Kaulich, Georg Pfeiler, Muy-Kheng Tea, Bella Kaufman, Shani Shimon Paluch, Yael Laitman, Anne-Marie Gerdes, Inge Sokilde Pedersen, Sanne Traasdahl Moeller, Torben A Kruse, Uffe Birk Jensen, Joseph Vijai, Mark Robson, Noah Kauff, Anna Marie Mulligan, Gord Glendon, Hilmi Ozcelik, Bent Ejlersen, Finn C Nielsen, Lars Jonson, Mette K Andersen, Yuan Chun Ding, Lenka Foretova, Alex Teulé, Miquel Angel Pujana, Phuong L Mai, Jennifer T Loud, Sandra Orsulic, Steven A Narod, Josef Herzog, Sharon R Sand, Silvia Tognazzo, Simona Agata, Tibor Vazsko, Joellen Weaver, Alexandra V Stavropoulou, Saundra S Buys, Atocha Romero, Miguel de la Hoya, Kristiina Aittomäki, Taru A Muranen, Mercedes Duran, Wendy K Chung, Cecilia M Dorfling, Dezheng Huo, Salina B Chan, Anna P Sokolenko, Laima Tihomirova, Tara M Friebe, Bjarni A Agnarsson, Karen H Lu, Flavio Lejbkowitz, Paul A James, Per Hall, Alison M Dunning, Daniel Tessier, Susan L Slager, Jacques Simard, Tomi Pastinen,

Vernon S Pankratz, Kenneth Offit, Douglas F Easton, Georgia Chenevix-Trench, Antonis C Antoniou, Andrew Lee, Adam Lee, Adriana Lasz, Alexander Miron, Caroline Seynaeve, Christian Sutter, Eitan Friedman, Elena Fineberg, Christine Lasset, Amanda B Spurdle, Anne-Bine Skytte, Alfons Meindl, Claude Houdayer, Fiona Douglas Francesca Damiola, Catherine Houghton, Alex Murray, Jan Lubinski, Conxi Lazaro, Christine Walsh, Chen Wang, Jenny Lester, Huw Dorkins, Helmut Deissler, Ian

Campbell, Isabelle Coupier, Judith Balmaña, Joan Brunet, Javier Benitez, Jackie Cook, Jocelyne Chiquette, Judy Garber, Jacek Gronwald, Kara Sarrel, Kristen Stevens, Laurie Small, Leigha Senter, Linda Steele, Mads Thomassen, Marc Tischkowitz, Niklas Loman, Noralane M Lindor, Pascal Pujol, Paolo Peterlongo, Steve Ellis, Stefanie Engert, Sue Healey, Shirley Hodgson, Steven Hart, Sylvie Mazoyer, Siranoush, Manoukian, Senno Verhoef, Sara Volorio.

References

- Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE et al. (2003) Average risks of breast and ovarian cancer associated with *BRCA1* or *BRCA2* mutations detected in case series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet* 72: 1117–1130.
- Antoniou AC, Chenevix-Trench G (2010) Common genetic variants and cancer risk in Mendelian cancer syndromes. *Curr Opin Genet Dev* 20: 299–307. S0959-437X(10)00044-4 [pii];10.1016/j.gde.2010.03.010 [doi].
- Begg CB, Haile RW, Borg A, Malone KE, Concannon P et al. (2008) Variation of breast cancer risk among *BRCA1/2* carriers. *JAMA* 299: 194–201.
- Simchoni S, Friedman E, Kaufman B, Gershoni-Baruch R, Orr-Urtreger A et al. (2006) Familial clustering of site-specific cancer risks associated with *BRCA1* and *BRCA2* mutations in the Ashkenazi Jewish population. *Proc Natl Acad Sci U S A* 103: 3770–3774.
- Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbaecker KB et al. (2012) Common variants at the 19p13.1 and *ZNFR365* loci are associated with ER subtypes of breast and ovarian cancer risk in *BRCA1* and *BRCA2* mutation carriers. *Cancer Epidemiol Biomarkers Prev* 21: 645–657. 1055-9965.EPI-11-0888 [pii];10.1158/1055-9965.EPI-11-0888 [doi].
- Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PD, Similnikova OM et al. (2010) Genetic variation at 9p22.2 and ovarian cancer risk for *BRCA1* and *BRCA2* mutation carriers. *J Natl Cancer Inst* 103: 105–116. djq494 [pii];10.1093/jnci/djq494 [doi].
- Ramus SJ, Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J et al. (2012) Ovarian cancer susceptibility alleles and risk of ovarian cancer in *BRCA1* and *BRCA2* mutation carriers. *Hum Mutat* 33: 690–702. 10.1002/humu.22025 [doi].
- Antoniou AC, Spurdle AB, Similnikova OM, Healey S, Pooley KA et al. (2008) Common breast cancer-predisposition alleles are associated with breast cancer risk in *BRCA1* and *BRCA2* mutation carriers. *Am J Hum Genet* 82: 937–948.
- Antoniou AC, Similnikova OM, McGuffog L, Healey S, Nevanlinna H et al. (2009) Common variants in *LSP1*, 2q35 and 8q24 and breast cancer risk for *BRCA1* and *BRCA2* mutation carriers. *Hum Mol Genet* 18: 4442–4456. ddp372 [pii];10.1093/hmg/ddp372 [doi].
- Antoniou AC, Kartsonaki C, Similnikova OM, Soucy P, McGuffog L et al. (2011) Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for *BRCA1* and *BRCA2* mutation carriers. *Hum Mol Genet* 20: 3304–3321. ddr226 [pii];10.1093/hmg/ddr226 [doi].
- Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X et al. (2012) Common variants at 12p11, 12q24, 9p21, 9q31.2 and in *ZNFR365* are associated with breast cancer risk for *BRCA1* and/or *BRCA2* mutation carriers. *Breast Cancer Res* 14: R33. bcr3121 [pii];10.1186/bcr3121 [doi].
- Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R et al. (2010) A locus on 19p13 modifies risk of breast cancer in *BRCA1* mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nat Genet* 42: 885–892. ng.669 [pii];10.1038/ng.669 [doi].
- Stevens KN, Vachon CM, Lee AM, Slager S, Lesnick T et al. (2011) Common breast cancer susceptibility loci are associated with triple negative breast cancer. *Cancer Res* 0008-5472.CAN-11-1266 [pii];10.1158/0008-5472.CAN-11-1266 [doi].
- Gaudet MM, Kuchenbaecker KB, Vijai J, Klein RJ, Kirchhoff T et al. (2013) Identification of a *BRCA2*-specific Modifier Locus at 6p24 Related to Breast Cancer Risk. *PLoS Genet* 9: e1003173. doi:10.1371/journal.pgen.1003173
- Robertson A, Hill WG (1984) Deviations from Hardy-Weinberg proportions: sampling variances and use in estimation of inbreeding coefficients. *Genetics* 107: 703–718.
- Antoniou AC, Goldgar DE, Andrieu N, Chang-Claude J, Brohet R et al. (2005) A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. *Genet Epidemiol* 29: 1–11.
- Barnes DR, Lee A, Easton DF, Antoniou AC (2012) Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations. *Genet Epidemiol* 36: 274–291. 10.1002/gepi.21620 [doi].
- Antoniou AC, Similnikova OM, Simard J, Leone M, Dumont M et al. (2007) RAD51 135G→C modifies breast cancer risk among *BRCA2* mutation carriers: results from a combined analysis of 19 studies. *Am J Hum Genet* 81: 1186–1200.
- Amin N, van Duijn CM, Aulchenko YS (2007) A genomic background based method for association analysis in related individuals. *PLoS ONE* 2: e1274. doi:10.1371/journal.pone.0001274
- Leutenegger AL, Prum B, Genin E, Verny C, Lemainque A et al. (2003) Estimation of the inbreeding coefficient through use of genomic data. *Am J Hum Genet* 73: 516–523. 10.1086/378207 [doi];S0002-9297(07)62015-1 [pii].
- Boos D.D. (1992) On generalised score tests. *American Statistician* 46: 327–333.
- Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 447: 661–678. nature05911 [pii];10.1038/nature05911 [doi].
- Aulchenko YS, Ripke S, Isaacs A, van Duijn CM (2007) GenABEL: an R library for genome-wide association analysis. *Bioinformatics* 23: 1294–1296. btm108 [pii];10.1093/bioinformatics/btm108 [doi].
- Lange K, Weeks D, Boehnke M (1988) Programs for pedigree analysis: MENDEL, FISHER, and dGENE. *Genet Epidemiol* 5: 471–472.
- Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F et al. (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. *Br J Cancer* 98: 1457–1466.
- Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D et al. (2011) Common breast cancer susceptibility alleles are associated with tumor subtypes in *BRCA1* and *BRCA2* mutation carriers: results from the Consortium of Investigators of Modifiers of *BRCA1/2*. *Breast Cancer Res* 13: R110. bcr3052 [pii];10.1186/bcr3052 [doi].
- Howie B, Marchini J, Stephens M (2011) Genotype imputation with thousands of genomes. *G3 (Bethesda)* 1: 457–470. 10.1534/g3.111.001198 [doi];GGG_001198 [pii].
- Antoniou AC, Beesley J, McGuffog L, Similnikova OM, Healey S et al. (2010) Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for *BRCA1* and *BRCA2* Mutation Carriers: Implications for Risk Prediction. *Cancer Res* 70: 9742–9754. 0008-5472.CAN-10-1907 [pii];10.1158/0008-5472.CAN-10-1907 [doi].
- Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D et al. (2012) Pathology of breast and ovarian cancers among *BRCA1* and *BRCA2* mutation carriers: results from the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA). *Cancer Epidemiol Biomarkers Prev* 21: 134–147. 1055-9965.EPI-11-0775 [pii];10.1158/1055-9965.EPI-11-0775 [doi].
- Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M et al. (2010) A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. *Nat Genet* 42: 874–879. ng.668 [pii];10.1038/ng.668 [doi].
- Bojesen S, Pooley KA, Johnatty SE, Beesley J, Michailidou K et al. (2012) Multiple independent TERT variants associated with telomere length and risks of breast and ovarian cancer. *Nat Genet* In Press.
- Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J et al. (2012) Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nat Genet* In Press.
- Sladek R, Rocheleau G, Rung J, Dina C, Shen L et al. (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. *Nature* 445: 881–885. nature05616 [pii];10.1038/nature05616 [doi].
- Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK et al. (2012) Genome-wide association studies identify four ER-negative specific breast cancer risk loci. *Nat Genet* In Press.
- Atwal GS, Kirchhoff T, Bond EE, Montagna M, Menin C et al. (2009) Altered tumor formation and evolutionary selection of genetic variants in the human *MDM1* oncogene. *Proc Natl Acad Sci U S A* 106: 10236–10241. 0901298106 [pii];10.1073/pnas.0901298106 [doi].
- Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM et al. (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* 486:346–352. nature10983 [pii];10.1038/nature10983 [doi].
- Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N et al. (2006) Inactivation of the p53 pathway in retinoblastoma. *Nature* 444: 61–66. nature05194 [pii];10.1038/nature05194 [doi].
- Wade M, Wahl GM (2009) Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? *Mol Cancer Res* 7: 1–11. 7/1/1 [pii];10.1158/1541-7786.MCR-08-0423 [doi].
- Fairfax BP, Makino S, Radhakrishnan J, Plant K, Leslie S et al. (2012) Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles. *Nat Genet* 44: 501–510. ng.2205 [pii];10.1038/ng.2205 [doi].
- Ge B, Pokholok DK, Kwan T, Grundberg E, Morcos L et al. (2009) Global patterns of cis variation in human cells revealed by high-density allelic expression analysis. *Nat Genet* 41: 1216–1222. ng.473 [pii];10.1038/ng.473 [doi].
- Grundberg E, Adoue V, Kwan T, Ge B, Duan QL et al. (2011) Global analysis of the impact of environmental perturbation on cis-regulation of gene expression. *PLoS Genet* 7: e1001279. doi:10.1371/journal.pgen.1001279
- Stefansson H, Helgason A, Thorleifsson G, Steinthorsdottir V, Masson G et al. (2005) A common inversion under selection in Europeans. *Nat Genet* 37: 129–137. ng1508 [pii];10.1038/ng1508 [doi].
- Bowen NJ, Walker LD, Matyunina LV, Logani S, Totten KA et al. (2009) Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. *BMC Med Genomics* 2: 71. 1755-8794-2-71 [pii];10.1186/1755-8794-2-71 [doi].
- Ikram MA, Fornage M, Smith AV, Seshadri S, Schmidt R et al. (2012) Common variants at 6q22 and 17q21 are associated with intracranial volume. *Nat Genet* 44: 539–544. ng.2245 [pii];10.1038/ng.2245 [doi].

45. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. *Nat Genet* 41: 1308–1312. ng.487 [pii];10.1038/ng.487 [doi].
46. Pharoah P, Tsai YY, Ramus S, Phelan C, Goode EL et al. (2012) GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nat Genet* In Press.

Published in final edited form as:

Nat Commun. 2013 ; 4: 1627. doi:10.1038/ncomms2613.

Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31

Jennifer Permuth-Wey^{1,*}, Kate Lawrenson^{2,*}, Howard C. Shen^{2,*}, Aneliya Velkova¹, Jonathan P. Tyrer³, Zhihua Chen⁴, Hui-Yi Lin⁵, Y. Ann Chen⁵, Ya-Yu Tsai¹, Xiaotao Qu⁴, Susan J. Ramus², Rod Karevan², Janet Lee², Nathan Lee², Melissa C. Larson⁶, Katja K. Aben^{7,8}, Hoda Anton-Culver⁹, Natalia Antonenkova¹⁰, Antonis Antoniou¹¹, Sebastian M. Armasu⁶, Australian Cancer Study¹², Australian Ovarian Cancer Study^{12,13}, François Bacot¹⁴, Laura Baglietto^{15,16}, Elisa V. Bandera¹⁷, Jill Barnholtz-Sloan¹⁸, Matthias W. Beckmann¹⁹, Michael J. Birrer²⁰, Greg Bloom⁴, Natalia Bogdanova²¹, Louise A. Brinton²², Angela Brooks-Wilson²³, Robert Brown²⁴, Ralf Butzow^{25,26}, Qiuyin Cai²⁷, Ian Campbell^{13,28}, Jenny Chang-Claude²⁹, Stephen Chanock²², Georgia Chenevix-Trench¹², Jin Q. Cheng³⁰, Mine S. Cicek³¹, Gerhard A. Coetzee³², Consortium of Investigators of Modifiers of BRCA1/2^{33,34}, Linda S. Cook³⁵, Fergus J. Couch³⁴, Daniel W. Cramer³⁶, Julie M. Cunningham³¹, Agnieszka Dansonka-Mieszkowska³⁷, Evelyn Despierre³⁸, Jennifer A Doherty³⁹, Thilo Dörk²¹, Andreas du Bois^{40,41}, Matthias Dürst⁴², Douglas F Easton^{11,43}, Diana Eccles⁴⁴, Robert Edwards⁴⁵, Arif B. Ekici⁴⁶, Peter A. Fasching^{19,47}, David A. Fenstermacher⁴, James M. Flanagan²⁴, Montserrat Garcia-Closas⁴⁸, Aleksandra Gentry-Maharaj⁴⁹, Graham G. Giles^{15,16,50}, Rosalind M. Glasspool⁵¹, Jesus Gonzalez-Bosquet⁵², Marc T. Goodman⁵³, Martin Gore⁵⁴, Bohdan Górski⁵⁵, Jacek Gronwald⁵⁵, Per Hall⁵⁶, Mari K. Halle^{57,58}, Philipp Harter^{40,41}, Florian Heitz^{40,41}, Peter Hillemanns⁵⁹, Maureen Hoatlin⁶⁰, Claus K. Høgdall⁶¹, Estrid Høgdall^{62,63}, Satoyo Hosono⁶⁴, Anna Jakubowska⁵⁵, Allan Jensen⁶³, Heather Jim⁶⁵, Kimberly R. Kall⁶⁶, Beth Y. Karlan⁶⁷, Stanley B. Kaye⁶⁸, Linda E. Kelemen⁶⁹, Lambertus A. Kiemeny^{7,8,70}, Fumitaka Kikkawa⁷¹, Gottfried E. Konecny⁴⁷, Camilla Krakstad^{57,58}, Susanne Krüger Kjaer^{61,63}, Jolanta Kupryjanczyk³⁷, Diether Lambrechts^{72,73}, Sandrina Lambrechts³⁸, Johnathan M. Lancaster⁵², Nhu D. Le⁷⁴, Arto Leminen²⁶, Douglas A. Levine⁷⁵, Dong Liang⁷⁶, Boon Kiong Lim⁷⁷, Jie Lin⁷⁸, Jolanta Lissowska⁷⁹, Karen H. Lu⁸⁰, Jan Lubiński⁵⁵, Galina Lurie⁸¹, Leon F.A.G. Massuger⁸²,

Correspondence: Jennifer Permuth-Wey, PhD, Moffitt Cancer Center, 12902 Magnolia Dr., MRC-CANT, Tampa, Florida 33612, Jenny.Wey@moffitt.org Telephone: 813-745-5744, Fax: 813-745-6525; Thomas A. Sellers, PhD, Moffitt Cancer Center, 12902 Magnolia Dr, Tampa, Florida 33612, Thomas.Sellers@moffitt.org, Telephone: 813-745-1315, Fax: 813-449-8126; Simon Gayther, PhD, University of Southern California/Keck School of Medicine, Harlyne Norris Research Tower 1450 Biggy Street Los Angeles, CA 90033, gayther@usc.edu, Telephone: 323 442-8112, Fax: 323 442-7787.

*contributed equally to this manuscript

Author Contributions: These authors contributed equally to this work: JPW, KL, and HCS, and ANAM, TAS, and SAG. Writing group: JPW, KL, HCS, AV, ANAM, SAG, TAS, ELG, BLF, SJR, and PDPP. All authors read and approved the final version of the manuscript.

Provision of data and/or samples from contributing studies and institutions: JPW, KL, HCS, AV, JT, ZC, H-YL, YAC, Y- Y T, XQ, SJR, RK, JL, NL, MCL, KA, HA-C, NA, AA, SMA, FB, LB, EB, JBS, MWB, MJB, GB, NB, LAB, ABW, RB, RB, QC, IC, JCC, SC, GCT, JQC, MSC, GAC, LSC, FJC, DWC, JMC, ADM, ED, JAD, TD, AdB, MD, DFE, DE, RE, ABE, PAF, DAF, JMF, MGC, AGM, GGG, RMG, JGB, MTG, MG, BG, JG, PH, MH, PH, FH, PH, MH, CH, EH, SH, AJ, AJ, HJ, KK, BYK, SBK, LEK, LAK, FK, GK, CK, SKK, JK, DL, SL, JML, NDL, AL, DAL, DL, JL, BKL, JL, KHL, JL, GL, LFAGM, KM, VM, JRM, UM, FM, KBM, TN, SAN, LN, RBN, HN, SN, HN, KO, SHO, IO, JP, CLP, TP, LMP, MCP, EMP, PR, SPR, HAR, LRR, MAR, AR, IR, IKR, HBS, IS, GS, VS, X-OS, YBS, WS, HS, MCS, BS, DS, RS, S-HT, KLT, DCT, PJT, SST, AMvA, IV, RAV, DV, AV, SW-G, RPW, NW, ASW, EW, LRW, BW, YLW, AHW, Y-BX, HPY, WZ, AZ, FZ, CMP, EI, JMS, AB, BLF, ELG, PDDP, ANAM, TAS, and SAG.

Collated and organized samples for genotyping: SJR and CMP.

Genotyping: JMC, DCT, FB, and DV.

Data analysis: JPW, JT, H-YL, YAC, BLF, MLL, and Y-Y T.

Functional analyses: SAG, ANAM, KL, HC S, AV, JL, RK, and SJR.

Bioinformatics support: ZC, XQ.

Keitaro Matsuo⁶⁴, Valerie McGuire⁸³, John R McLaughlin^{84,85}, Usha Menon⁴⁹, Francesmary Modugno^{78,80,86}, Kirsten B. Moysich⁸⁷, Toru Nakanishi⁸⁸, Steven A. Narod⁸⁹, Lotte Nedergaard⁹⁰, Roberta B. Ness⁹¹, Heli Nevanlinna²⁶, Stefan Nickels²⁹, Houtan Noushmehr^{32,92}, Kunle Odunsi⁹³, Sara H. Olson⁹⁴, Irene Orlow⁹⁴, James Paul⁵¹, Celeste L Pearce², Tanja Pejovic^{95,96}, Liisa M. Pelttari²⁶, Malcolm C. Pike^{2,94}, Elizabeth M. Poole^{97,98}, Paola Raska¹⁸, Stefan P. Renner¹⁹, Harvey A. Risch⁹⁹, Lorna Rodriguez-Rodriguez¹⁷, Mary Anne Rossing^{100,101}, Anja Rudolph²⁹, Ingo B. Runnebaum⁴², Iwona K. Rzepecka³⁷, Helga B. Salvesen^{57,58}, Ira Schwaab¹⁰², Gianluca Severi^{15,16}, Vijayalakshmi Shridhar¹⁰³, Xiao-Ou Shu²⁷, Yurii B. Shvetsov⁸¹, Weiva Sieh⁸³, Honglin Song³, Melissa C. Southey¹⁰⁴, Beata Spiewankiewicz¹⁰⁵, Daniel Stram², Rebecca Sutphen¹⁰⁶, Soo-Hwang Teo⁷⁷, Kathryn L. Terry³⁶, Daniel C. Tessier¹⁴, Pamela J. Thompson⁵³, Shelley S. Tworoger^{97,98}, Anne M. van Altena⁸², Ignace Vergote³⁸, Robert A. Vierkant³¹, Daniel Vincent¹⁴, Allison F. Vitonis³⁶, Shan Wang-Gohrke¹⁰⁷, Rachel Palmieri Weber¹⁰⁸, Nicolas Wentzensen²², Alice S. Whittemore⁸³, Elisabeth Wik^{57,58}, Lynne R. Wilkens⁸¹, Boris Winterhoff¹⁰⁹, Yin Ling Woo⁷⁷, Anna H. Wu², Yong-Bing Xiang¹¹⁰, Hannah P. Yang²², Wei Zheng²⁷, Argyrios Ziogas¹¹¹, Famida Zulkifli⁷⁷, Catherine M. Phelan¹, Edwin Iversen¹¹², Joellen M. Schildkraut^{108,113}, Andrew Berchuck¹¹⁴, Brooke L. Fridley¹¹⁵, Ellen L. Goode³¹, Paul D. P. Pharoah^{11,43}, Alvaro N.A. Monteiro¹, Thomas A. Sellers¹, and Simon A. Gayther²

¹Department of Cancer Epidemiology, Division of Population Sciences, Moffitt Cancer Center, Tampa, FL, USA, 33612 ²Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA, 90033 ³Department of Oncology, University of Cambridge, Cambridge, CB1 8RN, UK ⁴Department of Biomedical Informatics, Moffitt Cancer Center, Tampa, FL, USA, 33612 ⁵Department of Biostatistics, Moffitt Cancer Center, Tampa, FL, USA, 33612 ⁶Department of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA, 55905 ⁷Department of Epidemiology, Biostatistics and HTA, Radboud University Medical Centre, Nijmegen, HB 6500, Netherlands ⁸Comprehensive Cancer Center, the Netherlands, Utrecht, Amsterdam, 1066CX, The Netherlands ⁹Department of Epidemiology, Director of Genetic Epidemiology Research Institute, UCI Center of Medicine, University of California Irvine, Irvine, CA, USA, 92697 ¹⁰Byelorussian Institute for Oncology and Medical Radiology Aleksandrov N.N., 223040, Minsk, Belarus ¹¹Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK ¹²Queensland Institute of Medical Research, Brisbane QLD 4006, Australia ¹³Cancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC 3002, Australia ¹⁴McGill University and Génome Québec Innovation Centre, Montréal (Québec) Canada, H3A 0G1 ¹⁵Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Carlton VIC 3053, Australia ¹⁶Centre for Molecular, Environmental, Genetic and Analytical Epidemiology, University of Melbourne, Melbourne, VIC 3010, Australia ¹⁷The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ, USA, 08901 ¹⁸Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA, 44195 ¹⁹University Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center, Erlangen, 91054, Germany ²⁰Massachusetts General Hospital, Boston, MA, USA, 02114 ²¹Gynaecology Research Unit, Hannover Medical School, Hannover, 30625, Germany ²²Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda MD, USA, 20892 ²³Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada, V5Z 1L3 ²⁴Department of Surgery and Cancer, Imperial College London, London, SW7 2AZ, UK ²⁵Department of Pathology, Helsinki University Central Hospital, Helsinki, Finland, 00530 ²⁶Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland, 00530 ²⁷Vanderbilt Epidemiology Center and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA, 37232

²⁸Department of Pathology, University of Melbourne, Parkville, VIC 3053, Australia ²⁹German Cancer Research Center, Division of Cancer Epidemiology, 69120, Heidelberg, Germany ³⁰Department of Interdisciplinary Oncology, Moffitt Cancer Center, Tampa, FL, USA, 33612 ³¹Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA, 55905 ³²Department of Urology, Microbiology and Preventive Medicine, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USA, 90089 ³³Cancer Research UK, Genetic Epidemiology Unit, Dept of Public Health & Primary Care, University of Cambridge, Strangeways Research Lab, Cambridge, CB1 8RN, UK ³⁴Department of Laboratory of Medicine and Pathology, Mayo Clinic, Rochester, MN, USA, 55905 ³⁵Division Epidemiology and Biostatistics, University of New Mexico, Albuquerque, NM, USA, 87131 ³⁶Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, 02115 ³⁷Department of Molecular Pathology, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland, 02-781 ³⁸Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium, 3000 ³⁹Section of Biostatistics and Epidemiology, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA, 03755 ⁴⁰Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Klinik Wiesbaden, 65199, Wiesbaden, Germany ⁴¹Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, 45136, Essen, Germany ⁴²Department of Gynecology and Obstetrics, Jena University Hospital, 07743, Jena, Germany ⁴³Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, CB1 8RN, UK ⁴⁴Faculty of Medicine, University of Southampton, University Hospital Southampton, SO17 1BJ, UK ⁴⁵Maggee Women's Hospital, Pittsburg, PA, USA, 15213 ⁴⁶Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, 91054, Erlangen, Germany ⁴⁷Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA, 90095 ⁴⁸Sections of Epidemiology and Genetics at the Institute of Cancer Research and Breakthrough Breast Cancer Research Centre, London, UK, SW7 3RP ⁴⁹Gynaecological Cancer Research Centre, UCL EGA Institute for Women's Health, London, NW1 2BU, United Kingdom ⁵⁰Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3806, Australia ⁵¹The Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, UK ⁵²Department of Women's Oncology, Moffitt Cancer Center, Tampa, FL, USA, 33612 ⁵³Samuel Oschin Comprehensive Cancer Center Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA, 90048 ⁵⁴Gynecological Oncology Unit, The Royal Marsden Hospital, London, SW3 6JJ, United Kingdom ⁵⁵International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland, 70-115 ⁵⁶Department of Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, 171-77 ⁵⁷Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, HB 5006, Norway ⁵⁸Department of Clinical Medicine, University of Bergen, 5006, Bergen, Norway ⁵⁹Clinics of Obstetrics and Gynaecology, Hannover Medical School, 30625, Hannover, Germany ⁶⁰Department of Biochemistry and Molecular Biology, Oregon Health and Science University, Portland, OR, USA, 97239 ⁶¹The Juliane Marie Centre, Department of Obstetrics and Gynecology, Rigshospitalet, Copenhagen, 2100, Denmark ⁶²Department of Pathology, Molecular Unit, Herlev Hospital, University of Copenhagen, Denmark, 2730 ⁶³Virus, Lifestyle and Genes, Danish Cancer Society Research Center, DK-2100, Copenhagen, Denmark ⁶⁴Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, 464-8681, Japan ⁶⁵Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA, 33612 ⁶⁶Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA, 55905 ⁶⁷Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA, 90048 ⁶⁸Section of Medicine, Institute of Cancer Research, Sutton, SM2 5NG, UK ⁶⁹Department of Population Health Research, Alberta Health Services-Cancer Care, Calgary, Alberta, Canada and Departments of Medical Genetics

and Oncology, University of Calgary, Calgary, AB, Canada, T2N 2T9 ⁷⁰Department of Urology, Radboud University Medical Centre, Nijmegen, HB 6500, Netherlands ⁷¹Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, 466-8550, Japan ⁷²Vesalius Research Center, VIB, 3000, Leuven, Belgium ⁷³Laboratory for Translational Genetics, Department of Oncology, University of Leuven, 3000, Leuven, Belgium ⁷⁴Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada, G12 0YN ⁷⁵Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, 10021 ⁷⁶College of Pharmacy and Health Sciences, Texas Southern University, Houston, Texas, USA, 77044 ⁷⁷Department of Obstetrics and Gynaecology, University Malaya Medical Centre, University Malaya, 59100 Kuala Lumpur, Federal Territory of Kuala Lumpur, Malaysia ⁷⁸Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 77030 ⁷⁹Department of Cancer Epidemiology and Prevention, The Maria Sklodowska-Curie Memorial Cancer Center, 02-781, Warsaw, Poland ⁸⁰Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 77030 ⁸¹Cancer Epidemiology Program, University of Hawaii Cancer Center, Hawaii, USA, 96813 ⁸²Department of Gynaecology, Radboud University Medical Centre, Nijmegen, HB 6500, Netherlands ⁸³Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford CA, USA, 94305 ⁸⁴Dalla Lana School of Public Health, Faculty of Medicine, University of Toronto, ON, M5T 3M7, Canada ⁸⁵Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, M5G 1X5 ⁸⁶Women's Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA, 15213 ⁸⁷Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA, 14263 ⁸⁸Department of Gynecologic Oncology, Aichi Cancer Center Central Hospital, Nagoya, Aichi, Nagoya, 464-8681, Japan ⁸⁹Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada, M5G 1N8 ⁹⁰Department of Pathology, Rigshospitalet, University of Copenhagen, 2100, Denmark ⁹¹The University of Texas School of Public Health, Houston, TX, USA, 77030 ⁹²USC Epigenome Center, Keck School of Medicine, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, 90089 ⁹³Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA, 14263 ⁹⁴Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, 10065 ⁹⁵Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, USA, 97239 ⁹⁶Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA, 97239 ⁹⁷Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA, 02115 ⁹⁸Channing Laboratory, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA, 02115 ⁹⁹Department of Epidemiology and Public Health, Yale University School of Public Health and School of Medicine, New Haven, CT, USA, 06520 ¹⁰⁰Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 98109 ¹⁰¹Department of Epidemiology, University of Washington, Seattle, WA, USA, 98109 ¹⁰²Institut für Humangenetik Wiesbaden, 65187, Wiesbaden, Germany ¹⁰³Department of Laboratory Medicine and Pathology, Division of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA, 55905 ¹⁰⁴Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Melbourne, VIC 3053, Australia ¹⁰⁵Department of Gynecologic Oncology, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland, 02-781 ¹⁰⁶Pediatrics Epidemiology Center, College of Medicine, University of South Florida, Tampa, FL, USA, 33612 ¹⁰⁷Department of Obstetrics and Gynecology, University of Ulm, Ulm, 89081, Germany ¹⁰⁸Department of Community and Family Medicine, Duke University Medical Center, Durham, NC, USA, 27708 ¹⁰⁹Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA, 55905 ¹¹⁰Shanghai Cancer Institute, Shanghai, China, 2200-25 ¹¹¹Department of Epidemiology, Center for Cancer Genetics Research and Prevention, School of Medicine, University of California Irvine, Irvine, California, USA, 92697 ¹¹²Department of Statistical Science, Duke University, Durham,

NC, USA, 27708 ¹¹³Cancer Prevention, Detection and Control Research Program, Duke Cancer Institute, Durham, North Carolina, USA, 27708-0251 ¹¹⁴Department of Obstetrics and Gynecology, Duke Comprehensive Cancer Center, Durham, NC, USA, 27708 ¹¹⁵Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA, 66160

Abstract

Epithelial ovarian cancer (EOC) has a heritable component that remains to be fully characterized. Most identified common susceptibility variants lie in non-protein-coding sequences. We hypothesized that variants in the 3' untranslated region at putative microRNA (miRNA) binding sites represent functional targets that influence EOC susceptibility. Here, we evaluate the association between 767 miRNA binding site single nucleotide polymorphisms (miRSNPs) and EOC risk in 18,174 EOC cases and 26,134 controls from 43 studies genotyped through the Collaborative Oncological Gene-environment Study. We identify several miRSNPs associated with invasive serous EOC risk ($OR=1.12$, $P=10^{-8}$) mapping to an inversion polymorphism at 17q21.31. Additional genotyping of non-miRSNPs at 17q21.31 reveals stronger signals outside the inversion ($P=10^{-10}$). Variation at 17q21.31 associates with neurological diseases, and our collaboration is the first to report an association with EOC susceptibility. An integrated molecular analysis in this region provides evidence for *ARHGAP27* and *PLEKHM1* as candidate EOC susceptibility genes.

Genome wide association studies (GWAS) have identified hundreds of genetic variants conferring low penetrance susceptibility to cancer¹. More than 90% of these variants lie in non protein-encoding sequences including non-coding RNAs and regions containing regulatory elements (i.e. enhancers, promoters, untranslated regions (UTRs))¹. The emerging hypothesis is that common variants within non-coding regulatory regions influence expression of target genes, thereby conferring disease susceptibility¹.

MicroRNAs (miRNAs) are short non-coding RNAs that regulate gene expression post-transcriptionally by binding primarily to the 3' UTR of target messenger RNA (mRNA), causing translational inhibition and/or mRNA degradation²⁻⁴. MiRNAs have been shown to play a key role in the development of epithelial ovarian cancer (EOC)². We^{5,6} and others⁷ have found evidence that various miRNA-related single nucleotide polymorphisms (miRSNPs) are associated with EOC risk, suggesting they may be key disruptors of gene function and contributors to disease susceptibility^{8,9}. However, studies of miRSNPs that affect miRNA-mRNA binding have been restricted by small sample sizes and therefore have limited statistical power to identify associations at genome wide levels of significance⁷⁻⁹. Larger-scale studies and more systematic approaches are warranted to fully evaluate the role of miRSNPs and their contribution to disease susceptibility.

Here, we use the *in silico* algorithms, TargetScan^{10,11} and Pictar^{12,13} to predict miRNA:mRNA binding regions involving genes and miRNAs relevant to EOC, and align identified regions with SNPs in the dbSNP database (Methods). We then genotype 1,003 miRSNPs (or tagging SNPs with $r^2>0.80$) in 18,174 EOC cases and 26,134 controls from 43 studies from the Ovarian Cancer Association Consortium (OCAC) (Supplementary Table S1). Genotyping was performed on a custom Illumina Infinium iSelect array designed as part of the Collaborative Oncological Gene-environment Study (COGS), an international effort that evaluated 211,155 SNPs and their association with ovarian, breast, and prostate cancer risk. Our investigation uncovers 17q21.31 as a new susceptibility locus for EOC, and we provide insights into candidate genes and possible functional mechanisms underlying disease development at this locus.

Results

Association analyses

Seven hundred and sixty-seven of the 1,003 miRSNPs passed genotype quality control (QC) and were evaluated for association with invasive EOC risk; most of the miRSNPs that failed QC were monomorphic (see Methods). Primary analysis of 14,533 invasive EOC cases and 23,491 controls of European ancestry revealed four strongly correlated SNPs ($r^2=0.99$; rs1052587, rs17574361, rs4640231, and rs916793) that mapped to 17q21.31 and were associated with increased risk (per allele odds ratio (OR) = 1.10, 95% CI 1.06-1.13) at a genome-wide level of significance (10^{-7}); no other miRSNPs had associations stronger than $P<10^{-4}$ (Supplementary Fig. S1). The most significant association was for rs1052587 ($P=1.9\times 10^{-7}$), and effects varied by histological subtype, with the strongest effect observed for invasive serous EOC cases (OR=1.12, $P=4.6\times 10^{-8}$) (Table 1). No heterogeneity in ORs was observed across study sites (Supplementary Fig. S2).

Rs1052587, rs17574361, and rs4640231 reside in the 3'UTR of microtubule-associated protein tau (*MAPT*), KAT8 regulatory NSL complex subunit 1 (*KANSL1/KIAA1267*), and corticotrophin releasing hormone receptor 1 (*CRHR1*) genes, at putative binding sites for miR-34a, miR-130a, and miR-34c, respectively. The fourth SNP, rs916793, is perfectly correlated with rs4640231 and lies in a non-coding RNA, *MAPT*-antisense 1. 17q21.31 contains a ~900kb inversion polymorphism¹⁴ (ch 17: 43,624,578-44,525,051 MB, human genome build 37), and all three miRSNPs and the tagSNP are located within the inversion (Fig. 1).

Chromosomes with the non-inverted or inverted segments of 17q21.31, respectively known as haplotype 1 (H1) and haplotype 2 (H2), represent two distinct lineages that diverged ~3 million years ago and have not undergone any recombination event¹⁴. The four susceptibility alleles identified here reside on the H2 haplotype that is reported to be rare in Africans and East Asians, but is common (frequency >20%) and exhibits strong linkage disequilibrium (LD) among Europeans¹⁴, consistent with our findings. The H2 haplotype has a frequency of 22% among European women in our primary analysis (Table 1) but only 3.2% and 0.3% among Africans (151 invasive cases, 200 controls) and Asians (716 invasive cases, 1573 controls), respectively.

To increase genomic coverage at this locus, we evaluated an additional 142 non-miRSNPs at 17q21.31 that were also genotyped as part of COGS in the same series of OCAC cases and controls. We also imputed genotypes using data from the 1000 Genomes Project¹⁵. These approaches identified a second cluster of strongly correlated SNPs ($r^2>0.90$) in a distinct region proximal to the inversion (centered at chromosome 17: 43.5 MB, human genome build 37) that was more significantly associated with the risk of all invasive EOCs ($P=10^{-9}$) and invasive serous EOC specifically ($P=10^{-10}$) than the cluster of identified miRSNPs (Fig. 1). Association results and annotation for SNPs in this second cluster are shown in Supplementary Table S2; this cluster includes three directly genotyped SNPs (rs2077606, rs17631303, and rs12942666), with the strongest association observed for rs2077606 among all invasive cases (OR=1.12, 95% CI: 1.08-1.16), $P=7.8\times 10^{-9}$) and invasive serous cases (OR=1.15, 95% CI: 1.12-1.19, $P=3.9\times 10^{-10}$). These SNPs were chosen for genotyping in COGS because they had shown evidence of association as modifiers of EOC risk in BRCA1 gene mutation carriers by the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)¹⁶. Several imputed SNPs in strong LD ($r^2>0.90$) were more strongly associated with risk than their highly correlated genotyped SNPs (Supplementary Table S2). This risk-associated region at 17q21.31 is distinct from a previously reported ovarian cancer susceptibility locus at 17q21¹⁷; neither the genotyped or imputed SNPs we report here are

strongly correlated (maximum $r^2 = 0.01$) with SNPs from the 17q21 locus (spanning 46.2-46.5 MB, build 37).

Genotype clustering was poor for rs2077606, but clustering was good for its correlated SNP, rs12942666 ($r^2 = 0.99$), and so results for this SNP are presented instead (Supplementary Fig. S2; Table 1). Subgroup analysis revealed marginal evidence of association for rs12942666 with endometrioid ($P = 0.04$), but not mucinous or clear cell EOC subtypes (Table 1), and results were consistent across studies (Supplementary Fig. S4). Rs12942666 is correlated with the top-ranked miRSNP, rs1052587 ($r^2 = 0.76$) (Fig. 1). To evaluate whether associations observed for rs12942666 and rs1052587 represented independent signals, stepwise logistic regression was used; only rs12942666 was retained in the model. This suggests that the cluster which includes rs12942666 is driving the association with EOC risk that was initially identified through the candidate miRSNPs.

Functional and molecular analyses

To evaluate functional evidence for candidate genes, risk-associated SNPs, and regulatory regions at 17q21.31, we examined a one megabase region centered on rs12942666 using a combination of locus specific and genome-wide assays and *in silico* analyses of publicly available datasets, including The Cancer Genome Atlas (TCGA) Project¹⁸ (see Methods). Rs12942666 and many of its correlated SNPs lie within introns of Rho GTPase activating protein 27 (*ARHGAP27*) or its neighboring gene, pleckstrin homology domain containing, family M (with RUN domain) member 1 (*PLEKHM1*) (Supplementary Table S2). There are another 15 known protein-coding genes within the region: *KIF18B*, *C1QL1*, *DCAKD*, *NMT1*, *PLCD3*, *ACBD4*, *HEXIM1*, *HEXIM2*, *FMNL1*, *C17orf46*, *MAP3K14*, *C17orf69*, *CRHR1*, *IMP5*, and *MAPT* (Fig. 2a).

To evaluate the likelihood that one or more genes within this region represent target susceptibility gene(s), we first analyzed expression, copy number variation, and methylation involving these genes in EOC tissues and cell lines (Fig. 2b-g; Supplementary Tables S3 and S4). Most genes showed significantly higher expression ($P < 10^{-4}$) in EOC cell lines versus normal ovarian cancer-precursor tissues (OCPTs); *ARHGAP27* showed the most pronounced difference in gene expression between cancer and normal cells ($P = 10^{-16}$) (Fig. 2b and Supplementary Table S3). For nine genes, we also found overexpression in primary high-grade serous (HGS) EOC tumors versus normal ovarian tissue in at least one of two publicly available datasets, The Cancer Genome Atlas (TCGA) of 568 tumors¹⁸ and/or the Gene Expression Omnibus (GEO) series GSE18520 dataset consisting of 53 tumors¹⁹ (Fig. 2c and Supplementary Table S3). Analysis of DNA copy number variation in TCGA revealed frequent loss of heterozygosity in this region rather than gains (Supplementary Fig. 5a-b; Supplementary Methods). We observed significant hypomethylation ($P < 0.01$) in ovarian tumors compared to normal tissue for *DCAKD*, *PLCD3*, *ACBD4*, *FMNL1*, and *PLEKHM1* (Fig. 2d and Supplementary Table S4), which is consistent with the overexpression observed for *DCAKD*, *PLCD3*, and *FMNL1*. Taken together, these data suggest that the mechanism underlying overexpression may be epigenetic rather than based on copy number alterations.

We evaluated associations between genotypes for the top risk SNP rs12942666 (or a tagSNP) and expression of all genes in the region (expression quantitative trait locus (eQTL) analysis) in normal OCPTs, lymphoblastoid cell lines (LCLs), and primary tumors from TCGA. We observed significant eQTL associations ($P < 0.05$) in normal OCPTs only for *ARHGAP27* ($P = 0.04$) (Fig. 2e; Supplementary Table S3). Because rs12942666 was not genotyped in tissues analyzed in TCGA, we used data for its correlated SNP rs2077606 ($r^2 = 0.99$) to evaluate eQTLs in tumor tissues. Rs2077606 genotypes were strongly associated with *PLEKHM1* expression in primary HGS-EOCs ($P = 1 \times 10^{-4}$) (Fig. 2f;

Supplementary Table S3). We also detected associations between rs12942666 (and rs2077606) genotypes and methylation for *PLEKHM1* and *CRHR1* in primary tumors ($P=0.020$ and 0.001 , respectively) using methylation quantitative trait locus (mQTL) analyses (Fig. 2g; Supplementary Table S4). Finally, the Catalogue of Somatic Mutations in Cancer (COSMIC) database²⁰ showed that nine genes in the region, including *PLEKHM1*, have functionally significant mutations in cancer, although for most genes mutations were not reported in ovarian carcinomas (Supplementary Table S3).

Taken together, these data suggest that several genes at the 17q21.31 locus may play a role in EOC development. The risk-associated SNPs we identified fall within non-coding DNA, suggesting the functional SNP(s) may be located within an enhancer, insulator, or other regulatory element that regulates expression of one of the candidate genes we evaluated. One hypothesis emerging from these molecular analyses is that rs12942666 (or a correlated SNP) mediates regulation of *PLEKHM1*, a gene implicated in osteopetrosis and endocytosis²¹ and/or *ARHGAP27*, a gene that may promote carcinogenesis through dysregulation of Rho/Rac/Cdc42-like GTPases²². To identify the most likely candidate for being the causal variant at 17q21.31, we compared the difference between log-likelihoods generated from un-nested logistic regression models for rs12942666 and each of 198 SNPs in a 1 MB region featured in Supplementary Table 2. As expected, the log likelihoods were very similar due to the strong LD; no SNPs emerged as having a likelihood ratio greater than 20 for being the causal variant.

To explore the possible functional significance of rs12942666 and strongly correlated variants ($r^2>0.80$), we then generated a map of regulatory elements around rs12942666 using ENCODE data and FAIRE-seq analysis of OCPTs (Supplementary Methods). We observed no evidence of putative regulatory elements coinciding with rs12942666 or correlated SNPs (Fig. 3a). A map of regulatory elements in the entire 1 MB region can be seen in Supplementary Fig. 5c-f. We subsequently used *in silico* tools (ANNOVAR²³, SNPinfo²⁴, and SNPnexus²⁵) to evaluate the putative function of possible causal SNPs (Supplementary Methods). Of 50 SNPs with possible functional roles, more than 30 reside in putative transcription factor binding sites (TFBS) within or near *PLEKHM1* or *ARHGAP27*; 12 SNPs may affect methylation or miRNA binding, and two are non-synonymous coding variants predicted to be of no functional significance (Supplementary Table S2).

Since most of the top-ranked 17q21.31 SNPs with putative functions (including two of the top directly genotyped SNPs, rs2077606 and rs17631303), are predicted to lie in TFBS (Supplementary Table S2), we used the *in silico* tool, JASPAR²⁶ to further examine TFBS coinciding with these SNPs. Two SNPs scored highly in this analysis (Supplementary Table S5); the first, rs12946900, lies in a GAGGAA motif and canonical binding site for *SPIB*, an Ets family member²⁷. Ets factors have been implicated in the development of ovarian cancer and other malignancies²⁸, but little evidence supports a specific role for *SPIB* in EOC etiology. The second hit was for rs2077606, which lies in an E-box motif CACCTG at the canonical binding site for *ZEB1* (chr. 10p11.2), a zinc-finger E-box binding transcription factor that represses E-cadherin^{29,30} and contributes to epithelial-mesenchymal transition in EOCs³¹.

We analyzed expression of *SPIB* and *ZEB1* in primary ovarian cancers using TCGA data; we found no significant difference in *SPIB* expression in tumors compared to normal tissues (Fig. 3bi). In contrast, *ZEB1* expression was significantly lower in primary HGS-EOCs compared to normal tissues ($P=0.005$) (Fig. 3bii). We validated this finding using qPCR analysis in 123 EOC and OCPT cell lines ($P=8.8 \times 10^{-4}$) (Fig. 3biii). Since rs2077606 lies within an intron of *PLEKHM1*, this gene is a candidate target for *ZEB1* binding at this site.

Our eQTL analysis also suggests *ARHGAP27* is a strong candidate *ZEB1* target at this locus; *ARHGAP27* expression is highest in OCPT cell lines carrying the minor allele of rs2077606 ($P=0.034$) (Figure 3ci). Although we observed no eQTL associations between rs2077606 and *ZEB1* expression in LCLs (Figure 3cii), we found evidence of eQTL between rs2077606 and *ZEB1* expression in HGS-EOCs ($P=0.045$) (Figure 3ciii). *ZEB1* binding at the site of the common allele is predicted to repress gene expression while loss of *ZEB1* binding conferred by the minor allele may enable expression of *ARHGAP27*, consistent with the eQTL association in OCPTs (Fig. 3ci). Although this data supports a repressor role for *ZEB1* in EOC development and suggests *ARHGAP27* may be a functional target of rs2077606 (or a correlated SNP) in OCPTs through trans-regulatory interactions with *ZEB1*, it is important to investigate additional hypotheses as we continue to narrow down the list of target susceptibility genes, SNPs, and regulatory mechanisms that contribute to EOC susceptibility at this locus.

Discussion

The present study represents the largest, most comprehensive investigation of the association between putative miRSNPs in the 3' untranslated region and cancer risk. This and the systematic follow-up to evaluate associations with EOC risk for non-miRSNPs in the region identified 17q21.31 as a new susceptibility locus for EOC. Although the miRSNPs identified here may have some biological significance, our findings suggest that other types of variants in non-coding DNA, especially non-miRSNPs at the 17q21.31 locus, are stronger contributors to EOC risk. It is possible, however, that highly significant miRSNPs exist that were not identified in our study because a) they were not pre-selected for evaluation (i.e. they do not reside in a binding site involving miRNAs or genes with known relevance to EOC, or they reside in regions other than the 3' UTR^{3,4}) and/or b) they were very rare and could not be designed or detected with our genotyping platform and sample size, respectively. Despite these limitations, the homogeneity between studies of varying designs and populations in the OCAC and the genome-wide levels of statistical significance imply that all detected associations are robust. Furthermore, molecular correlative analyses of genes within the region suggest that cis-acting genetic variants influencing non-coding DNA regulatory elements, miRNAs, and/or methylation underlie disease susceptibility at the 17q21.31 locus. Finally, these studies point to a subset of candidate genes (i.e. *PLEKHM1*, *ARHGAP27*) and transcription factors (i.e. *ZEB1*) that may influence EOC initiation and development.

This novel locus is one of eleven loci now identified that contains common genetic variants conferring low penetrance susceptibility to EOC in the general population^{17,32,33,34}. Genetic variants at several of these loci influence risks of more than one cancer type, suggesting that several cancers may share common mechanisms. For example, alleles at 5p15.33 and 19p13.1 are associated with estrogen-receptor-negative breast cancer and serous EOC susceptibility^{32,35}, and variants at 8q24 are associated with risk of EOC and other cancers^{17,36}. Genetic variation at 17q21.31 is also associated with frontotemporal dementia-spectrum disorders, Parkinson's disease, developmental delay, and alopecia³⁷⁻⁴². Through COGS, the CIMBA also recently identified 17q21.31 variants as modifying EOC risk in *BRCA1* and *BRCA2* carriers ($P<10^{-8}$ in *BRCA1/2* combined)¹⁶. In particular, rs17631303, which is perfectly correlated with rs2077606 and rs12942666, was among the top-ranking SNPs detected by CIMBA¹⁶. Consistent with our findings, CIMBA also provide data that suggests EOC risk is associated with altered expression of one or more genes in the 17q21.31 region¹⁶. Thus, results from this large-scale collaboration support a role for this locus in both *BRCA1/2* and non-*BRCA1/2* mediated EOC development. Before these findings can be integrated with variants from other confirmed loci and non-genetic factors to predict women at greatest risk of developing EOC and provide options for medical

management of these risks, continued efforts will be needed to fine map the 17q21.31 region and to fully characterize the functional and mechanistic effects of potential causal SNPs in disease etiology and development.

Methods

Study population

Forty-three individual OCAC studies contributed samples and data to the COGS initiative. Nine of the 43 participating studies were case-only (GRR, HSK, LAX, ORE, PVD, RMH, SOC, SRO, UKR); cases from these studies were pooled with case-control studies from the same geographic region. The two national Australian case-control studies were combined into a single study to create 34 case-control sets. Details regarding the 43 participating OCAC studies are summarized in Supplementary Table S1. Briefly, cases were women diagnosed with histologically confirmed primary EOC (invasive or low malignant potential), fallopian tube cancer, or primary peritoneal cancer ascertained from population- and hospital-based studies and cancer registries. The majority of OCAC cases (>90%) do not have a family history of ovarian or breast cancer in a first-degree relative, and most have not been tested for *BRCA1/2* mutations as part of their parent study. Controls were women without a current or prior history of ovarian cancer with at least one ovary intact at the reference date. All studies had data on disease status, age at diagnosis/interview, self-reported racial group, and histologic subtype. Most studies frequency-matched cases and controls on age-group and race.

Selection of Candidate Genes and SNPs

To increase the likelihood of identifying miRSNPs with biological relevance to EOC, we reviewed published literature and consulted public databases to generate two lists of candidate genes: 1) 55 miRNAs reported to be deregulated in EOC tumors compared to normal tissue in at least one study⁴³⁻⁴⁶, and 2) 665 genes implicated in the pathogenesis of EOC through gene expression analyses^{47,48}, somatic mutations⁴⁹, or genetic association studies^{50,51}. Many genes were identified through the Gene Prospector database⁵¹, a web-based application that selects and prioritizes potential disease-related genes using a highly curated, up-to-date database of genetic association studies.

Using each candidate gene list as input, we identified putative sites of miRNA:mRNA binding with the computational prediction algorithms TargetScan version 5.1^{10,11} and PicTar^{12,13} and Supplementary Methods). Each algorithm generated start and end coordinates for regions of miRNA binding, and database SNP (dbSNP)⁵² version 129 was mined to identify SNPs falling within the designated binding regions. Of 3,246 unique miRSNPs that were identified, 1102 obtained adequate design scores using Illumina's Assay Design Tool. The majority (n=1085, 98.5%) of the 1102 SNPs resided in predicted sites of miRNA binding (and therefore represent miRSNPs), while the remainder (n=17) are tagSNPs ($r^2 > 0.80$) for miRSNPs that were not designable or had poor to moderate design scores. Ninety nine of the 1102 SNPs failed during custom assay development, leaving a total of 1,003 SNPs that were designed and genotyped.

Genotyping and QC

The candidate miRSNPs selected for the current investigation were genotyped using a custom Illumina Infinium iSelect Array as part of the international Collaborative Oncological Gene-environment Study (COGS), an effort to evaluate 211,155 genetic variants for association with the risk of ovarian, breast, and prostate cancer. Samples and data were included from several consortia, including OCAC, the Breast Cancer Association Consortium (BCAC), the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA),

and the Prostate Cancer Association Group to Investigate Cancer- Associated Alterations in the Genome (PRACTICAL). Although one of the primary goals of COGS was to replicate and fine-map findings from pooled genome-wide association studies (GWAS) from each consortia, this effort also aimed to genotype candidate SNPs of interest (such as the miRSNPs). The genotyping and QC process has been described recently in our report of OCAC's pooled GWAS findings³⁴. Briefly, COGS genotyping was conducted at six centers, two of which were used for OCAC samples: McGill University and Génome Québec Innovation Centre (Montréal, Canada) (n=19,806) and Mayo Clinic Medical Genomics Facility (n=27,824). Each 96-well plate contained 250ng genomic DNA (or 500 ng whole genome-amplified DNA). Raw intensity data files were sent to the COGS data coordination center at the University of Cambridge for genotype calling and QC using the GenCall algorithm.

Sample QC—One thousand two hundred and seventy three OCAC samples were genotyped in duplicate. Genotypes were discordant for greater than 40 percent of SNPs for 22 pairs. For the remaining 1,251 pairs, concordance was greater than 99.6 percent. In addition we identified 245 pairs of samples that were unexpected genotypic duplicates. Of these, 137 were phenotypic duplicates and judged to be from the same individual. We used identity-by-state to identify 618 pairs of first-degree relatives. Samples were excluded according to the following criteria: 1) 1,133 samples with a conversion rate (the proportion of SNPs successfully called per sample) of less than 95 percent; 2) 169 samples with heterozygosity >5 standard deviations from the intercontinental ancestry specific mean heterozygosity; 3) 65 samples with ambiguous sex; 4) 269 samples with the lowest call rate from a first-degree relative pair 5) 1,686 samples that were either duplicate samples that were non-concordant for genotype or genotypic duplicates that were not concordant for phenotype. A total of 44,308 eligible subjects including 18,174 cases and 26,134 controls were available for analysis.

SNP QC—The process of SNP selection by the participating consortia has been summarized previously³⁴. In total, 211,155 SNP assays were successfully designed, including 23,239 SNPs nominated by OCAC. Overall, 94.5% of OCAC-nominated SNPs passed QC. SNPs were excluded if: (1) the call rate was less than 95% with MAF > 5% or less than 99% with MAF < 5% (n=5,201); (2) they were monomorphic upon clustering (n=2,587); (3) p values of HWE in controls were less than 10^{-7} (n=2,914); (4) there was greater than 2% discordance in duplicate pairs (n=22); (5) no genotypes were called (n=1,311). Of 1,003 candidate miRSNPs genotyped, 767 passed QC criteria and were available for analysis; the majority of miRSNPs that were excluded were monomorphic (n=158, 67%). Genotype intensity cluster plots were visually inspected for the most strongly associated SNPs.

Population stratification

HapMap DNA samples for European (CEU, n=60), African (YRI, n=53) and Asian (JPT +CHB, n=88) populations were also genotyped using the COGS iSelect. We used the program LAMP⁵³ to estimate intercontinental ancestry based on the HapMap (release no. 23) genotype frequency data for these three populations. Eligible subjects with greater than 90 percent European ancestry were defined as European (n=39,773) and those with greater than 80 percent Asian or African ancestry were defined as Asian (n=2,382) or African respectively (n=387). All other subjects were defined as being of mixed ancestry (n=1,766). We then used a set of 37,000 unlinked markers to perform principal components analysis within each major population subgroup. To enable this analysis on very large sample sizes we used an in-house program written in C++ using the Intel MKL libraries for eigenvectors (available at <http://ccge.medschl.cam.ac.uk/software/>).

Tests of association

We used unconditional logistic regression treating the number of minor alleles carried as an ordinal variable (log-additive model) to evaluate the association between each SNP and EOC risk. Separate analyses were carried out for each ancestry group. The model for European subjects was adjusted for population substructure by including the first 5 eigenvalues from the principal components analysis. African- and Asian- ancestry-specific estimates were obtained after adjustment for the first two components representing each respective ancestry. Due to the heterogeneous nature of EOC, subgroup analysis was conducted to estimate genotype-specific odds ratios for serous carcinomas (the most predominant histologic subtype) and the three other main histological subtypes of EOC: endometrioid, mucinous, and clear cell. Separate analyses were also carried out for each study site, and site-specific ORs were combined using a fixed-effect meta-analysis. The I^2 test of heterogeneity was estimated to quantify the proportion of total variation due to heterogeneity across studies, and the heterogeneity of odds ratios between studies was tested with Cochran's Q statistic. The R statistical package 'r-meta' was used to generate forest plots. Statistical analysis was conducted in PLINK⁵⁴.

Imputation of genotypes at 17q21.31

To increase genomic coverage, we imputed genotype data for the 17q21.31 region (chr17: 40,099,001-44,900,000, human genome build 37) with IMPUTE2.2⁵⁵ using phase 1 haplotype data from the January 2012 release of the 1000 genome project data¹⁵. For each imputed genotype the expected number of minor alleles carried was estimated (as weights). IMPUTE provides estimated allele dosage for SNPs that were not genotyped and for samples with missing data for directly genotyped SNPs. Imputation accuracy was estimated using an r^2 quality metric. We excluded imputed SNPs from analysis where the estimated accuracy of imputation was low ($r^2 < 0.3$).

Functional studies and *in silico* analysis of publicly available datasets

We performed the following assays for each gene in the one megabase region centered on the most significant SNP at the 17q21.31 locus (see Supplementary Methods): gene expression analysis in EOC cell lines (n=51) compared to normal cell lines from ovarian cancer precursor tissues (OCPTs)⁵⁶, including ovarian surface epithelial cells (OSECs) and fallopian tube secretory epithelial cells (FTSECs) (n=73), and CpG island methylation analysis in high grade serous ovarian cancer (HGS-EOC) tissues (n=106) and normal tissues (n=7). Genes in the region were also evaluated *in silico* by mining publicly available molecular data generated for primary EOCs and other cancer types, including The Cancer Genome Atlas (TCGA) analysis of 568 HGS EOCs¹⁸, the Gene Expression Omnibus series GSE18520 dataset of 53 HGS EOCs¹⁹, and the Catalogue Of Somatic Mutations In Cancer (COSMIC) database²⁰.

We used these data to 1) compare gene expression between a) EOC cell lines and normal cell lines and b) tumor tissue and normal tissue from TCGA, 2) compare gene methylation status in HGS-EOCs and normal tissue, 3) conduct gene expression quantitative trait locus (eQTL) analyses to evaluate genotype-gene expression associations in normal OCPTs, lymphoblastoid cells, and HGS-EOCs, and 4) conduct methylation quantitative trait locus (mQTL) analyses in HGS-EOCs to evaluate genotype-gene methylation associations. Data from ENCYCLOPEDIA OF DNA ELEMENTS (ENCODE)⁵⁷ were used to evaluate the overlap between regulatory elements in non-coding regions and risk-associated SNPs. ENCODE describes regulatory DNA elements (e.g. enhancers, insulators and promoters) and non-coding RNAs (e.g. miRNAs, long non-coding and piwi-interacting RNAs) that may be targets for susceptibility alleles. However, ENCODE does not include data for EOC associated tissues, and activity of such regulatory elements often varies in a tissue specific

manner^{57,58}. Therefore, we profiled the spectrum of non-coding regulatory elements in OSECs and FTSECs using a combination of formaldehyde assisted isolation of regulatory elements sequencing (FAIRE-seq) and RNA sequencing (RNA-seq) (Supplementary Methods).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank all the individuals who took part in this study and all the researchers, clinicians and administrative staff who have made possible the many studies contributing to this work. In particular, we thank: D. Bowtell, P Webb, A. deFazio, D. Gertig, A. Green, P. Parsons, N. Hayward, and D. Whiteman (AUS); D. L. Wachter, S. Oeser, S. Landrith (BAV); G. Peuteman, T. Van Brussel and D. Smeets (BEL); the staff of the genotyping unit, S LaBoissière and F Robidoux (McGill University and Génome Québec Innovation Centre); U. Eilber and T. Koehler (GER); L. Gacucova (HMO); P. Schürmann, F. Kramer, T.-W. Park-Simon, K. Beer-Grondke and D. Schmidt (HJO); G.L. Keeney, C. Hilker and J. Vollenweider (MAY); the state cancer registries of AL, AZ, AR, CA, CO, CT, DE, FL, GA, HI, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WYL (NHS); L. Paddock, M. King, U. Chandran, A. Samoilu, and Y. Bensman (NJO); M. Insua and R. Evey (Moffitt); M. Sherman, A. Hutchinson, N. Szeszenia-Dabrowska, B. Peplonska, W. Zatonski, A. Soni, P. Chao and M. Stagner (POL); C. Luccarini, P. Harrington the SEARCH team and ECRIC (SEA); the Scottish Gynaecological Clinical Trials group and SCOTROC1 investigators (SRO); W-H. Chow, Y-T. Gao, G. Yang, B-T. Ji (SWH); I. Jacobs, M. Widschwendter, E. Wozniak, N. Balogun, A. Ryan and J. Ford (UKO); M. Notaridou (USC); C. Pye (UKR); and V. Slusher (U19).

The COGS project is funded through a European Commission's Seventh Framework Programme grant (agreement number 223175 - HEALTH-F2-2009-223175). The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). The scientific development and funding for this project were in part supported by the US National Cancer Institute (R01-CA-114343 and R01-CA114343-S1) and the Genetic Associations and Mechanisms in Oncology (GAME-ON): a NCI Cancer Post-GWAS Initiative (U19-CA148112).

This study made use of data generated by the Wellcome Trust Case Control consortium. A full list of the investigators who contributed to the generation of the data is available from <http://www.wtccc.org.uk/>. Funding for the project was provided by the Wellcome Trust under award 076113. The results published here are in part based upon data generated by The Cancer Genome Atlas Pilot Project established by the National Cancer Institute and National Human Genome Research Institute. Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at <http://cancergenome.nih.gov/>.

D.F.E. is a Principal Research Fellow of Cancer Research UK G.C.-T. and P.M.W. are supported by the National Health and Medical Research Council. BK holds an American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN). LEK is supported by a Canadian Institutes of Health Research Investigator award (MSH-87734). A.C.A. is Cancer Research-UK Senior Cancer Research Fellow.

Funding of the constituent studies was provided by the American Cancer Society (CRTG-00-196-01-CCE); the California Cancer Research Program (00-01389V-20170, N01-CN25403, 2II0200); the Canadian Institutes for Health Research (MOP-86727); Cancer Council Victoria; Cancer Council Queensland; Cancer Council New South Wales; Cancer Council South Australia; Cancer Council Tasmania; Cancer Foundation of Western Australia; the Cancer Institute of New Jersey; Cancer Research UK (C490/A6187, C490/A10119, C490/A10124, C536/A13086, C536/A6689); the Celma Mastry Ovarian Cancer Foundation; the Danish Cancer Society (94-222-52); the Norwegian Cancer Society, Helse Vest, the Norwegian Research Council; ELAN Funds of the University of Erlangen-Nuremberg; the Eve Appeal; the Helsinki University Central Hospital Research Fund; Imperial Experimental Cancer Research Centre (C1312/A15589); the Ovarian Cancer Research Fund; Nationaal Kankerplan of Belgium; Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health Labour and Welfare of Japan; the L & S Milken Foundation; the Radboud University Nijmegen Medical Centre; the Polish Ministry of Science and Higher Education (4 PO5C 028 14, 2 PO5A 068 27); the Roswell Park Cancer Institute Alliance Foundation; the US National Cancer Institute (K07-CA095666, K07-CA143047, K22-CA138563, N01-CN55424, N01-PC067001, N01-PC035137, P01-CA017054, P01-CA087696, P50-CA105009, P50-CA136393, R01-CA014089, R01-CA016056, R01-CA017054, R01-CA049449, R01-CA050385, R01-CA054419, R01-CA058598, R01-CA058860, R01-CA061107, R01-CA061132, R01-CA063682, R01-CA064277, R01-CA067262, R01-CA071766, R01-CA074850, R01-CA076016, R01-CA080742, R01-CA080978, R01-CA087538, R01-CA092044, R01-095023, R01-CA106414, R01-CA122443, R01-CA136924, R01-CA112523, R01-CA114343, R01-CA126841, R01-CA149429, R03-CA113148, R03-CA115195, R37-

CA070867, R37-CA70867, R01-CA83918, U01-CA069417, U01-CA071966, P30-CA15083, PSA 042205, and Intramural research funds); the US Army Medical Research and Materiel Command (DAMD17-98-1-8659, DAMD17-01-1-0729, DAMD17-02-1-0666, DAMD17-02-1-0669, W81XWH-10-1-02802); the Department of Defense Ovarian Cancer Research Program (W81XWH-07-1-0449); the National Health and Medical Research Council of Australia (199600 and 400281); the German Federal Ministry of Education and Research of Germany Programme of Clinical Biomedical Research (01 GB 9401); the state of Baden-Württemberg through Medical Faculty of the University of Ulm (P.685); the German Cancer Research Center; Pomeranian Medical University; the Minnesota Ovarian Cancer Alliance; the Mayo Foundation; the Fred C. and Katherine B. Andersen Foundation; the Malaysian Ministry of Higher Education (UM.C/HIR/MOHE/06) and Cancer Research Initiatives Foundation; the Lon V. Smith Foundation (LVS-39420); the Oak Foundation; the OHSU Foundation; the Mermaid I project; the Rudolf-Bartling Foundation; the UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge, Imperial College London, University College Hospital “Womens Health Theme” and the Royal Marsden Hospital; WorkSafeBC.

Access to genotype data for SNPs that were not nominated by OCAC was provided by FJC and ACA on behalf of CIMBA BRCA1 GWAS investigators and was funded by the US National Cancer Institute (R01 CA128978) and U.S. Department of Defense Ovarian Cancer Idea award (W81XWH-10-1-0341). CIMBA BRCA1 GWAS investigators include: Irene L. Andrulis, Ontario Cancer Genetics Network, Cancer Care Ontario and Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada; Trinidad Caldes, Molecular Oncology Laboratory, Hospital Clínico San Carlos, Madrid, Spain; Maria Adelaide Caligo, Section of Genetic Oncology, University Hospital of Pisa, Pisa, Italy; Olga Sinilnikova for GEMO Study Collaborators, Cancer Genetics Network “Groupe Genetique et Cancer”, Federation Nationale des Centres de Lutte Contre le Cancer, Lyon, France; Thomas V. O. Hansen, Genomic Medicine, Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Matti Rookus and Frans Hogervorst for HEBON Investigators, Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Anna Jakubowska and Jan Lubinski, International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland; Susan Peock for EMBRACE Investigators, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge, United Kingdom; Georgia Chenevix-Trench for kConFab Investigators, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; BCFR Investigators, Breast Cancer Family Registry, Epidemiology and Genetics Research Program, DCCPS, National Cancer Institute, Rockville, Maryland, USA; Katherine L. Nathanson and Susan Domchek, Departments of Medicine and Medical Genetics and Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Heli Nevanlinna, Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland; Kenneth Offit, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Ana Osorio and Javier Benitez, Human Genetics Group, Human Cancer Genetics Programme, Spanish National Cancer Centre, Madrid, Spain; Paolo Radice for CONSIT investigators, Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT); IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy; Christian F. Singer, Division of Special Gynecology, Medical University of Vienna, Vienna, Austria; SWE-BRCA Investigators, Karolinska University Hospital, Stockholm, Sweden; Rita Schmutzler for GC-HBOC investigators, Center of Familial Breast and Ovarian Cancer, Department of Obstetrics and Gynaecology and Center for Integrated Oncology (CIO), University of Cologne, Cologne, Germany; Andrew Godwin, Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas; Ignacio Blanco and Conxi Lazaro, Hereditary Cancer Program, Instituto Catalan de Oncologia, Barcelona, Spain; Marco Montagna, Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy; Mary S. Beattie, Cancer Risk Program, Departments of Medicine, Epidemiology, and Biostatistics, University of California at San Francisco, San Francisco, California, USA; Antonis C. Antoniou and Douglas F. Easton, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom; Fergus J. Couch, Mayo Clinic, Rochester, Minnesota, USA.

References

1. Freedman ML, et al. Principles for the post-GWAS functional characterization of cancer risk loci. *Nat Genet.* 2011; 43:513–518. [PubMed: 21614091]
2. Dahiya N, Morin PJ. MicroRNAs in ovarian carcinomas. *Endocr Relat Cancer.* 2010; 17:F77–89. [PubMed: 19903743]
3. Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. *Proc Natl Acad Sci U S A.* 2007; 104:9667–9672. [PubMed: 17535905]
4. Lee I, et al. New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites. *Genome Res.* 2009; 19:1175–1183. [PubMed: 19336450]
5. Permuth-Wey J, et al. LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. *Cancer Res.* 2011

6. Permuth-Wey J, et al. MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium. *Cancer Epidemiol Biomarkers Prev.* 2011; 20:1793–1797. [PubMed: 21636674]
7. Liang D, et al. Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. *Cancer Res.* 2010; 70:9765–9776. [PubMed: 21118967]
8. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. *Nat Rev Cancer.* 2010; 10:389–402. [PubMed: 20495573]
9. Sethupathy P, Collins FS. MicroRNA target site polymorphisms and human disease. *Trends Genet.* 2008; 24:489–497. [PubMed: 18778868]
10. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell.* 2005; 120:15–20. [PubMed: 15652477]
11. TargetScanHuman. 2009. <http://genes.mit.edu/targetscan>
12. Krek A, et al. Combinatorial microRNA target predictions. *Nat Genet.* 2005; 37:495–500. [PubMed: 15806104]
13. PicTar. 2009. pictar.mdc-berlin.de/
14. Stefansson H, et al. A common inversion under selection in Europeans. *Nat Genet.* 2005; 37:129–137. [PubMed: 15654335]
15. 1,000 Genomes. 2012. <http://www.1000genomes.org/page.php>
16. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbacecker KB, et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics.* XYZ. in press.
17. Goode EL, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. *Nat Genet.* 2010
18. Integrated genomic analyses of ovarian carcinoma. *Nature.* 2011; 474:609–615. [PubMed: 21720365]
19. Mok SC, et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. *Cancer Cell.* 2009; 16:521–532. [PubMed: 19962670]
20. Forbes SA, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. *Nucleic Acids Res.* 2011; 39:D945–950. [PubMed: 20952405]
21. Tabata K, et al. Rubicon and PLEKHM1 negatively regulate the endocytic/autophagic pathway via a novel Rab7-binding domain. *Mol Biol Cell.* 2010; 21:4162–4172. [PubMed: 20943950]
22. Katoh Y, Katoh M. Identification and characterization of ARHGAP27 gene in silico. *Int J Mol Med.* 2004; 14:943–947. [PubMed: 15492870]
23. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* 2010; 38:e164. [PubMed: 20601685]
24. Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. *Nucleic Acids Res.* 2009; 37:W600–605. [PubMed: 19417063]
25. Dayem Ullah AZ, Lemoine NR, Chelala C. SNPnexus: a web server for functional annotation of novel and publicly known genetic variants (2012 update). *Nucleic Acids Res.* 2012
26. JASPAR. 2012. <http://jaspar.cgb.ki.se/>
27. Ray D, et al. Characterization of Spi-B, a transcription factor related to the putative oncoprotein Spi-1/PU.1. *Molecular and cellular biology.* 1992; 12:4297–4304. [PubMed: 1406622]
28. Fujimoto J, et al. Clinical implications of expression of ETS-1 related to angiogenesis in metastatic lesions of ovarian cancers. *Oncology.* 2004; 66:420–428. [PubMed: 15331930]
29. Spaderna S, et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. *Cancer research.* 2008; 68:537–544. [PubMed: 18199550]
30. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? *Nature reviews Cancer.* 2007; 7:415–428.

31. Bendoraite A, et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. *Gynecol Oncol.* 2010; 116:117–125. [PubMed: 19854497]
32. Bolton KL, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nat Genet.* 2010
33. Song H, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. *Nat Genet.* 2009; 41:996–1000. [PubMed: 19648919]
34. Pharoah, et al. GWAS meta-analysis and replication identifies three novel common susceptibility loci for ovarian cancer. *Nat Genet.* XYZ. in press.
35. Couch FJ, et al. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiol Biomarkers Prev.* 2012; 21:645–657. [PubMed: 22351618]
36. Ghousaini M, et al. Multiple loci with different cancer specificities within the 8q24 gene desert. *J Natl Cancer Inst.* 2008; 100:962–966. [PubMed: 18577746]
37. Coppola G, et al. Evidence for a Role of The Rare p.A152T Variant in MAPT in increasing the Risk for FTD-Spectrum and Alzheimer's Diseases. *Hum Mol Genet.* 2012
38. Ghidoni R, et al. The H2 MAPT haplotype is associated with familial frontotemporal dementia. *Neurobiol Dis.* 2006; 22:357–362. [PubMed: 16410051]
39. Koolen DA, et al. A new chromosome 17q21.31 microdeletion syndrome associated with a common inversion polymorphism. *Nat Genet.* 2006; 38:999–1001. [PubMed: 16906164]
40. Tobin JE, et al. Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. *Neurology.* 2008; 71:28–34. [PubMed: 18509094]
41. Li R BF, Kiefer AK, Steffanson H, Nyholt DR, et al. Six Novel Susceptibility Loci for Early-Onset Androgenic Alopecia and Their Unexpected Association with Common Diseases. *PLoS Genet.* 2012; 8(5):e1002746. [PubMed: 22693459]
42. Edwards TL, et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. *Ann Hum Genet.* 2010; 74:97–109. [PubMed: 20070850]
43. Dahiya N, et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. *PLoS ONE.* 2008; 3:e2436. [PubMed: 18560586]
44. Iorio MV, et al. MicroRNA signatures in human ovarian cancer. *Cancer Res.* 2007; 67:8699–8707. [PubMed: 17875710]
45. Nam EJ, et al. MicroRNA expression profiles in serous ovarian carcinoma. *Clin Cancer Res.* 2008; 14:2690–2695. [PubMed: 18451233]
46. Yang H, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. *Cancer Res.* 2008; 68:425–433. [PubMed: 18199536]
47. Tothill RW, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. *Clin Cancer Res.* 2008; 14:5198–5208. [PubMed: 18698038]
48. Zorn KK, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. *Clin Cancer Res.* 2005; 11:6422–6430. [PubMed: 16166416]
49. Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. *J Clin Oncol.* 2008; 26:995–1005. [PubMed: 18195328]
50. Fasching PA, et al. Role of genetic polymorphisms and ovarian cancer susceptibility. *Mol Oncol.* 2009; 3:171–181. [PubMed: 19383379]
51. Yu W, Wulf A, Liu T, Khoury MJ, Gwinn M. Gene Prospector: an evidence gateway for evaluating potential susceptibility genes and interacting risk factors for human diseases. *BMC Bioinformatics.* 2008; 9:528. [PubMed: 19063745]
52. NCBI dbSNP database. 2009. <http://ncbi.nlm.nih.gov/SNP>
53. Sankararaman S, Sridhar S, Kimmel G, Halperin E. Estimating local ancestry in admixed populations. *Am J Hum Genet.* 2008; 82:290–303. [PubMed: 18252211]
54. Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet.* 2007; 81:559–575. [PubMed: 17701901]

55. Howie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. *G3* (Bethesda). 2011; 1:457–470. [PubMed: 22384356]
56. Lawrenson K, et al. Senescent fibroblasts promote neoplastic transformation of partially transformed ovarian epithelial cells in a three-dimensional model of early stage ovarian cancer. *Neoplasia*. 2010; 12:317–325. [PubMed: 20360942]
57. Ernst J, et al. Mapping and analysis of chromatin state dynamics in nine human cell types. *Nature*. 2011; 473:43–49. [PubMed: 21441907]
58. Heintzman ND, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. *Nature*. 2009; 459:108–112. [PubMed: 19295514]




Figure 1. Regional association plot for genotyped and imputed SNPs at 17q21.31

The middle portion of the plot contains the region of the inversion polymorphism (ch 17: 43,624,578-44,525,051, hg build 37), with the four blue dots representing the candidate miRSNPs (rs4640231, rs1052587, and rs17574361) and the tagSNP, rs916793. rs1052587 in the 3' UTR of *MAPT* has the strongest signal ($P=4.6 \times 10^{-8}$) among the miRSNPs. The cluster on the left side of the plot (around 43.5 MB) contains highly correlated SNPs ($r^2=0.99$), including three directly genotyped intronic SNPs, rs2077606 and rs17631303 in *PLEKHM1* ($P=3.9 \times 10^{-10}$ and $P=4.7 \times 10^{-10}$, respectively), and rs12942666 in *ARHGAP27* ($P=1.0 \times 10^{-9}$). The linkage disequilibrium between each plotted SNP and the top-ranked SNP in the region with the best clustering, rs12942666, is depicted by the color scheme; the deeper the color red, the stronger the correlation between the plotted SNP and rs12942666. The top miRSNP, rs1052587, is moderately correlated ($r^2=0.76$) with rs2077606, rs17631303, and rs12942666 in our study population. (n=8,371 invasive serous cases and n= 23,491 controls, of European ancestry).




Figure 2. Expression and methylation analyses at the 17q21.31 ovarian cancer susceptibility locus

(a) Genomic map and LD structure. The location and approximate size of 17 known protein coding genes (grey) and one microRNA (blue) in the region are shown relative to the location of rs12942666. Orange indicates the location of the inversion polymorphism, and green indicates the region outside the inversion.

(b) Gene expression (EOC and normal cell lines). Gene expression analysis in Epithelial Ovarian Cancer (EOC) cell lines (T; n=51) compared to normal ovarian surface epithelial cells (OSECs) and fallopian tube secretory epithelial cells (FTSEC) (N; n=73) (* p<0.05, **p<0.01, ***p<0.001).

(c) Gene expression (Primary EOCs and Normal Tissue). Boxplots of The Cancer Genome Atlas (TCGA) Affymetrix U133A-array based gene expression in primary high-grade serous ovarian tumors (T; n=568) and normal fallopian tube tissues (N; n=8). Where data were not available in TCGA, gene expression data from the Gene Expression Omnibus series GSE18520 dataset containing 53 high-grade serous tumors and 10 normal ovarian tissues are shown (indicated by a red asterisk).

(d) Methylation (Primary Tumors and Normal Tissue). Methylation analysis of 106 high-grade serous ovarian tumors compared to normal ovarian tissues (n=7). Methylation data were generated for CpG site(s) associated with each gene using the Illumina 450 methylation array. Pairwise analysis of methylation for an individual CpG for each gene is based on the CpG with most significant inverse relationship to gene expression (i.e. cis negative), for a subset of 43 tumors having available gene expression data. Statistically significant cis-negative probes are indicated by a red open circle.

(e) Expression quantitative trait locus (eQTL) analysis (OSECs/FTSECs). eQTL analysis comparing expression for each gene to genotype for the most statistically significant SNP at 17q21.31 (rs12942666), for 73 normal OSEC/FTSEC lines. Data are presented as box plots comparing expression levels in cases carrying rare homozygotes/heterozygotes, with cases homozygous for the common allele.

(f) Expression quantitative trait locus (eQTL) analysis (Primary EOCs). eQTL analysis comparing expression for each gene to genotype using level 3 gene expression profiling data from Agilent 244K custom arrays and level 2 genotype data from the Illumina 1M-Duo BeadChip for 568 high-grade serous ovarian cancer patients from TCGA. In all panels * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. Grey X's indicate data not available. Here, genotype data for rs2077606 is used (rather than rs12942666) because rs12942666 was not genotyped in the TCGA dataset.

(g) Methylation quantitative trait locus (mQTL) analysis (Primary EOCs). mQTL analysis showing methylation status in 227 high-grade serous EOCs relative to rs12942666 genotype.




Figure 3. eQTL associations between the rs2077606 susceptibility SNP at 17q21

(a) Analysis of the chromatin landscape at *ARHGAP27* and *PLEKHM1* in normal ovarian surface epithelial and fallopian tube secretory epithelial cells (OSECs/FTSECs) by formaldehyde assisted isolation of regulatory elements sequencing (FAIRE-seq). Alignment with ENCODE FAIRE-seq tracks (shown) and ChIP-seq tracks (not shown) from non-EOC related cell lines reveals open chromatin peaks corresponding to (a) promoters (b) CTCF insulator binding sites and (c) H3K4me3 signals, suggestive of a dynamic regulatory region. An H3K4me3 signal at a coding *ARHGAP27* mRNA variant (c) located between the genes is highly pronounced in OSEC/FTSEC, suggesting tissue-specific expression and function. Several of the top-ranking SNPs fall within transcription factor binding sites (TFBS) (Supplementary Table S2). rs12942666 did not coincide with TFBS, but tightly linked SNPs, rs12946900 and rs2077606 fell within predicted binding sites for SPIB and ZEB1, respectively.

(b) We analyzed the expression of *SPIB* and *ZEB1* in primary high-grade serous tumors from TCGA and found (i) no significant change in *SPIB* expression but (ii) significant down-regulation of *ZEB1* in tumors compared to normal tissues. (iii) QPCR analysis of *ZEB1* expression in 73 OCPT and 50 EOC cell lines replicated the finding that *ZEB1*

expression is lower in cancer cell lines compared to normal precursor tissues. (c) eQTL analysis in OSECs/FTSECs for different alleles of rs2077606. There was a (i) significant eQTL for *ARHGAP27*, with the minor (A) allele being associated with increased *ARHGAP27* expression ($P=0.034$), (ii) no evidence of an association between rs2077606 genotypes and *ARHGAP27* expression in lymphoblastoid cell lines suggesting this association may be tissue-specific. (iii) We observed a borderline significant eQTL association between *ZEB1* mRNA and rs2077606 in tumors from TCGA, with the minor risk allele also associated with lower expression.

Table 1
Tests of association by histological subtype for directly genotyped and imputed SNPs at 17q21.31 most strongly associated with invasive epithelial ovarian cancer risk among Europeans

SNP Major>minor allele	Coordinate ^a	MAF	Subtype	Number of cases (versus 23,491 controls)	Per-allele OR (95% CI) ^b	P-value
rs1052587 ^c (T>C)	44102604	0.22	All Invasives	14,533	1.10 (1.06-1.13)	1.9×10^{-7}
			Serous	8,371	1.12 (1.08-1.17)	4.6×10^{-8}
			Endometrioid	2,068	1.11 (1.04-1.19)	5.2×10^{-3}
			Clear Cell	1,025	0.98 (0.88-1.09)	0.68
			Mucinous	944	1.07 (0.96-1.20)	0.22
rs12942666 ^d (A>G)	43499839	0.22	All Invasives	14,533	1.11 (1.07-1.15)	3.3×10^{-8}
			Serous	8,371	1.15 (1.11-1.20)	1.0×10^{-9}
			Endometrioid	2,068	1.10 (1.02-1.18)	0.04
			Clear Cell	1,025	1.04 (0.92-1.14)	0.61
			Mucinous	944	1.04 (0.92-1.16)	0.55
rs2960000 ^e (T>C)	43534353	0.18	All Invasives	14,533	1.12 (1.08-1.16)	4.2×10^{-9}
			Serous	8,371	1.16 (1.12-1.20)	3.3×10^{-10}
			Endometrioid	2,068	1.12 (1.03-1.20)	0.01
			Clear Cell	1,025	1.05 (0.93-1.16)	0.44
			Mucinous	944	1.03 (0.90-1.15)	0.65

Abbreviations: MAF=minor allele frequency in controls; OR=Odds ratio; CI=Confidence intervals

^a Genome build NCBI B37/human genome build 19 assembly.

^b OR and 95% CI per copy of the minor allele, with adjustment for the first five eigenvalues from principal components analysis.

^c rs1052587 is the most statistically significant miRNA binding site SNP among all invasives and serous; it resides in a putative miRNA binding site between microtubule-associated protein tau (*MAPT*) and miR-34a-5p (chr 1:9134225-9134425).

^d rs12942666 is a SNP at 17q21.31 that was directly genotyped as part of COGs; it is in strong linkage disequilibrium ($r^2=0.99$) with two other 17q21.31 SNPs that were directly genotyped but had less optimal clustering: rs2077606 ($P=3.9 \times 10^{-10}$ for the serous subtype) and rs17631303 ($P=4.7 \times 10^{-10}$ for the serous subtype).

^e rs2960000 represents the most statistically significant SNP at 17q21.31 (among all invasives) that was imputed from the 1000 genome Project reference panel with an R-squared quality metric of 95% or greater (<http://www.1000genomes.org/page.php>).

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

Genome-wide association studies (GWAS) have identified 12 epithelial ovarian cancer (EOC) susceptibility alleles. The pattern of association at these loci is consistent in *BRCA1* and *BRCA2* mutation carriers who are at high risk of EOC. After imputation to 1000 Genomes Project data, we assessed associations of 11 million genetic variants with EOC risk from 15,437 cases unselected for family history and 30,845 controls and from 15,252 *BRCA1* mutation carriers and 8,211 *BRCA2* mutation carriers (3,096 with ovarian cancer), and we combined the results in a meta-analysis. This new study design yielded increased statistical power, leading to the discovery of six new EOC susceptibility loci. Variants at 1p36 (nearest gene, *WNT4*), 4q26 (*SYNPO2*), 9q34.2 (*ABO*) and 17q11.2 (*ATAD5*) were associated with EOC risk, and at 1p34.3 (*RSPO1*) and 6p22.1 (*GPX6*) variants were specifically associated with the serous EOC subtype, all with $P < 5 \times 10^{-8}$. Incorporating these variants into risk assessment tools will improve clinical risk predictions for *BRCA1* and *BRCA2* mutation carriers.

The risk of developing invasive EOC is higher than the population average for relatives of women diagnosed with the disease^{1,2}, indicating the importance of genetic factors in disease susceptibility. Approximately 25% of the familial aggregation of EOC is explained by rare, high-penetrance alleles of *BRCA1* and *BRCA2* (ref. 3). Furthermore, population-based GWAS have identified common variants associated with invasive EOC at 11 loci^{4–9}, but only 6 have also been evaluated in *BRCA1* and/or *BRCA2* mutation carriers. All loci analyzed displayed associations in mutation carriers that were consistent with the associations observed in the general population^{10–12}. In addition, the 4q32.3 locus is associated with EOC risk for *BRCA1* mutation carriers only¹³. However, the common genetic variants identified explain less than 3.1% of the excess familial risk of EOC, so additional susceptibility loci are likely to exist.

Women diagnosed with EOC and unaffected women from the general population ascertained through the Ovarian Cancer Association Consortium (OCAC)¹⁴ and *BRCA1* and *BRCA2* mutation carriers from the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA)¹⁵ were genotyped as part of the Collaborative Oncological Gene-environment Study (COGS) using the iCOGS custom array. In addition, data were available for cases and controls from three EOC GWAS. We first evaluated whether the EOC susceptibility loci at 8q21.13, 10p12.31, 17q12, 5p15.33 and 17q21.31 recently identified by OCAC^{7–9} also showed evidence of association in *BRCA1* and *BRCA2*

mutation carriers. Using data from >200,000 genotyped SNPs^{7,13,16}, we performed imputation of common variants from 1000 Genomes Project data¹⁷ and evaluated the associations of these SNPs with invasive EOC risk in OCAC samples and in *BRCA1* and *BRCA2* mutation carriers from CIMBA. Given the strong evidence for a significant overlap in loci predisposing to EOC in the general population and those associated with risk in *BRCA1* and *BRCA2* mutation carriers, we carried out a meta-analysis of the EOC risk associations to identify new EOC susceptibility loci.

Genotype data were available for imputation on 15,252 *BRCA1* mutation carriers and 8,211 *BRCA2* mutation carriers, of whom 2,462 and 631, respectively, were affected with EOC^{13,16}. For OCAC samples, genotyping data were available from 15,437 women with invasive EOC (including 9,627 with serous EOC) and 30,845 controls from the general population⁷. Imputation was performed separately for *BRCA1* mutation carriers, *BRCA2* mutation carriers, OCAC-COGS samples and samples included in the three OCAC GWAS (Supplementary Figs. 1 and 2, and Supplementary Tables 1 and 2). The meta-analysis was based on data for 11,403,952 SNPs (Supplementary Fig. 3).

Of the five EOC susceptibility loci that had not yet been evaluated in mutation carriers, two were associated with EOC risk for both *BRCA1* and *BRCA2* mutation carriers at $P < 0.05$ (10p12.31 and 17q21.31) (Supplementary Table 3). Overall, 7 of the 12 known EOC susceptibility loci provided evidence of association in *BRCA1* mutation carriers and 6 were associated in *BRCA2* mutation carriers. With the exception of 5p15.33 (*TERT*), all loci had hazard ratio (HR) estimates in *BRCA1* and *BRCA2* mutation carriers that were in the same direction as the odds ratio (OR) estimates for the serous subtype EOC samples in OCAC (Fig. 1). Analyzing the associations jointly in *BRCA1* and *BRCA2* mutation carriers and serous EOC cases in OCAC provided stronger evidence of association, with smaller P values for eight of the susceptibility variants in comparison to the analysis in OCAC samples alone.

Using the imputed genotypes, we observed no new associations at $P < 5 \times 10^{-8}$ in the analysis of associations in *BRCA1* and *BRCA2* mutation carriers separately. However, we identified seven previously unreported associations ($P < 5 \times 10^{-8}$) in OCAC samples alone, in the meta-analysis of EOC associations in *BRCA1* and *BRCA2* mutation carriers and OCAC samples, or in the meta-analysis in *BRCA1* and *BRCA2* mutation carriers and serous EOC cases from OCAC (Supplementary Fig. 4 and Supplementary Tables 4 and 5). SNPs in six of these loci remained genome-wide statistically significant after we reimputed genotypes with imputation parameters set to

A full list of authors and affiliations appears at the end of the paper.

Received 2 June 2014; accepted 5 December 2014; published online 12 January 2015; doi:10.1038/ng.3185




Figure 1 HR estimates for association with EOC of 12 previously reported EOC susceptibility variants and the 6 new susceptibility variants for OCAC samples, *BRCA1* mutation carriers and *BRCA2* mutation carriers. Error bars indicate 95% confidence intervals. The arrow indicates that the confidence interval extends beyond the scale of the x axis.

maximize accuracy (Fig. 1 and Table 1). We found SNPs at 17q11.2 (near *ATAD5*) to be associated with invasive EOC in the OCAC samples ($P < 5 \times 10^{-8}$) (Table 1). For the lead SNP, chr17:29181220:I, the estimated HR value for *BRCA1* mutation carriers was significantly different from the estimate in OCAC samples ($P = 0.005$); the association for *BRCA2* mutation carriers was consistent with the OCAC OR estimate (*BRCA2*-OCAC meta-analysis $P = 2.6 \times 10^{-9}$). SNPs at four loci were associated at $P < 5 \times 10^{-8}$ with risk of all invasive EOC subtypes in the meta-analysis (Supplementary Fig. 5): 1p36, 1p34.3, 4q26 and 9q34.2. At 1p34.3, the most strongly associated SNP, rs58722170, displayed stronger associations in the meta-analysis of serous EOC cases from OCAC ($P = 2.7 \times 10^{-12}$). In addition, SNPs at 6p22.1 were associated at a genome-wide significance level in the meta-analysis of associations with serous EOC ($P = 3.0 \times 10^{-8}$) but not in the meta-analysis of all invasive EOC associations ($P = 6.8 \times 10^{-6}$).

The most significantly associated SNP at each of the six new loci had high imputation accuracy ($r^2 \geq 0.83$). At the 1p34.3, 1p36 and 6p22.1 loci, there was at least one genome-wide significant genotyped SNP correlated with the lead SNP (pairwise $r^2 \geq 0.73$) (Supplementary Fig. 5, Supplementary Table 6 and Supplementary Note). We genotyped the leading (imputed) SNPs of the three other loci in a subset of the samples using iPLEX technology (Supplementary Note). Correlations between the expected allele dosages from imputation and the observed genotypes for the variants at 4q26 and 9q34.2 ($r^2 = 0.90$ and 0.84 , respectively) were consistent with the estimated imputation accuracy scores (0.93 and 0.83 for CIMBA samples). The lead SNP at 17q11.2 failed iPLEX design. However, the risk-associated allele was highly correlated with the AA haplotype of two genotyped variants on the iCOGS array (rs9910051 and rs3764419). This haplotype was strongly associated with ovarian cancer risk in the subset of samples genotyped using the iCOGS array (*BRCA2*-OCAC meta-analysis $P = 8.6 \times 10^{-8}$ for this haplotype and $P = 1.8 \times 10^{-8}$ for chr17:29181220:I) (Supplementary Table 7).

None of the regions contained additional SNPs that displayed EOC associations at $P < 1 \times 10^{-4}$ in OCAC samples, *BRCA1* mutation carriers or *BRCA2* mutation carriers in multi-variable analyses adjusted

Table 1 Association test results for loci associated at $P < 5 \times 10^{-8}$ in the second imputation stage

Locus	Nearest gene	rs ID	Ref ^g	Eff ^g	EAF ^h	OCAC all histologies		OCAC serous		BRCA1 mutation carriers		BRCA2 mutation carriers		Meta-analysis all histologies ^b	Meta-analysis serous ^c
						<i>r</i> ² ^a	OR (95% CI)	<i>P</i>	OR (95% CI)	<i>P</i>	<i>r</i> ² ^a	HR (95% CI)	<i>P</i>		
1p36	WNT4	rs56318008	C	T	0.15	0.98	1.11 (1.07–1.16)	3.9 × 10 ^{−7}	1.12 (1.07–1.18)	3.1 × 10 ^{−6}	0.98	1.15 (1.05–1.26)	1.03 (0.86–1.23)	7.6 × 10 ^{−9}	5.7 × 10 ^{−8}
1p34.3	RSP01	rs58722170	G	C	0.23	0.85	1.08 (1.04–1.12)	9.7 × 10 ^{−5}	1.12 (1.08–1.18)	1.1 × 10 ^{−7}	0.83	1.14 (1.05–1.23)	1.35 (1.17–1.57)	5.2 × 10 ^{−5}	2.7 × 10 ^{−12}
4q26	SYNP02	rs17329882	A	C	0.24	0.95	1.09 (1.06–1.13)	5.9 × 10 ^{−7}	1.11 (1.07–1.16)	6.4 × 10 ^{−7}	0.93	1.08 (1.00–1.17)	0.93 (1.00–1.33)	1.4 × 10 ^{−8}	1.6 × 10 ^{−8}
6p22.1	GPX6	rs116133110 ^e	T	C	0.31	0.99	0.93 (0.91–0.97)	9.0 × 10 ^{−5}	0.91 (0.87–0.94)	2.6 × 10 ^{−7}	0.99	0.92 (0.86–0.99)	0.97 (0.85–1.10)	6.8 × 10 ^{−6}	3.0 × 10 ^{−8}
9q34.2	ABO	rs635634	C	T	0.19	0.85	1.11 (1.07–1.16)	1.1 × 10 ^{−7}	1.12 (1.08–1.18)	1.0 × 10 ^{−6}	0.83	1.11 (1.02–1.21)	1.05 (0.89–1.23)	4.4 × 10 ^{−9}	4.2 × 10 ^{−8}
17q11.2	ATAD5	chr17:29181220: ^f	A	AT	0.28	0.95	0.91 (0.88–0.94)	5.4 × 10 ^{−9}	0.91 (0.87–0.94)	8.1 × 10 ^{−7}	0.94	1.01 (0.94–1.08)	0.92 (0.80–1.05)	2.6 × 10 ^{−9d}	3.9 × 10 ^{−7d}

Results are reported for ovarian cancer in *BRCA1* and *BRCA2* mutation carriers, for ovarian cancer as well as the serous subtype of ovarian cancer in OCAC, for the meta-analysis for ovarian cancer, and for the meta-analysis for all tumor histologies in *BRCA1* and *BRCA2* mutation carriers and serous ovarian cancer cases in OCAC. The SNP with the smallest P value is reported for each locus.

^aImputation accuracy r^2 estimate. ^b P value from the meta-analysis association test for ovarian cancer in OCAC samples and *BRCA1* and *BRCA2* mutation carriers. ^c P value from the meta-analysis association test for ovarian cancer in OCAC samples. ^dMeta-analysis of ovarian cancer associations in *BRCA2* mutation carriers and OCAC samples only. ^ers116133110 is listed as rs6456822 in dbSNP. ^fchr17:29181220:I is listed as rs199661266 in dbSNP. ^gReference and effect alleles. ^hEffect allele frequency.

Table 2 Associations with ovarian cancer subtypes in OCAC samples for loci associated with ovarian cancer at $P < 5 \times 10^{-8}$ in the meta-analysis

Locus	rs ID	All histologies		Serous		Endometrioid		Clear cell		Mucinous		P_{het}^a
		OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	
1p36	rs56318008	1.11 (1.06–1.15)	8×10^{-7}	1.12 (1.06–1.17)	6×10^{-6}	1.09 (1.00–1.19)	0.05	1.24 (1.10–1.39)	5×10^{-4}	1.03 (0.91–1.17)	0.65	0.22
1p34.3	rs58722170	1.07 (1.03–1.11)	2×10^{-4}	1.12 (1.07–1.17)	4×10^{-7}	0.94 (0.87–1.02)	0.16	1.00 (0.89–1.12)	0.98	1.08 (0.97–1.21)	0.17	0.001
4q26	rs17329882	1.09 (1.06–1.13)	3×10^{-7}	1.11 (1.07–1.16)	3×10^{-7}	1.09 (1.01–1.18)	0.020	1.06 (0.96–1.18)	0.26	1.11 (0.99–1.23)	0.06	0.88
6p22.1	rs116133110	0.94 (0.91–0.97)	9×10^{-5}	0.91 (0.87–0.94)	3×10^{-7}	0.95 (0.89–1.02)	0.16	1.05 (0.95–1.15)	0.34	1.03 (0.94–1.14)	0.53	0.008
9q34.2	rs635634	1.12 (1.08–1.16)	9×10^{-9}	1.13 (1.08–1.18)	2×10^{-7}	1.12 (1.03–1.21)	0.007	1.03 (0.92–1.16)	0.58	1.23 (1.10–1.38)	3×10^{-4}	0.23
17q11.2	chr17:29181 220:1	0.90 (0.87–0.93)	1×10^{-9}	0.90 (0.87–0.94)	2×10^{-7}	0.88 (0.82–0.95)	5×10^{-4}	0.88 (0.80–0.98)	0.020	1.01 (0.91–1.12)	0.84	0.18

^a P value for the heterogeneity in associations with different tumor subtypes.

for the lead SNP in each region, indicating that they each contain only one independent set of correlated, highly associated variants (iCHAVs). Relative to 1000 Genomes Project data, we had genotyped or imputed data covering 91% of the genetic variation at 1p36, 84% of the variation at 1p34.3 and 83% of the variation at 4q26. The other three new loci had coverage of less than 80% (Supplementary Note). There was evidence for heterogeneity at $P < 0.05$ in the associations with histological subtype in OCAC samples for the lead SNPs at 1p34.4 and 6p22.1 but not for the lead SNPs at 1p36, 4q26, 9q34.2 and 17q11.2 (Table 2).

We carried out a competing risks association analysis in *BRCA1* and *BRCA2* mutation carriers to investigate whether these loci were also associated with breast cancer risk for mutation carriers (Supplementary Note). We used the most strongly associated genotyped SNPs for this purpose because the statistical method required actual genotypes¹⁸. The HR estimates for EOC were consistent with the estimates from the main analysis for all SNPs (Supplementary Table 8). None of the SNPs displayed associations with breast cancer risk at $P < 0.05$.

At each of the six loci, we identified a set of SNPs with odds of less than 100 to 1 against them being the causal variant; most were in non-coding DNA regions (Supplementary Table 9). None were predicted to have likely deleterious functional effects, although some were in

or near chromatin biofeatures in fallopian tube and ovarian epithelial cells, which might represent the functional regulatory targets of the risk-associated SNPs (Table 3 and Supplementary Table 10). We also evaluated the protein-coding genes in each region for their role in EOC development and as candidate susceptibility gene targets. Molecular profiling data from 496 high-grade serous ovarian cancers (HGSOCs) collected by The Cancer Genome Atlas (TCGA) indicated frequent loss or deletion at 4 risk loci (1p36, 4q26, 9q34.2 and 17q11.2) (Supplementary Table 11). Consistent with this observation, the expression of *WNT4*, *SYNPO2* and *ABO* was significantly downregulated in ovarian tumors, whereas *ATAD5* expression was upregulated ($P < 6 \times 10^{-5}$, HuEx platform). Somatic coding-sequence mutations in the six genes nearest the index SNPs were rare. We performed expression quantitative trait locus (eQTL) analysis in a series of 59 normal ovarian tissues (Supplementary Table 12) to evaluate the gene nearest the top ranked SNP at each locus. For the five genes expressed in normal cells, we found no statistically significant eQTL associations for any of the putative causal SNPs at each locus; neither did we find any significant tumor-eQTL associations for these genes based on data from TCGA (Supplementary Table 12). At the 1p36 locus, the most strongly associated variant, rs56318008, was located


Table 3 Summary of data on SNPs, closest gene and all genes in a 1-Mb region for each locus

Loci	Position of top SNP	Number of putatively causal SNPs	Genes in window of putatively causal SNP	Number of SNPs aligned with biofeatures	Normal eQTL closest gene	Tumor DNA copy number	Significant expression difference in tumor versus normal ^c	Known role of gene in cancer	Number of genes in 1-Mb region	Other known cancer genes in 1-Mb region
1p36	Promoter region of <i>WNT4</i>	39	<i>WNT4</i> , <i>CDC42</i> , <i>LINC00339</i>	11	NS	Loss	Down	Yes	11	<i>RAP1GAP</i> , <i>CDC42</i>
1p34.3	Intron 3 of <i>RSP01</i>	15	<i>RSP01</i>	0	NS	Gain		Yes	22	<i>C1orf109</i> , <i>FHL3</i>
4q26	Intron 3 of <i>SYNPO2</i>	4	<i>SYNPO2</i>	2	NS ^b	Loss	Down	Yes	12	None
6p22.1	Intron 1 of <i>GPX6</i>	22	<i>GPX6</i> , <i>GPX5</i>	1	NA	Gain			23	<i>ZKSCAN3</i> , <i>TRIM27</i>
9q34.2	4.3 kb upstream of <i>ABO</i>	18	<i>ABO</i> , <i>SLC2A6</i> ^a	1	NS	Loss	Down	Yes	32	<i>TSC1</i> , <i>RALGDS</i> , <i>RPL7A</i> , <i>VAV2</i>
17q11.2	Intron 6 of <i>ATAD5</i>	16	<i>ATAD5</i> , <i>TEFM</i> , <i>ADAP2</i> , <i>CRLF3</i> , <i>SUZ12P1</i>	0	NS	Loss	Up	Yes	17	<i>NF1</i>

Proximal promoter regions were defined as the regions 1 kb upstream of the transcription start site. NA indicates no expression of *GPX6* in normal tissues. NS, not significant. Biofeatures are defined as open chromatin H3K4me3 or H3K27ac marks detected in normal ovarian and/or fallopian tube cells.

^aThere are 16 genes in this region—*ABO*, *SURF6*, *MED22*, *RPL7A*, *SNORD24*, *SNORD36B*, *SNORD36A*, *SNORD36C*, *SURF1*, *SURF2*, *SURF4*, *C9orf96*, *REXO4*, *ADAMTS13*, *CACFD1* and *SLC2A6*; however, all SNPs are within or upstream of *ABO* or upstream of *SLC2A6*. ^bTrend $P = 0.067$. ^c $P < 6 \times 10^{-5}$ with the HuEx platform.

Figure 2 The 1p36 EOC susceptibility locus. **(a)** The Manhattan plot depicts the strength of association between all imputed and genotyped SNPs across the region bound by hg19 coordinates chr. 1: 21,922,893–22,991,643. The dotted line represents the genome-wide significance level of 5×10^{-8} . Additional tracks show genes and enhancers in the ovary as described in Hnisz *et al.*³⁸. Positions of SNPs for which imputation $r^2 < 0.3$ and/or minor allele frequency (MAF) < 0.005 are shown in the bottom track as 'untyped' SNPs. H3K27ac, acetylation of histone H3 at lysine 27; H3K4me1, monomethylation of histone H3 at lysine 4. **(b)** The shaded iCHAV region from **a** is shown, depicting the genes and the location of the *WNT4* promoter construct as a red box. Red ticks show the positions of the putative causal variants following likelihood ratio testing. Signals from formaldehyde-assisted regulatory element sequencing (FAIRE-seq) data derived from ovarian cells are represented by black marks, and the locations of predicted *CDC42* enhancers³⁸ are represented by blue boxes. The positions of genotyped SNPs and those that were neither genotyped nor well imputed ('untyped') are shown. **(c)** Normalized luciferase reporter activity following triplicate transfections of wild-type and risk haplotype *WNT4* promoter constructs in iOSE4 cells. Error bars represent the s.e.m. from three independent experiments.



in the promoter region of *WNT4*, which encodes a ligand in the WNT signal transduction pathway, critical for cell proliferation and differentiation. Using a luciferase reporter assay, we found no effect of these putatively causal SNPs on *WNT4* transcription in iOSE4 normal ovarian cells (**Fig. 2**). Some of the putative causal SNPs at 1p36 were located in *CDC42* and *LINC00339*, and several were in putative regulatory domains in ovarian tissues (**Fig. 2** and **Supplementary Table 10**). *CDC42* is known to have a role in migration and signaling in ovarian and breast cancers^{19,20}. SNPs at 1p36 are also associated with increased risk of endometriosis, and *WNT4*, *CDC42* and *LINC00339* have all been implicated in endometriosis²¹, a known risk factor for endometrioid and clear cell EOCs²².

The strongest associated variant at 1q34, rs58722170, was located in *RSPO1*, which encodes R-spondin 1, a protein involved in cell proliferation (**Supplementary Fig. 6**). *RSPO1* is important in tumorigenesis and early ovarian development^{23,24}, and it regulates *WNT4* expression in the ovaries²⁵. *SYNPO2* at 4q26 encodes myopodin, which is involved in cell motility and growth²⁶ and has a reported tumor-suppressor role^{27–30}. rs635634 is located upstream of the *ABO* gene (**Supplementary Fig. 7**). A moderately correlated variant (rs505922; $r^2 = 0.52$) determines ABO blood group and is associated with increased risk of pancreatic cancer^{31,32}. Previous studies in OCAC also showed a modestly increased risk of EOC for individuals with the A blood group³³. The moderate correlation between rs635634 and rs505922 and the considerably weaker EOC association of rs505922 ($P = 1.2 \times 10^{-5}$) suggest that the association with blood group is probably not driving the risk association. The indel chr17:29181220:I at 17q11.2 is located in *ATAD5*, which acts as a tumor-suppressor gene^{34–36} (**Supplementary Fig. 8**). *ATAD5* protein modulates the interaction between RAD9A and BCL2 to induce DNA damage-related apoptosis. Finally, rs116133110, at 6p22.1, lies in *GPX6*, which has no known role in cancer.

The 6 new loci reported in this study increase the number of genome-wide significant common variant loci so far identified for

EOC to 18. Taken together, these loci explain approximately 3.9% of the excess familial relative risk of EOC in the general population and account for approximately 5.2% of the polygenic modifying variance for EOC in *BRCA1* mutation carriers and 9.3% of the variance in *BRCA2* mutation carriers. The similarity in the magnitude of the associations between *BRCA1* and *BRCA2* mutation carriers and cases from population-based studies suggests a general model of susceptibility whereby *BRCA1* and *BRCA2* mutations and common alleles interact multiplicatively on the relative risk scale for EOC³⁷. This model predicts large differences in absolute EOC risk between individuals carrying many risk-associated alleles and individuals carrying few alleles for EOC susceptibility in *BRCA1* and *BRCA2* mutation carriers^{13,16}. Incorporating EOC susceptibility variants into risk assessment tools will improve risk prediction and might be particularly useful for *BRCA1* and *BRCA2* mutation carriers.

URLs. Nature Publishing Group, *Nature Genetics*–iCOGS, <http://www.nature.com/icogs/>; The Cancer Genome Atlas (TCGA) Project, <http://cancergenome.nih.gov/>; cBio Cancer Genomics Portal, <http://www.cbioportal.org/>; Pupasuite 3.1, <http://pupasuite.bioinfo.cipf.es/>; CIMBA quality control guidelines, <http://ccge.medschl.cam.ac.uk/consortia/cimba/members/data%20management/CIMBA%20and%20BCAC%20Quality%20Control%20November%202008%20v2.doc>; R software, <http://www.r-project.org/>.

METHODS

Methods and any associated references are available in the [online version of the paper](#).

Note: Any Supplementary Information and Source Data files are available in the online version of the paper.

ACKNOWLEDGMENTS

We thank all the individuals who took part in this study and all the researchers, clinicians, and technical and administrative staff who made possible the many studies contributing to this work (a full list is provided in the **Supplementary Note**),

including X.Q. Chen for iPLEX genotyping. The COGS project is funded through a European Commission Seventh Framework Programme grant (agreement number 223175-HEALTH-F2-2009-223175). CIMBA data management and data analysis were supported by Cancer Research UK grants C12292/A11174 and C1287/A10118. The Ovarian Cancer Association Consortium (OCAC) is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). Scientific development and funding for this project were in part supported by the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). This study made use of data generated by the Wellcome Trust Case Control Consortium. Funding for the project was provided by the Wellcome Trust under award 076113. The results published here are in part based on data generated by The Cancer Genome Atlas (TCGA) Pilot Project established by the US National Cancer Institute and US National Human Genome Research Institute (database of Genotypes and Phenotypes (dbGaP) accession [phs000178.v8.p7](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=phs000178.v8.p7)). The cBio Portal is developed and maintained by the Computational Biology Center at the Memorial Sloan-Kettering Cancer Center. S. Healey is supported by a National Health and Medical Research Council of Australia Program Grant to G.C.-T. Details of the funding of individual investigators and studies are provided in the **Supplementary Note**. A full list of the investigators who contributed to the generation of the data is available on the CIMBA website (see URLs).

AUTHOR CONTRIBUTIONS

Writing group: K.B.K., A.C.A., G.C.-T., S.J.R., J. Beesley, P.P.P., S.G. Performed statistical analyses for CIMBA: K.B.K. Performed statistical analyses for OCAC: J.T. Performed the meta-analyses: K.B.K. CIMBA database management: L.M. and D.B. Supervised CIMBA statistical analyses, meta-analyses and CIMBA data management: A.C.A. Supervised OCAC statistical analyses: P.P.P. Initiated and coordinated CIMBA: G.C.-T. Coordinated OCAC: A. Berchuck and P.P.P. Conceived and coordinated the synthesis of the iCOGS array: D.F.E. Coordinated iCOGS genotyping: J.S., K. Offit, F.J.C. iCOGS genotyping, calling and quality control: J.M. Cunningham, J.D., P.S., D.F.E., K.B.K., J.T., P.P.P., A.C.A., G.C.-T. Programming support: A. Lee. Provided DNA samples and/or phenotypic data: S.J.R., J.T., A. Lee, H.C.S., K.L., S. Healey, J.M.L., T.J.S., Y.G.L., T.P., Y.B., Q.L., S.C., D.H., A. Miron, M. Southey, M.B.T., D.E.G., S.S.B., R.J., C.M.D., E.J.v.R., S.L.N., Y.C.D., T.V.O.H., L.J., A.-M.G., B.E., J.D., J. Benitez, A.O., M.J.G., I. Komenaka, J.N.W., P.G., P.P., L. Bernard, A.V., B.B., B.P., S. Manoukian, P.R., L.P., L.O., F.F., I. Konstantopoulou, J. Garber, D.F., J. Perkins, R.P., S.E., EMBRACE, A.K.G., R.K.S., A. Meindl, C.E., C.S., O.M.S., GEMO, F.D., S. Mazoyer, D.S.-L., K. Claes, K.D.L., J. Kirk, G.C.R., M. Piedmonte, D.M.O., M.d.I.H., T.C., K.A., H. Nevanlinna, J.M. Collée, M.A. Rookus, J.C.O., F.B.L.H., HEBON, E.O., O.D., I.B., J. Brunet, C.L., M.A.P., A. Jakubowska, J. Gronwald, J. Lubinski, G.S., R.B.B., M. Plante, J.S., P.S., M.M., S. Tognazzo, M.R.T., KConFab, V.S.P., X. Wang, N.L., C.I.S., N.K., J.V., C.A.A., G.P., A. Berger, C.F.S., M.-K.T., C.M.P., M.H.G., P.L.M., G.R., A.M.M., S. Tchatchou, I.L.A., G.G., A.E.T., U.B.J., T.A.K., M. Thomassen, A. Bojesen, J.Z., E.F., Y.L., M. Soller, A. Liljegren, B.A., Z.E., M.S.-A., O.I.O., R.L.N., T.R.R., K.L.N., S.M.D., K.H.L., B.Y.K., C.W., J. Lester, Australian Cancer Society, Australian Ovarian Cancer Study Group, A.H., A.B.E., M.W.B., P.A.F., D. Lambrechts, E.V.N., I.V., S. Lambrechts, E.D., J.A.D., K.G.W., M.A. Rossing, A.R., J.C.-C., S.W.-G., U.E., K.B.M., K. Odunsi, L.S., S. Lele, L.R.W., M.T.G., P.J.T., Y.B.S., I.B.R., M.D., P. Hillemanns, T.D., N.A., N.B., A. Leminen, L.M.P., R.B., F.M., J.L.K., R.P.E., R.B.N., A.d.B., F.H., I.S., P. Harter, K.M., S. Hosono, S.O., A. Jensen, S.K.K., E.H., H.N.H., M.A.N.A., S.-H.T., Y.-L.W., B.L.F., E.L.G., J.M. Cunningham, R.A.V., F.B., G.G.G., D. Liang, M.A.T.H., X. Wu, D.A.L., M.B., A. Berchuck, E.S.I., J.M.S., P.C., R.P.W., D.W.C., K.L.T., E.M.P., S.S.T., E.V.B., I.O., S.H.O., C.K., H.B.S., I.L.T., L. Borge, A.M.v.A., K.K.H.A., L.A.K., L.F.A.G.M., M.K., A.B.-W., L.E.K., L.S.C., N.D.L., C.C., H.Y., J. Lissowska, L.A.B., N.W., C.H., L.L., L.N., H.B., H.S., D.E., I.G.C., I.M., J. Paul, K. Carty, N.S., R.G., A.S.W., J.H.R., V.M., W.S., B.-T.J., W.Z., X.-O.S., Y.-T.G., B.R., H.A.R., J.R.M., S.A.N., A.N.M., A.C., H.-Y.L., J.P.-W., T.A.S., Y.-Y.T., Z.C., A.Z., H.A.-C., A.G.-M., U.M., P. Harrington, A.W.L., A.H.W., C.L.P., G.C., M.C.P., A.D.-M., A.T., I.K.R., J. Kupryjanczyk, M.F., H. Noushmehr, L.T., N.T., U.H., C.I., M. Tischkowitz, E.N.I., M.A.C., D.F.E., K. Offit, F.J.C., S.G., P.P.P., A.C.A., G.C.-T. All authors read and approved the final manuscript.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

- Auranen, A. *et al.* Cancer incidence in the first-degree relatives of ovarian cancer patients. *Br. J. Cancer* **74**, 280–284 (1996).
- Stratton, J.F., Pharoah, P., Smith, S.K., Easton, D. & Ponder, B.A. A systematic review and meta-analysis of family history and risk of ovarian cancer. *Br. J. Obstet. Gynaecol.* **105**, 493–499 (1998).

- Jeris, S. *et al.* Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. *J. Med. Genet.* **51**, 108–113 (2014).
- Bolton, K.L. *et al.* Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nat. Genet.* **42**, 880–884 (2010).
- Goode, E.L. *et al.* A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. *Nat. Genet.* **42**, 874–879 (2010).
- Song, H. *et al.* A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. *Nat. Genet.* **41**, 996–1000 (2009).
- Pharoah, P.D. *et al.* GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nat. Genet.* **45**, 362–370 (2013).
- Permeth-Wey, J. *et al.* Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nat. Commun.* **4**, 1627 (2013).
- Bojesen, S.E. *et al.* Multiple independent variants at the *TERT* locus are associated with telomere length and risks of breast and ovarian cancer. *Nat. Genet.* **45**, 371–384 (2013).
- Couch, F.J. *et al.* Common variants at the 19p13.1 and *ZNF365* loci are associated with ER subtypes of breast cancer and ovarian cancer risk in *BRCA1* and *BRCA2* mutation carriers. *Cancer Epidemiol. Biomarkers Prev.* **21**, 645–657 (2012).
- Ramus, S.J. *et al.* Ovarian cancer susceptibility alleles and risk of ovarian cancer in *BRCA1* and *BRCA2* mutation carriers. *Hum. Mutat.* **33**, 690–702 (2012).
- Ramus, S.J. *et al.* Genetic variation at 9p22.2 and ovarian cancer risk for *BRCA1* and *BRCA2* mutation carriers. *J. Natl. Cancer Inst.* **103**, 105–116 (2011).
- Couch, F.J. *et al.* Genome-wide association study in *BRCA1* mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genet.* **9**, e1003212 (2013).
- Bolton, K.L., Ganda, C., Berchuck, A., Pharoah, P.D. & Gayther, S.A. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). *J. Intern. Med.* **271**, 366–378 (2012).
- Chenevix-Trench, G. *et al.* An international initiative to identify genetic modifiers of cancer risk in *BRCA1* and *BRCA2* mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). *Breast Cancer Res.* **9**, 104 (2007).
- Gaudet, M.M. *et al.* Identification of a *BRCA2*-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genet.* **9**, e1003173 (2013).
- 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. *Nature* **491**, 56–65 (2012).
- Barnes, D.R. *et al.* Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations. *Genet. Epidemiol.* **36**, 274–291 (2012).
- Bourguignon, L.Y., Gilad, E., Rothman, K. & Peyrolier, K. Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERK signaling, leading to actin binding, Elk-1/estrogen receptor transcriptional activation, and ovarian cancer progression. *J. Biol. Chem.* **280**, 11961–11972 (2005).
- Zuo, Y., Wu, Y. & Chakraborty, C. Cdc42 negatively regulates intrinsic migration of highly aggressive breast cancer cells. *J. Cell. Physiol.* **227**, 1399–1407 (2012).
- Pagliardini, L. *et al.* An Italian association study and meta-analysis with previous GWAS confirm *WNT4*, *CDKN2BAS* and *FN1* as the first identified susceptibility loci for endometriosis. *J. Med. Genet.* **50**, 43–46 (2013).
- Pearce, C.L. *et al.* Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. *Lancet Oncol.* **13**, 385–394 (2012).
- Tomaselli, S. *et al.* Human *RSP01/R-spondin1* is expressed during early ovary development and augments β -catenin signaling. *PLoS ONE* **6**, e16366 (2011).
- Parma, P. *et al.* R-spondin1 is essential in sex determination, skin differentiation and malignancy. *Nat. Genet.* **38**, 1304–1309 (2006).
- Tomizuka, K. *et al.* R-spondin1 plays an essential role in ovarian development through positively regulating Wnt-4 signaling. *Hum. Mol. Genet.* **17**, 1278–1291 (2008).
- De Ganc, A. *et al.* Multiple isoforms of the tumor suppressor myopodin are simultaneously transcribed in cancer cells. *Biochem. Biophys. Res. Commun.* **370**, 269–273 (2008).
- Jing, L. *et al.* Expression of myopodin induces suppression of tumor growth and metastasis. *Am. J. Pathol.* **164**, 1799–1806 (2004).
- Lin, F. *et al.* Myopodin, a synaptopodin homologue, is frequently deleted in invasive prostate cancers. *Am. J. Pathol.* **159**, 1603–1612 (2001).
- Sanchez-Carbayo, M., Schwarz, K., Charytonowicz, E., Cordon-Cardo, C. & Mundel, P. Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome. *Oncogene* **22**, 5298–5305 (2003).
- Yu, Y.P. & Luo, J.H. Myopodin-mediated suppression of prostate cancer cell migration involves interaction with zyxin. *Cancer Res.* **66**, 7414–7419 (2006).
- Amundadottir, L. *et al.* Genome-wide association study identifies variants in the *ABO* locus associated with susceptibility to pancreatic cancer. *Nat. Genet.* **41**, 986–990 (2009).
- Rummel, S., Shriver, C.D. & Ellsworth, R.E. Relationships between the *ABO* blood group SNP rs505922 and breast cancer phenotypes: a genotype-phenotype correlation study. *BMC Med. Genet.* **13**, 41 (2012).
- Poole, E.M. *et al.* *ABO* blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium. *Cancer Causes Control* **23**, 1805–1810 (2012).
- Sikdar, N. *et al.* DNA damage responses by human ELG1 in S phase are important to maintain genomic integrity. *Cell Cycle* **8**, 3199–3207 (2009).

35. Bell, D.W. *et al.* Predisposition to cancer caused by genetic and functional defects of mammalian Atad5. *PLoS Genet.* **7**, e1002245 (2011).
36. Lee, K.Y. *et al.* Human ELG1 regulates the level of ubiquitinated proliferating cell nuclear antigen (PCNA) through its interactions with PCNA and USP1. *J. Biol. Chem.* **285**, 10362–10369 (2010).
37. Wacholder, S., Han, S.S. & Weinberg, C.R. Inference from a multiplicative model of joint genetic effects for ovarian cancer risk. *J. Natl. Cancer Inst.* **103**, 82–83 (2011).
38. Hnisz, D. *et al.* Super-enhancers in the control of cell identity and disease. *Cell* **155**, 934–947 (2013).

Karoline B Kuchenbaecker^{1,203}, Susan J Ramus^{2,203}, Jonathan Tyrer^{3,203}, Andrew Lee¹, Howard C Shen², Jonathan Beesley⁴, Kate Lawrenson², Lesley McGuffog¹, Sue Healey⁴, Janet M Lee², Tassja J Spindler², Yvonne G Lin⁵, Tanja Pejovic^{6,7}, Yukie Bean^{6,7}, Qiyuan Li⁸, Simon Coetzee^{9–11}, Dennis Hazelett^{2,12}, Alexander Miron¹³, Melissa Southey¹⁴, Mary Beth Terry¹⁵, David E Goldgar¹⁶, Sandra S Buys¹⁷, Ramunas Janavicius^{18,19}, Cecilia M Dorfling²⁰, Elizabeth J van Rensburg²⁰, Susan L Neuhausen²¹, Yuan Chun Ding²¹, Thomas V O Hansen²², Lars Jønson²², Anne-Marie Gerdes²³, Bent Ejlersen²⁴, Daniel Barrowdale¹, Joe Dennis^{1,3}, Javier Benitez^{25–27}, Ana Osorio^{25,27}, Maria Jose Garcia^{25,27}, Ian Komenaka²⁸, Jeffrey N Weitzel²⁹, Pamela Ganschow³⁰, Paolo Peterlongo³¹, Loris Bernard^{32,33}, Alessandra Viel³⁴, Bernardo Bonanni³⁵, Bernard Peissel³⁶, Siranoush Manoukian³⁶, Paolo Radice³⁷, Laura Papi³⁸, Laura Ottini³⁹, Florentia Fostira⁴⁰, Irene Konstantopoulou⁴⁰, Judy Garber⁴¹, Debra Frost¹, Jo Perkins¹, Radka Platte¹, Steve Ellis¹, EMBRACE⁴², Andrew K Godwin⁴³, Rita Katharina Schmutzler^{44–47}, Alfons Meindl⁴⁸, Christoph Engel⁴⁹, Christian Sutter⁵⁰, Olga M Sinilnikova^{51,52}, GEMO Study Collaborators⁴², Francesca Damiola⁵¹, Sylvie Mazoyer⁵¹, Dominique Stoppa-Lyonnet^{53–55}, Kathleen Claes⁵⁶, Kim De Leeneer⁵⁶, Judy Kirk⁵⁷, Gustavo C Rodriguez⁵⁸, Marion Piedmonte⁵⁹, David M O'Malley⁶⁰, Miguel de la Hoya⁶¹, Trinidad Caldes⁶¹, Kristiina Aittomäki⁶², Heli Nevanlinna⁶³, J Margriet Collée⁶⁴, Matti A Rookus⁶⁵, Jan C Oosterwijk⁶⁶, Breast Cancer Family Registry⁴², Laima Tihomirova⁶⁷, Nadine Tung⁶⁸, Ute Hamann⁶⁹, Claudine Isacs⁷⁰, Marc Tischkowitz⁷¹, Evgeny N Imyanitov⁷², Maria A Caligo⁷³, Ian G Campbell⁷⁴, Frans B L Hogervorst⁷⁵, HEBON⁴², Edith Olah⁷⁶, Orland Diez⁷⁷, Ignacio Blanco⁷⁸, Joan Brunet⁷⁹, Conxi Lazaro⁸⁰, Miquel Angel Pujana⁸⁰, Anna Jakubowska⁸¹, Jacek Gronwald⁸¹, Jan Lubinski⁸¹, Grzegorz Sukiennicki⁸¹, Rosa B Barkardottir⁸², Marie Plante⁸³, Jacques Simard⁸⁴, Penny Soucy⁸⁴, Marco Montagna⁸⁵, Silvia Tognazzo⁸⁵, Manuel R Teixeira^{86,87}, KConFab Investigators⁴², Vernon S Pankratz⁸⁸, Xianshu Wang⁸⁹, Noralane Lindor⁸⁸, Csilla I Szabo⁹⁰, Noah Kauff⁹¹, Joseph Vijai⁹¹, Carol A Aghajanian⁹¹, Georg Pfeiler⁹², Andreas Berger⁹², Christian F Singer⁹², Muy-Kheng Tea⁹², Catherine M Phelan⁹³, Mark H Greene⁹⁴, Phuong L Mai⁹⁴, Gad Rennert⁹⁵, Anna Marie Mulligan^{96,97}, Sandrine Tchatchou⁹⁸, Irene L Andrulis^{96,99}, Gord Glendon⁹⁸, Amanda Ewart Toland¹⁰⁰, Uffe Birk Jensen¹⁰¹, Torben A Kruse¹⁰², Mads Thomassen¹⁰², Anders Bojesen¹⁰³, Jamal Zidan¹⁰⁴, Eitan Friedman¹⁰⁵, Yael Laitman¹⁰⁵, Maria Soller¹⁰⁶, Annelie Liljegren¹⁰⁷, Brita Arver¹⁰⁷, Zakaria Einbeigi¹⁰⁸, Marie Stenmark-Askmal¹⁰⁹, Olufunmilayo I Olopade¹¹⁰, Robert L Nussbaum¹¹¹, Timothy R Rebbeck¹¹², Katherine L Nathanson¹¹², Susan M Domchek¹¹², Karen H Lu¹¹³, Beth Y Karlan¹¹⁴, Christine Walsh¹¹⁴, Jenny Lester¹¹⁴, Australian Cancer Study (Ovarian Cancer Investigators)⁴², Australian Ovarian Cancer Study Group⁴², Alexander Hein¹¹⁵, Arif B Ekici¹¹⁶, Matthias W Beckmann¹¹⁵, Peter A Fasching^{115,117}, Diether Lambrechts^{118,119}, Els Van Nieuwenhuysen¹²⁰, Ignace Vergote¹²⁰, Sandrina Lambrechts¹²⁰, Ed Dicks³, Jennifer A Doherty¹²¹, Kristine G Wicklund¹²², Mary Anne Rossing^{122,123}, Anja Rudolph¹²⁴, Jenny Chang-Claude¹²⁴, Shan Wang-Gohrke¹²⁵, Ursula Eilber¹²⁴, Kirsten B Moysich¹²⁶, Kunle Odunsi¹²⁷, Lara Sucheston¹²⁶, Shashi Lele¹²⁶, Lynne R Wilkens¹²⁸, Marc T Goodman^{129,130}, Pamela J Thompson^{129,130}, Yurii B Shvetsov¹²⁸, Ingo B Runnebaum¹³¹, Matthias Dürst¹³¹, Peter Hillemanns¹³², Thilo Dörk¹³³, Natalia Antonenkova¹³⁴, Natalia Bogdanova¹³³, Arto Leminen⁶³, Liisa M Peltari⁶³, Ralf Butzow^{63,135}, Francesmary Modugno^{136–139}, Joseph L Kelley¹³⁷, Robert P Edwards^{137,138}, Roberta B Ness¹⁴⁰, Andreas du Bois^{141,142}, Florian Heitz^{141,142}, Ira Schwaab¹⁴³, Philipp Harter^{141,142}, Keitaro Matsuo¹⁴⁴, Satoyo Hosono¹⁴⁵, Sandra Orsulic¹¹⁴, Allan Jensen¹⁴⁶, Susanne Kruger Kjaer^{146,147}, Estrid Hogdall^{146,148}, Hanis Nazihah Hasmad¹⁴⁹, Mat Adenan Noor Azmi¹⁵⁰, Soo-Hwang Teo^{149,151}, Yin-Ling Woo^{150,151}, Brooke L Fridley¹⁵², Ellen L Goode⁸⁸, Julie M Cunningham⁸⁹, Robert A Vierkant¹⁵³, Fiona Bruinsma¹⁵⁴, Graham G Giles¹⁵⁴, Dong Liang¹⁵⁵, Michelle A T Hildebrandt¹⁵⁶, Xifeng Wu¹⁵⁶, Douglas A Levine¹⁵⁷, Maria Bisogna¹⁵⁷, Andrew Berchuck¹⁵⁸, Edwin S Iversen¹⁵⁹, Joellen M Schildkraut^{160,161}, Patrick Concannon^{162,163}, Rachel Palmieri Weber¹⁶¹, Daniel W Cramer^{164,165}, Kathryn L Terry^{164,165}, Elizabeth M Poole^{166,167}, Shelley S Tworoger^{166,167}, Elisa V Bandera¹⁶⁸, Irene Orlow¹⁶⁹, Sara H Olson¹⁶⁹, Camilla Krakstad^{170,171}, Helga B Salvesen^{170,171}, Ingvild L Tangen^{170,171}, Line Bjorge^{170,171}, Anne M van Altena¹⁷², Katja K H Aben^{173,174}, Lambertus A Kiemeny^{174,175}, Leon F A G Massuger¹⁷²,

Melissa Kellar^{6,7}, Angela Brooks-Wilson^{176,177}, Linda E Kelemen¹⁷⁸, Linda S Cook¹⁷⁹, Nhu D Le¹⁸⁰, Cezary Cybulski¹⁸¹, Hannah Yang¹⁸², Jolanta Lissowska¹⁸³, Louise A Brinton¹⁸², Nicolas Wentzensen¹⁸², Claus Hogdall¹⁴⁷, Lene Lundvall¹⁴⁷, Lotte Nedergaard¹⁸⁴, Helen Baker³, Honglin Song³, Diana Eccles¹⁸⁵, Ian McNeish¹⁸⁶, James Paul¹⁸⁷, Karen Carty¹⁸⁷, Nadeem Siddiqui¹⁸⁸, Rosalind Glasspool¹⁸⁷, Alice S Whittemore¹⁸⁹, Joseph H Rothstein¹⁸⁹, Valerie McGuire¹⁸⁹, Weiva Sieh¹⁸⁹, Bu-Tian Ji¹⁸², Wei Zheng¹⁹⁰, Xiao-Ou Shu¹⁹⁰, Yu-Tang Gao¹⁹¹, Barry Rosen^{192,193}, Harvey A Risch¹⁹⁴, John R McLaughlin¹⁹⁵, Steven A Narod¹⁹⁶, Alvaro N Monteiro⁹³, Ann Chen¹⁹⁷, Hui-Yi Lin¹⁹⁷, Jenny Permuth-Wey⁹³, Thomas A Sellers⁹³, Ya-Yu Tsai⁹³, Zhihua Chen¹⁹⁷, Argyrios Ziogas¹⁹⁸, Hoda Anton-Culver¹⁹⁸, Aleksandra Gentry-Maharaj¹⁹⁹, Usha Menon¹⁹⁹, Patricia Harrington³, Alice W Lee², Anna H Wu², Celeste L Pearce², Gerry Coetzee^{2,12}, Malcolm C Pike^{2,200}, Agnieszka Dansonka-Mieszkowska²⁰¹, Agnieszka Timorek²⁰², Iwona K Rzepecka²⁰¹, Jolanta Kupryjanczyk²⁰¹, Matt Freedman⁸, Houtan Noushmehr⁹, Douglas F Easton¹, Kenneth Offit⁹¹, Fergus J Couch^{88,89}, Simon Gayther², Paul P Pharoah³, Antonis C Antoniou^{1,204} & Georgia Chenevix-Trench^{4,204} for the Consortium of Investigators of Modifiers of *BRCA1* and *BRCA2*⁴²

¹Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. ²Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA. ³Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK. ⁴Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. ⁵Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, California, USA. ⁶Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, Oregon, USA. ⁷Knight Cancer Institute, Portland, Oregon, USA. ⁸Department of Medical Oncology, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. ⁹Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil. ¹⁰Center for Cell-Based Therapy, Monte Alegre, Ribeirão Preto, Brazil. ¹¹Center for Integrative Systems Biology, Monte Alegre, Ribeirão Preto, Brazil. ¹²Department of Urology, University of Southern California, Los Angeles, California, USA. ¹³Department of Genomics and Genome Sciences, Case Western Reserve University Medical School, Cleveland, Ohio, USA. ¹⁴Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Parkville, Victoria, Australia. ¹⁵Department of Epidemiology, Columbia University, New York, New York, USA. ¹⁶Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah, USA. ¹⁷Department of Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, USA. ¹⁸Department of Molecular and Regenerative Medicine, Hematology, Oncology and Transfusion Medical Center, Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania, Vilnius University Hospital Santariskiu Clinics, Hematology, Oncology and Transfusion Medicine Center, Department of Molecular and Regenerative Medicine, Vilnius, Lithuania. ¹⁹State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania. ²⁰Department of Genetics, University of Pretoria, Pretoria, South Africa. ²¹Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California, USA. ²²Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. ²³Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. ²⁴Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. ²⁵Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Centre (CNIO), Madrid, Spain. ²⁶Human Genotyping Unit (CEGEN), Human Cancer Genetics Program, Spanish National Cancer Centre (CNIO), Madrid, Spain. ²⁷Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain. ²⁸Maricopa Medical Center, care of City of Hope Clinical Cancer Genetics Community Research Network, Duarte, California, USA. ²⁹Clinical Cancer Genetics, for the City of Hope Clinical Cancer Genetics Community Research Network, Duarte, California, USA. ³⁰Cook County Health and Hospital System, care of City of Hope Clinical Cancer Genetics Community Research Network, Duarte, California, USA. ³¹Fondazione Istituto FIRC (Italian Foundation for Cancer Research) di Oncologia Molecolare (IFOM), Milan, Italy. ³²Department of Experimental Oncology, Istituto Europeo di Oncologia, Milan, Italy. ³³Cogentech Cancer Genetic Test Laboratory, Milan, Italy. ³⁴Division of Experimental Oncology, CRO (Centro di Riferimento Oncologico) Aviano National Cancer Institute, Aviano, Italy. ³⁵Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, Milan, Italy. ³⁶Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico (Italian Research Hospital)) Istituto Nazionale Tumori (INT), Milan, Italy. ³⁷Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy. ³⁸Unit of Medical Genetics, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy. ³⁹Department of Molecular Medicine, University La Sapienza, Rome, Italy. ⁴⁰Molecular Diagnostics Laboratory, INRASTES (Institute of Nuclear and Radiological Sciences and Technology), National Centre for Scientific Research 'Demokritos', Aghia Paraskevi Attikis, Athens, Greece. ⁴¹Cancer Risk and Prevention Clinic, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. ⁴²A full list of members appears in the **Supplementary Note**. ⁴³Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA. ⁴⁴Center for Hereditary Breast and Ovarian Cancer, Medical Faculty, University Hospital Cologne, Cologne, Germany. ⁴⁵Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany. ⁴⁶Center for Molecular Medicine Cologne (CMCC), University of Cologne, Cologne, Germany. ⁴⁷On behalf of the German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC). ⁴⁸Department of Gynaecology and Obstetrics, Division of Tumor Genetics, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany. ⁴⁹Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany. ⁵⁰Institute of Human Genetics, University Heidelberg, Heidelberg, Germany. ⁵¹INSERM U1052, CNRS UMR 5286, Université Lyon, Centre de Recherche en Cancérologie de Lyon, Lyon, France. ⁵²Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon—Centre Léon Bérard, Lyon, France. ⁵³Institut Curie, Department of Tumour Biology, Paris, France. ⁵⁴Institut Curie, INSERM U830, Paris, France. ⁵⁵Université Paris Descartes, Sorbonne Paris Cité, Paris, France. ⁵⁶Center for Medical Genetics, Ghent University, Ghent, Belgium. ⁵⁷Australia New Zealand Gynecologic Oncology Group (ANZGOG) and Familial Cancer Service, Westmead Hospital, Sydney, New South Wales, Australia. ⁵⁸Division of Gynecologic Oncology, NorthShore University HealthSystem, Evanston, Illinois, USA. ⁵⁹Gynecologic Oncology Group, Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, New York, USA. ⁶⁰James Cancer Center, Ohio State University, Columbus, Ohio, USA. ⁶¹Molecular Oncology Laboratory, Hospital Clínico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain. ⁶²Department of Clinical Genetics, Helsinki University Central Hospital, Helsinki, Finland. ⁶³Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland. ⁶⁴Department of Clinical Genetics, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, the Netherlands. ⁶⁵Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands. ⁶⁶Department of Genetics, University Medical Center, Groningen University, Groningen, the Netherlands. ⁶⁷Latvian Biomedical Research and Study Centre, Riga, Latvia. ⁶⁸Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. ⁶⁹Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany. ⁷⁰Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. ⁷¹Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada. ⁷²N.N. Petrov Institute of Oncology, St. Petersburg, Russia. ⁷³Section of Genetic Oncology, Department of Laboratory Medicine, University of Pisa and University Hospital of Pisa, Pisa, Italy. ⁷⁴VBCRC (Victorian Breast Cancer Research Consortium) Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. ⁷⁵Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, the Netherlands. ⁷⁶Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary. ⁷⁷Oncogenetics Group, University Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO) and Universitat Autònoma de Barcelona, Barcelona, Spain. ⁷⁸Genetic Counseling Unit, Hereditary Cancer Program, IDIBELL (Bellvitge Biomedical Research Institute)—Catalan Institute of Oncology, Barcelona, Spain. ⁷⁹Genetic Counseling Unit, Hereditary Cancer Program, IDIBGI (Institut d'Investigació Biomèdica de Girona)—Catalan Institute of Oncology, Girona, Spain. ⁸⁰Molecular Diagnostic Unit, Hereditary Cancer Program, IDIBELL—Catalan Institute of Oncology, Barcelona, Spain. ⁸¹Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. ⁸²Department of Pathology, Landspítali University Hospital and Biomedical Centre (BMC), Faculty of Medicine, University of Iceland, Reykjavik, Iceland. ⁸³Gynaecologic Oncology Service, Centre Hospitalier Universitaire de Québec (CHUQ), Québec City, Québec, Canada. ⁸⁴Centre Hospitalier Universitaire de Québec (CHUQ) Research Center, Laval University, Québec City, Québec, Canada. ⁸⁵Immunology and Molecular

Oncology Unit, Istituto Oncologico Veneto (IOV)-IRCCS, Padua, Italy. ⁸⁶Biomedical Sciences Institute (ICBAS), Porto University, Porto, Portugal. ⁸⁷Department of Genetics, Portuguese Oncology Institute, Porto, Portugal. ⁸⁸Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA. ⁸⁹Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. ⁹⁰National Human Genome Research Institute, US National Institutes of Health, Bethesda, Maryland, USA. ⁹¹Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. ⁹²Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. ⁹³Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, USA. ⁹⁴Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Rockville, Maryland, USA. ⁹⁵Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel. ⁹⁶Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. ⁹⁷Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada. ⁹⁸Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada. ⁹⁹Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada. ¹⁰⁰Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus, Ohio, USA. ¹⁰¹Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark. ¹⁰²Department of Clinical Genetics, Odense University Hospital, Odense, Denmark. ¹⁰³Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark. ¹⁰⁴Institute of Oncology, Rivka Ziv Medical Center, Zefat, Israel. ¹⁰⁵Susanne Levy Gertner Oncogenetics Unit, Sheba Medical Center, Tel Aviv, Israel. ¹⁰⁶Department of Clinical Genetics, Lund University Hospital, Lund, Sweden. ¹⁰⁷Department of Oncology, Karolinska University Hospital, Stockholm, Sweden. ¹⁰⁸Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden. ¹⁰⁹Division of Clinical Genetics, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. ¹¹⁰Center for Clinical Cancer Genetics and Global Health, University of Chicago Medical Center, Chicago, Illinois, USA. ¹¹¹Department of Medicine and Genetics, University of California, San Francisco, San Francisco, California, USA. ¹¹²Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. ¹¹³Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. ¹¹⁴Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. ¹¹⁵Department of Obstetrics and Gynecology, Erlangen University Hospital, University of Erlangen-Nuremberg, Erlangen, Germany. ¹¹⁶Institute of Human Genetics, University of Erlangen-Nuremberg, Erlangen, Germany. ¹¹⁷Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA. ¹¹⁸Vesalius Research Center, VIB, Leuven, Belgium. ¹¹⁹Laboratory for Translational Genetics, Department of Oncology, University of Leuven, Leuven, Belgium. ¹²⁰Division of Gynecological Oncology, Department of Oncology, University Hospitals Leuven, Leuven, Belgium. ¹²¹Department of Community and Family Medicine, Section of Biostatistics and Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA. ¹²²Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. ¹²³Department of Epidemiology, University of Washington, Seattle, Washington, USA. ¹²⁴Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. ¹²⁵Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany. ¹²⁶Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York, USA. ¹²⁷Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA. ¹²⁸Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA. ¹²⁹Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. ¹³⁰Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA. ¹³¹Department of Gynecology, Jena University Hospital-Friedrich Schiller University, Jena, Germany. ¹³²Clinics of Obstetrics and Gynaecology, Hannover Medical School, Hannover, Germany. ¹³³Gynaecology Research Unit, Hannover Medical School, Hannover, Germany. ¹³⁴Byelorussian Institute for Oncology and Medical Radiology Aleksandrov N.N., Minsk, Belarus. ¹³⁵Department of Pathology, Helsinki University Central Hospital, Helsinki, Finland. ¹³⁶Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ¹³⁷Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. ¹³⁸Ovarian Cancer Center of Excellence, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ¹³⁹Women's Cancer Research Program, Magee-Women's Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA. ¹⁴⁰University of Texas School of Public Health, Houston, Texas, USA. ¹⁴¹Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany. ¹⁴²Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany. ¹⁴³Institut für Humangenetik Wiesbaden, Wiesbaden, Germany. ¹⁴⁴Department of Preventive Medicine, Kyushu University Faculty of Medical Sciences, Fukuoka, Japan. ¹⁴⁵Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan. ¹⁴⁶Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark. ¹⁴⁷Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. ¹⁴⁸Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark. ¹⁴⁹Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Subang Jaya, Malaysia. ¹⁵⁰Department of Obstetrics and Gynaecology, University Malaya Medical Centre, University Malaya, Kuala Lumpur, Malaysia. ¹⁵¹University Malaya Cancer Research Institute, Faculty of Medicine, University Malaya Medical Centre, University Malaya, Kuala Lumpur, Malaysia. ¹⁵²Biostatistics and Informatics Shared Resource, University of Kansas Medical Center, Kansas City, Kansas, USA. ¹⁵³Department of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA. ¹⁵⁴Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, Australia. ¹⁵⁵College of Pharmacy and Health Sciences, Texas Southern University, Houston, Texas, USA. ¹⁵⁶Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. ¹⁵⁷Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. ¹⁵⁸Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina, USA. ¹⁵⁹Department of Statistical Science, Duke University, Durham, North Carolina, USA. ¹⁶⁰Cancer Control and Population Sciences, Duke Cancer Institute, Durham, North Carolina, USA. ¹⁶¹Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina, USA. ¹⁶²Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida, USA. ¹⁶³Genetics Institute, University of Florida, Gainesville, Florida, USA. ¹⁶⁴Harvard School of Public Health, Boston, Massachusetts, USA. ¹⁶⁵Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. ¹⁶⁶Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. ¹⁶⁷Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. ¹⁶⁸Cancer Prevention and Control, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA. ¹⁶⁹Department of Epidemiology and Biostatistics, Epidemiology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. ¹⁷⁰Centre for Cancer Biomarkers, Department of Clinical Medicine, University of Bergen, Bergen, Norway. ¹⁷¹Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway. ¹⁷²Department of Gynaecology, Radboud University Medical Centre, Nijmegen, the Netherlands. ¹⁷³Comprehensive Cancer Center The Netherlands, Utrecht, the Netherlands. ¹⁷⁴Department for Health Evidence, Radboud University Medical Centre, Nijmegen, the Netherlands. ¹⁷⁵Department of Urology, Radboud University Medical Centre, Nijmegen, the Netherlands. ¹⁷⁶Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. ¹⁷⁷Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, British Columbia, Canada. ¹⁷⁸Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA. ¹⁷⁹Division of Epidemiology and Biostatistics, Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA. ¹⁸⁰Cancer Control Research, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. ¹⁸¹International Hereditary Cancer Center, Department of Genetics and Pathology, Clinic of Ophthalmology, Pomeranian Medical University, Szczecin, Poland. ¹⁸²Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA. ¹⁸³Department of Cancer Epidemiology and Prevention, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. ¹⁸⁴Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. ¹⁸⁵Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK. ¹⁸⁶Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Beatson Institute for Cancer Research, Glasgow, UK. ¹⁸⁷Cancer Research UK Clinical Trials Unit, Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK. ¹⁸⁸Department of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow, UK. ¹⁸⁹Department of Health Research and Policy-Epidemiology, Stanford University School of Medicine, Stanford, California, USA. ¹⁹⁰Vanderbilt University School of Medicine, Nashville, Tennessee, USA. ¹⁹¹Shanghai Cancer Institute, Shanghai, China. ¹⁹²Department of Obstetrics and Gynecology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. ¹⁹³Department of Gynecologic-Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada. ¹⁹⁴Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA. ¹⁹⁵Prosserman Centre for Health Research, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada. ¹⁹⁶Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada. ¹⁹⁷Department of Biostatistics, Moffitt Cancer Center, Tampa, Florida, USA. ¹⁹⁸Department of Epidemiology, University of California-Irvine, Irvine, California, USA. ¹⁹⁹Women's Cancer, University College London Elizabeth Garrett Anderson (EGA) Institute for Women's Health, London, UK. ²⁰⁰Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. ²⁰¹Department of Pathology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. ²⁰²Department of Obstetrics, Gynecology and Oncology, 2nd Faculty of Medicine, Warsaw Medical University and Brodowski Hospital, Warsaw, Poland. ²⁰³These authors contributed equally to this work. ²⁰⁴These authors jointly supervised this work. Correspondence should be addressed to G.C.-T. (georgia.trench@qimrberghofer.edu.au).

ONLINE METHODS

Study populations. We obtained data on *BRCA1* and *BRCA2* mutation carriers through CIMBA. Eligibility in CIMBA is restricted to females 18 years or older with pathogenic mutations in *BRCA1* or *BRCA2*. The majority of the participants were sampled through cancer genetics clinics¹⁵, including some related participants. Fifty-four studies from 27 countries contributed data. After quality control, data were available on 15,252 *BRCA1* mutation carriers and 8,211 *BRCA2* mutation carriers, of whom 2,462 and 631, respectively, were affected with EOC (**Supplementary Table 1**).

Data were available for stage 1 of three population-based EOC GWAS. These included 2,165 cases and 2,564 controls from a GWAS from North America ('US GWAS')³⁹, 1,762 cases and 6,118 controls from a UK-based GWAS ('UK GWAS')⁶, and 441 cases and 441 controls from the Mayo GWAS. Furthermore, 11,069 cases and 21,722 controls were genotyped using the iCOGS array ('OCAC-iCOGS' stage data). Overall, 43 studies from 11 countries provided data on 15,437 women diagnosed with invasive EOC, 9,627 of whom were diagnosed with serous EOC, and 30,845 controls from the general population.

All subjects included in this analysis were of European descent and provided written informed consent as well as data and blood samples under ethically approved protocols. Further details of the OCAC and CIMBA study populations as well as the genotyping, quality control and statistical analyses have been described elsewhere^{7,13,16}.

Genotype data. Genotyping and imputation details for each study are shown in **Supplementary Table 1**.

Confirmatory genotyping of imputed SNPs. To evaluate the accuracy of imputation for the SNPs we found to be associated with EOC risk, we genotyped rs17329882 (4q26) and rs635634 (9q34.2) in a subset of 3,541 subjects from CIMBA using Sequenon's iPLEX technology. The lead SNP at 17q11.2, chr17:29181220:I, failed iPLEX design. We performed quality control of the iPLEX data according to CIMBA guidelines. After quality control, we used the imputation results to generate the expected allele dosage for each genotyped sample and computed the Pearson product-moment correlation coefficient between the expected allele dosage and the observed genotype. The squared correlation coefficient was compared to the imputation accuracy as estimated from the imputation.

Quality control of GWAS and iCOGS genotyping data. We carried out quality control separately for *BRCA1* mutation carriers, *BRCA2* mutation carriers, the three OCAC GWAS and the OCAC-iCOGS samples, but quality criteria were mostly consistent across studies. We excluded samples if they were not of European ancestry, if they had a genotyping call rate of <95%, if they showed low or high heterozygosity, if they were not female or had ambiguous sex or if they were duplicates (cryptic or intended). In the OCAC studies, one individual was excluded from each pair of samples found to be first-degree relatives, and duplicate samples between the iCOGS stage and any of the GWAS were excluded from the iCOGS data. SNPs were excluded if they were monomorphic, had a call rate of <95%, showed evidence of deviation from Hardy-Weinberg equilibrium or had low concordance between duplicate pairs. For the Mayo GWAS and the UK GWAS, we also excluded rare SNPs (MAF < 1% or allele count < 5, respectively). We visually inspected genotype cluster plots for all SNPs with association $P < 1 \times 10^{-5}$ from each of the newly identified loci. We used the R GenABEL library version 1.6.7 for quality control.

Genotype data were available for analysis from iCOGS for 199,526 SNPs in OCAC-iCOGS samples, 200,720 SNPs in *BRCA1* mutation carriers and 200,908 SNPs in *BRCA2* mutation carriers. After quality control, for the GWAS, data were available on 492,956 SNPs for the US GWAS, 543,529 SNPs for the UK GWAS and 1,587,051 SNPs for the Mayo GWAS (**Supplementary Table 2**).

Imputation. We performed imputation separately for *BRCA1* mutation carriers, *BRCA2* mutation carriers, OCAC-iCOGS samples and each of the OCAC GWAS. We imputed variants from 1000 Genomes Project data using the v3 April 2012 release¹⁷ as the reference panel. For OCAC-iCOGS samples, the UK GWAS and the Mayo GWAS, imputation was based on the 1000 Genomes

Project data with singleton sites removed. To improve computation efficiency, we initially used a two-step procedure, which involved pre-phasing in the first step and imputation of the phased data in the second step. We carried out pre-phasing using SHAPEIT software⁴⁰. We used IMPUTE version 2 software for the subsequent imputation⁴¹ for all studies with the exception of the US GWAS, for which the MACH algorithm implemented in Minimac software version 2012.8.15, MACH version 1.0.18, was used. To perform imputation, we divided the data into segments of approximately 5 Mb each. We excluded SNPs from the association analysis if their imputation accuracy was $r^2 < 0.3$, their MAF was <0.005 in *BRCA1* or *BRCA2* mutation carriers or their accuracy was $r^2 < 0.25$ in OCAC-iCOGS samples, the UK GWAS, the US GWAS or the Mayo GWAS.

We performed more accurate imputation for the regions around the new EOC loci from the joint analysis of the data from *BRCA1* and *BRCA2* mutation carriers and the general population (any SNP with association $P < 5 \times 10^{-8}$). The boundaries of these regions were set 500 kb away from any significantly associated SNP in the region. As in the first run, 1000 Genomes Project data v3 were used as the reference panel, and IMPUTE2 software was applied. However, for the second round of imputation, we imputed genotypes without pre-phasing to improve accuracy. To further increase imputation accuracy, we changed some of the default parameters in the imputation procedure. These included an increase in the MCMC iterations to 90 (out of which the first 15 were used as burn-in), an increase in the buffer region to 500 kb and an increase in the number of haplotypes used as templates when phasing observed genotypes to 100. These changes were applied consistently for all data sets.

Statistical analyses. Association analyses in the unselected ovarian cancer cases and controls from OCAC. We evaluated the association between genotype and disease using logistic regression by estimating the associations with each additional copy of the minor allele (log-additive models). The analysis was adjusted for study and for population substructure by including the eigenvectors of the first five ancestry-specific principal components as covariates in the model. We used the same approach to evaluate SNP associations with serous ovarian cancer after excluding all cases with any other or unknown tumor subtype. For imputed SNPs, we used expected dosages in the logistic regression model to estimate SNP effect sizes and P values. We carried out analyses separately for OCAC-iCOGS samples and the three GWAS and pooled data thereafter using a fixed-effects meta-analysis. We carried out the analysis of reimputed genotypes for putative new susceptibility loci jointly for the OCAC-iCOGS samples and the GWAS samples. All results are based on the combined data from iCOGS and the three GWAS. We used custom written software for the analysis.

Associations in *BRCA1* and *BRCA2* mutation carriers from CIMBA. We carried out the ovarian cancer association analyses separately for *BRCA1* and *BRCA2* mutation carriers. The primary analysis was carried out within a survival analysis framework, with time to ovarian cancer diagnosis as the endpoint. Mutation carriers were followed until the age of ovarian cancer diagnosis or risk-reducing salpingo-oophorectomy (RRSO) or to the age at last observation. Breast cancer diagnosis was not considered to be a censoring event. To account for the non-random sampling of *BRCA1* and *BRCA2* mutation carriers with respect to their disease status, we conducted the analyses by modeling the retrospective likelihood of the observed genotypes conditional on the disease phenotype¹⁸. We assessed the associations between genotype and risk of ovarian cancer using the 1-degree-of-freedom score test statistic based on retrospective likelihood^{18,42}. To account for the non-independence among related individuals in the sample, we used an adjusted version of the score test statistic, which uses a kinship-adjusted variance of the score⁴³. We evaluated associations between imputed genotypes and ovarian cancer risk using a version of the score test as described above but with the posterior genotype probabilities replacing the genotypes. All analyses were stratified by the country of origin of the samples.

We carried out retrospective likelihood analyses in CIMBA using custom written functions in Fortran and Python. The score test statistic was implemented in R version 3.0.1 (ref. 44).

We evaluated whether there was evidence for multiple independent association signals in the region around each newly identified locus by evaluating the associations of genetic variants in the region while adjusting for the SNP with the smallest meta-analysis P value in the

respective region. This was done separately for *BRCA1* mutation carriers, *BRCA2* mutation carriers and OCAC samples.

For one of the new associations, it was not possible to confirm the imputation accuracy of the lead SNP chr17:29181220:1 at 17q11.2 through genotyping. Therefore, we inferred two-allele haplotypes for rs9910051 and rs3764419, highly correlated with the lead SNP ($r^2 = 0.95$), using an in-house program. These variants were genotyped on the iCOGS array, and this analysis was therefore restricted to 14,733 ovarian cancer cases and 9,165 controls from OCAC-COGS and 8,185 *BRCA2* mutation carriers for whom genotypes were available for both variants based on iCOGS. The association between the AA haplotype and risk was tested using logistic regression in OCAC samples and using Cox regression in *BRCA2* mutation carriers.

Meta-analysis. We conducted a meta-analysis of the EOC associations in *BRCA1* mutation carriers, *BRCA2* mutation carriers and the general population for genotyped and imputed SNPs using an inverse variance approach assuming fixed effects. We combined the logarithm of the per-allele HR estimate for the association with EOC risk in *BRCA1* and *BRCA2* mutation carriers and the logarithm of the per-allele OR estimate for the association with disease status in OCAC. For associations in *BRCA1* and *BRCA2* carriers, we used the kinship-adjusted variance estimator⁴³, which allows for the inclusion of related individuals in the analysis. We only used SNPs with results in OCAC and in at least one of the *BRCA1* or the *BRCA2* analyses. We carried out two separate meta-analyses, one for the associations with EOC in *BRCA1* mutation carriers, *BRCA2* mutation carriers and EOC samples in OCAC, irrespective of tumor histological subtype, and a second using only the associations with serous EOC in OCAC samples. The number of *BRCA1* and *BRCA2* mutation carriers with tumor histology information was too small to allow for subgroup analyses. However, previous studies have demonstrated that the majority of EOCs in *BRCA1* and *BRCA2* mutation carriers are high-grade serous^{45–49}. Meta-analyses were carried out using Meta software, 2011-03-25 release⁵⁰.

Candidate causal SNPs in each susceptibility region. To identify a set of potentially causal variants, we excluded SNPs with a likelihood of being causal of less than 1:100, by comparing the likelihood of each SNP from the association analysis with the likelihood of the most strongly associated SNPs⁵¹. The remaining variants were then analyzed using Pupasuite 3.1 to identify potentially functional variants^{52,53} (**Supplementary Table 9**).

Functional analysis. *Expression quantitative trait locus analysis in normal ovarian and fallopian tube cells.* Early-passage primary normal ovarian surface epithelial cells (OSECs) and fallopian tube epithelial cells were collected from disease-free ovaries and fallopian tubes. Normal ovarian epithelial cells were collected by brushing the surface of the ovary with a sterile cytobrush and were cultured in NOSE-CM⁵⁴. Fallopian tube epithelial cells were collected by Pronase digestion as previously described⁵⁵, plated onto collagen-coated plastics (Sigma) and cultured in DMEM/F12 (Sigma-Aldrich) supplemented with 2% Ultrosor G (BioSeptra) and 1× penicillin-streptomycin (Lonza). By the time of RNA isolation, the fallopian tube cultures tested consisted of PAX8-positive fallopian tube secretory epithelial cells (FTSECs), consistent with previous observations that ciliated epithelial cells from the fallopian tube do not proliferate *in vitro*. Cell lines were routinely tested for mycoplasma.

For gene expression analysis, RNA was isolated from 59 early-passage samples: 54 OSECs and 5 FTSECs from cell cultures collected at ~80% confluency using the Qiagen miRNAeasy kit with on-column DNase I digestion. RNA (500 ng) was reverse transcribed using the Superscript III kit (Life Technologies). We preamplified 10 ng of cDNA using TaqMan Preamp Mastermix; the resulting product was diluted 1:60 and used to quantify gene expression with the following TaqMan gene expression probes: *WNT4*, Hs01573504_m1; *RSPO1*, Hs00543475_m1; *SYNPO2*, Hs00326493_m1; *ATAD5*, Hs00227495_m1; and *GPX6*, Hs00699698_m1. Four control genes were also included: *ACTB*, Hs00357333_g1; *GAPDH*, Hs02758991_g1; *HMBS*, Hs00609293_g1; and *HPRT1*, Hs02800695_m1 (all Life Technologies). Assays were run on an ABI 7900HT Fast Real-Time PCR system (Life Technologies).

Data analysis. Expression levels for each gene were normalized to the average of all four control genes. Relative expression levels were calculated using the $\Delta\Delta C_t$ method. Genotyping was performed on the iCOGS chips, as described above. Where genotyping data were not available for the most

risk-associated SNP, the next most significant SNP was used: rs3820282 at 1p36, rs12023270 at 1p34.3, rs752097 at 4q26, rs445870 at 6p22.1, rs505922 at 9q34.2 and rs3764419 at 17q11.2. Correlations between genotype and gene expression were calculated in R. Genotype-specific gene expression in normal tissue cell lines (eQTL analysis) was compared using the Jonckheere-Terpstra test. Data were normalized to the four control genes, and we tested for eQTL associations, grouping OSECs and FTSECs together. Second, OSECs were analyzed alone. eQTL analyses were performed using three genotype groups or two groups (with the rare homozygote samples grouped together with the heterozygote samples).

eQTL analysis in primary ovarian tumors. eQTL analysis in primary tumors was based on publicly available data from the TCGA Project, which included 489 primary HGSOs. The methods have been described elsewhere⁵⁶. Briefly, we determined the ancestry for each case on the basis of germline genotype data using EIGENSTRAT software with 415 HapMap genotype profiles as a control set. Only populations of northern and western European ancestry were included. We first performed a *cis*-eQTL analyses using a method we described previously, in which the association between 906,600 germline genotypes and the expression levels of mRNA or miRNA (located within 500 kb on either side of the variant) were evaluated using a linear regression model with the effects of somatic copy number and CpG methylation being deducted. (For miRNA expression, the effect of CpG methylation was not adjusted for because these data were not available.) To correct for multiple tests, we adjusted the test *P* values using the Benjamini-Hochberg method. A significant association was defined by a false discovery rate (FDR) of <0.1.

Having established genome-wide *cis*-eQTL associations in this series of tumors, we then evaluated *cis*-eQTL associations for the top risk associations between each of the six new loci and the gene in closest proximity to the risk SNP. For each risk locus, we retrieved the genotype of all SNPs in ovarian cancer cases on the basis of the Affymetrix 6.0 array. Using these genotypes and the IMPUTE2 March 2012 1000 Genomes Project Phase I integrated variant cosmopolitan reference panel of 1,092 individuals (haplotypes were phased via SHAPEIT), we imputed the genotypes of SNPs in the 1000 Genomes Project in the target regions for TCGA samples⁵⁷. For each risk locus where data for the most risk-associated variant were not available, we retrieved the imputed variants tightly correlated with the most risk-associated variant. We then tested for association between imputed SNPs and gene expression using the linear regression algorithm described above, where each imputed SNP was coded as an expected allele count. Again, significant associations were defined by an FDR of <0.1.

Regulatory profiling of normal ovarian cancer precursor tissues. We performed genome-wide FAIRE and chromatin immunoprecipitation with sequencing (ChIP-seq) for H3K27ac and H3K4me in two normal OSECs, two normal FTSECs and two HGSO cell lines (UWB1.289 and CAO3) (S.C., H.S., D.H., K.L. and K.B.K. *et al.*, unpublished data). Cell lines were routinely tested for mycoplasma. These data sets annotate the epigenetic signatures of open chromatin and collectively indicate transcriptional enhancer regions. We analyzed the FAIRE-seq and ChIP-seq data sets and publically available genomic data on promoter and UTR domains, intron-exon boundaries and the positions of noncoding RNA transcripts to identify SNPs from the 100:1 likely causal set that aligned with biofeatures that might provide evidence of SNP functionality.

Candidate gene analysis using genome-wide profiling of primary ovarian cancers. *Data sets: the TCGA Project and COSMIC data sets.* TCGA has performed extensive genomic analysis of tumors from a large number of tissue types, including almost 500 high-grade serous ovarian tumors. These data include somatic mutations, DNA copy number, mRNA and miRNA expression, and DNA methylation. COSMIC is the catalog of somatic mutations in cancer that collates information on mutations in tumors from the published literature⁵⁸. They have also identified the Cancer Gene Census, which is a list of genes known to be involved in cancer. Data are available on a large number of tissue types, including 2,809 epithelial ovarian tumors.

Somatic coding sequence mutations. We analyzed all genes for coding somatic sequence mutations generated from either whole-exome or whole-genome sequencing. In TCGA, whole-exome sequencing data were available for 316 high-grade serous EOC cases. In addition, we determined whether mutations had been reported in COSMIC⁵⁸ and whether the gene was a known cancer gene in the Sanger Cancer Gene Census.

mRNA expression in tumor and normal tissue. Normalized and gene expression values (level 3) from gene expression profiling data were obtained from the TCGA data portal for three different platforms (Agilent, Affymetrix HuEx and Affymetrix U133A). We analyzed only the 489 primary serous ovarian tumor samples included in the final clustering analysis⁵⁷ and 8 normal fallopian tube samples. The boxplot function in R was used to compare ovarian tumor samples to the fallopian tube samples for 91 coding genes with expression data on any platform within a 1-Mb region around the most significant SNP at the 6 loci. A difference in relative expression between EOC samples and normal tissue was analyzed using the Wilcoxon rank-sum test.

DNA copy number analysis. Serous EOC samples for 481 tumors with log₂ copy number data were analyzed using the cBio Portal for the analysis of TCGA data^{59,60}. For each gene in a region, the classes of copy number; homozygous deletion, heterozygous loss, diploid, gain and amplification were queried individually using the advanced onco query language (OQL) option. At a region, the frequency of gain and amplification were combined as 'gain', and homozygous deletion and heterozygous loss were combined as 'loss'.

Analysis of copy number versus mRNA expression. Serous EOC samples for 316 complete tumors (those with CNA, mRNA and sequencing data) were analyzed. Graphs were generated using the cBio Portal for the analysis of TCGA data, and the settings were mRNA expression data z score (all genes) with a z-score threshold of 2 (default setting) and putative CNAs (GISTIC). The z score was the number of s.d. away from the mean of expression in the reference population. GISTIC is an algorithm that attempts to identify significantly altered regions of amplification or deletion across sets of patients.

Luciferase reporter assays. The putative causal SNPs at the 1p36 locus lie in the *WNT4* promoter, and we therefore tested their effect on transcription in a luciferase reporter assay (Fig. 2d). Wild-type and risk haplotype (comprising five correlated variants) sequences corresponding to the region bound by hg19 coordinates chr. 1: 22,469,416–22,470,869 were generated by Custom Gene Synthesis (GenScript) and then subcloned into pGL3-basic (Promega). Equimolar amounts of luciferase constructs (800 ng) and pRL-TK *Renilla* (50 ng) were cotransfected into $\sim 8 \times 10^4$ iOSE4 (ref. 61) normal ovarian cells in triplicate wells of 24-well plates using Lipofectamine 2000 (Life Technologies). Independent transfections were repeated three times. The Dual-Glo Luciferase Assay kit (Promega) was used to assay luciferase activity 24 h after transfection using a BioTek Synergy H4 plate reader. Statistical significance was tested by log transforming the data and performing two-way ANOVA, followed by Dunnett's multiple-comparisons test in GraphPad Prism. The iOSE4 cell line (derived by K. Lawrenson) was maintained under standard conditions; it was routinely tested for mycoplasma and underwent short tandem repeat profiling.

39. Permut-Wey, J. *et al.* *LIN28B* polymorphisms influence susceptibility to epithelial ovarian cancer. *Cancer Res.* **71**, 3896–3903 (2011).
40. Delaneau, O., Marchini, J. & Zagury, J.F. A linear complexity phasing method for thousands of genomes. *Nat. Methods* **9**, 179–181 (2012).
41. Howie, B.N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet.* **5**, e1000529 (2009).
42. Antoniou, A.C. *et al.* *RAD51* 135G→C modifies breast cancer risk among *BRCA2* mutation carriers: results from a combined analysis of 19 studies. *Am. J. Hum. Genet.* **81**, 1186–1200 (2007).
43. Antoniou, A.C. *et al.* A locus on 19p13 modifies risk of breast cancer in *BRCA1* mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nat. Genet.* **42**, 885–892 (2010).
44. *R: A Language and Environment for Statistical Computing v. 3.0.1* (R Foundation for Statistical Computing, 2013).
45. Mavaddat, N. *et al.* Pathology of breast and ovarian cancers among *BRCA1* and *BRCA2* mutation carriers: results from the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA). *Cancer Epidemiol. Biomarkers Prev.* **21**, 134–147 (2012).
46. Lakhani, S.R. *et al.* Pathology of ovarian cancers in *BRCA1* and *BRCA2* carriers. *Clin. Cancer Res.* **10**, 2473–2481 (2004).
47. Rubin, S.C. *et al.* Clinical and pathological features of ovarian cancer in women with germ-line mutations of *BRCA1*. *N. Engl. J. Med.* **335**, 1413–1416 (1996).
48. Maehle, L. *et al.* High risk for ovarian cancer in a prospective series is restricted to *BRCA1/2* mutation carriers. *Clin. Cancer Res.* **14**, 7569–7573 (2008).
49. Shaw, P.A. *et al.* Histopathologic features of genetically determined ovarian cancer. *Int. J. Gynecol. Pathol.* **21**, 407–411 (2002).
50. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genome-wide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
51. Udler, M.S., Tyrer, J. & Easton, D.F. Evaluating the power to discriminate between highly correlated SNPs in genetic association studies. *Genet. Epidemiol.* **34**, 463–468 (2010).
52. Reumers, J. *et al.* Joint annotation of coding and non-coding single nucleotide polymorphisms and mutations in the SNPeff and PupaSuite databases. *Nucleic Acids Res.* **36**, D825–D829 (2008).
53. Conde, L. *et al.* PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. *Nucleic Acids Res.* **34**, W621–W625 (2006).
54. Li, N.F. *et al.* A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells *in vitro*. *Lab. Invest.* **84**, 923–931 (2004).
55. Fotheringham, S., Levanon, K. & Drapkin, R. *Ex vivo* culture of primary human fallopian tube epithelial cells. *J. Vis. Exp.* **51**, 2728 (2011).
56. Li, Q. *et al.* Expresson QTL-based analyses reveal candidate causal genes and loci across five tumor types. *Hum. Mol. Genet.* **23**, 5294–5302 (2014).
57. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. *Nature* **474**, 609–615 (2011).
58. Forbes, S.A. *et al.* The Catalogue of Somatic Mutations in Cancer (COSMIC). *Curr. Protoc. Hum. Genet.* Chapter 10, Unit 10.11 (2008).
59. Gao, J. *et al.* Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci. Signal.* **6**, p11 (2013).
60. Cerami, E. *et al.* The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* **2**, 401–404 (2012).
61. Lawrenson, K. *et al.* Senescent fibroblasts promote neoplastic transformation of partially transformed ovarian epithelial cells in a three-dimensional model of early stage ovarian cancer. *Neoplasia* **12**, 317–325 (2010).

Original Investigation

Association of Type and Location of *BRCA1* and *BRCA2* Mutations With Risk of Breast and Ovarian Cancer

Timothy R. Rebbeck, PhD; Nandita Mitra, PhD; Fei Wan, MS; Olga M. Sinilnikova, PhD[†]; Sue Healey; Lesley McGuffog; Sylvie Mazoyer, PhD; Georgia Chenevix-Trench, PhD; Douglas F. Easton, PhD; Antonis C. Antoniou, PhD; Katherine L. Nathanson, MD; and the CIMBA Consortium

IMPORTANCE Limited information about the relationship between specific mutations in *BRCA1* or *BRCA2* (*BRCA1/2*) and cancer risk exists.

OBJECTIVE To identify mutation-specific cancer risks for carriers of *BRCA1/2*.

DESIGN, SETTING, AND PARTICIPANTS Observational study of women who were ascertained between 1937 and 2011 (median, 1999) and found to carry disease-associated *BRCA1* or *BRCA2* mutations. The international sample comprised 19 581 carriers of *BRCA1* mutations and 11 900 carriers of *BRCA2* mutations from 55 centers in 33 countries on 6 continents. We estimated hazard ratios for breast and ovarian cancer based on mutation type, function, and nucleotide position. We also estimated RHR, the ratio of breast vs ovarian cancer hazard ratios. A value of RHR greater than 1 indicated elevated breast cancer risk; a value of RHR less than 1 indicated elevated ovarian cancer risk.

EXPOSURES Mutations of *BRCA1* or *BRCA2*.


MAIN OUTCOMES AND MEASURES Breast and ovarian cancer risks.

RESULTS Among *BRCA1* mutation carriers, 9052 women (46%) were diagnosed with breast cancer, 2317 (12%) with ovarian cancer, 1041 (5%) with breast and ovarian cancer, and 7171 (37%) without cancer. Among *BRCA2* mutation carriers, 6180 women (52%) were diagnosed with breast cancer, 682 (6%) with ovarian cancer, 272 (2%) with breast and ovarian cancer, and 4766 (40%) without cancer. In *BRCA1*, we identified 3 breast cancer cluster regions (BCCRs) located at c.179 to c.505 (BCCR1; RHR = 1.46; 95% CI, 1.22-1.74; $P = 2 \times 10^{-6}$), c.4328 to c.4945 (BCCR2; RHR = 1.34; 95% CI, 1.01-1.78; $P = .04$), and c. 5261 to c.5563 (BCCR2', RHR = 1.38; 95% CI, 1.22-1.55; $P = 6 \times 10^{-9}$). We also identified an ovarian cancer cluster region (OCCR) from c.1380 to c.4062 (approximately exon 11) with RHR = 0.62 (95% CI, 0.56-0.70; $P = 9 \times 10^{-17}$). In *BRCA2*, we observed multiple BCCRs spanning c.1 to c.596 (BCCR1; RHR = 1.71; 95% CI, 1.06-2.78; $P = .03$), c.772 to c.1806 (BCCR1'; RHR = 1.63; 95% CI, 1.10-2.40; $P = .01$), and c.7394 to c.8904 (BCCR2; RHR = 2.31; 95% CI, 1.69-3.16; $P = .00002$). We also identified 3 OCCRs: the first (OCCR1) spanned c.3249 to c.5681 that was adjacent to c.5946delT (6174delT; RHR = 0.51; 95% CI, 0.44-0.60; $P = 6 \times 10^{-17}$). The second OCCR spanned c.6645 to c.7471 (OCCR2; RHR = 0.57; 95% CI, 0.41-0.80; $P = .001$). Mutations conferring nonsense-mediated decay were associated with differential breast or ovarian cancer risks and an earlier age of breast cancer diagnosis for both *BRCA1* and *BRCA2* mutation carriers.

CONCLUSIONS AND RELEVANCE Breast and ovarian cancer risks varied by type and location of *BRCA1/2* mutations. With appropriate validation, these data may have implications for risk assessment and cancer prevention decision making for carriers of *BRCA1* and *BRCA2* mutations.

JAMA. 2015;313(13):1347-1361. doi:10.1001/jama.2014.5985
Corrected on July 9, 2015.

 Supplemental content at jama.com

 CME Quiz at jamanetworkcme.com and CME Questions page 1368

Author Affiliations: Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (Rebbeck, Nathanson); Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (Rebbeck, Mitra, Wan); Centre de Recherche en Cancérologie de Lyon, UMR Inserm, Centre Léon Bérard, Lyon, France (Sinilnikova, Mazoyer); Department of Genetics and Computational Biology, Queensland Institute of Medical Research, Brisbane, Australia (Healey, Chenevix-Trench); Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom (McGuffog, Easton, Antoniou); Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (Nathanson).

[†]Deceased.

Authors/Group Information: Members of the CIMBA Consortium are listed at the end of the article.

Corresponding Author: Timothy R. Rebbeck, PhD, Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, 217 Blockley Hall, 423 Guardian Dr, Philadelphia, PA 19104-6021 (rebbeck@upenn.edu).


Women who have inherited mutations in *BRCA1* (17q21, chromosome 17: base pairs 43,044,294 to 43,125,482) or *BRCA2* (13q12.3, chromosome 13: base pairs 32,315,479 to 32,399,671) have an increased risk of breast and ovarian cancers.^{1,2} Little is known about how cancer risks differ by *BRCA1* or *BRCA2* (*BRCA1/2*) mutation type. An “ovarian cancer cluster region” (OCCR) has been reported in both *BRCA1* and *BRCA2* using small sample sets. For *BRCA1*, initially mutations after exon 11 were associated with a 20% lower ovarian cancer risk than mutations in exons 1 through 11.³ Following that observation, Thompson et al⁴ reported an increased risk of ovarian vs breast cancer specifically was associated with mutations in the central portion of exon 11. This association was attributed to both a decrease in breast cancer risk and an increase in ovarian cancer risk in this region. Mutations in exon 11 of *BRCA2* also have been associated with higher ovarian vs breast cancer risk than in other regions of the gene.⁵ It was hypothesized that this risk variation might be explained by the failure of *BRCA1/2* exon 11 truncating mutations to trigger nonsense-mediated messenger RNA (mRNA) decay (NMD) because of their extremely large size, contrary to truncating mutations in smaller exons. However, this postulate was not supported by the measures of the relative amounts of mRNA transcript encoded by *BRCA1/2* alleles.^{6,7} Murine models of different mutations in *BRCA1/2* also suggest that genotype-phenotype correlations exist.^{8,9} To our knowledge, no study has reported whether *BRCA1/2* mutation type is associated with differences in breast and ovarian cancer risk. Thus, we evaluated whether *BRCA1* and *BRCA2* mutation type or location is associated with variation in breast and ovarian cancer risk.

Methods

The Consortium of Investigators of Modifiers of BRCA (CIMBA) initiative is an international collaboration of centers on 6 continents that has collected information about carriers of disease-associated *BRCA1* and *BRCA2* mutations with associated clinical, risk factor, and genetic data.¹⁰ All carriers participated in clinical assessment or research studies at the host institutions after providing informed consent under protocols approved by institutional review boards. For some individuals, ascertainment date reflects the earliest date at which they came to the attention of a clinician or research investigator (eg, when they were first seen in a clinic), even though their research participation, genetic testing, and research data collection may have occurred many years later. Fifty-five centers and multicenter consortia (eTable 1 in the Supplement) in 33 countries submitted deidentified data that met the CIMBA inclusion criteria.¹⁰ Study eligibility criteria included carriage of a disease-associated mutation and clinical data necessary to estimate hazard ratios (ie, cancer diagnosis, ascertainment and follow-up dates). Women were excluded if they carried both a *BRCA1* and *BRCA2* mutation (n = 84).

No races/ethnicities were excluded from this study. All races/ethnicities were included in this report to provide maximal generalizability of results for populations who may be un-

Figure 1. Analysis Workflow



Analyses undertaken are listed in the order in which they are presented in the text.

^a The functional domains were the RING, coiled coil, BRCT, BRC, DNA binding, oligonucleotide-binding folds, and tower domains.

dergoing genetic testing and counseling. All race/ethnicity designations were based on self-report. Race/ethnicity data were collected across the various centers using either fixed categories or open-ended questions.

Mutation Classification


Only carriers with clearly pathogenic *BRCA1/2* mutations were included in this analysis. Pathogenic mutations were defined as (1) mutations generating a premature termination codon, except variants generating a premature termination codon in exon 27 after codon 3010 of *BRCA2*¹¹; (2) large in-frame deletions that span 1 or more exons; and (3) deletions of transcription regulatory regions (promoter and/or first exon) expected to cause lack of expression of mutant allele. We also included missense variants considered pathogenic by the Breast Cancer Information Core committee or published variants classified as pathogenic using multifactorial likelihood approaches.^{12,13}

Mutations are described here using the Human Genome Variation Society nomenclature in which the nucleotide numbering is from the A of the ATG translation initiator codon, and use the c.XXX numbering convention (eAppendix 1 in the Supplement).

Creation of Mutation Groups for Analysis

Mutation Bins

To identify segments across the intronic and exonic regions of the *BRCA1* or *BRCA2* genes associated with different breast vs ovarian cancer risks, we created bins of mutations by base pair location (Figure 1). We divided the genomic regions of both genes to create bins of genomic sequence that contained

Figure 2. Hazard Ratio of Breast Cancer Relative to the Hazard Ratio of Ovarian Cancer by *BRCA1* Nucleotide Position

The graph shows the ratio of hazard ratios (blue data markers) and 95% CI (error bars) for the mutation bins defined across the span of the coding DNA sequence of the *BRCA1* gene. Black arrowheads under the bins indicate 2 founder mutations of clinical interest in the Ashkenazi Jewish population. Regions inferred to be breast cancer cluster regions (BCCRs) and ovarian cancer


cluster regions (OCCRs) are shown at the bottom. Solid light blue lines indicate regions found to be statistically significant; dashed light blue lines indicate regions in the same direction of effect that were not statistically significant. eTable 2 in the Supplement lists the bins and risks used to define the BCCRs and OCCRs.

all deleterious mutations regardless of category or function. Bins were constructed by using an algorithm in which each bin contained approximately equal numbers of participants with bin length defined by distance in base pairs. We excluded large genomic rearrangements from this analysis as those mutations span multiple bins and also undertook a subset analysis with and without missense mutations. The resulting bins are presented in Figure 2 and eTable 2 in the Supplement for *BRCA1* and Figure 3 and eTable 3 in the Supplement for *BRCA2*.

Mutation Type and Functional Domains

Mutations were grouped by type and function as frame shift, nonsense, missense, splice site, and then by in-frame and out-of-frame. Mutation groups included individuals who

carried in-frame deletions, nonsplice out-of-frame deletions, and out-of-frame deletions. Missense mutations in *BRCA1* were grouped into those within the RING^{14,15} and BRCT domains.¹⁶⁻¹⁹ Only 17 *BRCA2* carriers (0.1%) had missense mutations classified as pathogenic; these were removed from the analysis because the sample size was too small to provide statistically meaningful inferences. Comparisons also were made of mutations predicted not to lead to NMD vs those that do lead to NMD. Mutations predicted not to cause NMD were defined as those that lead to a stop codon within 50 nucleotides before or within the last exon.²⁰ In *BRCA1*, a subgroup including premature termination codons before c.297, presumed to allow reinitiation of translation at the AUG at that site, was examined separately.²¹ Premature termination codons refer to all mutations leading

Figure 3. Hazard Ratio of Breast Cancer Relative to the Hazard Ratio of Ovarian Cancer by *BRCA2* Nucleotide Position

The graph shows the ratio of hazard ratios (blue data markers) and 95% CI (error bars) for the mutation bins defined across the span of the coding DNA sequence of the *BRCA2* gene. The black arrowhead under the bins indicates a founder mutation of clinical interest in the Ashkenazi Jewish population. The

regions inferred to be breast cancer cluster regions (BCCRs) and ovarian cancer cluster regions (OCCRs) are shown at the bottom; the solid light blue lines indicate regions found to be statistically significant. eTable 3 in the Supplement lists the bins and risks used to define the BCCRs and OCCRs.

to a truncated open reading frame. Putative functional domains in *BRCA1* and *BRCA2* were defined using the boundaries in the Pfam database.²² We also identified reported domains in *BRCA1* or *BRCA2* that are involved in binding putative proteins.

Statistical Analysis

The primary outcomes of interest were diagnosis of ovarian cancer or breast cancer. For ovarian cancer, observations were censored at the earliest of the following outcomes: bilateral risk-reducing salpingo-oophorectomy, death, or having reached the

end of follow-up without an ovarian cancer or other censoring event. In women with both breast and ovarian cancer diagnoses, prior breast cancer diagnoses were ignored in the analysis of ovarian cancer. Time to event was computed from birth to age at first ovarian cancer diagnosis or age at censoring. For the primary event of breast cancer, observations were censored at the earliest of the following outcomes: ovarian cancer, risk-reducing salpingo-oophorectomy, risk-reducing mastectomy, death, or having reached the end of follow-up without a cancer or other censoring event. Time to event was computed from birth to age at first cancer diagnosis or age at

censoring. To account for intracluster dependence due to multiple individuals from the same family, a robust sandwich variance estimate was specified in Cox proportional hazards models.²³ All analyses were undertaken in *BRCA1* and *BRCA2* mutation carriers separately. The proportional hazards assumption was tested using log(−log) plots and Schoenfeld residuals.

Our analyses assessed the relationship of mutation groups with cancer risk. First, we used mutation bins to evaluate whether there is evidence to support the previous report of an OCCR^{3,5} and whether breast cancer cluster regions (BCCRs) may exist. To assess whether specific genomic regions of these genes were associated with greater breast vs ovarian cancer risk, we computed the hazard ratio of breast cancer, the hazard ratio of ovarian cancer, and a statistic RHR, defined as the ratio of breast vs ovarian cancer hazard ratio estimates. Values of RHR greater than 1 indicate elevated breast cancer risk; values of RHR less than 1 indicate elevated ovarian cancer risk. We evaluated bins of mutations across the span of *BRCA1* or *BRCA2* compared with all other mutations not contained in that bin by fitting a multiple correlated outcomes model stratified by cancer site.²⁴ This approach allowed us to achieve 2 goals: first, to estimate the correlation between ovarian and breast cancer outcomes within an individual, and second, to provide an estimate of the RHR (estimated via an interaction term between cancer site and mutation bin) with the correct confidence interval using robust sandwich variance estimates to account for the correlation between outcomes within a woman. All analyses were adjusted for birth year and race, stratified by center, and controlled for clustering within family.

Second, we compared each mutation type or functional group against a common reference group. The use of a common reference group allowed us to compare hazard ratio estimates across different mutation classes. For both *BRCA1* and *BRCA2*, we chose exon 11 nonsense mutations as the common reference group. Exon 11 nonsense mutations are common in diverse ethnic backgrounds and have been demonstrated to have the same biological effect, leading to NMD.²⁵

Approximate cancer risks to age 70 years for specific mutation classes were derived from the relative risk estimates. For *BRCA1* and *BRCA2*, estimated lifetime breast cancer penetrances were assumed to be 59% and 51% and ovarian cancer penetrance 34% and 11%, respectively.²⁶ Mutation-specific penetrance estimates were derived using the method presented in eAppendix 2 in the Supplement.

Statistical tests were judged significant based on 2-sided hypothesis tests with $P < .05$. All P values were corrected for multiple hypothesis testing within each table of results by controlling the false discovery rate (FDR) using the method of Benjamini and Hochberg.²⁷ Analyses were conducted in SAS version 9 (SAS Institute) or R version 2.7.2 (R Foundation for Statistical Computing).

Results

A total of 19 581 female carriers of *BRCA1* mutations and 11 900 carriers of *BRCA2* mutations were eligible for inclusion in this

study. Table 1 reports the distribution of dates of ascertainment to the study as well as time from ascertainment to cancer diagnosis or censoring, as used in the survival analysis models reported in this section. Mean age of breast cancer diagnosis was 39.9 years in *BRCA1* mutation carriers and 42.8 years in *BRCA2* mutation carriers. Mean age of ovarian cancer diagnosis was 50.0 years in *BRCA1* mutation carriers and 54.5 years in *BRCA2* mutation carriers. The 3 ovarian cancer cases diagnosed before age 18 years were germ cell tumors and included in the analysis (Table 1). Of note, all analyses also were undertaken excluding these 3 cases and there was no difference in the results. The majority of the sample consisted of white women for both *BRCA1* and *BRCA2* mutation carriers: 92% to 93% white, including 8% to 9% Jewish women. Both *BRCA1* and *BRCA2* mutation carriers had a median parity of 2.0 live births and age at menarche of 13 years. Median age at menopause was 44 years in *BRCA1* and 46 years in *BRCA2* mutation carriers, reflecting in part the use of preventive surgeries.

BRCA1: Breast and Ovarian Cancer Cluster Regions

We observed an OCCR bounded by c.1380 and c.4062 (Figure 2), suggesting a relative decrease in breast relative to ovarian cancer risk (RHR = 0.62; 95% CI, 0.56–0.70; FDR-corrected $P = 9 \times 10^{-17}$). This estimate was obtained by considering all mutations across multiple bins spanning the OCCR. The OCCR is explained by both a relative decrease in breast cancer risk and a relative increase in ovarian cancer risk (eTable 2 in the Supplement), which was statistically significant in bins 9, 11–13, 15–16, and 23 (Figure 2). The OCCR extends further 5' of the previously reported OCCR, which was defined by the interval c.2282 to c.4071.³ The OCCR is entirely contained within exon 11 (c.670–c.4096) with bins 6 and 23 being approximately coincident with the boundaries of the exon.

We also observed a relative increase in breast cancer risk and a relative decrease in ovarian cancer risk for mutations occurring in the 5' and 3' regions of *BRCA1*, potentially defining 2 BCCRs (Figure 2). BCCR1 mutations within bins 4–5 (c.179–c.505) were associated with excess risks of breast vs ovarian cancer (eTable 2 in the Supplement) and lie within the 3' region of the RING domain (c.72–c.192). Mutations in the BCCR1 were associated with a relative increase in breast cancer risk relative to ovarian cancer risk (RHR = 1.46; 95% CI, 1.22–1.74; FDR-corrected $P = 2 \times 10^{-6}$). When all mutations in the RING domain were considered together as compared with all others, they were associated with a significant increase in breast cancer risk (HR = 1.13; 95% CI, 1.02–1.26) and a significant decrease in ovarian cancer risk (HR = 0.81; 95% CI, 0.67–0.97). Bin 2, which contains only the founder mutation *BRCA1* c.68_69delAG (185delAG), did not provide statistically significant evidence for elevated breast vs ovarian cancer risks, suggesting that this mutation is associated with relatively equivalent risks of both cancers.

Mutations in bins 26 and 29–30 in the 3' region of *BRCA1* also provided evidence for additional BCCRs. BCCR2 was associated with an increase in breast cancer relative to ovarian cancer risk (RHR = 1.34; 95% CI, 1.01–1.78; $P = .04$) bounded by c.4328 and c.4945. The second segment of this BCCR (denoted BCCR2') includes the BRCT domains (c.4926–c.5169 and

Table 1. Characteristics of Study Sample: Ascertainment, Diagnosis, Demographics, and Risk Factors

Variable	BRCA1 Mutation Carriers			BRCA2 Mutation Carriers		
	No.	Median or Mean (Range)	SD	No.	Median or Mean (Range)	SD
Women with breast cancer	10 093			6452		
Year of breast cancer diagnosis		1999 (1942-2011)			1999 (1937-2011)	
Mean age at breast cancer diagnosis, y		39.9 (17-85)	9.2		42.8 (17-86)	9.8
Women without breast cancer	9488			5448		
Mean age of women with no breast cancer diagnosis, y		41.0 (12-102) ^a	12.0		42.6 (13-94) ^a	13.1
Women with ovarian cancer	3358			954		
Year of ovarian cancer diagnosis		2001 (1949-2011)			2001 (1967-2010)	
Mean age at ovarian cancer diagnosis, y		50.0 (16-92) ^b	9.5		56.5 (19-89) ^b	9.9
Women without ovarian cancer	16 223			10 946		
Mean age of women with no ovarian cancer diagnosis, y		42.0 (12-102) ^a	12.0		45.4 (13-96) ^a	12.6
Race/ethnicity						
White	16 481			10 014		
African/African American	176			87		
Asian	392			404		
Hispanic	333			175		
Jewish	1800			971		
Other	399			249		
Parity, No. of live births		2.0 (0-14)	1.4		2.0 (0-14)	1.4
Age at menarche, y		13.0 (8-23)	1.5		13.0 (7-22)	1.6
Age at natural or surgical menopause, y		44.0 (16-68)	6.3		46.0 (14-68)	6.6

^a Includes age at time of original family ascertainment for some women who were never diagnosed with cancer.

^b Includes 3 germ cell carcinoma cases diagnosed before age 21 years.

c.5268-c.5526) and was associated with a relative excess of breast vs ovarian cancers (RHR = 1.38; 95% CI, 1.22-1.55; $P = 6 \times 10^{-9}$) (Figure 2). In the BRCT domains, the preponderance of mutations was missense, not expected to trigger NMD. This region also includes bin 29, which contains only the *BRCA1* c.5266dupC (5382insC) mutation, which also is not predicted to lead to NMD as it introduces a premature termination codon in the last exon.⁶ In bin 30, *BRCA1* c.5277 + 1G>A, a common splice site mutation in the Netherlands, is observed and not expected to lead to NMD.

We compared breast and ovarian cancer risks between women who had a mutation in a specified functional domain compared with all other women who did not have mutations in that domain. Mutations in the RING domain were associated with higher breast cancer risks and nonsignificant lower ovarian cancer risks than other mutations. These results are consistent with the colocation of the BCCR1 (Figure 2) and RING domain. Mutations in the BRCT domains were associated with higher breast cancer risk. When analyses were limited to mutations conferring NMD, breast cancer risk became significantly associated with mutations in the coiled coil domain.

BRCA1: Risks by Category and Function

We observed variability in breast and ovarian cancer risks by mutation class (Table 2 and Table 3). For *BRCA1*-associated breast cancer, most risk groups were associated with higher breast cancer risk than the exon 11 nonsense mutation reference group. This result is consistent with the data shown in

Figure 2 and eTable 2 in the Supplement as it is similar in location with the OCCR. Groups with elevated breast cancer risk include all mutations leading to NMD (group 1), all premature termination codon mutations except for exon 11 nonsense mutations (group 2), frame shift and nonsense mutations occurring 5' of c.297 that are predicted to lead to NMD and reinitiation (group 3), nonpremature termination codon mutations (group 4), all founder mutations (group 5) and the founder mutation c.5266dup C (group 5b), missense mutations (group 6) and missense mutations in the RING domain (group 6a), missense and in-frame deletions (group 7), all in-frame deletions (group 8), and premature termination codon mutations not leading to NMD (group 9). The majority of the last group is comprised of c.5266dupC (83%). For *BRCA1*-associated ovarian cancer (Table 2), mutations associated with significantly lower ovarian cancer risks compared with the reference group included mutations 5' of c.297 (group 3), nonpremature termination codons (group 4), founder mutations (group 5, 5a, 5b), missense mutations (group 6, 6a), missense and in-frame deletions (group 7), and premature termination codons not leading to NMD (group 9).

When comparing mean age differences among women with or without a specific mutation category or function, we found small but statistically significant differences. In *BRCA1*, exon 11 mutations were associated with earlier ages at breast and ovarian cancer diagnosis. Mutations conferring NMD or premature termination codon were associated with a later age at breast cancer diagnosis. Conversely, an earlier

Table 2. Mutation-Specific Risk Groups: Risks Relative to Noninsertion or Nondeletion Exon 11 Mutations

Group	Description	Mutation Types Included	NMD	Protein	No. (%) With Mutation	Breast Cancer, HR (95% CI)	No. of Women With Breast Cancer	Ovarian Cancer, HR (95% CI)	No. of Women With Ovarian Cancer
BRCA1 (n = 19 581)									
a	Exon 11 nonsense mutations	NS	Yes	No	1770 (9.0)	1 [Reference]	796	1 [Reference]	336
1	NMD	FS, NS, OF-GR, OF-SP	Yes	No	11 027 (56.3)	1.20 (1.08-1.33)	5469	0.94 (0.80-1.11)	2038
2	All premature termination mutations	FS, NS, OF-GR, OF-SP	Yes	No	14 453 (73.8)	1.25 (1.12-1.38)	7318	0.93 (0.79-1.09)	2524
3	Mutations before c.297 ATG presumed transcription reinitiation	FS, NS	No	No	2763 (14.1)	1.40 (1.12-1.74)	250	0.66 (0.46-0.95)	74
4	Not premature termination	MS, IF, GR, IF-SP, FS	No	Yes	5398 (27.6)	1.51 (1.34-1.70)	2986	0.73 (0.61-0.88)	781
5	All founder mutations	FS			5375 (27.5)	1.41 (1.23-1.61)	2698	0.72 (0.60-0.88)	850
5a	Founder mutation c.68_69delAG	FS		No	2324 (11.9)	1.14 (0.94-1.38)	1033	0.67 (0.51-0.87)	391
5b	Founder mutation c.5266dupC	FS		Yes	3051 (15.6)	1.63 (1.41-1.89)	1665	0.73 (0.57-0.92)	459
6	All missense mutations	MS		Yes	1620 (8.3)	1.40 (1.20-1.64)	899	0.73 (0.57-0.92)	241
6a	Missense mutations in RING domain (c.72-192)	MS		Yes	1213 (6.2)	1.56 (1.32-1.84)	681	0.73 (0.56-0.96)	171
6b	Missense mutations in BRCT domain (c.4866-5325)	MS		Yes	372 (1.9)	1.09 (0.82-1.45)	202	0.72 (0.48-1.09)	64
7	Missense mutations and in-frame deletions	MS+IF, IF-SP, IF-GR		Yes	1658 (8.5)	1.42 (1.22-1.66)	925	0.71 (0.56-0.91)	249
8	In-frame deletions (splice, single codon, large deletion)	IF, IF-SP, IF-GR		Yes	38 (0.2)	2.41 (1.41-4.11)	26	0.51 (0.15-1.76)	8
9	All premature termination codons not leading to NMD	FS, NS, OF-SP, OF-GR	No	Yes	3663 (18.7)	1.58 (1.38-1.80)	2000	0.74 (0.60-0.91)	520
BRCA2 (n = 11 900)									
a	Exon 11 nonsense mutations	NS	Yes	No	1001 (8.4)	1 [Reference]	534	1 [Reference]	155
1	NMD	FS, NS, OF-GR, OF-SP	Yes	No	9961 (83.7)	1.10 (0.95-1.27)	5383	0.78 (0.56-1.08)	803
2	Not premature termination codon	IF-S, IF-FS, NS	No	Yes	203 (1.7)	1.35 (0.92-1.97)	118	0.34 (0.13-0.88)	12
3	In-frame deletions (splice, frame shift)	IF-FS, IF-S	No	Yes	117 (1.0)	1.41 (0.85-2.35)	76	0.26 (0.08-0.88)	9
4	Premature termination codons in last exon not leading to NMD	FS, NS	No	Yes	86 (0.7)	1.32 (0.79-2.19)	42	0.51 (0.13-2.09)	3
5	Founder mutation c.5946delT				1341 (11.3)	0.79 (0.60-1.03)	579	0.77 (0.46-1.32)	155

Abbreviations: FS, frame shift; GR, genomic rearrangement; HR, hazard ratio; IF, in-frame; NE, not estimable; NMD, nonsense-mediated decay; NS, nonsense; MS, missense; OF, out of frame; SP, splicing.

age at breast cancer diagnosis was associated with nonpremature termination codon mutations and the founder mutations (Table 3).

BRCA2: Breast and Ovarian Cancer Cluster Regions

We observed an OCCR (OCCR1) bounded by c.3249 and c.5681, containing c.5946delT (6174delT), with statistically significant evidence for a relatively higher ovarian cancer vs breast cancer risk among carriers of mutations in bins 6-9

and 11 (Figure 3). OCCR1 is explained by both a relative increase in ovarian cancer risk and a relative decrease in breast cancer risk, with an increase in ovarian cancer relative to breast cancer risk (RHR = 0.51; 95% CI, 0.44-0.60; $P = 6 \times 10^{-17}$) (eTable 3 in the Supplement). The putative OCCR1 lies within the previously reported OCCR³ and approximately colocalized with the BRC repeats within exon 11.^{17,18,28} A second putative OCCR (OCCR2) outside of the original OCCR boundaries also was observed defined by bin

Table 3. Mutation-Specific Risk Groups: Ages at Diagnosis of Breast Cancer or Ovarian Cancer

Group ^a	No. of Women With Breast Cancer	No. of Women With Ovarian Cancer	Mean Age at Diagnosis, y					
			Breast Cancer			Ovarian Cancer		
			With Mutation	Without Mutation	FDR <i>P</i> Value	With Mutation	Without Mutation	FDR <i>P</i> Value
BRCA1 (n = 19 581)								
a	796	336	40.4	42.4	<.001	50.2	52.5	<.001
1	5469	2038	41.2	40.1	<.001	50.8	50.3	.32
2	7318	2524	41.2	40.4	.001	51.2	50.2	.06
3	250	74	40.7	39.4	.07	50.5	52.2	.29
4	2986	781	40.5	41.1	.006	50.6	50.0	.32
5	2698	850	40.2	41.1	<.001	50.27	51.11	.03
5a	1033	391	40.43	42.41	<.001	50.22	52.49	<.001
5b	1665	459	40.5	41.5	<.001	50.6	50.0	.34
6	899	241	40.6	49.8	.60	50.5	49.8	.59
6a	681	171	40.6	41.1	.39	50.6	49.3	.32
6b	202	64	40.7	40.2	.60	50.5	51.2	.59
7	925	249	40.6	40.9	.60	50.6	49.8	.34
8	26	8	40.6	41.8	.60	50.5	48.4	.59
9	2000	520	40.5	41.1	.02	50.6	50.1	.34
BRCA2 (n = 11 900)								
a	534	155	43.3	45.8	<.001	56.5	56.9	.83
1	5383	803	44.5	43.4	.008	56.5	56.5	.93
2	118	12	42.4	43.6	.42	55.7	55.6	.94
3	76	9	42.4	43.6	.42	56.3	56.5	.94
4	42	3	42.4	43.6	.50	53.0	56.5	.94
5	579	155	43.33	45.83	<.001	56.47	56.88	.65

Abbreviations: FDR, false discovery rate.

^a Group descriptions appear in Table 2.

14 (c.6645-c.7471). OCCR2 was associated with an increase in ovarian cancer relative to breast cancer risk (RHR = 0.57; 95% CI, 0.41-0.80; *P* = .001).

We also observed a relative increase in breast cancer risk and a relative decrease in ovarian cancer risk for mutations occurring in the 5' and 3' regions of *BRCA2*, potentially defining multiple BCCRs (ie, BCCR1, BCCR1', and BCCR2) (Figure 3). These 3 regions were associated with relatively increased breast cancer risk relative to ovarian cancer risk with RHR = 1.71 (95% CI, 1.06-2.78; *P* = .03), RHR = 1.63 (95% CI, 1.10-2.40; *P* = .01), and RHR = 2.31 (95% CI, 1.69-3.16; *P* = .00002), respectively. These regions were associated with both increased breast cancer risk and decreased ovarian cancer risk (eTable 3 in the Supplement).

We also observed small but statistically significant differences in the mean age at breast cancer diagnosis associated with some of these regions. The mean age was greater for mutations in OCCR vs mutations not in OCCR (45.0 vs 43.9 years, *P* < .001; mean difference: 1.17; 95% CI, 0.65 to 1.69), lower for mutations in BCCR1 vs mutations not in BCCR1 (42.6 vs 44.3 years; *P* = .004; mean difference: -1.66, 95% CI, -2.80 to -0.53), and lower for mutations in BCCR2 vs mutations not in BCCR2 (43.5 vs 44.3 years, *P* = .04; mean difference: -0.80, 95% CI, -1.55 to -0.05).

To complement the prior set of analyses, we also present associations of breast and ovarian cancers among

groups of *BRCA2* mutation carriers defined by known DNA binding domains (Table 4). Mutations in the BRC repeats were associated with lower breast cancer risks and higher ovarian cancer risks than those mutations not occurring in the BRC repeats consistent with their colocation with the OCCR1 (Figure 3).

BRCA2: Risks by Category and Function

For *BRCA2*-associated cancer, the reference exon 11 mutation group was associated with decreased breast cancer risk compared with most other mutation classes (Table 2), consistent with colocalization with OCCR1. Compared with the reference group, ovarian cancer risks were further reduced among women who carried premature truncation codons (HR = 0.27; 95% CI, 0.11-0.66). We observed an association with earlier age at breast cancer diagnosis with exon 11 mutations and for mutations not conferring NMD (Table 3).

Absolute Risks

To illustrate potential mutation-specific effects on absolute cancer risks, we used the hazard ratio estimates to derive approximate absolute risks and 95% confidence intervals, based on published estimates for the overall risks of breast and ovarian cancer by age 70 years.²⁶ These estimates are for illustration and do not represent absolute risk estimates that would be required in a genetic counseling setting, as

Table 4. Risks Associated With Specific Binding Domains: Comparison of Mutations Not in the Domain (ie, the Reference Group) vs Those Within the Domain

Gene	Domain	Binding Partner	Region	Breast Cancer			Ovarian Cancer		
				No. With/Without Mutation ^a	HR (95% CI)	FDR P Value	No. With/Without Mutation ^a	HR (95% CI)	FDR P Value
BRCA1	RING	BARD1	c.72-192	781/595	1.13 (1.02-1.26) ^{b,c}	.04	205/1171	0.81 (0.67-0.97)	.07
	Coiled coil	PALB2	c.3759-3819 or c.4191-4272	122/90	1.20 (0.93-1.54) ^d	.16	39/173	0.97 (0.62-1.50)	.88
	BRCT	BACH1	c.4926-5169 or c.5268-5526	1203/832	1.26 (1.15-1.38) ^{e,f}	<.001	298/1737	0.86 (0.74-1.01)	.09
BRCA2	BRC	RAD51	c.3006-3108, c.3636-3738, c.4263-4365, c.4551-4653, c.4992-5094, c.5511-5613, c.5913-6015, or c.6153-6255	810/992	0.67 (0.56-0.79) ^{g,h}	<.001	205/1597	1.09 (0.78-1.53)	.77
	DNA binding		c.7437-8001	464/336	1.17 (0.99-1.38)	.08	63/737	1.06 (0.71-1.59)	.77
	OB folds	ssDNA	c.8010-8400 or c.9156-9570	512/364	1.18 (1.01-1.37) ^{h,i}	.07	50/826	0.57 (0.39-0.84)	.02
	Tower	RAD51	c.8443-8616	193/154	1.20 (0.92-1.56)	.19	18/329	0.42 (0.18-1.00) ^j	.10

Abbreviations: FDR, false discovery rate; HR, hazard ratio; NMD, nonsense-mediated decay; OB, oligonucleotide-binding.

^a Among 19 581 carriers of *BRCA1* mutations and 11 900 carriers of *BRCA2* mutations.

^b Missense mutations only: HR = 1.42; 95% CI, 1.06-1.90.

^c Mutations conferring NMD only: HR = 2.56; 95% CI, 1.03-6.34.

^d Mutations conferring NMD only: HR = 1.35; 95% CI, 1.05-1.72.

^e Premature termination codon mutations only: HR = 1.31; 95% CI, 1.17-1.47.

^f Mutations conferring NMD only: HR = 1.38; 95% CI, 1.20-1.59.

^g Premature termination codon mutations only contributed to this estimate.

^h Mutations conferring NMD only: HR = 1.26; 95% CI, 1.07-1.48.

ⁱ Premature termination codon mutations only: HR = 1.26; 95% CI, 1.07-1.48.

^j Mutations conferring NMD only: HR = 0.31; 95% CI, 0.13-0.77.

Table 5. Representative Cancer Penetrances by Age 70 Years: Baseline Risk and Modified Risk in Mutation Group

Gene	Cancer Site	Statistically Significant Mutation-Specific Relative Risk	Mutation Groups Corresponding to These Relative Risks, Tables 2-3 (Group No.)	Mutation Prevalence, % ^a (EMBRACE Data)	Overall Penetrance to Age 70 Years, % (BOADICEA)	Mutation-Specific Penetrance to Age 70 Years, % (95% CI)
BRCA1	Breast	1.4	All founder mutations (5)	16	59	69 (56-83)
	Ovary	0.7	All founder mutations (5)	16	34	26 (10-43)
BRCA2	Breast	0.7	Truncating mutations within the BRC domains (Table 3)	11	51	40 (27-54)
	Ovary	0.3	Not PTC (2)	0.6	11	3 (0-38)

^a Defined as the proportion of heterozygous mutation carriers with this mutation class with the specified cancer and *BRCA1* or *BRCA2* mutation in the EMBRACE data set.

they do not account for noncancer outcomes that may influence a woman's life expectancy, the effects of family history, and nonrandom ascertainment of mutation carriers in this sample and depend on assumptions about the prevalence of different mutation classes in the population. Using the *BRCA1/2* baseline breast and ovarian cancer risks of Antoniou et al,²⁶ we estimated risks and confidence intervals about these risks (eAppendix 2 in the [Supplement](#)). These confidence limits assume that the overall risk for a given individual is provided by our estimates and should not be interpreted as measuring the overall uncertainty in the absolute risk estimates, as shown in [Table 5](#). The overall breast cancer risk for *BRCA1* mutation carriers by age 70 years is 59%, which increases to 69% (95% CI, 56%-83%) in women who carry a missense mutation, Jewish founder mutation, or a mutation that undergoes NMD with reinitia-

tion. The ovarian cancer risk in *BRCA1* mutation carriers by age 70 years is 34% overall but decreases to 26% (95% CI, 10%-43%) among women who carry a founder mutation.

Discussion

We have identified mutations in *BRCA1* or *BRCA2* that are associated with significantly different risks of breast and ovarian cancers. These mutation-specific risks coincide with known or hypothesized functional domains and provide a basis around which accurate risk estimates can be generated for women who have inherited a particular *BRCA1/2* mutation. These results are consistent with prior reports of OCCRs in both *BRCA1* and *BRCA2* that lie in or near exon 11 of both genes.^{3,5,29,30} Mutations in exon 11

could produce a partial BRCA1 protein encoded by the known exon 11 splice variant, while the full-length protein is lost by the process of NMD.⁶ Murine embryos carrying the exon 11-deleted isoform survive longer than those that are *BRCA1* null, and *BRCA1* that has lost exon 11 appear to retain partial function.³¹ Thus, for *BRCA1*, it is biologically plausible that individuals carrying mutations within exon 11 (and the OCCR) may have a different phenotype than other mutations. In *BRCA2*, we have identified OCCRs, coincident with the 8 BRC repeats. Mutations in this region appear to be associated with NMD, which would lead to loss of *BRCA2* expression.⁷ However, it is possible that there is persistence of an alternatively spliced variant of *BRCA2*, without exon 11 (as for *BRCA1*), which would represent in-frame mutations. In addition, the *BRCA2* BRC repeats interact with *RAD51*, which has been consistently shown to be a modifier of *BRCA2*-associated breast and ovarian cancer risk.³² Without the BRC repeats, *BRCA2* might differ in interactions with *RAD51* and lead to genotype-phenotype variation. However, the biological basis of the *BRCA2* OCCR remains speculative, in particular as it does not extend throughout all of exon 11.

In *BRCA2*, several putative BCCRs were defined. The 3' BCCR coincides approximately with mutations occurring in the oligonucleotide binding (OB) fold domains and the tower domain. When examined independently, both of these domains were associated with relatively elevated breast cancer risk and lower ovarian cancer risk. These mutations in *BRCA2* would be predicted to undergo NMD. However, it has been demonstrated experimentally for only a few mutations, leaving the functional basis unknown.⁷

We have also identified a decreased risk of ovarian cancer associated with all types of mutations predicted not to lead to NMD in *BRCA2*; the estimated risk was only significant for all mutations together and those mutations leading to in-frame splice site or frame shift mutations. These mutations all occur after nucleotide 7000 in the C-terminus of *BRCA2*, which includes the DNA binding domains, tower domains, and OB folds.³³ These functional domains are associated with localization of *BRCA2* to sites of double-stranded DNA breaks to accomplish repair.³³ These data suggest that intact protein may be protective when it comes to ovarian cancer risk. However, the number of individuals is small and further replication is needed.

A number of limitations of this research may influence the generalizability and translational potential of this research. Despite the very large sample size, we were not able to investigate some mutation and risk groups with adequate statistical power. Carriers of *BRCA2* mutations composed a smaller sample set; in particular, the number of women with *BRCA2*-associated ovarian cancers was relatively small. Although all women with a documented disease-associated mutation in the CIMBA database were included, some populations use screening for founder mutations as a primary method of mutation detection, such as for the 3 Ashkenazi Jewish mutations. This testing strategy may lead to underreporting of nonfounder mutations. As such, some bias in the ascertainment of the full spectrum of mutations could have occurred. The ascertainment

strategy generally followed clinical and research protocols similar across all centers. However, we did not correct for ascertainment, and thus bias may have affected some variables (eg, age at diagnosis), which should be interpreted with caution. Mutation testing was performed using methods acceptable for clinical practice at each center, which was not uniform across all centers.

The present sample set does not reflect the general population of all mutation carriers but reflects those women who have undergone genetic testing for *BRCA1/2* mutations, a relevant population of inference. We have presented the mutations in terms of category or effect, but these designations are in some cases extrapolated based on experimental evidence for similar mutations. An example is the designation of NMD inferred from mutation location, which is based on experimental validation of only a small proportion of the mutations.^{6,7} Similarly, inference of protein truncation based on predicted protein-truncating mutations without experimental verification may lead to erroneous classification.²⁵ Penetrances that are presented here are limited because other factors that are not accounted for here could influence these estimates. These factors include family history and competing mortality. These risks also depend on knowing the true prevalence of the mutation-specific classes, which is likely to be population-specific.

In addition, the present report of more than 32 000 mutation carriers could include some of those individuals who were included in the 1995 and 1997 articles that originally reported the OCCR.³ It is not possible at this time to know if any of the 32 families carrying *BRCA1* mutations or 25 families carrying *BRCA2* originally reported also are included in the present sample. However, it is highly unlikely that the small sample of individuals represented in the original reports would outweigh a potential null effect among the more than 32 000 individuals studied here.

This study is the first step in defining differences in risk associated with location and type of *BRCA1* and *BRCA2* mutations. Pending additional mechanistic insights into the observed associations, knowledge of mutation-specific risks could provide important information for clinical risk assessment among *BRCA1/2* mutation carriers, but further systematic studies will be required to determine the absolute cancer risks associated with different mutations. It is yet to be determined what level of absolute risk change will influence decision making among carriers of *BRCA1/2* mutations. Additional research will be required to better understand what level of risk difference will change decision making and standards of care, such as preventive surgery,³⁴ for carriers of *BRCA1* and *BRCA2* mutations.

Conclusions

Breast and ovarian cancer risks varied by type and location of *BRCA1/2* mutations. With appropriate validation, these data may have implications for risk assessment and cancer prevention decision making among carriers of *BRCA1* and *BRCA2* mutations.

ARTICLE INFORMATION

Authors/CIMBA Consortium members include the byline authors as well as the following individuals:

Yael Laitman, MSC; Anya Kushnir, MSC; Shani Paluch-Shimon, MD; Raanan Berger, MD; Jamal Zidan, MD; Eitan Friedman, MD, PhD; Hans Ehrencrona, MD; Marie Stenmark-Askmalin, MD; Zakaria Einbeigi, MD; Niklas Loman, MD; Katja Harbst, PhD; Johanna Rantala, PhD; Beatrice Melin, MD, PhD; Dezheng Huo, PhD; Olufunmilayo I. Olopade, MD; Joyce Seldon, MSGC; Patricia A. Ganz, MD; Robert L. Nussbaum, MD; Salina B. Chan, BS; Kunle Odunsi, MD, PhD; Simon A. Gayther, PhD; Susan M. Domchek, MD; Banu K. Arun, MD; Karen H. Lu, MD; Gillian Mitchell, MD; Beth Y. Karlan, MD; Christine Walsh, MD; Jenny Lester, MPH; Andrew K. Godwin, PhD; Harsh Pathak, PhD; Eric Ross, PhD; Mary B. Daly, MD, PhD; Alice S. Whittemore, PhD; Esther M. John, PhD, MSPH; Alexander Miron, PhD; Mary Beth Terry, PhD; Wendy K. Chung, MD, PhD; David E. Goldgar, PhD; Saundra S. Buys, MD; Ramūnas Janavičius, MD, PhD; Laima Tihomirova, MD; Nadine Tung, MD; Cecilia M. Dorfling, PhD; Elizabeth J. van Rensburg, PhD; Linda Steele, BS; Susan L. Neuhausen, PhD; Yuan Chun Ding, PhD; Bent Ejlersen, MD, PhD; Anne-Marie Gerdes, MD; Thomas v. O. Hansen, MD; Teresa Ramón y Cajal, MD; Ana Osorio, PhD; Javier Benitez, MD; Javier Godino, MD; Maria-Isabel Tejada, PhD; Mercedes Duran, PhD; Jeffrey N. Weitzel, MD; Kristie A Bobolis, MD; Sharon R. Sand, CCRP; Annette Fontaine, MD; Antonella Savarese, MD; Barbara Pasini, MD; Bernard Peissel, MD; Bernardo Bonanni, MD; Daniela Zaffaroni, PhD; Francesca Vignolo-Lutati, PhD; Giulietta Scuvera, MD; Giuseppe Giannini, MD; Loris Bernard, PhD; Maurizio Genuardi, MD; Paolo Radice, PhD; Riccardo Dolcetti, MD; Siranoush Manoukian, MD; Valeria Pensotti, PhD; Viviana Gismondi, PhD; Drakoulis Yannoukakos, PhD; Florentia Fostira, PhD; Judy Garber, MD, MPH; Diana Torres, MD; Muhammad Usman Rashid, MD; Ute Hamann, PhD; Susan Peock, MS; Debra Frost, MS; Radka Platte, BS; D. Gareth Evans, MD; Rosalind Eeles, PhD; Rosemarie Davidson, PhD; Diana Eccles, MD; Trevor Cole, MD; Jackie Cook, MD; Carole Brewer, MD; Shirley Hodgson, MD; Patrick J. Morrison, MD, DSc; Lisa Walker, MS; Mary E. Porteous, MD; M. John Kennedy, PhD; Louise Izatt, MBBChir, PhD; Julian Adlard, MD; Alan Donaldson, MD; Steve Ellis, MSc; Priyanka Sharma, PhD; Rita Katharina Schmutzler, MD; Barbara Wappenschmidt, MD; Alexandra Becker, MD; Kerstin Rhiem, MD; Eric Hahnen, MD; Christoph Engel, MD; Alfons Meindl, MD; Stefanie Engert, MD; Nina Ditsch, MD; Norbert Arnold, MD; Hans Jörg Plendl, MD; Christoph Mundhenke, MD; Dieter Niederacher, MD; Markus Fleisch, MD; Christian Sutter, PhD; C. R. Bartram, MD; Nicola Dikow, MD; Shan Wang-Gohrke, MD; Dorothea Gadzicki, MD; Doris Steinemann, MD; Karin Kast, MD; Marit Beer, MD; Raymonda Varon-Mateeva, MD; Andrea Gehrig, MD; Bernhard H. Weber, MD; Dominique Stoppa-Lyonnet, PhD; Olga M. Sinilnikova, PhD; Sylvie Mazoyer, PhD; Claude Houdayer, PhD; Muriel Belotti, PhD; Marion Gauthier-Villars, PhD; Francesca Damiola, PhD; Nadia Boutry-Kryza, PhD; Christine Lasset, PhD; Hagay Sobol, PhD; Jean-Philippe Peyrat, PhD; Danièle Muller, PhD; Jean-Pierre Fricker, MD; Marie-Agnès Collonge-Rame, PhD; Isabelle Mortemousque, PhD; Catherine Nogues, PhD;

Etienne Rouleau, PhD; Claudine Isaacs, MD; Anne De Paeppe, MD; Bruce Poppe, MD; Kathleen Claes, PhD; Kim De Leeneer, MD; Marion Piedmonte, MA; Gustavo Rodriguez, MD; Katie Wakely, MD; John Boggess, MD; Stephanie V. Blank, MD; Jack Basil, MD; Masoud Azodi, MD; Kelly-Anne Phillips, MD; Trinidad Caldes, MD; Miguel de la Hoya, PhD; Atocha Romero, PhD; Heli Nevanlinna, PhD; Kristiina Aittomäki, MD; Annemarie H. van der Hout, PhD; Frans B. L. Hogervorst, PhD; Senno Verhoef, PhD; J. Margriet Collée, PhD; Caroline Seynaeve, MD, PhD; Jan C. Oosterwijk, MD, PhD; Johannes J. P. Gille, PhD; Juul T. Wijnen, PhD; Encarna B. Gómez García, MD; Carolien M. Kets, MD; Margreet G. E. M. Ausems, MD; Cora M. Aalfs, MD; Peter Devilee, MD; Arjen R. Mensenkamp, PhD; Ava Kwong, MD; Edith Olah, PhD, DSc; Janos Papp, PhD; Orland Diez, PhD; Conxi Lazaro, PhD; Esther Darder, PhD; Ignacio Blanco, MD; Mónica Salinas, MS; Anna Jakubowska, PhD; Jan Lubinski, MD; Jacek Gronwald, PhD; Katarzyna Jaworska-Bieniacka, PhD; Katarzyna Durda, PhD; Grzegorz Sukiennicki, PhD; Tomasz Huzarski, PhD; Tomasz Byrski, PhD; Cezary Cybulski, PhD; Aleksandra Toloczko-Grabarek, PhD; Elżbieta Złowocka-Perłowska, PhD; Janusz Menkiszak, ND; Adalgeir Arason, ND; Rosa B. Barkardottir, ND; Jacques Simard, PhD; Rachel Laframboise, MD; Marco Montagna, PhD; Simona Agata, PhD; Elisa Alducci, PhD; Ana Peixoto, PhD; Manuel R. Teixeira, MD, PhD; Amanda B. Spurdle, PhD; Min Hyuk Lee, MD; Sue K. Park, MD; Sung-Won Kim, MD, PhD; Tara M. Friebe, MPH; Fergus J. Couch, PhD; Noralane M. Lindor, MD; Vernon S. Pankratz, PhD; Lucia Guidugli, PhD; Xianshu Wang, PhD; Marc Tischkowitz, PhD; Lenka Foretova, MD; Joseph Vijai, MD; Kenneth Offit, MD; Mark Robson, MD; Rohini Rau-Murthy, MD; Noah Kauff, MD; Anneliese Fink-Retter, MD; Christian F. Singer, MD; Christine Rappaport, MD; Daphne Gschwantler-Kaulich, MD; Georg Pfeiler, MD; Muy-Kheng Tea, MD; Andreas Berger, MD; Mark H. Greene, MD; Phuong L. Mai, PhD; Evgeny N. Imyanitov, MD; Amanda Ewart Toland, PhD; Leigha Senter, MD; Anders Bojesen, PhD; Inge Sokilde Pedersen, PhD; Anne-Bine Skytte, PhD; Lone Sunde, PhD; Mads Thomassen, PhD; Sanne Traasdahl Moeller, PhD; Torben A. Kruse, PhD; Uffe Birk Jensen, PhD; Maria Adelaide Caligo, MD; Paolo Aretini, MD; Soo-Hwang Teo, PhD; Christina G. Selkirk, MS, CCRP; Peter J. Hulick, MD, MMSc; Irene Andriulis.

Affiliations of Authors/CIMBA Consortium:

Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (Domchek); Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (Friebe); Department of Genetics and Computational Biology, Queensland Institute of Medical Research, Brisbane, Australia (Spurdle); Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom (Peock, Frost, Platte, Ellis); Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (Domchek); Sheba Medical Center, Tel Aviv, Israel (Laitman, Paluch-Shimon, Friedman); Susanne Levy Gertner Oncogenetics Unit, Sheba Medical Center, Tel Hashomer, Israel (Kushnir); Oncology Institute,

Sheba Medical Center, Tel Hashomer, Israel (R. Berger); Oncology Institute, Rivkah Ziv Medical Center Zefat, Israel (Zidan); Department of Oncology, Lund University, Lund, Sweden (Ehrencrona, Loman, Harbst); Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden (Ehrencrona); Division of Clinical Genetics, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden (Stenmark-Askmalin); Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden (Einbeigi); Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden (Rantala); Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden (Melin); Center for Clinical Cancer Genetics and Global Health, University of Chicago Medical Center, Chicago, Illinois (Huo, Olopade); UCLA Schools of Medicine and Public Health, Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center, Los Angeles, California (Seldon, Ganz); Department of Medicine and Genetics, University of California, San Francisco (Nussbaum); Cancer Risk Program, Helen Diller Family Cancer Center, University of California, San Francisco (Chan, Whittemore); Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York (Odunsi); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (Gayther); University of Texas MD Anderson Cancer Center, Houston (Arun, Lu); Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia (Mitchell, Phillips); Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (Mitchell, Phillips); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California (Karlan, Walsh, Lester); Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City (Godwin, Pathak); Fox Chase Cancer Center, Philadelphia, Pennsylvania (Ross); Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California (Daly); Department of Epidemiology, Cancer Prevention Institute of California, Fremont (John); Dana-Farber Cancer Institute, Boston, Massachusetts (Miron, Garber); Department of Epidemiology, Columbia University, New York, New York (Terry); Departments of Pediatrics and Medicine, Columbia University, New York, New York (Chung); Department of Dermatology, University of Utah School of Medicine, Salt Lake City (Goldgar); Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City (Buys); Vilnius University Hospital Santariskiu Clinics, Hematology, Oncology, and Transfusion Medicine Center, Department of Molecular and Regenerative Medicine, State Research Institute Innovative Medicine Center, Vilnius, Lithuania (Janavičius); Latvian Biomedical Research and Study Centre, Riga, Latvia (Tihomirova); Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts (Tung); Department of Genetics, University of Pretoria, Pretoria, South Africa (Dorfling, van Rensburg); Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California (Steele, Neuhausen, Ding); Departments of Oncology or Clinical

Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark (Ejlertsen, Gerdes); Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark (Hansen); Oncology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (Ramón y Cajal); Human Genetics Group, Spanish National Cancer Centre (CNIO), and Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Osorio); Human Genetics Group and Genotyping Unit, Spanish National Cancer Centre (CNIO), and Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain (Benitez); Hospital clinico Universitario "Lozano Blesa," Instituto de investigación sanitaria de Aragón (IIS), Zaragoza, Spain (Godino); Molecular Genetics Laboratory (Department of Genetics), Cruces University Hospital Barakaldo, Bizkaia, Spain (Tejada); Institute of Biology and Molecular Genetics, Universidad de Valladolid (IBGM-UVA), Valladolid, Spain (Duran); Clinical Cancer Genetics, City of Hope Clinical Cancer Genetics Community Research Network, Duarte, California (Weitzel, Bobolis, Sand, Fontaine); Unit of Genetic Counselling, Medical Oncology Department, Istituto Nazionale Tumori Regina Elena, Rome, Italy (Savarese); Department of Medical Science, University of Turin, and AO Città della Salute e della Scienza, Turin, Italy (Pasini); Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy (Peissel, Zaffaroni, Scuvera, Manoukian); Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, Milan, Italy (Bonanni); AO Città della Salute e della Scienza, Turin, Italy (Vignolo-Lutati); Department of Molecular Medicine, University La Sapienza, Rome, Italy (Giannini); Department of Experimental Oncology, Istituto Europeo di Oncologia, Milan, Italy (Bernard); Cogentech Cancer Genetic Test Laboratory, Milan, Italy (Bernard, Pensotti); Institute of Medical Genetics, Catholic University, "A. Gemelli" Hospital, Rome, Italy (Genuardi); Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy (Radice); IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy (Radice, Pensotti); Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy (Gismondi); Molecular Diagnostics Laboratory, IRRP, National Centre for Scientific Research "Demokritos" Aghia Paraskevi Attikis, Athens, Greece (Yannoukakos, Fostira); Instituto de Genética Humana, Pontificia Universidad Javeriana, Bogotá, Colombia (Torres); Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany (Torres, Rashid, Hamann); Department of Basic Sciences, Shaikat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan (Rashid); Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals, NHS Foundation Trust, Manchester, United Kingdom (Evans); Oncogenetics Team, Institute of Cancer Research and Royal Marsden, NHS Foundation Trust, London, United Kingdom (Eeles); Ferguson-Smith Centre for Clinical Genetics, Yorkhill Hospitals, Glasgow, United Kingdom (Davidson); Wessex Clinical Genetics

Service, Princess Anne Hospital, Southampton, United Kingdom (Eccles); West Midlands Regional Genetics Service, Birmingham Women's Hospital Healthcare NHS Trust, Edgbaston, Birmingham, United Kingdom (Cole); Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, United Kingdom (Cook); Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom (Brewer); Clinical Genetics Department, St Georges Hospital, University of London, United Kingdom (Hodgson); Northern Ireland Regional Genetics Centre, Belfast City Hospital, Belfast, United Kingdom (Morrison); Oxford Regional Genetics Service, Churchill Hospital, Oxford, United Kingdom (Walker); South East of Scotland Regional Genetics Service, Western General Hospital, Edinburgh, United Kingdom (Porteous); Academic Unit of Clinical and Molecular Oncology, Trinity College Dublin and St James's Hospital, Dublin, Eire (Kennedy); South East Thames Regional Genetics Service, Guy's Hospital London, United Kingdom (Izzat); Yorkshire Regional Genetics Service, Leeds, United Kingdom (Adlard); South West Regional Genetics Service, Bristol, United Kingdom (Donaldson); Department of Hematology and Oncology, University of Kansas Medical Center, Kansas City (Sharma); Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), and Center for Molecular Medicine Cologne (CMC), Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany (Schmutzler, Wappenschmidt, Becker, Rhiem, Hahnen); Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany (Engel); Department of Gynaecology and Obstetrics, Division of Tumor Genetics, Klinikum rechts der Isar, Technical University Munich, Munich, Germany (Meindl, Engert, Ditsch); Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Campus Kiel, Germany (Arnold, Mundhenke); Institute of Human Genetics, University Medical Center Schleswig-Holstein, Campus Kiel, Germany (Plendl); Department of Gynaecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany (Niederacher, Fleisch); Institute of Human Genetics, Department of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany (Sutter, Bartram, Dikow); Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany (Wang-Gohrke); Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany (Gadzicki, Steinemann); Department of Gynaecology and Obstetrics, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany (Kast); Institute of Human Genetics, Technical University Dresden, Dresden, Germany (Beer); Institute of Human Genetics, Campus Virchow Klinikum, Charité Berlin, Berlin, Germany (Varon-Mateeva); Centre of Familial Breast and Ovarian Cancer, Department of Medical Genetics, Institute of Human Genetics, University of Würzburg, Würzburg, Germany (Gehrig); Institute of Human Genetics, University of Regensburg, Regensburg, Germany (Weber); Institut Curie, Department of Tumour Biology, Paris, France (Stoppa-Lyonnet, Houdayer, Belotti, Gauthier-Villars); Institut Curie, INSERM U830, Paris, France (Stoppa-Lyonnet); Université Paris Descartes, Sorbonne Paris Cité, France (Stoppa-Lyonnet, Houdayer); Unité Mixte de

Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon—Centre Léon Bérard, Lyon, France (Sinilnikova, Boutry-Kryza); INSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France (Sinilnikova, Mazoyer, Damiola); Université Lyon 1, CNRS UMR5558, Lyon, France (Lasset); Unité de Prévention et d'Epidémiologie Génétique, Centre Léon Bérard, Lyon, France (Lasset); Département Oncologie Génétique, Prévention et Dépistage, INSERM CIC-P9502, Institut Paoli-Calmettes/Université d'Aix-Marseille II, Marseille, France (Sobol); Laboratoire d'Oncologie Moléculaire Humaine, Centre Oscar Lambret, Lille, France (Peyrat); Unité d'Oncogénétique, CLCC Paul Strauss, Strasbourg, France (Muller, Fricker); Service de Génétique Biologique-Histologie-Biologie du Développement et de la Reproduction, Centre Hospitalier Universitaire de Besançon, Besançon, France (Collonge-Rame); Service de Génétique, Centre Hospitalier Universitaire Bretonneau, Tours, France (Mortemousque); Oncogénétique Clinique, Hôpital René Huguenin/Institut Curie, Saint-Cloud, France (Nogues); Laboratoire d'Oncogénétique, Hôpital René Huguenin/Institut Curie, Saint-Cloud, France (Rouleau); Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC (Isaacs); Center for Medical Genetics, Ghent University, Ghent, Belgium (De Paepe, Poppe, Claes, De Leeneer); GOG Statistical and Data Center, Buffalo, New York (Piedmonte); Evanston Hospital, Evanston, Illinois (Rodriguez); Tufts University, Medford, Massachusetts (Wakely); University of North Carolina, Chapel Hill (Boggess); New York University, New York, New York (Blank); Ohio State, Good Samaritan Hospital, Cincinnati (Basil); Yale University School of Medicine, New Haven, Connecticut (Azodi); Molecular Oncology Laboratory, Hospital Clinico San Carlos, IdISSC, Madrid, Spain (Caldes, de la Hoya, Romero); Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland (Nevanlinna); Department of Clinical Genetics, Helsinki University Central Hospital, Helsinki, Finland (Aittomäki); Department of Genetics, University Medical Center, Groningen University, Groningen, The Netherlands (van der Hout, Oosterwijk); Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, The Netherlands (Hogervorst, Verhoef); Department of Clinical Genetics, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The Netherlands (Collée); Department of Medical Oncology, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The Netherlands (Seynaeve); Department of Clinical Genetics, VU University Medical Centre, Amsterdam, The Netherlands (Gille); Department of Human Genetics and Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands (Wijnen); Department of Clinical Genetics and GROW, School for Oncology and Developmental Biology, MUMC, Maastricht, The Netherlands (Garcia); Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands (Kets, Mensenkamp); Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands (Ausems); Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands (Aalfs); Department of Human Genetics and Department of Pathology, Leiden

University Medical Center, Leiden, The Netherlands (Devilee); Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong (Kwong); Cancer Genetics Center, Hong Kong Sanatorium and Hospital, Hong Kong (Kwong); Department of Surgery, University of Hong Kong, Hong Kong (Kwong); Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary (Olah, Papp); Oncogenetics Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain (Diez); University Hospital of Vall d'Hebron, Barcelona, Spain (Diez); Molecular Diagnostic Unit, Hereditary Cancer Program, IDIBELL-Catalan Institute of Oncology, Barcelona, Spain (Lazaro); Genetic Counseling Unit, Hereditary Cancer Program, IDIBGI-Catalan Institute of Oncology, Girona, Spain (Darder); Genetic Counseling Unit, Hereditary Cancer Program, IDIBELL-Catalan Institute of Oncology, Barcelona, Spain (Blanco, Salinas); Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland (Jakubowska, Lubinski, Gronwald, Jaworska-Bieniek, Durda, Sukiennicki, Huzarski, Byrski, Cybulski, Toloczko-Grabarek, Złowocka-Perłowska); Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, Poland (Jaworska-Bieniek); Department of Surgical Gynecology and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland (Menkiszak); Department of Pathology, Landspítali University Hospital, Reykjavík, Iceland (Arason, Barkardottir); BMC, Faculty of Medicine, University of Iceland, Reykjavík, Iceland (Arason, Barkardottir); Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center, Québec City, Québec, Canada (Simard); Laval University, Québec City, Québec, Canada (Simard); Medical Genetics Division, Centre Hospitalier Universitaire de Québec, Québec City, Québec, Canada (Laframboise); Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy (Laframboise, Montagna, Agata, Alducci); Department of Genetics, Portuguese Oncology Institute, Porto, Portugal (Peixoto, Teixeira); Biomedical Sciences Institute (ICBAS), University of Porto, Portugal (Teixeira); Department of Surgery, Soonchunhyang University and Hospital, Seoul, Korea (Lee); Department of Preventive Medicine, Seoul National University College of Medicine and Cancer Research Institute, Seoul National University, Seoul, Korea (Park); Department of Surgery, Daerim St Mary's Hospital, Seoul, Korea (Kim); Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (Couch, Guidugli, Wang); Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota (Couch, Lindor, Pankratz); Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill University, Montreal, Québec, Canada (Tischkowitz); Department of Medical Genetics, University of Cambridge, Cambridge, United Kingdom (Tischkowitz); Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute and MF MU, Brno, Czech Republic (Foretova); Clinical Genetics Service, Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York (Vijai, Offit); Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York, New York (Robson, Rau-Murthy, Kauff);

Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria (Fink-Retter, Singer, Rappaport, Gschwantler-Kaulich, Pfeiler, Tea, A. Berger); Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland (Greene, Mai); N. N. Petrov Institute of Oncology, St Petersburg, Russia (Imyanitov); Division of Human Cancer Genetics, Departments of Internal Medicine and Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus (Toland); Division of Human Genetics, Department of Internal Medicine, Comprehensive Cancer Center, Ohio State University, Columbus (Senter); Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark (Bojesen, Skytte); Section of Molecular Diagnostics, Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark (Pedersen); Department of Clinical Genetics, Aarhus University Hospital, Aarhus N, Denmark (Sunde, Jensen); Department of Clinical Genetics, Odense University Hospital, Odense C, Denmark (Thomassen, Moeller, Kruse); Section of Genetic Oncology, Department of Oncology, University of Pisa and University Hospital of Pisa, Pisa, Italy (Caligo, Aretini); Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Subang Jaya, Malaysia (Teo); Department of Surgery, Faculty of Medicine, University Malaya Cancer Research Institute, University Malaya, Kuala Lumpur, Malaysia (Teo); NorthShore University HealthSystem, Department of Medicine, Evanston, Illinois (Selkirk, Hulick); Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada (Andrulis).

Author Contributions: Dr Rebbeck had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Wan, Mitra, Nathanson, and Rebbeck conducted and are responsible for the data analysis.

Study concept and design: Rebbeck, Chenevix-Trench, Easton, Antoniou, Nathanson, Zidan, Goldgar, Evans, Varon-Mateeva, Weber, Paepe, Lee, Park, Gschwantler-Kaulich.

Acquisition, analysis, or interpretation of data: Rebbeck, Mitra, Wan, Sinilnikova, Healey, McGuffog, Mazoyer, Chenevix-Trench, Easton, Nathanson, Laitman, Kushnir, Paluch-Shimon, R. Berger, Zidan, Friedman, Ehrencrona, Stenmark-Askmal, Einbeigi, Loman, Harbst, Rantala, Melin, Huo, Olopade, Seldon, Ganz, Nussbaum, Chan, Odunsi, Gayther, Domchek, Arun, Lu, Mitchell, Karlan, Walsh, Lester, Godwin, Pathak, Ross, Daly, Whittemore, John, Miron, Terry, Chung, Goldgar, Buys, Janavicius, Tihomirova, Tung, Dorfing, van Rensburg, Steele, Neuhausen, Ding, Ejlersen, Gerdes, Hansen, Cajal, Osorio, Benitez, Godino, Tejada, Duran, Weitzel, Bobolis, Sand, Fontaine, Savarese, Pasini, Peissel, Bonanni, Zaffaroni, Vignolo-Lutati, Scuvera, Giannini, Bernard, Genuardi, Radice, Dolcetti, Manoukian, Pensotti, Gismond, Yannoukakos, Fostira, Garber, Torres, Rashid, Hamann, Peock, Frost, Platte, Evans, Eeles, Davidson, Eccles, Cole, Cook, Brewer, Hodgson, Morrison, Walker, Porteous, Kennedy, Izatt, Adlard, Donaldson, Ellis, Sharma, Schmutzler, Wappenschmidt, Becker, Rhiem, Hahnen, Engel, Meindl, Engert, Ditsch, Arnold, Plendl, Mundhenke, Niederacher, Fleisch, Sutter, Bartram, Dikow, Wang-

Gohrke, Gadzicki, Steinemann, Kast, Beer, Gehrig, Stoppa-Lyonnet, Houdayer, Belotti, Gauthier-Villars, Damiola, Boutry-Kryza, Lasset, Sobol, Peyrat, Muller, Fricker, Collonge-Rame, Mortemousque, Nogues, Rouleau, Isaacs, Poppe, Claes, De Leeneer, Piedmonte, Rodriguez, Wakely, Boggess, Blank, Basil, Azodi, Phillips, Caldes, de la Hoya, Romero, Nevanlinna, Aittomaki, van der Hout, Hogervorst, Verhoef, Collee, Seynaeve, Oosterwijk, Gille, Wijnen, Garcia, Kets, Ausems, Aalfs, Devilee, Mensenkamp, Kwong, Olah, Papp, Diez, Lazaro, Darder, Blanco, Salinas, Jakubowska, Lubinski, Gronwald, Jaworska-Bieniek, Durda, Sukiennicki, Huzarski, Byrski, Cybulski, Toloczko-Grabarek, Złowocka-Perłowska, Menkiszak, Arason, Barkardottir, Simard, Laframboise, Montagna, Agata, Alducci, Peixoto, Teixeira, Spurdle, Park, Kim, Friebel, Couch, Lindor, Pankratz, Guidugli, Wang, Tischkowitz, Foretova, Vijai, Offit, Robson, Rau-Murthy, Kauff, Fink-Retter, Singer, Rappaport, Pfeiler, Tea, A. Berger, Greene, Mai, Imyanitov, Toland, Senter, Bojesen, Pedersen, Skytte, Sunde, Thomassen, Møller, Kruse, Jensen, Caligo, Aretini, Teo, Selkirk, Hulick, Andrulis.

Drafting of the manuscript: Rebbeck, Mitra, Chenevix-Trench, Nathanson, Zidan, Chan, Tejada, Pasini, Garber, Rashid, Evans, Gehrig, Belotti, Collonge-Rame, Nogues, Paepe, Blank, Kets, Lubinski, Jaworska-Bieniek, Durda, Sukiennicki, Huzarski, Toloczko-Grabarek, Lee, Kim, Rau-Murthy.

Critical revision of the manuscript for important intellectual content: Rebbeck, Mitra, Wan, Sinilnikova, Healey, McGuffog, Mazoyer, Chenevix-Trench, Easton, Antoniou, Nathanson, Laitman, Kushnir, Paluch-Shimon, R. Berger, Zidan, Friedman, Ehrencrona, Stenmark-Askmal, Einbeigi, Loman, Harbst, Rantala, Melin, Huo, Olopade, Seldon, Ganz, Nussbaum, Odunsi, Gayther, Domchek, Arun, Lu, Mitchell, Karlan, Walsh, Lester, Godwin, Pathak, Ross, Daly, Whittemore, John, Miron, Terry, Chung, Goldgar, Buys, Janavicius, Tihomirova, Tung, Dorfing, van Rensburg, Steele, Neuhausen, Ding, Ejlersen, Gerdes, Hansen, Cajal, Osorio, Benitez, Godino, Duran, Weitzel, Bobolis, Sand, Fontaine, Savarese, Peissel, Bonanni, Zaffaroni, Vignolo-Lutati, Scuvera, Bernard, Genuardi, Radice, Dolcetti, Manoukian, Pensotti, Gismond, Yannoukakos, Fostira, Garber, Torres, Hamann, Peock, Frost, Platte, Evans, Eeles, Davidson, Eccles, Cole, Cook, Brewer, Hodgson, Morrison, Walker, Porteous, Kennedy, Izatt, Adlard, Donaldson, Ellis, Sharma, Schmutzler, Wappenschmidt, Becker, Rhiem, Hahnen, Engel, Meindl, Engert, Ditsch, Arnold, Plendl, Mundhenke, Niederacher, Fleisch, Sutter, Bartram, Dikow, Wang-Gohrke, Gadzicki, Steinemann, Kast, Beer, Varon-Mateeva, Weber, Stoppa-Lyonnet, Houdayer, Gauthier-Villars, Damiola, Boutry-Kryza, Lasset, Sobol, Peyrat, Muller, Fricker, Mortemousque, Rouleau, Isaacs, Poppe, Claes, De Leeneer, Piedmonte, Rodriguez, Wakely, Boggess, Blank, Basil, Azodi, Phillips, Caldes, de la Hoya, Romero, Nevanlinna, Aittomaki, van der Hout, Hogervorst, Verhoef, Collee, Seynaeve, Oosterwijk, Gille, Wijnen, Garcia, Ausems, Aalfs, Devilee, Mensenkamp, Kwong, Olah, Papp, Diez, Lazaro, Darder, Blanco, Salinas, Jakubowska, Gronwald, Byrski, Cybulski, Złowocka-Perłowska, Menkiszak, Arason, Barkardottir, Simard, Laframboise, Montagna, Agata, Alducci, Peixoto, Teixeira, Spurdle, Park, Friebel, Couch, Lindor, Pankratz,

Guidugli, Wang, Tischkowitz, Foretova, Vijai, Offit, Robson, Kauff, Fink-Retter, Singer, Rappaport, Gschwantler-Kaulich, Pfeiler, Tea, A. Berger, Greene, Mai, Imyanitov, Toland, Senter, Bojesen, Pedersen, Skytte, Sunde, Thomassen, Møller, Kruse, Jensen, Caligo, Aretini, Teo, Selkirk, Hulick, Andrulis.

Statistical analysis: Rebbeck, Mitra, Wan, Easton, Antoniou, Nathanson, Zidan, Whittemore, Goldgar, Kennedy, Park, Pankratz.

Obtained funding: Rebbeck, Chenevix-Trench, Easton, Antoniou, Nathanson, Domchek, Ross, Daly, John, Buys, van Rensburg, Benitez, Genuardi, Yannoukakos, Schmutzler, Weber, Mortemousque, Azodi, Phillips, de la Hoya, Nevanlinna, Kwong, Olah, Salinas, Simard, Kim, Lindor, Offit, Kruse, Caligo.

Administrative, technical, or material support: Rebbeck, Healey, McGuffog, Nathanson, Laitman, Kushnir, Paluch-Shimon, Zidan, Stenmark-Askmal, Einbeigi, Harbst, Melin, Huo, Seldon, Ganz, Odunsi, Gayther, Domchek, Arun, Lu, Karlan, Lester, Godwin, Miron, Dorfling, van Rensburg, Steele, Ejlersen, Hansen, Calaj, Osorio, Duran, Weitzel, Sand, Bernard, Pensotti, Gismondi, Yannoukakos, Fostira, Garber, Rashid, Peock, Frost, Platte, Evans, Eeles, Eccles, Cole, Brewer, Morrison, Donaldson, Ellis, Sharma, Schmutzler, Wappenschmidt, Becker, Rhiem, Hahnen, Meindl, Engert, Ditsch, Arnold, Mundhenke, Niederacher, Fleisch, Sutter, Bartram, Dikow, Wang-Gohrke, Steinemann, Kast, Gehrig, Weber, Houdayer, Belotti, Damiola, Peyrat, Isaacs, Claes, De Leeneer, Piedmonte, Azodi, de la Hoya, Romero, Nevanlinna, Aittomaki, van der Hout, Hogervorst, Collee, Garcia, Devilee, Mensenkamp, Kwong, Olah, Papp, Lazaro, Salinas, Jakubowska, Lubinski, Huzarski, Byrski, Cybulski, Toloczko-Grabarek, Złowocka-Perłowska, Menkiszak, Arason, Barkardottir, Simard, Laframboise, Montagna, Agata, Alducci, Peixoto, Teixeira, Kim, Friebel, Couch, Guidugli, Wang, Foretova, Vijai, Offit, Rau-Murthy, Rappaport, Gschwantler-Kaulich, Pfeiler, A. Berger, Greene, Mai, Toland, Senter, Bojesen, Pedersen, Møller, Kruse, Jensen, Teo, Hulick, Andrulis.

Study supervision: Rebbeck, Mitra, Antoniou, Nathanson, Zidan, Friedman, John, van Rensburg, Rashid, Sobol, Paape, Caldes, Gille, Lazaro, Laframboise, Agata, Lee, Singer, Kruse.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Mitra reported having received grants from the National Institutes of Health (NIH). Ms McGuffog reported having receiving salary funded by a grant from Cancer Research UK. Dr Easton reported having received grants from Cancer Research UK. Dr Harbst reported having received grants from the Swedish Cancer Society. Dr Nussbaum reported having received grants from NIH and US Department of Defense and other support from Complete Genomics, Personalis, Oblon Spivak Law Firm, Guidepoint Global, Monness, and El Camino Hospital. Dr Ross reported having received grants from the National Cancer Institute (NCI). Dr Daly reported having received grants from NCI. Dr John reported having received grants from the Cancer Prevention Institute of California. Dr Goldgar reported having a patent for *BRCA1* and *BRCA2* with royalties paid. Dr Dorfling reported having received grants from the Cancer Association of South Africa (CANSa). Dr van Rensburg reported having received grants from CANSa. Ms Steele reported

having received grants and support from NIH. Dr Ejlersen reported having received grants from Amgen, Novartis, and Roche. Dr Radice reported having received grants from the Italian Association for Cancer Research. Dr Manoukian reported having received grants from the Fondazione IRCCS Istituto Nazionale Tumori. Dr Garber reported having received research support from Myriad Genetics Laboratories. Dr Eeles reported having received travel and education support from Succinct Health Communications and Janssen Pharmaceuticals. Dr Davidson reported having received funding from Cancer Research UK. Dr Cook reported having been an EMBRACE study coordinator. Dr Schmutzler reported having served on a board and speakers' bureau for and having received travel expenses from AstraZeneca and having a patent for RMD51C with royalties paid. Dr Engel reported having received grants from German Cancer Aid. Dr Devilee reported having patents for a diagnostic kit for determining a predisposition for breast and ovarian cancer. Dr Simard reported having been named as inventor on *BRCA1/2* gene patents but not receiving royalties. Dr Couch reported being co-holder of a patent on the *BRCA2* gene with royalties paid. Dr Robson reported having received grants from the Breast Cancer Research Foundation. Dr Toland reported having received grants from NIH and the American Cancer Society and travel support from NIH and serving on a board for NIH. No other disclosures were reported.

Funding/Support: Dr Antoniou and the CIMBA data management are funded by Cancer Research UK. Dr Easton is a Principal Research Fellow of Cancer Research UK. Dr Rebbeck is supported by R01-CA083855, R01-CA102776, and P50-CA083638 from the National Institutes of Health (NIH). Dr Rebbeck, Dr Nathanson, Ms Friebel, and Dr Domchek are supported by the Bassett Research Center at the University of Pennsylvania. Dr Nathanson is supported by the Breast Cancer Research Foundation. Drs Domchek and Nathanson are supported by the Rooney Family Foundation. Dr Poppe is supported by R01-CA112520 from NIH. Cancer Research UK provided financial support for this work. Dr Antoniou is a Senior Cancer Research UK Cancer Research Fellow. Dr Phillips is a National Breast Cancer Foundation (Australia) Practitioner Fellow.

Role of the Funder/Sponsor: The funders and sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank Jinbo Chen, PhD, of the University of Pennsylvania for her valuable input regarding appropriate statistical methods. Dr Chen did not receive any financial compensation for her role in this work. We dedicate this article to the memory of Dr Olga M. Sinilnikova, who contributed substantively to this work by contributing her knowledge of the mutations and domains studied herein, as well as advancing our understanding of nonsense-mediated decay of *BRCA1* and *BRCA2*.

Additional Information: Funding and acknowledgments are presented in eAppendix 2 and 3 in the [Supplement](#).

Correction: This article was corrected online July 9, 2015, for an incorrectly labeled *BRCA2* exon 11 in Figure 3.

REFERENCES

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene *BRCA1*. *Science*. 1994; 266(5182):66-71.
2. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, *BRCA2*, to chromosome 13q12-13. *Science*. 1994;265(5181):2088-2090.
3. Gayther SA, Warren W, Mazoyer S, et al. Germline mutations of the *BRCA1* gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. *Nat Genet*. 1995; 11(4):428-433.
4. Thompson D, Easton D; Breast Cancer Linkage Consortium. Variation in *BRCA1* cancer risks by mutation position. *Cancer Epidemiol Biomarkers Prev*. 2002;11(4):329-336.
5. Gayther SA, Mangion J, Russell P, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the *BRCA2* gene. *Nat Genet*. 1997;15(1):103-105.
6. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S. The nonsense-mediated mRNA decay pathway triggers degradation of most *BRCA1* mRNAs bearing premature termination codons. *Hum Mol Genet*. 2002;11(23):2805-2814.
7. Ware MD, DeSilva D, Sinilnikova OM, Stoppa-Lyonnet D, Tavtigian SV, Mazoyer S. Does nonsense-mediated mRNA decay explain the ovarian cancer cluster region of the *BRCA2* gene? *Oncogene*. 2006;25(2):323-328.
8. Dine J, Deng CX. Mouse models of *BRCA1* and their application to breast cancer research. *Cancer Metastasis Rev*. 2013;32(1-2):25-37.
9. Evers B, Jonkers J. Mouse models of *BRCA1* and *BRCA2* deficiency: past lessons, current understanding and future prospects. *Oncogene*. 2006;25(43):5885-5897.
10. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE; CIMBA. An international initiative to identify genetic modifiers of cancer risk in *BRCA1* and *BRCA2* mutation carriers: the Consortium of Investigators of Modifiers of *BRCA1* and *BRCA2* (CIMBA). *Breast Cancer Res*. 2007;9(2):104.
11. Claes K, Poppe B, Machackova E, et al. Differentiating pathogenic mutations from polymorphic alterations in the splice sites of *BRCA1* and *BRCA2*. *Genes Chromosomes Cancer*. 2003;37(3):314-320.
12. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ; Breast Cancer Information Core (BIC) Steering Committee. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to *BRCA1* and *BRCA2*. *Am J Hum Genet*. 2004;75(4):535-544.
13. Chenevix-Trench G, Healey S, Lakhani S, et al; kConFab Investigators. Genetic and histopathologic evaluation of *BRCA1* and *BRCA2* DNA sequence variants of unknown clinical significance. *Cancer Res*. 2006;66(4):2019-2027.
14. Brzovic PS, Rajagopal P, Hoyt DW, King MC, Klevit RE. Structure of a *BRCA1*-BARD1 heterodimeric RING-RING complex. *Nat Struct Biol*. 2001;8(10):833-837.
15. Bienstock RJ, Darden T, Wiseman R, Pedersen L, Barrett JC. Molecular modeling of the

amino-terminal zinc ring domain of *BRCA1*. *Cancer Res*. 1996;56(11):2539-2545.

16. Huyton T, Bates PA, Zhang X, Sternberg MJ, Freemont PS. The *BRCA1* C-terminal domain: structure and function. *Mutat Res*. 2000;460(3-4):319-332.

17. Williams RS, Green R, Glover JN. Crystal structure of the BRCT repeat region from the breast cancer-associated protein *BRCA1*. *Nat Struct Biol*. 2001;8(10):838-842.

18. Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. *FASEB J*. 1997;11(1):68-76.

19. Wu LC, Wang ZW, Tsan JT, et al. Identification of a RING protein that can interact in vivo with the *BRCA1* gene product. *Nat Genet*. 1996;14(4):430-440.

20. Palacios IM. Nonsense-mediated mRNA decay: from mechanistic insights to impacts on human health. *Brief Funct Genomics*. 2013;12(1):25-36.

21. Buisson M, Anczuków O, Zetoune AB, Ware MD, Mazoyer S. The 185delAG mutation (c.68_69delAG) in the *BRCA1* gene triggers translation reinitiation at a downstream AUG codon. *Hum Mutat*. 2006;27(10):1024-1029.

22. Pfam 27.0 database. <http://pfam.xfam.org>. Accessed March 9, 2015.

23. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. *J Am Stat Assoc*. 1989;84:1074-1078.

24. Therneau T, Grambsch P. *Modeling Survival Data: Extending the Cox Model*. New York, NY: Springer Verlag; 2000:169-229.

25. Anczuków O, Ware MD, Buisson M, et al. Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated *BRCA1*, *CHK2*, and *p53* proteins? *Hum Mutat*. 2008;29(1):65-73.

26. Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. *Br J Cancer*. 2008;98(8):1457-1466.

27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Series B Stat Methodol*. 1995;57:289-300.

28. Bignell G, Micklem G, Stratton MR, Ashworth A, Wooster R. The BRC repeats are conserved in mammalian *BRCA2* proteins. *Hum Mol Genet*. 1997;6(1):53-58.

29. Thompson D, Easton D; Breast Cancer Linkage Consortium. Variation in cancer risks, by mutation position, in *BRCA2* mutation carriers. *Am J Hum Genet*. 2001;68(2):410-419.

30. Lubinski J, Phelan CM, Ghadirian P, et al. Cancer variation associated with the position of the mutation in the *BRCA2* gene. *Fam Cancer*. 2004;3(1):1-10.

31. Ludwig T, Fisher P, Ganesan S, Efstratiadis A. Tumorigenesis in mice carrying a truncating *Brcal* mutation. *Genes Dev*. 2001;15(10):1188-1193.

32. Antoniou AC, Sinilnikova OM, Simard J, et al; Genetic Modifiers of Cancer Risk in *BRCA1/2* Mutation Carriers Study (GEMO); Epidemiological Study of *BRCA1* and *BRCA2* Mutation Carriers (EMBRACE); German Consortium for Hereditary Breast and Ovarian Cancer (GCHBOC); Kathleen Cuninghams Consortium for Research into Familial Breast Cancer (kConFab); Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA). RAD51 135G-->C modifies breast cancer risk among *BRCA2* mutation carriers: results from a combined analysis of 19 studies. *Am J Hum Genet*. 2007;81(6):1186-1200.

33. Yang H, Jeffrey PD, Miller J, et al. *BRCA2* function in DNA binding and recombination from a *BRCA2*-DSS1-ssDNA structure. *Science*. 2002;297(5588):1837-1848.

34. Domchek SM, Friebe TM, Singer CF, et al. Association of risk-reducing surgery in *BRCA1* or *BRCA2* mutation carriers with cancer risk and mortality. *JAMA*. 2010;304(9):967-975.